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The IKs current constitutes part of the repolarisation reserve in the human myocardium, and whilst it 
does not play a major role at resting heart rates, it becomes a crucial component of repolarisation in 
the setting of increased sympathetic tone and high heart rates. The formation of the IKs current 
requires the KCNQ1 α-subunit and the KCNE1 β-subunit. Mutations in either of these subunits can 
lead to long QT syndrome types 1 and 5, respectively. Loss-of-function mutations in the IKs channel 
can reduce the repolarisation reserve and lead to action potential prolongation, predisposing to 
lethal cardiac arrhythmias such as torsades de pointes and ventricular fibrillation.  
It is widely recognised that the IKs channel requires the minor membrane phospholipid PIP2 for its 
function, and previous work in this laboratory found that mutations in a PIP2-binding region in 
KCNQ1 led to retention of the channel in the endoplasmic reticulum, suggesting that PIP2 may play a 
role in anterograde trafficking.  
Here, the rapamycin-inducible dimerisation system was used to manipulate levels of PIP2 and/or PI4P 
at the plasma membrane or Golgi, and the effect of this on IKs channel trafficking and function was 
investigated using molecular biology, confocal microscopy and electrophysiology.  
Despite difficulties with optimising the rapamycin-induced dimerisation system, it was observed that 
the IKs channel does not require PIP2 for anterograde trafficking, but is heavily reliant on PIP2 for 
channel opening. In addition, activation of the β1-adrenergic receptor (β 1-AR) led to an increase in 
the IKs current amplitude. The potential interplay between β1-AR and PIP2 signalling was also 
explored by depleting PIP2 during β1-AR stimulation. PIP2 depletion was less effective at inhibiting 
the IKs current during β1-AR stimulation, but this requires further investigation. 
In conclusion, the results suggest that the IKs channel is reliant on PIP2 for function, but not 
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RISC   RNA-induced silencing complex 
RGS   regulators of G protein signalling 
Rm   resting membrane potential 
RNAi   RNA interference 
RPr   reverse primer 
Rseries   series resistance 
RT   room temperature 
RTK   receptor tyrosine kinase 
RWS   Romano Ward Syndrome 
siRNA   small interfering RNA 
SR   sarcoplasmic reticulum  
SAN    sinoatrial node 
SDM   site-directed mutagenesis 
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SGK1   serum- and glucocorticoid-inducible kinase 1 
SNARE   soluble N-ethylmaleimide-sensitive factor attachment protein receptor 
SR   sarcoplasmic reticulum 
SS   sum of squares 
ssDNA   single-stranded DNA 
SSA   steady state of activation 
SUR   sulphonylurea receptor 
T   time course 
Taq   Thermus aquaticus 
TdP   torsades de pointes 
TGN   trans-Golgi network 
TM   transmembrane 
TT   top10 competent Escherichia coli 
UVRAG   UV radiation resistance-associated gene protein 
V   voltage 
V0.5   half-maximal activation 
Vcmd   command voltage 
Vm   transmembrane potential 
Vp   pipette voltage 
VSP   voltage-sensitive phosphatase  
WCPC   whole-cell patch clamp 
WTM   wortmannin 







Glossary of constructs used for PI manipulation 
 
Components of the rapamycin-dimerisation system 
Pseudojanin – contains the FKBP domain allowing dimerisation with FRB using rapamycin, and the 
SAC1 and INPP5E lipid-depleting domains for dephosphorylation of PI4P and PIP2, respectively. 
(Tagged with RFP) 
PJ-INPP5E – contains the FKBP domain allowing dimerisation with FRB using rapamycin, and the 
SAC1 and INPP5E lipid-depleting domains. The SAC1 domain contains an inactivating mutation, so PJ-
INPP5E dephosphorylates only PIP2. (Tagged with RFP) 
PJ-SAC – contains the FKBP domain allowing dimerisation with FRB using rapamycin, and the SAC1 
and INPP5E lipid-depleting domains. The INPP5E domain contains an inactivating mutation, so PJ-SAC 
dephosphorylates only PI4P. (Tagged with RFP) 
PJ-DEAD – contains the FKBP domain allowing dimerisation with FRB using rapamycin, and the SAC1 
and INPP5E lipid-depleting domains. Both the SAC1 and INPP5E domains contains an inactivating 
mutation, so PJ-DEAD does not dephosphorylate any PIs and is used as a control construct. (Tagged 
with RFP) 
CF-PIPK – contains the FKBP domain allowing dimerisation with FRB using rapamycin, and the PIPK 
domain for PI4P phosphorylation to PIP2. (Tagged with RFP) 
LYN11-FRB-CFP – contains the FRB domain for dimerisation with FKBP using rapamycin, and the 
LYN11 sequence for PM tethering. (Tagged with CFP) 
LYN11-FRB-mCherry – contains the FRB domain for dimerisation with FKBP using rapamycin, and the 
LYN11 sequence for PM tethering. (Tagged with mCherry) 
LYN11-targeted-FRB – contains the FRB domain for dimerisation with FKBP using rapamycin, and the 
LYN11 sequence for PM tethering. (Untagged) 
Tgn38-FRB – contains the FRB domain for dimerisation with FKBP using rapamycin, and the Tgn38 
sequence for trans-Golgi membrane tethering. (Tagged with mCherry) 
Components of the gibberellin-induced dimerisation system 
YFP-GID1 – contains the GID1 domain for dimerisation with LYN-CFP-GAI(1–92) using GA3-AM. 
(Tagged with YFP) 
PJ-GID1 – contains the GID1 domains for dimerisation with LYN-CFP-GAI(1–92) using GA3-AM, and 
the SAC1 and INPP5E domains for dephosphorylation of PI4P and PIP2, respectively. (Tagged with 
RFP) 
LYN-CFP-GAI(1–92) – conatins the GAI domain (residues 1–92) for dimerisation with GID1 using GA3-




CHAPTER 1: Introduction 
1.1 The Cardiac Conduction System 
1.1.1 Normal electrical conduction in the heart 
 
The heart is responsible for the pumping of blood containing oxygen and nutrients to the lungs via 
the pulmonary arteries and the rest of the body via the aorta (figure 1). To do this efficiently, a 
complex conduction system is in place to ensure the coordination of myocyte contraction. Initiating 
this is the sinoatrial node (SAN), the small but specialised area of tissue in the right atrium, first 
discovered by Keith and Flack (1907). Approximately 70 years later, the function of the SAN was 
established by Taylor and co-workers (1978). Action potentials are generated by the SAN at a rate of 
around 100 per minute, which is slowed at rest to approximately 60 per minute due to the 
domination of the parasympathetic nervous system over the sympathetic nervous system (SNS). The 
regular firing of action potentials that leads to the normal contraction of the heart, which the SAN is 
responsible for, is known as sinus rhythm. 
Action potentials from the SAN travel through the atria via cell-to-cell conduction. Myocytes are 
coupled to adjacent cells through gap junctions at the intercalated disc, which provide a low-
resistance pathway for the passage of ions between cells and allow the rapid depolarisation required 
to propagate the action potential (Lo et al., 2000; Rohr, 2004). As the action potential travels through 
the atria, myocyte contraction follows, and this is responsible for forcing blood into the ventricles. 
The term ‘excitation-contraction coupling’ was coined by Sandow in 1952 to describe this process. 
The influx of calcium ions (Ca2+) through L-type Ca2+ channels in the plasma membrane (PM) causes 
release of Ca2+ stores from the sarcoplasmic reticulum (SR). This process, termed calcium-induced 
calcium release, causes large increases in local [Ca2+]. The free Ca2+ binds to troponin C, part of the 
regulatory protein complex, and causes a conformational change in the complex to occur. This 
change causes troponin-I to expose the myosin-ATPase (found on the myosin head) binding site on 
the actin filament. The ATP hydrolysis that occurs due to the action of the ATPase provides the 
energy required for the myosin head to pull the actin filament towards the centre of the sarcomere, 
shortening the sarcomere and consequently contracting the myocyte (Bers, 2002). 
Once the electrical signals have travelled the length of the atria they reach the physical barrier 
between the atria and ventricles, which they traverse via the atrioventricular node (AVN). The 
conduction is slower here owing to a lower density of high-conductance gap junctions, which allows 
for complete emptying of the atria before ventricular contraction starts (Temple et al., 2013). 
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The electrical impulses travel down the His bundle and the left and right bundle branches to the 
ventricles via a large network of Purkinje fibres. A rapid depolarisation of the ventricles follows, and 
contraction is initiated by excitation-contraction coupling in the same manner as atrial contraction.  
Across the ventricle wall, excitation propagates from the endocardium (the inner layer of the 
ventricle wall) through to the epicardium (the outer layer of the ventricle wall). The action potential 
duration (APD) of cells in the epicardium is shorter than in the endocardium, and so the termination 
of action potential propagation occurs from epi- to endocardium. During contraction, blood is forced 
out of the left ventricle into the aorta, and from the right ventricle into the pulmonary artery. 
The electrical activity associated with atrial and ventricular contraction can be seen on an 
electrocardiogram (ECG), and figure 2 shows how cellular depolarisation in different areas of the 
heart corresponds to characteristic inflections on the ECG. 
1.1.2 The Electrocardiogram 
 
The ECG trace corresponds to the electrical activity in the heart as it changes over time. Figure 3 
shows a representative ECG trace, containing a complete cycle of atrial depolarisation through to 
ventricular repolarisation. Various parameters of the ECG are measured to indicate whether an 
individual is in sinus rhythm or not.  
The P wave on the ECG represents the contraction of the right, then left atrium. The QRS complex, 
which is a combination of the three waves, corresponds to contraction of both ventricles. The QRS 
complex also masks the repolarisation of the atria on the ECG. The T wave shows ventricular 
repolarisation, which must occur before the next cycle commences (Hurst, 1998). 
The U wave shown in figure 2 and 3 is only sometimes present on a real ECG. It has been suggested 
that the U wave arises from repolarisation of the Purkinje cells or the midmyocardial (M) cells, as 
these have longer than average APDs. Although the true origin of the U wave is unknown, 
repolarisation of the whole ventricular myocardium corresponds with the end of the U wave and, 
therefore, the T and U wave are resultant of the same process (ventricular repolarisation) (Ritsema 
van Eck et al., 2005). 
The intervals in figure 2 measure the time between certain points of the ECG. The PR interval runs 
from the start of the P wave to the start of the QRS complex. The PR interval can give an indication of 
AV node function, as it measures the time taken for electrical signals to travel from the SA node to 
the ventricles. The QRS complex, which is measured from the start of the Q wave to the end of the S 
wave, measures the time taken for the ventricles to depolarise. The QT interval is measured from the 
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start of the Q wave to the end of the T wave, and encompasses ventricular depolarisation and 
repolarisation. The J point is described as being the point where the QRS complex ends and the ST 
segment begins (Brownfield & Herbert, 2008), and should lie on the isoelectric line. Deviation from 
this (elevation or depression) can indicate cardiac problems that manifest with ST segment 
abnormalities. The ST segment runs from the end of the QRS complex to the start of the T wave. 
The RR interval, which starts at the peak of one QRS wave and ends at the peak of the next, is used 




Figure 1. Anatomy of the heart. A schematic diagram of the heart showing both atria and ventricles, and the 
pulmonary artery and aorta. Blue and red arrows show the direction of blood flow. Adapted from the National 






Figure 2. Electrophysiology of the heart and the corresponding ECG. The waveforms for each of the 
specialised cells are shown on the right, and their locations in the heart on the left. The ECG trace below show 
how these waveforms shape the ECG. Image adapted from Bartos et al. (2015).  
  
1.1.3 Cardiomyocyte excitability and the action potential 
 
Cardiac cells, along with other cells such as those found in the nervous system, possess the ability to 
be electrically excited. This excitation causes a transient depolarisation of the membrane from the 
resting membrane potential (Rm). 
The potential difference across the membrane of an un-excited cell is the Rm, and describes the 
intracellular potential relative to the extracellular potential (Hoffman, 1959). The distribution of the 
main ionic species present in a cell at rest is tightly regulated. There is a large difference between the 
intra- and extracellular distribution of ions, the most notable being potassium (K+), sodium (Na+) and 
calcium (Ca2+) ions. These large differences create concentration gradients for each respective ion, to 
which the plasma membrane (PM) confers a level of permeability through the activity of ion 
channels, transporters and pumps. The resting membrane of a cardiomyocyte is more permeable to 
potassium (K+) ions than to other ions such as sodium (Na+) or chloride (Cl-), and therefore the Rm is 
closer to the K+ equilibrium potential. The equilibrium potential, or reversal potential, of an ion is the 
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voltage at which there is no net movement of that ion across the membrane, i.e. the distribution of 
ions means there is no gradient that causes a driving force for the ion to cross the membrane. 
 
 
Figure 3. The cardiac ECG and standard measurements.  A schematic diagram of an ECG trace showing the 
three waves (P, QRS and T) and the occasionally present U wave. The various measurable intervals can also be 
seen (PR, QRS, QT, ST and RR). ECG adapted from Ryan, S., accessed at: www.a-fib.com. 
 








)     Equation 1.1  
 







)          Equation 1.2 
 
Where E denotes the membrane potential (volts), R is the ideal gas constant (Joules per Kelvin per 
mole), T the temperature (Kelvin), F is the Faraday constant (Coulombs per mole), and z is the 




R (8.314 J.K-1mol-1) and F (96,485.33 C.mol-1) are constant values. T can be thought of as a constant, 
and at body temperate this is 37 °C (310 K). For the K+ ion, z=1, therefore 2.303 x (RT/zF) can be 
substituted to give: 
𝐸 = 0.0614 𝑙𝑜𝑔10 (
[𝑖𝑜𝑛]𝑜
[𝑖𝑜𝑛]𝑖
)    Equation 1.3 
  
Calculating the remaining equation using a physiological intracellular and extracellular concentration 
of K+ (150 mM and 4 mM, respectively) gives a K+ equilibrium potential (EK) of -96 mV. 
However, the PM is not solely permeable to K+, and the permeability to other ions contributes to the 
overall Rm. The Goldman-Hodgkin-Katz equation (Hodgkin & Katz, 1949), commonly known as the 
Goldman equation, is used to calculate the transmembrane (TM) potential (Vm) while considering the 
permeability of all ions across the membrane: 
 












 )  Equation 1.4 
 
Where Vm is the membrane potential, and pK, pNa and pCl are the relative membrane permeabilities 
of K+, Na+ and Cl- ions, respectively. [K+]o, [Na
+]o and [Cl
-]o are the extracellular concentrations of the 
named ions, and [K+]i, [Na
+]i and [Cl
-]i are the intracellular concentrations of the named ions. 
As the cardiomyocyte Rm does not lie at the reversal potential for any particular ion, an 
electrochemical gradient is created for each ion. Using K+ ions as an example, the further Rm is from 
EK, then the higher the driving force across the membrane for K
+. This driving force is a major 
contributor to the ion flux during an action potential. 
Despite an electrochemical gradient existing at rest for Na+ and K+ ions, and therefore movement of 
Na+ into and K+ out of the cell, the Rm is maintained due to the action of a number of adenosine 
triphosphate (ATP)-dependent ion pumps and transporters. To preserve Rm, the Na
+/K+-ATPase, 
which uses the energy provided from the conversion of ATP to adenosine diphosphate (ADP), pumps 
3 Na+ out of the cell and 2 K+ into the cell (against their concentration gradients). This pump is 
described as being electrogenic due to the imbalance of charge being passed across the membrane, 




conductance in comparison to other ions in a resting cell. This background K+ current is conducted 
through the leak K+ channels, which facilitate the diffusion of K+ ions down their concentration 
gradient and out of the cell (Enyedi & Czirják, 2010). 
Ionic flux during the action potential 
 
Upon depolarisation of the cell membrane, the permeability of ions change, and an action potential 
can be fired. Action potential form differs depending on the cellular origin (figure 2) due to the 
differential expression of ion channels in each cell type. However, most cardiac atrial and ventricular 
action potentials consist of the same basic structure (figure 4) (Hoffman, 1959; Grant, 2009): 
Phase 0: The rapid upstroke of the action potential caused by depolarisation of the Vm, which 
reaches +20 –30 mV during phase 0. 
Phase 1: A rapid repolarisation to approximately 0 mV occurs. 
Phase 2: The plateau phase follows. In ventricular myocytes this is more prolonged than in atrial 
myocytes. 
Phase 3: A fairly rapid repolarisation occurs that brings Vm back to Rm. 
Phase 4: The resting potential is restored (around Ek, approximately -90 mV). 
During phase 0, Na+ channels open and pNa increases allowing influx of Na+ ions down their 
electrochemical gradient. This causes membrane depolarisation. This, in turn, results in the opening 
of a vast number of Na+ channels, and Vm quickly reaches the threshold potential, causing the rapid 
upstroke of the action potential. These Na+ channels inactivate at positive potentials and give way to 
the repolarising currents. 
The repolarising phases that follow occur in different stages and are the result of a fine balance of 
inward Ca2+ and outward K+ currents. The rapid repolarisation in phase 1 is due to the fast activation 
of the voltage-gated transient outward K+ current (Ito). During the plateau phase (phase 2) there is a 
vast reduction in the net current flow as the L-type Ca2+ channel and the various K+ channels 
(depending on the cardiac cell type; figure 4) open and allow opposing ionic currents to cross the 
PM. Upon (voltage- and calcium-dependent) inactivation of the L-type Ca2+ channel and the release 
from inactivation of the rapid delayed rectifier K+ channel (IKr), the repolarising outward K
+  currents 
prevail, and Vm is brought back down to approximately -90mV. 
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The cardiac action potential is tightly regulated through activation kinetics and gating of each ion 
channel species, Ca2+ signalling and feedback mechanisms that occur during each action potential 
and the inactivation/deactivation mechanisms of ion channels that govern the effective and relative 
refractory period, in which another action potential cannot yet be fired. Alteration of any of these 
processes, by genetic or acquired causes, can lead to discrepancies in the action potential form. 
 
 
Figure 4. Action potentials in the human myocardium. A schematic diagram showing action potentials for 
(left) atrial and (right) ventricular cells, and the inward (downward deflection) and outward (upward 




 currents flow into the cell, and K
+
 currents flow out of 
the cell. Darker yellow currents indicate those studied in this project. ‘Action potentials’ adapted from Ravens 
& Cerbai (2008). 
1.2 Ion Channels 
1.2.1 An Overview of Ion Channel Structure and Function 
 
Ion channels are a subset of proteins that form TM pores in cell membranes to facilitate the diffusion 
of ions across that membrane. There are over 300 different ion channels, which are collectively 
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involved in a multitude of cellular processes. Ion channels constitute a crucial element of the cardiac 
conduction system where, as previously mentioned, any alteration in their function can have 
deleterious consequences. 
The structure of each species of ion channel is key to their specialised function, but the common 
structure to all ion channels is that they contain a number of TM domains that arrange to form a 
pore and a gating mechanism. Ion channels are commonly selective for one ionic species, and are 
classified into broad groups based on this selectivity, i.e. K+, Na+, Ca2+ and Cl- channels. 
Ion channels may have multiple ‘open’ or ‘closed’ states, and some also pass through an ‘inactivated’ 
state between the open and closed states. The open state of an ion channel corresponds with the 
conducting state, and the closed with the non-conducting state. A channel in the inactivated state 
has an open gate but a blocked pore, and, as a result, ions cannot flow through. Depending on the 
type of channel, the gate may be opened by either chemical, temperature, electrical or mechanical 
stimulus (Tabassum & Feroz , 2011). In addition to being classified based on the ion that the channel 
is selective for, an ion channel is further classified based on the gating mechanism it employs. For 
example, a K+ channel that opens in response to a change in TM voltage is termed a voltage-gated K+ 
(Kv) channel. 
Once in a conducting state, the ion channel can facilitate the passage of ions from one side of the 
membrane to the other. At the narrowest point of the pore lies the selectivity filter, which controls 
the type of ionic species that can pass through. The x-ray structure of the K+ channel from 
Streptomyces lividans (KcsA K+ channel), which is similar to a number of vertebrate K+ channels, 
allowed a detailed insight into the pore environment (Doyle et al., 1998). The selectivity filter of the 
KcsA K+ channel was found to be in an optimal position to allow dehydrated K+ ions to enter (figure 
5C). Usually, K+ ions are surrounded by eight water molecules, and so the pore mimics this 
environment with eight carbonyl oxygen atoms from residues that line the pore. This provides the 
perfect environment for K+ to transfer stably between the intra- or extracellular solution and the ion 
channel pore. Na+ ions, despite being smaller than K+ ions, cannot pass through the K+ channel pore. 
Doyle et al (1998) found that Na+ ions were unable to make stable interactions with the backbone 
carbonyl oxygens that line the selectivity filter due to the smaller size of the Na+ ions.   
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1.2.2 Potassium Channels 
 
K+ channels selectively allow the flow of K+ ions from one side of a membrane to the other. They 
contain a conserved sequence that confers this selectivity (TXXTXGYG), which was identified based 
on the Shaker channel sequence (TMTTVGYG) and is referred to as the signature sequence 
(Heginbotham et al., 1994). 
This selectivity for K+ ions allows K+ channels to perform a variety of functions throughout the 
human body, including controlling and limiting cardiac excitability (Snyders, 1999). 
Voltage-gated K+ channels 
 
The members of this large subset of K+ channels are dependent upon the membrane potential for 
opening and closing. The first cloned Kv channel, the Shaker channel, allowed analysis of the primary 
protein sequence of a Kv channel (Tempel et al., 1987). This sequence uncovered similarities with 
voltage-gated channels selective to other ions, namely the Na+ and Ca2+ voltage-gated channels.  
The Kv channel α-subunit contains the pore and gating mechanism, and it may interact with one or 
more β-subunits to modulate its function. Kv channel nomenclature begins with the family Kv1 and 
continues through to Kv12, with members of each family called, for example, Kv1.x, where x denotes 
a number starting at 1, which increases throughout the family. 
A single Kv channel gene codes for one of the four α-subunits that a channel complex consists of. One 
subunit contains 6 TM domains and an intracellular N- and C-terminus. The TM domains are named 
S1–S6, with S1–S4 of each of the 4 subunits comprising the voltage-sensing domain, and the S5–S6 
domains from each of the 4 subunits forming the pore domain (PD) (figure 5A & 5B). The S4 domain 
in Kv channels contains a number of positively-charged lysine (Lys) or arginine (Arg) residues, each 
separated by two hydrophobic residues (Bezanilla, 2000). Upon membrane depolarisation, the S4 
domain of each subunit moves outwards in the membrane in response to a change in the membrane 
potential, and the interaction of this with the positive charges in the S4 domain. This movement 
causes the channel to alter its conformation to one that favours the open state. S4 movement is 




Figure 5. The structure of a voltage-gated potassium channel. A – A schematic diagram of the structure of a Kv 
channel subunit. S1–4 form the voltage-sensing domain, while S5–6 form the pore domain. Four pore domains 
from each of the 4 subunits come together to form a single, central ion-conducting pore. The P-loop that lies in 
between S5 and S6 contains the selectivity filter sequence. B – A Ribbon diagram of two subunits of the KcsA K
+
 
channel. Each subunit comprises of M1 and M2, which are analogous to the S5 and S6 of Kv channels, and a P-
loop (P). The selectivity filter is shown in orange. The inner helix bundle forms the ion channel gate (adapted 
from Jiang et al., 2002). C – Selectivity filter from two subunits of the KcsA K
+
 channel, with the TVGYG 
signature sequence labelled. Two K
+
 ions can occupy the selectivity filter at any one time, at positions 2 and 4, 
or 1 and 3, before exiting via position 0 (adapted from Bichet et al., 2003). 
 
The 4 Kv channel subunits can assemble in a homotetrameric or heterotetrameric fashion. 
Homotetramers consist of 4 identical subunits, whereas heterotetramers contain different subunits, 
which can arrange in a number of configurations. Heterotetrameric channels can contain subunits 
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from the same class of Kv channel (Brown & Passmore, 2009), but interclass heterotetrameric 
channels also form (Bocksteins et al., 2012). 
Inwardly-rectifying K+ channels 
The inwardly-rectifying K+  (Kir) channels are named due to the fact that they conduct a larger current 
in the inward direction at potentials negative to EK, rather than the typical outward direction at 
potentials positive to EK, as is the case for other K
+ channels. At membrane potentials positive to EK, 
these channels are subject to open-channel block by intracellular Mg2+ and other molecules such as 
polyamines (Matsuda et al., 1987; Lopatin et al., 1994), which limits the current that can be 
conducted through the channel pore. Physiologically, Kir channels do not conduct this large inward 
current that they are capable of. The Kir channels are named due to the characteristics identified in 
experimental systems, which are able to force the membrane potential to negative voltages that 
would not occur in a physiological environment.   
The structure of Kir channels is different to that of Kv channels. Kir channels consist of 4 domains, but 
these domains are only made of 2 TM domains, as opposed to 6 in Kv channels. This was discovered 
by cloning the ROMK1/Kir1.1 (Ho et al., 1993) and IRK1/Kir2.1 (Kubo et al., 1993) from rat and mouse, 
respectively. Between the 2 TM domains, termed M1 and M2, lies the H5 region. This is responsible 
for K+ ion selectivity. Members of the Kir channel family do not contain an S4 segment, which serves 
as the voltage sensor in Kv channels, and as a result Kir channels lack voltage sensitivity. These 
channels therefore use other gating mechanisms to regulate the passage of ions through the pore. 
This group of channels possess a diverse range of activation mechanisms between them. For 
example, Kir3.x are activated by a G protein-coupled receptor (GPCR) (Kurachi et al., 1986), and are 
also classed as ligand-gated channels. The Kir6.x channels and Kir2.x channels are both thought of as 
constitutively-active channels in the heart, but both show different degrees of inward rectification, 
and Kir6.x channels are also sensitive to cellular ATP concentrations.   
Kir channels show varying degrees of inward rectification between them. They can be grouped into 
strong (Kir2.x and 3.x), intermediate (Kir4.x) and weak (Kir1.1 and 6.x) inward rectifiers.  The level of 
inward rectification depends highly on Asp172 in TM2 (Wible et al., 1994; Stanfield et al., 1994) and 
Glu224 and Glu229 in the large cytoplasmic region (Yang et al., 1995; Kubo & Murata, 2001) of each 
subunit. These negatively charged residues contribute to the strong inward rectification seen in some 
members of the Kir channel family, and it was found that Kir1.1 contains a neutral residue at this 
position, which is responsible for the lower Mg2+ affinity and consequent weak rectification. 
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However, the presence of these residues does not completely correlate with strength of rectification 
throughout the Kir channel family. 
Tandem two-pore domain channels 
The tandem-pore K+ (K2P) channels are characteristically composed of two subunits that form a 
dimer. Each subunit comprises 4 TM domains and 2 P loop domains (in contrast to K+ channels made 
from 4 subunits, each of which contain 1 P loop), which together form the pore domain and 
selectivity filter consisting of 4 P loops (Enyedi & Czirjak, 2010). 
The K2P channel family has 15 members, all of which conform to the tandem two-pore domain 
structure, but differ greatly in their protein structure (Lesege & Lazdunski, 2000).  
The K2P channels are responsible for the background, or leak, currents that are present in, for 
example, the cardiomyocyte. These channels contribute to the negative resting membrane potential 
of excitable cells (Sepúlveda et al., 2015). A true leak channel would be voltage independent, 
meaning that the P0 does not change with membrane potential, as with many other K
+ channels. 
These channels would also be ‘time independent’, in that they would not show activation, 
inactivation or deactivation kinetics. K2P channels, however, do show weak voltage dependence and 
rectification, but are widely considered to be leak channels (Enyedi & Czirjak, 2010).  
1.2.3 Cardiac K+ channels 
 
At physiological membrane potentials, cardiac K+ channels facilitate the outward flow of K+ ions. 
These channels are involved in almost all phases of the cardiac action potential, and provide crucial 
repolarising currents that restore and maintain the Rm between the firing of each action potential. 
Consequently, the activity of K+ channels during the action potential prevents spontaneous action 
potential firing that could lead to ectopic beats – a substrate for arrhythmia. 
The K+ current that first contributes to action potential repolarisation after the rapid depolarisation 
in phase 0 is the transient outward K+ current, Ito. This current can be divided into the fast, Ito, f and 
slow, Ito,s currents, which are conducted through channels consisting of Kv4.2/4.3 and Kv1.4 subunits, 
respectively (Niwa & Nerbonne, 2010). Kv4.3 channels interact with the auxiliary subunit KChIP2, 
which increases PM channel density and current amplitude, and decreases the time of recovery from 
inactivation and slows the rate of inactivation (Patel et al., 2002). It is thought that the expression of 
KChIP2 regulates the density of Ito, as the expression of Kv4.3 was found to be constant across the 
ventricular wall (Näbauer et al., 1996) whilst Ito density is higher in atrial, epicardial and 
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midmyocardial cells and Purkinje fibres compared to the endocardial cells (Roasti et al., 2001). The 
transient nature of this current coupled with the activation of the L-type Ca2+ channel, and hence 
increase of the L-type Ca2+ current (ICa,L) at potentials more positive than approximately -40 mV, 
prevents full repolarisation at this stage, so only a small repolarising notch is seen. 
During phase 2, when Ca2+ ions are still passing into the cell via the L-type Ca2+ channel, further 
depolarisation is prevented by the activation of the delayed rectifier Kv channels. The delayed 
rectifier current (IK) can be split into three components: the ultrarapid (IKur), rapid (IKr) and slow (IKs). 
IKur is conducted by the Kv1.5 channel, and has been recorded in human atrial cells, but not 
ventricular cells (Wang et al., 1993). The Kv11.1 α-subunit forms the human ether-a-go-go-related 
gene (hERG) channel, which is thought to interact with the KCNE2 β-subunit to form the channel that 
conducts the IKr current in human atrial and ventricular cells (Wang et al., 1994; Li et al., 1996). The 
IKr current rapidly activates at approximately -30 mV, and shows a strong inward rectification at 
positive potentials due to a rapid C-type inactivation. The remaining component of IK, the IKs current, 
also contributes to action potential repolarisation, but possesses much slower activation kinetics 
compared to IKr and IKur. The IKs channel in the heart corresponds to the channel formed by KCNQ1 
(Kv7.1) α-subunits and KCNE1 β-subunits. The channel activates at approximately -30 mV, and does 
not undergo inactivation. The IKs current was primarily thought to be present only in ventricular cells, 
but sporadic evidence has shown that this current may also contribute to atrial repolarisation (Hong 
et al., 2005; Wang et al., 1994) 
Phase 3 of the action potential begins when Ca2+-dependent inhibition of the L-type Ca2+ channel 
occurs and the sustained outward Kv currents cause a net outward flow of ions. In ventricular cells, 
the rapid and slow delayed-rectifier K+ currents, IKr and IKs, are responsible for the outward K
+ 
current. Upon repolarisation of the membrane to potentials of 0 mV and below, the IKr channel 
becomes relieved from inactivation and an outward flow of K+ ions occurs, increasing the rate of 
phase 3 repolarisation. The IKr channel then slowly deactivates. The IKs current gradually increases 




1.2.4 Cardiac repolarisation reserve 
 
The term repolarisation reserve was coined by Roden in 1998, who described it as a ‘mechanism to 
effect orderly and rapid repolarisation that runs essentially no risk of setting up re-entrant circuits or 
of generating EADs’, and suggested the normal functioning of IKr and IKs was a major contributor to a 
stable repolarisation (Roden, 1998). 
The repolarisation reserve is a mechanism of redundancy in cardiac cells to protect against unwanted 
disturbances in action potential duration that could lead to arrhythmia. Block of IKs has been shown 
to produce no ill effect on APD in human ventricular tissue without sympathetic stimulation, 
suggesting that this current does not play a role in repolarisation in normal physiological conditions. 
When sympathetic stimulation was increased pharmacologically by Jost et al. (2005), however, block 
of the IKs current increased the APD, supporting the hypothesis that IKs becomes a significant 
repolarising current in times of increased sympathetic drive. 
The availability of the repolarisation reserve can be reduced by pharmacological inhibition of the IKr 
channel, but the IKs current has been shown to compensate for the reduction in IKr due to the 
increased length and voltage of the action potential plateau (Jost et al., 2005). This enables an 
increased number of IKs channels, which are characteristically slow to activate, to move to the open 
and conducting state. This also allows a greater proportion of IKs channels to adopt a conformation 
close to the conducting state so they are able to open more rapidly during the following action 
potential.   
Mutations in the SCN5A gene, encoding the cardiac Nav channel, Nav1.5, can affect repolarisation 
reserve. Even though the Nav1.5 current undergoes characteristic rapid inactivation, a small fraction 
of the Na+ current is slow to inactivate – this so-called persistent Na+ current opposes the 
repolarising K+ currents and delays repolarisation. When the Na+ current becomes increased, for 
example in heart failure or in the presence of gain-of-function mutations in SCN5A, the capacity of 
the repolarisation reserve to overcome this can become compromised (Varró & Baczkó, 2011).  
In addition to mutations in the cardiac Na+ channel, mutations in the KCNQ1 and KCNH2 genes 
(which code for the IKs and IKr channel α-subunits, respectively) can profoundly influence action 
potential repolarisation by causing a reduction in repolarising K+ currents resulting in APD 
prolongation. Precipitation of arrhythmia under these circumstances usually occurs during periods of 
stress or exercise, when increased sympathetic stimulation requires an enhancement of outward K+ 




1.3.1 A Background to Arrhythmia 
 
A small aberration from the precisely-controlled cardiac electrical conduction can lead to life 
threatening cardiac conditions such as arrhythmias, which are characterised by heart rate and 
rhythm abnormalities. The understanding of arrhythmia began during the first observations and 
descriptions by William Harvey in the early 17th century, and the expansion of his ideas continued in 
the mid-18th century by Jean-Baptiste de Sénac. 
At present day, atrial fibrillation (AF) is the most common and sustained cardiac arrhythmia. The 
prevalence reaches almost 9% at aged 80+, and it is likely that the total number of AF sufferers will 
continue to increase due to the aging population (Colilla, 2013).  
Arrhythmias arising in the ventricles can manifest as torsades de pointes (TdP), ventricular 
tachycardia, ventricular bradycardia or ventricular fibrillation, and can be caused by a number of 
substrates, including long QT syndrome (LQTS). 
Across the wide range of arrhythmias there are those associated with underlying cardiac disease that 
can be rapidly fatal, and others that manifest as relatively asymptomatic conditions. The 
heterogeneous phenotype of arrhythmias is due to the number of different mechanisms and origins 
that exist. Many arrhythmias can be inherited or acquired, and these two distinct categories can 
contain multiple mechanisms of arrhythmogenesis. 
Tachyarrhythmia describes when the heart rate is faster than normal, and a bradyarrhythmia is 
described as being when the heart rate is slower than normal. Bradyarrhythmia can be caused by a 
slowing or blockage of conduction between, for example, the SAN and the atria or the AVN and the 
bundle of His. Other mechanisms include the alteration of gap junction expression at the intercalated 
disc, which affects cell-to-cell conductance, or decreased Nav channel activity, reducing the source of 
depolarisation (Dhein et al., 2014). 
1.3.2 Mechanisms of Arrhythmia 
 
In terms of action potential propagation from one cell to the next, the excited cell is known as the 
‘source’, and the unexcited cell is known as the ‘sink’. The excited cell ‘offloads’ a charge to the 
unexcited cell via gap-junction channels, which provides a level of excitation from the source to the 
electric sink. If the extent of excitation depolarises the unexcited cell to the threshold potential, an 
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action potential will propagate and the original unexcited cell will now become the new source of 
charge for downstream cells (Kléber & Rudy, 2004).  
Problems can arise in this source-sink relationship when the sink is larger than the source, i.e. when 
a small area of activated cells meets a large area of unexcited cells. In this situation, the unexcited 
cells would not likely depolarise to the threshold potential, and action potential propagation would 
terminate. This can occur at an ischemic area of tissue, which contains non-excitable cells (and 
therefore acts as an electric sink) that consequently causes conduction failure (Dhein et al., 2014). 
The Purkinje system is thought to be a common source of ventricular arrhythmias. As this source of 
electrical excitation meets a relatively large ventricular myocardium, it is prone to conduction block, 
which can lead to delayed ventricular activation. This unidirectional conduction block can lead to re-
entry circuits, which can lead to ventricular tachycardia and fibrillation. 
Afterdepolarisations and re-entry circuits 
 
Source-sink mismatch can be a protective measure against arrhythmia in well-coupled cardiac tissue; 
when an ectopic beat occurs (known as either an early afterdepolarisation (EAD) or delayed 
afterdepolarisation (DAD)) the small source (i.e. one action potential from one cell) cannot lead to 
action potential propagation because each cardiomyocyte is usually coupled to 4-6 other cells, which 
provides a large electrical sink.  
Afterdepolarisations are described as oscillations in the membrane potential that occur during, or 
immediately following, an action potential (figure 6). An EAD is caused by increased net Ca2+ 
conductance during phase 2 and 3 of the action potential, which occurs due to a loss of phase 2 and 
3 K+ conductance (for example, in the setting of acquired or congenital LQTS or heart failure). DADs 
are a result of intracellular Ca2+ overload thought to be caused by spontaneous Ca2+ release from the 
SR after termination of the preceding action potential (Gaztañaga et al., 2012; Volder et al., 2000).  
Xie et al (2010) found that the number of contiguous myocytes required for an EAD or DAD to trigger 
a premature ventricular complex (PVC), an ectopic beat arising from within the ventricles, was 
extremely high in normal cardiac tissue. Only in the presence of gap junction, electrical and 
structural remodelling, such as in cardiac disease, was a much smaller number of cells required to 
stimulate propagating PVC (Xie et al., 2010).   
If an ectopic depolarisation such as that caused by an EAD or DAD succeeds in propagation, the 
trigger for a re-entrant circuit may be created. There are two categories of re-entry: 
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classical/anatomical and functional. Anatomical re-entry occurs when a circular trajectory of 
activation reactivates the point of origin. This model of re-entry describes when the propagating 
impulse reaches, for example, a bifurcation or an obstacle, in which one path acts as a unidirectional 
block (figure 7). Activation of the tissue occurs down one path, and when reaching the distal end of 
the other it travels in a retrograde manner to the point of bifurcation. In the absence of 
unidirectional block, activation would occur down both paths and the circular re-entrant pathway 
would never be created. Maintenance of a re-entry circuit is dependent upon the length of the 
refractory periods in each pathway. The ‘excitable gap’, i.e. the period of time between the tail-end 
and the head-end of the re-entrant impulse wavefront, allows the re-entrant circuit to propagate. If 
there were no excitable gap because the tissue had not yet recovered from the previous action 
potential, the circuit would terminate (Kléber & Rudy, 2004). In contrast to anatomical re-entry, 
functional re-entry is facilitated by circuits that are not dependent on physical barriers, but on 
heterogeneities in neighbouring cells’ excitability. 
Unidirectional block is a prerequisite to re-entry. This can develop from local source-sink 
relationships that vary throughout the cardiac tissue, creating neighbouring areas with differing 
extents of refractoriness, or may be an inherent part of myocyte physiology; transmural differences 
in repolarisation between the three main cell types in the ventricular myocardium can also be a 
substrate for re-entry (Antzelevitch, 2005). 
Electrical remodelling 
 
Many types of cardiac abnormalities and cardiac disease lead to adaptive changes in the expression 
of ion channels, transporters and gap junctions. These changes are usually intended to counteract 
the initial dysfunction, but usually cause more damage due to the common induction of 
tachyarrhythmia (Nattel et al., 2007). Primary remodelling is a result of altered electrical activity, e.g. 
pacing. In contrast, secondary remodelling arises as a result of a structural insult to the cardiac 
tissue, as occurs in heart failure and myocardial infarction (Cutler et al, 2011). 
APD prolongation is commonly seen in people with heart failure, and delayed repolarisation is a 
prime cause of EAD generation. A cause of this phenomenon in heart failure is the change in K+ 
currents brought about by remodelling. Changes in K+ currents seen in experimental models of 
congestive heart failure include a decrease in the IKs and Ito currents, which would give rise to a net 
increased in the inward Ca2+ current. Decreased K+ current at this phase of the action potential can 
give rise to EADs via two mechanisms: delayed repolarisation reserve, or a prolongation of the 
plateau phase long enough for reactivation of the L-type Ca2+ channel (Viswanathan & Rudy, 1999). 
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Guo et al. (2012) found that chronic ischemia and reperfusion increased the incidence of ventricular 
arrhythmias in a rabbit model, and concluded that the downregulation of KCNQ1 may underlie this. 
Much of the ionic remodelling seen in heart failure mimics the effects of congenital ion channel 





Figure 6. Proposed mechanisms of afterdepolarisations in the heart.  Schematic representation of early (left) 
and delayed (right) afterdepolarisations in a ventricular action potential. EADs occur during phase 2 or 3, and 
DADs occur after action potential repolarisation, in phase 4. Orange dashed lines represent a normal action 
potential waveform; solid black lines represent the corresponding afterdepolarisation. 
 
 
Figure 7. Mechanism of re-entry circuit formation. Re-entry circuits can be caused by unidirectional block at a 
bifurcation/obstacle, where retrograde conduction then occurs (Gaztañaga et al., 2012). 
 
1.4 Long QT syndrome 
 
LQTS is named after the characteristic prolonged QT interval on an ECG, which represents the time 
between ventricular depolarisation and ventricular repolarisation. In its congenital form, LQTS is one 
of the leading causes of death in the paediatric population. Prolongation of the QT interval 
predisposes an individual to the potentially lethal arrhythmia TdP, which can degenerate into VF 
(figure 8).  TdP is characterised by a change in amplitude and a ‘twisting’ of the QRS complex around 
the isoelectric line. This change in morphology, however, may not be visible in all ECG leads. The 
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heart rate during periods of TdP can be between 160 and 240 bpm (but this is slower than during 
periods of VF). TdP often terminates spontaneously, but can progress to VF (Drew et al., 2010).  
Symptoms of LQTS include palpitations, syncope, seizures and sudden death (Beher & Weindling, 
2015).  
 
Figure 8. Torsade de pointes and ventricular fibrillation. A – an episode of self-limiting torsade de pointes. B – 
an episode of torsade de pointes, which degenerated into ventricular fibrillation. Figure taken from Yap & Cam 
(2003).  
 
Measuring the QT interval 
 
When determining the duration of the QT interval, heart rate is taken into consideration to give a 
‘corrected’ QT interval (QTc), enabling the comparison of QT interval measurements taken at 
different heart rates. One of the earliest, but still the most common, ways of correcting the QT 
interval for HR was published in the 1920s by Bazett, and uses the formula QTc = QT/RR1/2, where RR 
is determined from the previous RR interval. This formula, however, can lead to overcorrection and 
undercorrection of the QT interval at slower and faster heart rates, respectively (Postema & Wilde, 
2014). The Fridericia method uses the formula QTc = QT/RR1/3, and is considered to be more accurate 
at higher heart rates than the Bazett formula. Another formula used is the linear Framingham 
method, which uses the formula QTc = QT+0.154(1-RR) (Postema & Wilde, 2014). 
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The threshold beyond which QTc prolongation is diagnosed is 460 ms for females and 450 ms for 
males, in recognition that females have a higher resting heart rate than males. Table 1 details the 
boundaries that are used to determine the extent of QTc shortening/prolongation. 
 
QTc (ms) QT classification 
Females: <360; Males: < 350 Short QT interval 
Females: 360–460; Males: 350–450 Normal range 
Females: >460; Males: >450 Prolonged QT interval 
 
Table 1. QTc range and classification. The length in milliseconds (ms) of QTc values in males and females, and 
how this is interpreted and classified into short, normal or prolonged QT interval categories. Values taken from 
Vincent (2002) and Patel et al. (2010).  
 
Normal QTc values vary between individuals, between 350–460 ms, and as a result of this wide 
range, prolonged QTc values can lie anywhere from approximately 410 ms upwards. Values in the 
440–460 ms range are seen in around 12% of congenital LQTS (cLQTS) cases. Further complicating 
diagnosis, 30% of LQTS-causing mutation carriers have a QTc between 410–460 ms whilst 
approximately 60% of the normal population have a QTc in this range (Vincent, 2002).   
The diagnosis of LQTS poses particular difficulty because the measurement and calculation of the 
QTc value is prone to human error. In fact, Viskin et al. (2005) highlighted that many physicians, 
including cardiologists, cannot accurately measure QTc or identify a prolonged QT interval. Many 
physicians use clinical diagnostic assessment criteria to create a risk score to help in the diagnosis of 
LQTS. A significant portion of this score, however, relies heavily on the calculated QTc value for its 
result (Johnson & Ackerman, 2014).     
1.4.1 Acquired long QT syndrome 
 
Prolongation of the QT interval can occur upon exposure to environmental factors acting on the 
repolarising K+ currents or depolarising Na+ or Ca2+ currents (Anzelevitch, 2007). The majority of 
acquired LQTS (aLQTS) cases are a result of pharmacological blockade of the hERG channel, but can 
also occur due to hypokalemia and hypomagnesemia. Cases of aLQTS revert back to normal upon 





In the case of drug-induced aLQTS, anti-arrhythmic medication is responsible for more cases than 
non-cardiac medication. Commonly-used anti-arrhythmic drugs that cause aLQTS include 
disopyramide, dofetilide and amiodarone (Roden & Viswanathan, 2005).  The efficacy of anti-
arrhythmic medication varies significantly, and can be between 30–60%. The choice of anti-
arrhythmic drug in any given case is complicated by the fact that arrhythmias differ significantly in 
their aetiology. Nevertheless, these drugs are widely prescribed, but their success is often offset by 
their negative effects on mortality (Sanguinetti & Bennet, 2003). 
The first incidences of QT prolongation as a direct result of anti-arrhythmic medication were 
identified in the 1960s (Selzer & Wray, 1964), where quinidine treatment resulted in the emergence 
of a prolonged QT interval and ventricular fibrillation in a number of patients. Prior to this study, 
mortality during quinidine treatment was assumed to be due to a phenomenon known as ‘quinidine 
shock’, caused by toxic effects on the central nervous system (Thompson, 1956).  
The quintessential mechanism of drug-induced QT prolongation is blockade of the hERG (IKr) channel 
(Redfern et al., 2003; Sanguinetti et al., 1995). This channel’s unique pore structure gives rise to the 
increased rate of drug-block compared to other ion channels. Unlike other channels, the hERG 
channel contains many aromatic residues in its pore region. Two of these possess inwardly-facing 
side chains (Tyr652 & Pro656), giving rise to a high-affinity binding site for a wide range of drugs 
(Mitcheson et al., 2000). In addition to this, the hERG channel lacks the two proline residues 
responsible for the kink in S6 usually present in Kv channels. The absence of these residues causes a 
wider opening to the pore and consequently gives increased access to the binding site. Introduction 
of the ‘missing’ Pro-Val-Pro motif into the hERG channel reduces the channel’s sensitivity to drug 
binding (Fernandez et al., 2003; Roden & Viswanathan, 2005).  
Pharmacological inhibition of the hERG channel reduces the K+ efflux from myocytes during phase 3 
repolarisation, resulting in QT prolongation. This can lead to the generation of afterdepolarisations, 
and as detailed in section 1.3.2, and may contribute to the formation of re-entry circuits and increase 
the likelihood of arrhythmia.  
As it is now known that the pharmacological promiscuity of the hERG channel puts a high proportion 
of drugs at risk of causing adverse cardiac side effects, even with non-cardiac medication, ‘cardiac 
safety’ screening now takes place early in the drug-discovery process.  
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Risk factors for aLQTS 
 
Of those at risk of aLQTS, a small percentage (10–15 %) carry a mutation in one of the known LQTS-
causing genes (which are detailed in table 2). These patients do not usually suffer symptoms as a 
result of these mutations as there is little or no change in normal protein function. These mutations 
are classed as being ‘subclinical’. When control of the APD is challenged by hERG-blocking drugs, 
however, these underlying mutations increase the risk of aLQT. In individuals harbouring subclinical 
mutations that have been affected by drug-induced LQT, mutations have been found in the KCNQ1, 
KCNH2, KCNE1, KCNE2 and SCN5A genes (Yang et al., 2002; Paulussen et al., 2004).  
It is not only mutations in LQTS-causing genes that influence the risk of aLQT, but those also found in 
proteins involved in a drug’s metabolism. Mutations in certain drug-metabolising enzymes can 
increase the risk of aLQT by slowing down the metabolism of the active form of the drug, resulting in 
increased drug plasma concentration (Paulussen et al., 2004). In the past, high-profile drugs have 
been withdrawn from the market after it was discovered that their use was linked to sudden cardiac 
death. Notable examples include the antihistamine terfenadine (Woosley et al., 1993), and the 
gastroprokinetic agent cisapride (Rampe et al., 1997), both of which are metabolised by the CYP3A 
family of cytochrome P450 enzymes. These two drugs are rapidly metabolised into entities that do 
not inhibit the hERG channel, and rates of TdP are usually considered rare. However, in patients with 
compromised metabolism via the CYP3A pathway (e.g. due to overdose, liver disease or 
administration of CYP3A inhibitors), toxicity and TdP can ensue as the active compounds remain in 
circulation (Roden & Viswanathan, 2005). Besides terfenadine and cisapride, an example of this 
occurrence is in the case of treatment with thioridazine, an antipsychotic medication. This drug is 
eliminated by the cytochrome P450, CYP2D6, and loss-of-function variants of this enzyme are found 
in approximately 7% of the population. Individuals harbouring these mutations consequently risk TdP 
as a result of thioridazine treatment (Roden & Viswanathan, 2005).  
In addition to mutations in LQTS-causing genes and those involved in the metabolism of hERG-
blocking drugs, uncontrollable factors also increase the risk of QT prolongation and TdP. These 
include gender, and it was found that women are 2–3 times more likely to develop aLQT than men 
(Makkar et al., 1993). This disparity between the sexes is likely to result from the shortening of the 
QT interval that occurs in males after puberty (Rautaharju et al., 1992). 
Avoidable or controllable factors that can lead to aLQTS include high drug concentration, 





Divergence of electrolyte concentrations from their optimal range can lead to QT prolongation, and 
hence increases the risk of TdP generation. 
The most common electrolyte imbalance associated with QT prolongation is hypokalaemia, which is 
a deficiency of K+ in the bloodstream. This condition can result from a multitude of different 
situations, including gastrointestinal losses (i.e. diarrhoea and vomiting), hyperthyroidism, prolonged 
excess of caffeine, long-term inadequate intake and use of certain drugs (Widimsky, 2008).  
It is thought that the sensitivity of the hERG channel to extracellular K+ concentration provides the 
mechanistic link between hypokalaemia and QT prolongation. A study in guinea pig ventricular 
myocytes found that a reduction in extracellular [K+] reduced the IKr current, despite the existence of 
an increased concentration gradient for K+ (Sanguinetti & Jurkiewiez, 1992), and a study in rabbit 
hearts found that a reduction in extracellular [K+] lead to an increase in the rate of internalisation 
and degradation of hERG (Guo et al., 2009). Accordingly, an increase in serum [K+] corrected QT-
interval abnormalities in patients with mutation(s) in KCNH2 (Compton et al., 1996).   
In addition to causing prolongation of the QT interval itself, hypokalaemia may also influence the 
effect of hERG-blocking drugs. A study that investigated the [K+]-dependent block of hERG by 
quinidine found that by lowering [K+] from 5 mmol/L to 2.5 mmol/L, quinidine inhibition was 
enhanced (Lin et al., 2005). Supporting these observations, Yang et al. (1996) found that inhibition of 
hERG by either quinidine or dofetilide was highly dependent on extracellular [K+].   
Prolongation of the QT interval by hypokalaemia has also been reported to precipitate TdP in a 
patient with a subclinical KCNQ1 missense mutation (Arg259Cys) (Kubota et al., 2000).  
Besides hypokalaemia, a severe deficiency in extracellular magnesium, known as hypomagnesemia, 
can result in QT prolongation. This condition can be caused by low Mg2+ intake, poor intestinal 
absorption, excessive alcohol consumption or the use of diuretics (Efstradiadis et al., 2006). It has 
been shown in vivo that reduction of Mg+ has very little effect on the action potential (Surawicz, 
1989). However, Mg2+ deficiency can lead to disrupted Na+/K+-ATPase activity, which results in an 
increase in intracellular Na+ and a decrease in intracellular K+. Shils (1964) observed that 
experimentally-induced hypomagnesemia caused hypokalaemia in patients. As maintenance of the 
K+ gradient is disrupted in the setting of hypomagnesemia, inhibition of K+-dependent processes is 
likely to be the cause of arrhythmia generation in patients with low serum [Mg2+]. It has also been 
found by others that hypokalaemia cannot be corrected without first treating any underlying 
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magnesium deficiency (Huang & Kuo, 2007; Whang, 1997).  
In order to successfully prevent aLQT episodes of any origin, it was emphasised by Digby et al. (2011) 
that awareness of drug interactions and the early identification of individuals with a predisposition 
to QT prolongation are both crucial, so exacerbation of their risk does not occur.  
1.4.2 Congenital long QT syndrome 
 
The inherited, or congenital, form of LQTS is a collection of genetic disorders that can independently 
give rise to QT prolongation. Mutations are more commonly found in the cardiac K+ or Na+ channels, 
but are also found in accessory, regulatory and anchoring proteins (Table 2).  
The clinical manifestations of cLQTS were first identified in the late 1950s and early 1960s as two 
separate conditions: Jervell and Lange-Nielsen Syndrome (JLNS) and Romano Ward Syndrome (RWS) 
(Jervell & Lange-Nielsen, 1957; Romano et al., 1963; Ward, 1964). Once thought to be an extremely 
rare occurrence, the prevalence of cLQTS is now estimated at between 1:2000 and 1:2500 (Schwartz 
et al., 2009). The vast majority of cases are classified as RWS, and JLNS is an extremely rare condition 
that is accompanied by congenital deafness.  
Mutations in the KCNQ1 (LQT1), KCNH2 (LQT2) and SCN5A (LQT3) genes are by far the most common 
in cLQTS (Kapplinger et al., 2009). Despite causing a potentially fatal cardiac arrhythmia, the 
propagation of cLQTS continues because a large proportion of patients do not exhibit symptoms 
(Priori et al., 2003). Autosomal dominant inheritance of mutations in RWS gives offspring a 50% 
likelihood of inheriting the LQTS-causing gene, but with only 1 copy of the allele the effects can be 
mild enough to allow a carrier to live an average lifespan and pass on the mutated gene to their own 
offspring. An unfortunate consequence of the varying penetrance of this disease is that many people 
do not realise they suffer QT prolongation and are at risk of fatal ventricular arrhythmias; 
approximately 5% of mutation-carrying individuals suffer cardiac death as the first manifestation of 
LQTS (Tester & Ackerman, 2012).  
Mechanisms of APD prolongation in cLQTS 
 
Mutations in KCNQ1 more commonly lead to arrhythmia when an individual is under emotional 
stress or physical exertion, but particularly whilst swimming or diving. The adrenergic drive and 
release of catecholamines (such as norepinephrine) that occurs during these situations normally 
causes an increase in ICa,L amplitude to increase the force of myocyte contraction. This is 
accompanied by an increase in repolarising K+ currents, such as IKs, to counter the increased 
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depolarising Ca2+ current and shorten the APD. Individuals harbouring KCNQ1 mutations are less able 
to shorten their cardiac APD and are therefore prone to arrhythmia generation (Herbert et al., 2002).  
KCNH2 mutations are the second most common cause of cLQTS, and cause a reduction of the 
characteristic resurgent IKr current, which occurs after the channel becomes relieved from 
inactivation as the membrane potential repolarises. This reduced IKr current can occur through a 
variety of mechanisms, from acceleration in channel deactivation (which reduces the time the 
channel remains in the open state after relief from inactivation (Chen et al., 1999)), to a leftward 
shift in the voltage-dependence of inactivation (causing a reduction in the available resurgent IKr 
current (Nakajima et al., 1998)). A reduction in contribution of the IKr current to the repolarising K
+ 
current in the heart may also arise due to mutations causing defective channel trafficking (Zhou et 
al., 1998).  
Mutations in the SCN5A gene represent another major cause of LQTS (Wang et al., 1995), accounting 
for approximately 10% of cLQTS cases. Shortly after the first cLQTS-causing SCN5A mutation was 
described, it was discovered that the mechanism by which SCN5A mutations lead to APD 
prolongation was through a sustained inward Na+ current through the cardiac Na+ channel, Nav1.5, 
causing prolonged depolarisation (Bennet et al., 1995).  
Some of the less-common types of cLQTS affect the IKs, IKr and INa currents indirectly. For example, 
mutation of the β-subunits that are required by the pore-forming subunits for proper channel 




LQT Type Mutated gene Encoded protein Current/Function 
1 KCNQ1 Kv7.1 α-subunit IKs current in heart & K
+ 
current in inner ear (when 
complexed with KCNE1) 
2 KCNH2 Kv11.1 α-subunit IKr current in heart 
3 SCN5A Nav1.5 α-subunit INa current in heart 
4 ANK2 Ankyrin-B Involved in assembly of Na/Ca exchanger, Na/K 
ATPase and InsP3 receptor 
5 KCNE1 Kv7.1 β-subunit IKs current in heart & K
+
 current in inner ear (when 
complexed with KCNQ1) 
6 KCNE2 Kv11.1 β-subunit IKr current in heart 
7 KCNJ2 Kir2.1 α-subunit IK1 current in heart, skeletal muscle, nervous 
system 
8 CACNA1C Cav1.2 α-subunit L-type Ca
2+
 current in heart, nervous system 
9 CAV3 Caveolin 3 Scaffolding protein for caveolae-associated 
proteins in heart and muscle 
10 SCN4B Nav1.5 β-subunit INa current in heart (when complexed with SCN5A) 
11 AKAP9 Yotiao Anchor protein in IKs signalling complex 
12 SNTA1 α1-Syntrophin Membrane scaffold interacting with Nav1.5 
13 KCNJ5 Kir3.4 α-subunit IKAch current in heart (when complexed with KCNJ3 
(Kir3.1) 
14 CALM1 Calmodulin 1 Involved in adrenergic receptor signalling 
cascade, and essential for IKs gating and assembly 
15  CALM2 Calmodulin 2 Involved in adrenergic receptor signalling 
cascade, and essential for IKs gating and assembly 
Table 2. Mutated genes involved in Long QT Syndrome types 1–15. The 15 types of LQT, with corresponding 
mutated gene, encoded protein and the current conducted or normal role served. Mutations in ion channel α-
subunits are responsible for 6 types of LQT, whilst ion channel β-subunit mutations account for 3 types. The 
remaining 6 types of LQT are caused by mutations in ion channel-associated proteins, involved in trafficking, or 






As many carriers of single mutations show no (or mild) clinical symptoms, and therefore reach 
reproductive age with no indication they harbour a LQTS-associated mutation, the appearance of 
compound mutations can occur. This is estimated to occur in 4–11% of LQTS cases (Itoh et al., 2010). 
This usually arises when each parent passes on a single mutation to their child, who then possess 
two LQTS-causing mutations. 
Recent work in this laboratory identified the molecular mechanisms behind the increased clinical 
severity of 6 compound mutations in KCNQ1. It was found that 3 of these compound mutations 
(Thr391Ile/Gln530X, Ala525Thr/Arg518X and Ala178Thr/Lys422fs39X) caused severe disruption to 
channel trafficking when in compound form, and an additional mutation (Val310Ile/Arg594Gln) had a 
moderate, but not compound, effect on channel trafficking (Harmer et al., 2014).  
Compound mutations have been found in the same LQTS-causing gene or in different LQTS-causing 
genes. For example, Schwartz and colleagues identified 6 heterozygous carriers of LQTS mutations. 
Two of these probands carried 2 independent mutations in the KCNQ1 gene, two had mutations in 
KCNQ1/SCN5A, one had KCNQ1/hERG mutations and one had hERG/SCN5A mutations (Schwartz et 
al., 2002). The parents of these 6 probands were confirmed to have contributed one of the identified 
mutations each. Compound mutations can, however, be passed on by a single parent or appear de 
novo.   
Schwartz et al. (2002) also highlighted that carriers of compound mutations experience a more 
severe phenotype than would be expected taking into account the symptoms of the respective 
single-mutation carriers. This was also noted by Itoh and colleagues, whose larger Japanese study 
involved 26 compound mutation carriers (8.4% of genotyped probands). This study also found that 
compound mutation carriers exhibited a longer QT interval when compared to single mutation 
carriers, and an earlier age of onset for cardiac events (Itoh et al., 2010).  
1.4.3 KCNQ1 mutations 
 
Mutations in the KCNQ1 gene are the leading cause of LQTS, accounting for approximately 40–55 % 
of cases. Missense mutations are the most common occurrence, followed by frameshift mutations 
(Splawski et al., 2000). Most mutations reside in the intracellular and TM regions, and mutations 
within the TM regions, including S4, the pore domain and P-loop, lead to the highest number of 
cardiac events (Donger et al., 1997).  
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The study of mutations that are identified in LQTS patients is made possible by the introduction of 
these mutations into the KCNQ1 gene, and expression of the mutant protein in heterologous cell 
systems or induced pluripotent stem cells (iPSCs) (Bellin et al., 2013). Cells expressing the mutant 
KCNQ1 protein can then be studied using electrophysiological techniques to investigate its function, 
by molecular biology techniques to assess its expression and by imaging techniques to visualise its 
expression and localisation.  
Within the regions of high-risk mutations, those in the pore region were identified by Burgess et al. 
(2012) as particularly high risk in the onset of cardiac events in LQTS. The mutations studied by 
Burgess and colleagues (Thr322Met, Thr322Ala, and Gly325Arg) exhibited a DN effect over WT 
channel subunits, and hence generated non-functional channels. These mutations decreased the 
repulsion of K+ ions in the selectivity filter, and as a result of this, decreased the permeation of K+ 
through the pore.  
Distinguished from typical loss-of-function mutations, some KCNQ1 mutations can cause a shift in 
the voltage-dependence of activation (Boulet et al., 2006; Chouabe et al., 2000). When these 
mutations are expressed in heterologous cell lines and the membrane potential is depolarised to 
more positive potentials, the resulting current can reach a level comparable to WT. However, the 
activation is shifted to a more depolarised potential than the WT channel, and at physiological 
potentials (i.e. in a ventricular myocyte) the mutant channel would not produce a sufficient level of 
current required for repolarisation.   
In addition to mutations leading to functional defects in the channel, a number of mutations studied 
are now found to cause trafficking abnormalities. The effect of trafficking mutations can vary in 
severity, and are commonly studied using confocal microscopy to enable colocalisation analysis of 
the channel subunit with a fluorescent protein-tagged ER marker (i.e. DsRed-ER). On the other hand, 
a number of mutations have been identified that result in both functional aberrations and trafficking 
deficiencies (Schmitt et al., 2007). 
As a result of the extensive research into the mechanisms of different LQTS-causing mutations, it is 
now recognised that the classically-described dominant inheritance of RWS mutations and recessive 
inheritance of JLNS mutations is not always true. Mutations that cause RWS have been identified (i.e. 
no hearing loss) that follow a recessive inheritance pattern (Priori et al., 1998). The penetrance of 
different LQTS mutations is highly variable. Some individuals have life-threatening heterozygous 
mutations, and other have heterozygous mutations that only slightly increase their predisposition to 
cardiac events. Others have homozygous mutations that cause only cardiac effects, whereas some 
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individuals suffer from this and a loss of hearing (i.e. JLNS).  
Regardless of whether the function or trafficking of the IKs channel is affected, the outcome is the 
same. That is, the ability of the IKs current to contribute to ventricular repolarisation is partly or 
completely diminished.  
1.4.4 Treatment for long QT syndrome 
 
The response of a patient to treatment for cLQTS is thought to differ based upon the location of their 
LQTS-associated mutation(s). The majority of evidence for or against this is in the setting of LQT1-3, 
as these are most commonly seen and treated clinically.  
Some claim that the molecular substrate of cLQTS does not matter when it comes to prophylactic 
treatment strategies, and that administration of β-blockers can help reduce the chance of cardiac 
events in all types of LQTS. A recent study highlighted the effect of the β-blocker propranolol in 
preventing the induction of ventricular tachycardia and fibrillation in an established mouse model of 
LQT3 (Calvillo et al., 2014), and suggested that patients with LQT3 should also be placed on β-blocker 
therapy without hesitation. This is in contrast to previous findings by Moss and colleagues, who, in 
their study of 869 patients treated with β-blockers, found that the number of cardiac events in LQT1 
and LQT2 patients was reduced, but there was no beneficial effect of β-blocker therapy in LQT3 
patients (Moss et al., 2000).   
It is commonly thought that the origin of LQTS should be taken into consideration when deciding the 
most effective prophylactic strategy. LQT1 and LQT2 patients, with mutations residing in the KCNQ1 
and KCNH2 genes, respectively, have a reduced ability to provide sufficient repolarising current in 
phases 2 and 3 of the cardiac action potential. These patients are thought to be more responsive to 
β-blocker therapy because it removes the need of the repolarising K+ currents to counter the 
increased Ca2+ current normally induced by adrenergic stimulation (Moss et al., 2000).  
A retrospective study of 216 LQT1 patients treated with β-blockers revealed that this strategy is 
highly effective in LQT1, and that non-compliance was responsible for almost all life-threatening 
cardiac events in this patient group (Vincent et al, 2009). Supporting the effectiveness of β-blocker 
therapy in LQT1 patients, Schwartz et al. (2001) reported that in 162 LQTS patients treated with β-
blockers, patients with LQT2 and LQT3 had a higher rate of recurrence than LQT1 patients.  
Many LQTS patients that have a high risk of VF have a permanent pacemaker or implantable 
cardioverter defibrillator (ICD). A pacemaker is a small device that is placed in the chest, which 
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controls abnormal cardiac rhythms. It can be particularly beneficial in patients with LQT3, who may 
be unresponsive to β-blocker therapy. In addition, pacing the heart can reduce the heightened risk of 
arrhythmia in these patients during periods of bradycardia (Viskin, 2000). A portion of patients may 
benefit from a combination of β-blockers and a pacemaker, either due to the increased protection 
from episodes of TdP or by reducing the symptoms of bradycardia resulting from by β-blocker 
therapy (Eldar et al., 1987).  
An ICD is a device implanted inside the body that is able to perform cardioversion and defibrillation 
as well as pacing, and is hence able to abort life-threatening arrhythmias. In the past, the majority of 
LQTS patients receiving ICDs were aged >60. However, increased diagnosis of LQTS patients at earlier 
stages in their life has led to the implantation of ICDs into young patients also (Schwartz et al., 2010), 
as the first manifestation of LQTS can occasionally be sudden death.  
There is no hard and fast rule regarding the treatment strategies employed for LQTS patients of any 
genetic origin, and the precise management is commonly at the discretion of the clinician. However, 
increased knowledge on the mechanisms underlying each type of LQTS will provide an increased 
understanding of an individual patient’s disease, and enable clinicians to plan more effective 
treatment strategies accordingly.  
1.5 KCNQ1  
1.5.1 KCNQ1 structure and function 
 
The KCNQ1 protein is the founding member of the KCNQ family, of which there are 5 members. The 
KCNQ2-5 subunits may form homomeric or heteromeric complexes throughout the body to perform 
a multitude of functions, but the KCNQ1 subunit does not associate with any other members of the 
family (Schroeder et al., 2000a; Kubisch et al., 1999). 
The KCNQ1 homomeric channel, also called KvLQT1 or Kv7.1, follows the typical Kv channel structure, 
and consists of 4 pore-forming KCNQ1 α-subunits that are each made from one stretch of protein 
assembled into 6 TM domains. It is thought that physiologically, the KCNQ1 channel associates with a 
number of single-TM-domain KCNE1 β-subunits (between 1 and 4 subunits) (Chen et al., 2003; 
Murray et al., 2016; Plant et al., 2014; Wang et al., 1998) to form the IKs channel in the heart and 
inner ear (Barhanin et al., 1996; Sanguinetti et al., 1996). The KCNQ1 channel can also associate with 




KCNQ1 cytoplasmic domains 
 
The KCNQ1 subunit exists in a number of different splice variants, the two most common being 
isoform 1 and isoform 2. Each of the KCNQ1 isoform 1 subunits is 676 amino acids in length and 
possesses an intracellular N- and C-terminus, which are comprised of 122 and 322 residues, 
respectively. The C-terminus contains 4 helical domains that are conserved throughout the KCNQ 
family, named helix A, B, C and D, respectively. Isoform 2 is a truncated version of isoform 1, and 
consists of only 549 residues due to truncation of the N-terminus and the initial part of the first TM 
domain (Neyroud et al., 1999).  
Helices A and B form the proximal portion of the C-terminus, and create a calmodulin (CaM) binding 
site (Yus-Najera et al., 2002). It is thought that KCNQ channels require CaM for their function 
(Kosenko & Hoshi, 2013). The binding of CaM to KCNQ1 is also said to relieve channel inactivation 
and contribute to channel folding (Ghosh et al., 2006), and mutation of the CaM binding site has 
been shown to cause abnormalities in these processes (Shamgar et al., 2006). Bai et al., (2005) 
observed that in guinea pig myocytes there was a Ca2+-dependent increase in the IKs current, which 
was inhibited by a CaM antagonist. This suggests that CaM not only aids the channel in folding and 
assembly, but also provides a means of Ca2+-dependent modulation during the cardiac action 
potential. Further evidence supporting Ca2+-CaM modulation of KCNQ channels came from studies 
involving the KCNQ2 channel. Alaimo and colleagues found that binding of CaM to the KCNQ2 
channel was required for channel trafficking, and this was performed in a Ca2+-dependent manner 
(Alaimo et al., 2015). 
Also found in the proximal C-terminus of KCNQ1 is a cluster of basic residues that have been shown 
to bind a number of phospholipids, including phosphatidylinositol-4,5-bisphosphate (PIP2), with the 
most important residues in this region being Lys358 and Arg360 (Thomas et al., 2011). PIP2 is known 
to be required for IKs channel opening (Loussouarn et al., 2003; Zaydman et al., 2013). 
The distal portion of the C-terminus contains the coiled-coil helices C and D, which constitute the 
assembly domain. The assembly, or ‘A’-domain is responsible for the specific homomeric KCNQ1 
assembly.  Residues 589–620 show similarity to the tetramerization (T-1) domain in Shaker K+ 
channels. It was found that a KCNQ1 mutation that disrupts part of the assembly domain led to the 
inability of KCNQ1 mutant subunits to assemble with each other, resulting in a reduction of IKs 
channel cell-surface expression (Schmitt et al., 2000). 
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The distal C-terminus also contains a leucine zipper (LZ) motif, located within helix D, which is known 
to be required for the binding of the A-kinase anchoring protein (AKAP) 9, also named yotiao. 
Binding of yotiao enables IKs channel regulation by β-adrenergic receptor activation (Marx et al., 
2002). 
The most distal portion of the C-terminus contains a PY domain, which is required for interaction of 
the channel with Nedd4-2 ubiquitin ligase. Nedd4-2 is involved in controlling the regulation of 
channel recycling and degradation, and therefore the density of the IKs channel at the PM (Jespersen 
et al., 2007). 
The N terminus of KCNQ1 contains residues that can be phosphorylated to modulate channel 
activity. Ser27 (Kurokawa et al., 2004) and Ser92 (Lopes et al., 2007) are phosphorylated by protein 
kinase A (PKA), which is brought into close proximity to the IKs channel by binding to yotiao. 
Dahimène and colleagues suggested that the N-terminus could also play a role in channel trafficking, 
as they observed an increased ER retention of channels with N-terminal mutations (Tyr111Cys, 
Leu114Pro and Pro117Leu), and suggested that a juxtamembranous region of the KCNQ1 N-terminus 
is critical for channel surface expression (Dahimène et al., 2006). 
Gating and Electrophysiological properties 
 
Assembly of 4 KCNQ1 pore-forming subunits forms the Kv7.1 channel, which is gated by voltage due 
to the presence of the S4 TM α-helix in each subunit. The S4 domain contains multiple basic residues 
that occur at regular intervals, which allows the channel to be responsive to changes in membrane 
potential. The KCNQ1 subunit contains fewer basic residues in its S4 domain compared with other 
members of the Kv family, and as such its voltage dependency and gating characteristics are more 
flexible than other channels and can be highly modified by accessory subunits. The KCNQ1 channel is 
therefore able to fill many different roles physiologically (Panaghie & Abbott, 2007).    
The homomeric Kv7.1 channel and the IKs channel possess different electrophysiological properties 
due to the presence of the KCNE1 subunit in the IKs channel. The Kv7.1 channel activates rapidly at 
negative voltages and subsequently inactivates at positive voltages. The inactivation displayed by the 
Kv7.1 channel was studied by Pusch et al. (1998) by dropping the membrane voltage in oocytes to a 
negative value after a depolarising step, which revealed a transient increase in current that is 
indicative of a relief from inactivation. This inactivation is absent when the KCNE1 β-subunit is co-
expressed with the KCNQ1 α-subunit (Pusch et al., 1998; Tristani-Firouzi & Sanguinetti, 1998). In 
addition to preventing inactivation, co-assembly with the KCNE1 subunit causes a slowing of the IKs 
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channel’s activation kinetics, and depolarises the voltage-dependence of activation (Barhanin et al., 
1996; Sanguinetti et al., 1996). The single-channel conductance of IKs is also larger than that of the 
Kv7.1 channel (Sesti & Goldstein, 1998). Supporting the role of KCNE1 in modification of the KCNQ1 
channel’s electrophysiological properties, mutations in the S4 domain (Trp248Arg, Glu261Lys and 
Arg243Cys) were found to abrogate channel function and reduce KCNE1 binding, in the case of 
Glu261Lys, or slow activation and shift the voltage-dependence of activation and inactivation, in the 
case of Trp248Arg and Arg243Cys (Franqueza et al., 1999). These mutations are highly conserved 
throughout the KCNQ1 family, suggesting critical importance in this role.   
Unlike other Kv channels, the voltage dependence of Kv7.1 is drastically altered when the channel 
associates with other β-subunits. Co-assembly with KCNE2 or KCNE3 leads to the resulting channels 
taking on the characteristics of a leak channel, where the channel no longer responds to changes in 
membrane potential and is instead constitutively active (Schroeder et al., 2000; Tinel et al., 2000), 
and co-assembly with KCNE4 or KCNE5 leads to a drastic inhibition of the KCNQ1 current (Angelo et 
al., 2002; Grunnet et al., 2002). 
1.5.2 Regulation of KCNQ1 
Regulation by KCNE1 
 
The most studied KCNE subunit with regards to KCNQ1 regulation is KCNE1, as together they form 
the cardiac IKs channel. The KCNE1 subunit is a single TM domain of 129 amino acids in length, and 
was originally thought to comprise a K+-conducting channel itself because KCNE1 was cloned after 
recording a slow-activating voltage-dependent K+ current in Xenopus oocytes (Takumi et al., 1988). It 
was later found that this current was formed from the association of the KCNE1 subunit with KCNQ1 
channels, which are endogenously expressed in oocytes (Barhanin et al., 1996; Sanguinetti et al., 
1996). Although the effects of KCNE1 on the KCNQ1 current characteristics are known, the 
mechanism by which KCNE1 exerts these effects is still under speculation. 
Because KCNQ1 activation kinetics are drastically altered by KCNE1 it has been postulated that 
KCNE1 binds to the channel between the voltage-sensing domain (VSD) and the PD, as here it would 
be in a prime position to control voltage sensing and gating (Barro-Soria et al., 2014). 
To find out if KCNE1 alters KCNQ1 voltage-sensing, Nakajo & Kubo (2007) analysed the movement of 
S4 in the absence and presence of KCNE1, and found that KCNE1 stabilises the channel in the resting 
state and slows the transition of S4 to the activated conformation. It has been suggested that by 
interacting with the S4 domain, KCNE1 disrupts the positive charges in the C-terminal end of S4 that 
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stabilise the activated state of the channel, consequently destabilising the activated state (Wu et al., 
2010). Contradicting these observations, Rocheleau & Kobertz (2008) found that the S4 domain 
reaches equilibrium quickly upon membrane depolarisation in the presence of KCNE1, and 
concluded that the KCNE1 cytoplasmic domain slows the opening of the activation gate. 
Others have said that KCNE1 drastically slows the movement of the voltage sensor, as in the 
presence of KCNE1, KCNQ1 gating currents could not be resolved (Ruscic et al., 2013). In the same 
study, the gating and ionic currents of KCNQ1 channels coincided closely with each other, suggesting 
a tight coupling of voltage sensor movement and pore-opening. The gating and ionic currents were 
slowed to the same extent in the presence of KCNE1, and it was concluded that it is the KCNE1-
dependent slowing of voltage sensor movement that creates the rate-limiting step in the activation 
process (Ruscic et al., 2013). 
The slow activation of IKs is not the only modification KCNE1 affords KCNQ1 that is crucial to its role in 
ventricular repolarisation; KCNE1 grants the channel multiple closed states that are near the 
channel’s open state. This collection of closed states allows the channel to be in a state primed for 
rapid opening when required, particularly at higher heart rates in conditions of increased 
sympathetic tone (Silva & Rudy, 2005). 
Not only is KCNE1 crucial to the formation of the IKs channel, enabling the contribution of the IKs 
channel in cardiac repolarisation, it is also required in the inner ear to facilitate K+ recycling in the 
endolymph. The association of KCNE1 with KCNQ1 causes opening of the channel at membrane 
potentials positive of -40 mV, and abolishes channel inactivation. These properties of the channel 
allow its constitutive activity at the Vm of the apical membrane of inner ear cells, which is typically 
between 0 mV and +10 mV, creating a sustained K+ current (Hibino et al., 2009). Due to this crucial 
role in the inner ear, mutations in either KCNE1 or KCNQ1 can affect a mutation carrier’s hearing as 
well as their cardiac function, causing the condition JLNS.  
Regulation by other KCNE subunits 
 
Elsewhere in the body, KCNQ1 associates with other members of the KCNE family. Whilst KCNE1 
allows prolonged channel opening in depolarised cardiac cells due to the lack of channel inactivation, 
other KCNE subunits can confer constitutive activity at resting membrane potentials by modifying the 
state of the voltage-sensing domain. In contrast to other Kv channels, KCNQ1 contains a lower net 
positive charge in its S4 domain (+3 compared to +7 in Shaker and +5 in other KCNQ channels) 
(Panaghie & Abbot, 2007). Mutation of KCNQ1 to neutralise one positive residue in the N-terminal 
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portion of the S4 domain (Arg231Ala) rendered the channel voltage-independent. Mutation of the 
KCNQ4 S4 domain to resemble that of the KCNQ1(Arg231Ala) S4 domain allowed channel opening 
even at hyperpolarised potentials, suggesting that the propensity to switch from a voltage-activated 
channel to a ‘leak’ (i.e. constitutively active) K+ channel was determined by the S4 domain and not 
any properties of the KCNQ1 pore. This study also highlighted that the change in gating in response 
to voltage is not due to the gate gaining independence from the voltage sensor and becoming locked 
in the open state, but due to the voltage sensor becoming locked in the active configuration and 
communicating this to the channel gate (Panaghie & Abbot, 2007). 
Association of KCNQ1 with KCNE2 occurs in polarised epithelial cells in, for example, the thyroid and 
gastric epithelium. Here, the constitutive activity of the KCNQ1-KCNE2 complex is important for its 
function. The KCNE2 subunit stabilises the S4 VSD in the active position, rendering the channel 
insensitive to changes in membrane potential and consequently facilitating a K+ current at 
hyperpolarised potentials (Tinel et al., 2000). KCNQ1-KCNE2 channels have reduced current 
amplitude compared to the homomeric KCNQ1 channel, which is thought to be a result of the 
interactions between KCNQ1 and the KCNE2 N-terminus (Li et al, 2014). 
An additional way in which the KCNE2 subunit regulates the KCNQ1 channel is by altering the 
channel’s sensitivity and reaction to extracellular pH. Homomeric KCNQ1 channels are inhibited by 
extracellular protons, and the IKs channel is also inhibited, but is less sensitive. When KCNE2 is 
complexed with KCNQ1, the channel has the complete opposite response; KCNQ1-KCNE2 currents 
are augmented by increased extracellular protons, hence the channel’s importance in the gastric 
epithelium (Heitzmann et al., 2007). 
When KCNQ1 is in complex with KCNE3, it behaves as a constitutively active channel like the KCNQ1-
KCNE2 complex, but the KCNQ1-KCNE3 channel is not sensitive to extracellular pH. KCNE3 is also 
thought to exert its effect on the KCNQ1 channel through stabilisation of the S4 domain in the active 
configuration, even at resting membrane potentials (Nakajo & Kubo, 2007). 
These complexes are found in intestinal and airway epithelium. In the intestines, the KCNQ1-KCNE3 
channel is found in the basolateral membrane of colonic crypt cells (Schroeder et al., 2000), and 
tracheal epithelial cells (Preston et al., 2010). Their function in these cells is thought to involve the 
recycling of K+ to stimulate the secretion of Cl- ions by increasing the electrochemical driving force for 
Cl- across the apical membrane (Preston et al., 2010). 
Expression of KCNE4 with KCNQ1 was found to cause almost complete inhibition of the KCNQ1 
current at all membrane potentials tested. KCNE4 mRNA is found predominantly in embryo and 
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uterus, where KCNQ1 is also found (Grunnet et al., 2002). KCNE4 contains a tetraleucine motif in the 
juxtamembranous region of the C-terminus that confers CaM binding in a Ca2+-dependent manner. 
Mutation of this binding region or Ca2+ chelation reduced the ability of KCNE4 to inhibit KCNQ1 
Ciampa et al., 2011). Further supporting a role in the regulation of KCNQ1, the KCNE4 subunit was 
not found to regulate the KCNQ2–5 or hERG channels (Grunnet et al., 2002).  
KCNE5 also imposes an inhibitory effect on the KCNQ1 subunit; when KCNE5 associates with KCNQ1, 
the time- and voltage-dependent mechanisms are altered drastically, and there is approximately a 
140 mV depolarising shift in the voltage-dependence of activation curve. In addition, the KCNQ1-
KCNE5 complex activates slowly and deactivates rapidly, meaning the channel is largely inactive at 
physiological potentials. KCNE5 is expressed in cardiac myocytes, and it has been hypothesised that 
this accessory subunit, along with KCNE1, may regulate the contribution of the IKs current to cardiac 
repolarisation (Angelo et al., 2002).  
Regulation by phosphoinositides 
 
It is well documented that the IKs channel requires the presence of PIP2 to function, and it is thought 
that it stabilises the open state of the channel (Loussouarn et al., 2003). Other KCNQ channels also 
require PIP2 for voltage-dependent activation (Suh & Hille, 2002; Zhang et al., 2003). The M channel, 
consisting of the KCNQ2 and KCNQ3 subunits, requires PIP2 to open, and as a result of the 
dependency on PIP2 for function it was concluded that PIP2 depletion is the mechanism used by the 
muscarinic acetylcholine (M1) receptor to induce M channel closure and resulting inhibition of the M 
current (Li, et al., 2005;  Zhang et al., 2003). This is supported by Suh et al. (2006), who observed M 
current inhibition when using an inducible phosphatase to directly deplete PIP2 from the PM. 
The region of basic residues thought to be responsible for PIP2 binding is conserved throughout the 
KCNQ family, but not in other channels where PIP2 is not required for function. Despite PIP2 binding 
being crucial for channel opening, the rate-limiting step of the whole activation process is voltage-
sensor movement, which does not require PIP2 (Zaydman et al., 2013). 
A PIP2 binding region in the proximal C-terminus of the channel was identified by Thomas et al., 
(2011), the most important residues in this region being Lys358 and Arg360. Even though PIP2 bound 
to the channel with the highest affinity, other phosphoinositide (PI) species could also bind. It is 
possible that other membrane phospholipids can assume the role of PIP2 if it is in low abundance, or 




The two CaM-binding domains in the C-terminus of the KCNQ1 channel partially overlap with a PI 
binding region. In a competition assay, PIP2 and phosphatidylinositol-3,4,5-trisphosphate (PIP3) were 
both able to displace CaM binding from one of the CaM-binding domains, and PIP3 was able to 
reduce CaM binding from the other. PIP3 was the most potent at disrupting CaM binding to these 
two regions, and may play a role in regulating the binding of CaM to the channel (Kwon et al., 2008). 
Phosphatidylinositol-3,5-bisphosphate (PI(3,5)P2) is required for the RAB11-dependent cell-surface 
delivery of the channel after SNS activation (Seebohm et al., 2007).  Release of cortisol during SNS 
activation causes activation of serum- and glucocorticoid-inducible kinase 1 (SGK1), a 
serine/threonine kinase that promotes surface delivery of a number of ion channels (Debonneville et 
al., 2001). SGK1 has a dual effect with regards to KCNQ1 surface delivery: SGK1 inactivates Nedd4-2, 
a ubiquitin ligase that ubiquitinates the channel and prepares it for degradation, and activates 
PIKfyve, a phosphatidylinositol-3-phosphate (PI3P) 5-kinase that converts PI3P to PI(3,5)P2. 
1.6 Phosphoinositides 
1.6.1 Phosphoinositides and their synthesis 
 
PIs are a small family of acidic phospholipids that contains 8 members, each differing in the 
phosphorylation of their myo-inositol ring. These phospholipids are present on the cytosolic side of 
cellular membranes and are involved in almost all biological processes (Di Paolo & De Camilli, 2006). 
The simplest PI in structure, phosphatidylinositol (PtdIns), contains a phosphodiester linkage with 
diacylglycerol, and forms the backbone of all PIs (Balla, 2013). From this core PI structure, each of 
the 7 other members of the PI family can be produced (figure 10).  The nomenclature of the myo-
inositol ring was introduced by Bernard William Agranoff in 1978, who described the structure as 
similar to the shape of a turtle, where the body represents the ring, and the legs, tail and head 
represent the 6 OH groups (figure 9). Since the OH at position 1 is occupied by the phosphodiester 
linkage, 5 OH groups remain free for phosphorylation purposes, although physiologically only 
positions 3, 4 and 5 are phosphorylated (figure 9).   
The journey of PI species begins at the ER, where PtdIns is synthesised.  From cytidine-diphosphate 
diacylglycerol (DAG) and myo-inositol, PtdIns is synthesised by a PtdIns synthase enzyme, after which 
PtdIns is transported to other cellular compartments via PtdIns-transfer proteins (PITPs) or by 
vesicles. Transport of PtdIns to other cellular locations is required for the synthesis of 
polyphosphoinositides (PPIs) because PI kinases, which catalyse the transformation of PtdIns into 
each of the 7 PIs by phosphorylation, are localised to the specific cellular compartments relevant to 
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the PI that they produce. Each of the phosphorylated PI species, or PPIs, concentrates at a particular 
cellular membrane. For example, PIP2 is predominantly localised to the PM, phosphatidylinositol-4-
phosphate (PI4P) to the Golgi and PI3P to the early endosomes. 
Once PPIs are produced in their respective locations within a cell, their functions are not static – 
phosphorylation and dephosphorylation by PPI kinases and PPI phosphatases, respectively, allows 
PPIs to transfer between different phosphorylated states, enabling their involvement in many cellular 
processes. This can occur during specific signalling events, for example. One demonstration of this is 
the phosphorylation of PIP2 to PIP3 during growth factor signalling – despite PIP2 being an important 
signalling molecule in its own right, it is also the substrate for PIP3 synthesis.   
 
 
Figure 9. Nomenclature of the phosphoinositide myo-inositol head group. A – the myo-inositol head group in 
the Haworth projection, and B – in a more accurate representation of the ‘chair’ structure, both showing the 
nomenclature of the phosphorylation sites in the ring. C – A schematic interpretation of Agranoff’s turtle. 
Agranoff noted that the structure of the ring (ignoring the hydrogen atoms) superficially resembles a turtle. 
The numbering begins on the turtle’s right flipper and proceeds anticlockwise.   
 
1.6.2 PI- and PIP-kinases 
 
Kinase enzymes that add phosphate groups onto PtdIns are termed PI-kinases, and those that 
phosphorylate PPIs are known as PIP-kinases. This terminology is used to describe the primary 
function of the kinase or the position of the inositol ring that the enzyme phosphorylates, but some 
may also be able to phosphorylate both PtdIns and PPIs. 
4-kinases 
 
There are 4 mammalian PtdIns 4-kinases (PI4Ks): PI4KIIα, PI4KIIβ, PI4KIIIα and PI4KIIIβ. The PI4KIII 
enzymes are in part characterised by their sensitivity to wortmannin (Nakanishi et al., 1995), whilst 
the PI4KII enzymes are insensitive. The localisation and function of these enzymes has been better 
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characterised using yeast PI4Ks, but this does not always align with what is currently known about 
eukaryotic PI4K enzymes, and not all eukaryotic enzymes have corresponding yeast homologues. 
PI4KIIα and PI4KIIβ are both membrane-bound proteins, and were found to be expressed at the 
trans-Golgi network (TGN) and endosomes (Balla et al., 2002; Wang et al., 2003), where they are 
involved in the regulation of intracellular trafficking events (Jovic et al, 2012). Wei and colleagues 
found that PI4KII enzymes may have slightly overlapping functions, but PI4KIIβ is activated by 
recruitment from the cytosol to the PM where it then stimulates PIP2 synthesis (Wei et al, 2002). 
PI4KIIIα plays a major role in the synthesis of PIP2 at the PM as it is the primary kinase that produces 
the precursor pool of PI4P (Balla et al., 2005; Bojjireddy et al., 2014), despite originally thought to 
only reside in the Golgi membranes (Nakagawa et al., 1996).  
PI4KIIIβ, the yeast homologue of which was the first PI-kinase to be cloned (Flanagan & Thorner, 
1992), mainly resides at the Golgi in an ADP-ribosylation factor (ARF)1-dependent manner (Godi et 
al., 1999). This enzyme has also been found at the PM and nucleus, although the functional 
significance of this is unknown (De Graaf et al., 2002). 
3-Kinases 
 
In vivo, the class III PtdIns 3-kinase (PI3KCIII) is the dominant subtype that produces PtdIns 3-P (PI3P) 
from PtdIns. The yeast homologue of this enzyme, Vps34p, is the sole source of PI3P in yeast (Backer, 
2008). Among the 3-kinases, PI3KCIII is unique in that its only substrate is PtdIns, and it cannot 
phosphorylate PPIs. Like the yeast Vps34p, the mammalian PI3KCIII produces PI3P at endocytic 
membranes, which may bind a number of PI3P-binding domains such as the FYVE domain. 
Recruitment of such domains and the pathways downstream of this leads to processes including 
endocytic sorting and autophagy (Wirth et al., 2013). Despite the existence of other 3-kinase 
enzymes that also produce PI3P, it is thought that the activity of PI3KCIII produces the main source of 
PI3P that is involved in endocytic regulation (Ikonomov et al., 2015). 
Class II PI3Ks (PI3KCII) can also produce PI3P, but are involved to a lesser extent than PI3KCIII. PI3KCII 
also phosphorylates PI3P to PI(3,5)P2 (Falasca &Maffucci, 2012). There are 3 types of PI3KCII 
enzymes: PI3KCIIα, PI3KCIIβ and PI3KCIIγ. PI3KCIIα is reported to be involved in endocytosis (Posor et 
al., 2013), cell growth and survival. This role is shared with PI3KCIIβ, which also regulates cell cycle 
progression and cell migration, whilst PI3KCIIγ is involved in the homing of leukemic cells (Falasca & 
Maffucci, 2012). PI3KCII and PI3KCIII enzymes both produce PI3P, but this has been shown to occur in 
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different cellular compartments, suggesting that redundancy is not present in this system (Falasca & 
Maffucci, 2012).  
The class I PI3Ks (PI3KCI) consist of two subunits – a catalytic subunit that occurs in 4 isoforms: 
p110α, p110β, p110γ and p110δ, and a regulatory subunit. P110α, β and δ mainly associate with the 
regulatory subunit p85, whilst p110γ associates with the regulatory subunit p101 (Zhao & Vogt, 
2008). PI3KCIs are the only PI3K that can convert PIP2 to PIP3, and due to the important role of this PI 
in cell growth and survival, dysregulated PI3KCI is often involved in oncogenesis.  
These various PI and PIP 3-kinases can be characterised based on their sensitivity to wortmannin 
(WTM) and LY294002. In contrast to the WTM-sensitive PI4Ks, which are inhibited by micromolar 
concentration of WTM, PI3Ks are inhibited at nanomolar concentrations. However, Domin et al. 
(1997) found that the PI3KCIIα isoform is less sensitive to WTM inhibition than other isoforms, with a 
half-maximal inhibitory concentration (IC50) value of 420 nM compared to, for example, the IC50 of 
5 nM for p110α and 1.6 nM for PI3KCIIβ (Arcaro et al., 1998).  
5-kinases 
 
The 5-kinase known as the type I PIP-kinase (type I PIPK, or PIPKI) phosphorylates PI4P at the D-5 
position on the inositol ring to produce PIP2 (Rameh et al., 1997). This represents the second and 
more-common pathway of PIP2 synthesis after phosphorylation of PtdIns-5-P (PI5P) at the D-4 
position by type II PIP kinases. There is debate as to the location of PIP2 synthesis in the cell, but 
evidence exists to support synthesis at the Golgi. Jones et al. (2000) showed that PIPKIs directly 
interacts with ARF1, which is localised to the Golgi, and the subsequent activation of the kinase leads 
to production of PIP2 at the Golgi. Supporting this is a study that used the PH domain from 
phospholipase C (PLC) δ (PLCδ-PH), which binds to PIP2 and hence localises to the PM in a resting 
cell. Upon depletion of PIP2 from the PM, PLCδ-PH translocated to the cytoplasm and was then 
observed at the Golgi where de novo PIP2 synthesis is thought to occur. PLCδ-PH then translocated to 
the PM over time as the PIP2 concentration at this membrane returned to basal levels (Várnai & 
Balla, 1998).  
In addition to PIP2 synthesis at the Golgi, PIP2 synthesis at the PM is suggested due to the presence of 
PI4P. Although PI4P may have a regulatory role in its own right, it can be synthesised at the PM and 
Golgi by different PI 4-K enzymes, and thus there is the assumption that it resides in the PM as the 
precursor for PIP2 synthesis at this site (Hammond et al., 2009; Sarkes & Rameh, 2010). 
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There are 3 PIPKI isoforms: PIPKIα, PIPKIβ and PIPKIγ (Ishihara et al., 1996; Ishihara et al., 1998). 
There is evidence to suggest that the PIPKI isoforms are responsible for the production of distinct 
pools of PIP2 in the cell that may be functionally specialised (Sasaki et al., 2006). There are numerous 
splice variants of each PIPKI isoform (3 α, 4 β and 6 γ), which are localised to different parts of a cell 
to enable the production of PIP2 at various sites in response to different stimuli, including the 
nucleus, PM and Golgi (Choi et al., 2015).   
Another crucial 5-kinase is PIKfyve, which phosphorylates PtdIns to PI5P, and PI3P to PI(3,5)P2. This 
enzyme is conserved across most eukaryotes, and the yeast homologue is named Fab1 (McCartney 
et al., 2014). The activity of this kinase has been shown to be required for successful trafficking of a 
number of receptors (Hayashi et al., 2015; McCartney et al., 2014), and has been found localised to 
the early endosomes where it regulates retrograde trafficking from the endosomes to the TGN by 
producing PI(3,5)P2 (Rutherford et al., 2006). 
1.6.3 Phosphoinositide-binding domains 
 
One of the most important properties of PIs is their ability to bind a vast range of proteins, which can 
be critical to their regulation. Proteins regulated by PIs contain PI binding domains, which usually 
facilitate binding to the PI in question in a 1:1 stoichiometry. The discovery of the pleckstrin 
homology (PH) domain, which binds to PIP2 (and inositol trisphosphate (IP3)) (Garcia et al., 1995), 
provided a breakthrough in the knowledge of how PIs regulate a wide range of cellular processes. 
Since then, many other binding domains have been discovered, each with differing preference for 
the phosphorylation state of the inositol head group (table 3). 
Hammond and Balla (2015) detail a number of principles underlying the regulation of proteins by PI 
binding:  
 High-affinity binding recruits proteins to a particular cellular membrane. However, not all 
binding domains hold such high affinity, and the binding to a particular PI may not be strong enough 
to dictate protein localisation (Yu et al., 2004).  
 PI binding occurs alongside a second interaction, which together control membrane 
localisation. This phenomenon is termed 'coincidence detection', and is demonstrated by the 
localisation of the four phosphate adapter protein (FAPP) 1 domain to the TGN through binding to 
PI4P and ARF1 (Godi et al., 2004; Liu et al., 2014).  
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 PI binding contributes to the membrane localisation of a protein, but this time in a less 
specific manner. Many proteins harbour polybasic domains that can interact with anionic lipids, 
namely PIP2 and PI4P in the PM (Hammond et al., 2012), where any of the lipids can fulfil the 
requirement for membrane-targeting.  
 PIs are not only involved in protein targeting, and binding of PIs can alternatively result in 
activation of the protein in question. This is demonstrated in the case of the PIP3-dependent 
activation of the ARF GTPase activating protein (GAP), ARAP1 (Campa et al., 2009).  
 The hydrophilic head and hydrophobic acyl tail groups of the PI species may bind to lipid-
transfer proteins in order to facilitate movement of these lipids between cellular membranes 
(Mesmin et al., 2013).  
All of these principles allow the regulation of PI-binding proteins in time and space. 
The known PI-binding proteins differ in their specificity for particular PIs, and, as a consequence, vary 
in their value in experiments that have a need to exploit the compartmentalised nature of PI 
localisation. For example, PLCδ1-PH was first thought to bind with high specificity to PIP2, but it was 
later found that this domain also binds with high-affinity to IP3, one of 2 products of PIP2 hydrolysis. 
This hinders the quantification of PIP2 loss from the PM due to hydrolysis because as PIP2 levels 
decrease, IP3 levels increase, altering the ratio of PLCδ1-PH bound to each. Other PI-binding domains 
have high specificity, such as SidM, a protein found in Legionella pneumophila. SidM binds with high 
affinity to PI4P, and has been used as an effective biosensor due to its ability to detect lower levels of 
this lipid than other known PI4P-binding proteins (Schoebel et al., 2010). Table 3 contains a number 
of currently known PI-binding proteins that are used experimentally for PI detection and protein 
targeting. Not all are fully characterised, and for some it is unknown if binding to its PI binding 










Is PI binding 
specific? 
Is PI sufficient for 
localisation? 
PI3P FYVE-Hrsx2 Early endosomes Yes Unknown 
PX-p40phox Early endosomes Yes Unknown 
PI4P PH-OSBP Golgi/PM Also binds PIP2 ARF1-dependent 




PI5P PHD-Ing2x3 Nucleus/PM Also binds PI3P Yes at PM, unknown 
in nucleus 
PI(3,4)P2 TAPP1-PH-CT PM Yes Yes 
PI(3,5)P2 ML1-Nx2 Late endosomes Yes Unknown 
PI(4,5)P2 
(PIP2) 
PH-PLCδ1 PM Also binds IP3 Yes 






PH-Akt PM Also binds IP4 and 
PI(3,4)P2 
Unknown 
PH-Btk PM Also binds IP4 Unknown 
 
Table 3. The specificity and localisation of PI-binding domains. PI-Binding domains used experimentally for 






1.6.4 Phosphoinositides and the secretory pathway 
 
From the synthesis of a protein to the delivery of that protein to its final destination within a cell, the 
protein encounters a number of different membrane-bound organelles, each with a unique PI 
signature. Proteins involved in trafficking include soluble N-ethylmaleimide-sensitive factor 
attachment protein receptor (SNARE) proteins, which mediate fusion of membrane bilayers, coat 
proteins of transport vesicles and motor proteins that move cargo along the cytoskeleton. It is the 
disparity in PI make-up of secretory pathway membranes that allows the specific recruitment of 
these trafficking effector proteins via their PI-binding domains to their respective sites of action 
(Behnia & Munro, 2005). 
Endoplasmic reticulum 
 
Despite being the most abundant PI, the location and mechanism of mobility of PtdIns is not fully 
understood. PtdIns is synthesised in the ER, and evidence now suggests that PtdIns is transported to 
various membranes in highly mobile membrane compartments derived from the ER, although the 
precise mechanisms are yet to be determined (Kim et al., 2011). 
Despite being synthesised in the ER, PtdIns has no role in recruiting proteins to the ER to drive 
membrane trafficking. Surprisingly, PI3P, which has always been thought to be concentrated at the 
early endosomes, was found in relatively large concentrations in the ER/Golgi using subcellular 
fractionation techniques (Sarkes et al., 2010). Supporting the presence of PI3P in the ER, Amoasii and 
colleagues identified a PI-phosphatase involved in regulating PI3P in the SR of skeletal muscle 
(Amoasii et al., 2013). This pool of PI3P may be involved in membrane trafficking, as it was found 
that UV radiation resistance-associated gene protein (UVRAG), a PI-binding protein, depends on PI3P 
for ER-localisation. UVRAG is recruited to the ER where it is involved in a complex that docks COPI 
vesicles (from Golgi–ER retrograde trafficking) (He et al., 2013).   
Golgi Apparatus 
 
PI4P is the classical PI associated with the Golgi, where it recruits many proteins involved in the 
formation of vesicles, and the PH-domains of proteins that are involved in delivering lipids and 
proteins to the Golgi (Wang et al., 2003). 
In yeast, the PI4K enzymes Pik1 and STT4 are crucial to yeast viability, and deletion of either enzyme 
is lethal. Pik1 and STT4 both phosphorylate PI to PI4P, and mutation of these enzymes results in a 
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lower abundance of PI4P at the Golgi and consequent disturbance of Golgi functions including 
trafficking, actin cytoskeleton organization and secretion (Audhya et al., 2000). 
Despite PI4P playing important roles in Golgi function, 3-phosphorylated PIs also appear to serve 
functions at the TGN. Jones & Howell (1997) observed that p62cplx, the regulatory subunit of a PI3K, 
was required for the transport of polymeric IgA-receptor-containing vesicles from the TGN (Jones & 
Howell, 1997). Supporting the involvement of 3-phosphorylated PIs in protein trafficking from the 
Golgi, a class II PI3K, PI3KC2α, was found by Domin & colleagues to be localised to the TGN in several 
mammalian cell types (Domin et al., 2000). One role of 3-phosphorylated PIs at the Golgi could be to 
modulate the activity of ARFs, for example the ARF GAP known as ARAP1 is activated by binding PIP3 
(Campa et al., 2009). 
Plasma Membrane 
 
The most abundant PI at the PM is PIP2, amounting to approximately 1–2 % of total PM lipids. In 
addition to the many roles PIP2 plays in ion channel regulation, cell motility and polarity, PIP2 also 
plays a part in endocytosis and fusion/exocytosis events.  
Exocytosis is the process by which an intracellular vesicle fuses with the PM of a cell, and in the 
process incorporates its membrane with that of the PM, releasing any vesicular contents from the 
cell. Constitutive exocytosis of vesicles trafficking directly from the Golgi, or via endosomal 
intermediates, occurs in a Ca2+-independent manner, while the regulated exocytosis of ‘dense-core’ 
vesicles in neuronal/exocrine/endocrine cells occurs upon elevation of intracellular Ca2+ levels 
(Martin, 2009). The latter requires PIP2 for vesicle priming, which is a prerequisite to regulated 
exocytosis and was discovered through the ATP requirement and PITP involvement during this 
process (Eberhard et al., 1990; Hay & Martin, 1993).  
There is evidence to suggest that PIP2 may form clusters in the PM, enabling functional ‘hotspots’ to 
arise. These hotspots have been shown to concentrate at sites of Ca2+-dependent exocytosis, or 
release sites (Koch & Holt., 2012). Although the mechanism these PIP2-rich domains use to maintain 
the PIP2 concentration gradient is largely unknown, it has been suggested that the binding of 
proteins via their PI-binding domains could sequester PIP2 and concentrate the lipid at the sites of 
function. For example, at the site of endocytosis, the large GTPase dynamin binds PIP2 through its PH 
domain, and it was found that this led to a clustering of PIP2 at clathrin-coated pits (CCPs). Also, the 
adaptor protein (AP)-2 complex binds to multiple PI5Ks, which phosphorylate PI4P at the 5-position 
to form PIP2 (Posor et al., 2015).    
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It is evident that PIP2 is involved in both exocytosis and endocytosis, and Koch & Holt (2012) argue 
that in the case of regulated exocytosis, PIP2 acts as the central ‘hub’ to recruit and coordinate 
proteins involved in both processes, possibly using synaptotagmin as an effector protein.  
Endocytosis is a mechanism used by the cell to internalise membrane proteins and engulf 
extracellular particles. The resulting intracellular vesicle is initially composed of the same 
constituents of the PM (where it originates from), but its identity changes as it travels through the 
endocytic pathway.  
Clathrin-mediated endocytosis (CME) is the most-studied method of endocytosis in eukaryotic cells, 
and the local PIP2 concentration is crucial to its different stages, from initiation to maturation and 
budding. Clathrin, which was first identified and isolated by Barbara Pearse (1975), forms a three-
legged triskelion structure composed of 3 clathrin light chains and 3 clathrin heavy chains (the 
original component identified by Pearse). Clathrin triskelia form a lattice of pentagons and hexagons 
around the outer surface of the forming vesicle, which is thought to give the vesicle its spherical 
structure. PIP2 is known to be involved in clathrin-coated vesicle (CCV) formation (Jost et al., 1998), 
and deletion of a PI 5-phosphatase, synaptojanin 1 (which dephosphorylates PIP2), was found to 
increase CCV formation at synaptic terminals (Cremona et al, 1999). In addition, acute depletion of 
PIP2 resulted in a loss of CCPs and a dissociation of CME-associated adapter proteins (Zoncu et al., 
2007). Supporting this, Sun and colleagues suggested that a dynamic modulation of PIP2 is required 
for the complete CME process. They observed that the presence of PIP2 is required for CCV 
formation, but for the process to culminate in CCV budding, turnover (and hence loss) of PIP2 is 





Figure 10. The synthesis of phosphoinositides from PtdIns.  PtdIns is the phosphoinositide (PI) that each of 
the 7 phosphorylated PIs originate from. PtdIns can be phosphorylated on the 3, 4 or 5 position, and the 
products of this phosphorylation can further be phosphorylated to form PIs phosphorylated on the 3 and 5, 3 
and 4 or 4 and 5 position. PtdIns-3,4-P and PtdIns-4,5-P can also be phosphorylated again on the 5 or 3 
position, respectively, to form the only PI that is phosphorylated at 3 positions. PI kinases perform the 
phosphorylation step, whilst PI phosphatases remove the phosphate groups from the PIs.  
1.7 Phosphotidylinositol-4,5-bisphosphate 
 
PIP2 is a minor constituent of the PM PI pool in mammalian cells, contributing just 1–2% of the total 
acidic lipids (Suh & Hille, 2008). PIP2 can be synthesised by the sequential phosphorylation of PtdIns 
at the D-4 and -5 positions, which can be via PI4P or PI5P. However, as discussed in section 1.6.2, the 
71 
 
major pool of PIP2 is produced by the action of type I PIP-kinases on PI4P. PIP2 can also be produced 
by dephosphorylation of PIP3 by the phosphatase named phosphatase and tensin homologue (PTEN) 
(Lemmon, 2008). 
1.7.1 Phosphatidylinositol-3,4,5-trisphoshate synthesis 
 
PIP2 can be further phosphorylated at the D-3 position to produce PIP3, which occurs as a result of 
PIP 3-kinase activation resulting from either GPCR or receptor tyrosine kinase (RTK) activation. One 
of the key targets of PIP3 synthesis is the serine/threonine kinase Akt, also known as protein kinase 
B. 
Akt and its upstream activator, phosphoinositide-dependent kinase (PDK) 1 are recruited to PIP3 at 
the PM via their PH domains. Once in close proximity PDK1 activates Akt at Thr308, which partially 
activates Akt. Full activation of Akt is achieved by further phosphorylation by mTORC2 at Ser473. The 
activation of this pathway is regulated by PTEN, which dephosphorylates PIP3, and by protein 
phosphatase 2a, which dephosphorylates Akt. 
Akt has many downstream effectors that are involved in cell growth, proliferation and survival. 
Dysregulation of this pathway, for example by mutation of PTEN, upregulation of PI 3-kinase activity 
or gain-of-function mutations in Akt, has been implicated in diseases including cancer, cardiovascular 
disease and some neurological diseases. 
1.7.2 Hydrolysis by G protein-coupled receptors 
 
PIP2 levels are not only controlled by the action of PIP-kinases and PIP-phosphatases. Activation of 
Gq-GPCRs and RTKs that lead to the activation of different PLC isoforms also cause loss of PIP2 from 
the PM by hydrolysis. Hydrolysis of PIP2 by PLC results in the production of IP3 and DAG, as this 
enzyme hydrolyses PIP2 at the phosphodiester bond, releasing the myo-inositol head with 3 
phosphates attached (at the D-1, 4 and 5 positions) and the 1,2-diacylglycerol tail (figure 12). IP3 is 
released into the cytoplasm, while DAG remains in the membrane. The cellular effects of PIP2 
hydrolysis diverge down the two different pathways: the IP3 pathway and the DAG pathway. 
In the IP3 pathway, IP3 binds to its name-sake receptor (which is a ligand-gated Ca
2+ channel) at the 
ER, resulting in the release of Ca2+ from the intracellular stores. Ca2+ is tightly controlled within the 
cytoplasm due to the activity of Ca2+ pumps that actively transport Ca2+ out of the cell or into the ER. 
When Ca2+ is released from the intracellular stores, the Ca2+ concentration in the cell increases 
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dramatically, causing activation of Ca2+-dependent proteins and pathways. One such protein is CaM, 
a calcium-binding protein that is a major transducer of calcium-dependent signalling in eukaryotic 
cells. 
The DAG pathway involves the direct activation of protein kinase C family members, which are 
involved in growth and differentiation, by DAG. Some of these enzymes also require Ca2+ for 
activation, and thus depend on both pathways resulting from PIP2 hydrolysis. DAG is also an 
intermediate in the synthesis of phosphatidic acid and 2-arachidonylglycerol, both of which act as 
second messengers. 
In addition to the release of IP3 and DAG, the loss of PIP2 that occurs during this hydrolysis event also 
gives PIP2 a significant role in cellular signalling. In T lymphocytes, for example, PLC activation 
through GPCR signalling is involved in cell migration, and  it was found that PIP2 depletion by PLC 
activation or activity of a PM-recruitable phosphatase caused the dissociation of 
ezrin/radixin/moesin (ERM) proteins from the PM due to dephosphorylation (Hao et al., 2009). ERM 
proteins link the cytoskeleton to the PM, so depletion or reduction of PM PIP2 could be involved in 
controlling cytoskeletal arrangement and reorganisation. 
Although this is a major role that PIP2 plays in the PM, the loss of PIP2 from the PM as a result of 
hydrolysis may also be a regulatory mechanism that the cell uses to control membrane-restricted 
proteins such as ion channels.   
1.7.3 Regulation of ion channels and transporters 
 
Evidence that PIP2 could directly regulate the function of ion channels and transporters first came 
from Hilgemann and Ball (1996). In their study of the Na+/Ca2+ exchanger, they observed that ATP 
hydrolysis was required for activation and that this generated PIP2 from PI, which could be mimicked 
by addition of exogenous PIP2. They also found that the ATP-sensitive K
+ channel (KATP) was regulated 
by PIP2 and, conversely, that the Na
+ channel and the Na+ and K+ pumps were insensitive. Hilgemann 
and Ball asserted that PIP2 may be an important regulator of ion channels and transporters. 
Since this discovery, PIP2 has been found to be involved in the regulation of many different channels 
and transporters (Hilgemann et al., 2001; Logothetis et al., 2007; Suh & Hille, 2007). Although a full 
characterisation of PIP2 regulation is not available for most channels, a large body of evidence has 
been collected for many that is highly supportive of a PIP2-dependent mechanism of regulation. 
Within this group of PIP2-regulated channels (and transporters), there exists scales of PIP2 selectivity 
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and PIP2 sensitivity. PIP2 selectivity describes a scale where at the most selective end a channel will 
only bind PIP2, and at the opposite end of the scale a channel will bind a broad range of PIs. PIP2 
sensitivity relates to a channel's affinity for PIP2, where a low-affinity channel will be more sensitive 
to changing PIP2 levels than a channel with a high PIP2 affinity. 
Two theories as to why some channels are regulated by PIP2 have been put forward. The first 
suggests that due to the unique PI signature of different membranes, the maturation and activation 
of channels can be regulated throughout the secretory pathway. When a channel finally reaches the 
PM, the high relative concentration of PIP2 allows the regulation of activation (Hilgemann et al., 
2001). On the other hand, a second theory suggests that the depletion or reduction of PIP2 from the 
PM that can occur in some signalling events is the mechanism of regulation. PIP2 depletion by 
hydrolysis occurs as a result of Gq-GPCRs/RTK activation, and could be a mechanism of rapid 
regulation for particularly PIP2-sensitive channels. 
Regulation of Kir channels by PIP2 
 
One of the most-studied groups of channels with regards to PIP2 regulation is the Kir channels. After 
the observation that the KATP channel was sensitive to PIP2 levels it was suggested that PIP2 may bind 
to positive charges in the cytoplasmic domains of the Kir6.2 subunit and stabilise the open state of 
the channel as a result, as well as antagonising the inhibitory effect of ATP (Fan & Makielski, 1997; 
Shyng & Nichols, 1998).   
More recently, it has been shown that as well as regulating the activity of KATP channels through 
interaction with Kir6.2, PIP2 sequesters Syntaxin-1A (part of the SNARE complex involved in 
membrane fusion and secretion) and limits its availability for binding to sulphonylurea receptor 
(SUR) subunits (the auxiliary subunit of the KATP channel). In this way, PIP2 can regulate KATP channels 
in islet β-cells in a dual and highly-controlled manner (Liang et al., 2014). 
Kir channels exhibit differing affinities for PIP2 as well as other PIs. For example, the GIRK1/4 channel, 
which has a weak interaction with PIP2, is also activated with similar efficacy by PI(3,4)P2, PI(3,5)P2 
and PIP3 (Rohacs et al., 1999). Similarly, KATP channels have a low selectivity for PIP2, also binding 
PI(3,4)P2 and PIP3 (Krauter et al., 2001). Supporting this broad binding ability of the KATP channel, the 
negatively charged long-chain (LC) acyl-coenzyme A (CoA) could also activate the channel. LC acyl-
CoA did not, however, result in activation of other Kir channels tested, but could activate mutant 
Kir2.1 channels that exhibited a low PI specificity (Rohacs et al., 2003). 
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The positively charged residues Arg67, Lys118, Arg189, Arg218 and Arg312 in Kir2.1 are involved in 
PIP2 binding. It has been suggested that polyamines regulate the PIP2-dependent activation of Kir2.1 
channels by acting as cofactors, and Xie et al. (2005) concluded that long polyamines such as 
spermine play a dual role in channel regulation by influencing the effects of PIP2 and inducing inward 
rectification. Others have found that mutants with a lower PIP2-binding affinity decreased single-
channel open probability and led to the emergence of sublevels of activation (Lopes et al., 2002). Xie 
et al. (2008) show that the interaction of PIP2 with a single Kir2.1 subunit is sufficient to shift the 
channel into an ‘available’ mode for opening with a high open probability, and that further binding of 
PIP2 to other subunits increases this further.  
Regulation of the IKs channel by PIP2 
 
The role that PIP2 plays in IKs channel function is known, but the mechanism underlying this role is 
yet to be fully elucidated. Thomas and colleagues (2011) identified a cluster of basic residues in the 
proximal C terminus that are involved in the binding of PIs, including PIP2. Using charge 
neutralisation scanning, 9 residues were also identified by another group, which may form 2 distinct 
binding pockets (Eckey et al., 2014). The residues identified here were in the C-terminal portion of S6 
(Lys354, Arg360, and Lys362), the S2-S3 intracellular linker (Arg181, Lys183, Arg190 and Arg192) and 
the intracellular S4-S5 linker (Arg249 and Arg259). PIP2 binding was only studied in the C terminus by 
Thomas and colleagues, but Zaydman et al. (2013) also found that Arg190 and Arg192 in the S2-S3 
linker and Arg259 in the S4-S5 linker were involved in PIP2 binding, and mutation of these residues 
mimicked the effect of PIP2 depletion. Mutations introduced to neutralise other positive residues in 
the distal C-terminus of the channel (Arg234His, Arg539Trp and Arg555Cys) were also found to 
reduce the IKs channel’s PIP2 binding affinity (Park et al., 2005). 
The crystal structure of the GIRK2 channel (Whorton & MacKinnon, 2011), and biochemical assays 
performed on the KATP channel (Shyng et al., 2000) and the Kir3 channel family (Thomas et al., 2006) 
have previously revealed PIP2 binding regions outside of the C terminus, and it is therefore possible 
that this is also the case for the IKs channel. Eckey et al. (2014) postulate that binding of PIP2 at the 
two separate binding regions that were identified leads to a stabilisation of the overall channel 
structure in both the open and closed conformation. This group also found that when PIP2 was 
absent from the PM there was higher structural flexibility of the pore domain and a distortion of the 
channel in both conformations, but they concluded that the closed conformation may be structurally 
more stable in the absence of PIP2.  
The crystal structure of KCNQ1 has not been solved, but a model of the open and closed state has 
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been constructed by Smith et al. (2007). Using the rat Kv1.2 structure that had recently been 
determined (Long et al., 2005), the open state of the IKs channel was modelled, and using the crystal 
structures of bacterial K+ channels and the closed state model of Kv1.2 (Yarov-Yarovoy et al., 2006), 
the closed state of the IKs channel was modelled.   
Using this model, Zaydman et al. (2013) were able to identify a region of 16 basic residues located at 
the VSD-PD interface, which is thought to be involved in PIP2 binding. Each of these 16 residues was 
neutralised and the effect on IKs current density was investigated using two-electrode clamp. There 
were 8 different mutations in this region that caused a reduction in current density whilst retaining 
channel cell-surface expression and voltage-sensor movement, indicating that PIP2 that binds at this 
site couples voltage-sensor movement to pore opening. This group also measured the time course of 
current rundown after patch excision, where PIs are gradually lost from the PM. Supporting the role 
of the 8 basic residues in PIP2 binding was the observation that these mutant channels experienced 
an increased rate of rundown after patch excision compared to WT and gain-of-function mutants, 
suggesting a reduced affinity for PIP2.  
The dependence on PIP2 for IKs channel function has been demonstrated using a number of methods. 
For example, voltage-sensitive phosphatases that deplete PIP2 from the PM (Hossain et al., 2008), 
chemically inducible dimerisation systems involving PIP2-specific phosphatases that can be recruited 
to the PM (Kruse et al., 2012), and activation of receptors that leads to depletion of PIP2 through 
activation of PLC (Matavel & Lopes, 2009).  
Due to the sensitivity to PIP2 depletion that the IKs channel exhibits, it has become of great interest to 
establish whether this mechanism of regulation is used physiologically. A cell can manipulate the 
concentration of phosphoinositides in a given membrane through the activation of PI phosphatases, 
or at the PM by activation of Gq-coupled GPCRs. Activation of members of this family of GPCRs and 
the downstream hydrolysis and concomitant depletion of PIP2 can occur in the cardiac myocyte. The 
rapid manipulation of PIs in the PM could be a mechanism to silence the channel during periods of 
Gq-coupled GPCR agonist signalling.  
1.8 G protein-coupled receptors 
1.8.1 GPCR overview 
 
G protein-coupled receptors (GPCRs) are the largest group of cell-surface receptors in the eukaryotic 
kingdom. This diverse group of receptors act to convey extracellular messages to effectors inside the 
cell, and can react to light, lipids, sugars, peptides and proteins. This large family of receptors share a 
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common structure: one large polypeptide that forms 7 TM domains (hence these receptors are 
occasionally called the 7-TM receptors). The extracellular loops between TM segments commonly 
form part of the binding pocket for the receptor’s specific ligand. 
Humans possess more than 800 GPCRs, most of which can be grouped into 5 main families: 
Glutamate, rhodopsin, adhesion, frizzled/taste2 (frizzled) and secretin (Fredriksson et al., 2003). To 
be classed as a GPCR, receptors have to satisfy two criteria. The first is that the receptor should 
contain 7 stretches of sequence that are predicted to show a high degree of hydrophobicity, 
correlating to the 7 α-helices that span the membrane. The second criterion is that the receptor 
should be able to interact with a heterotrimeric G protein (Fredriksson et al., 2003). Despite these 
criteria, the homology between GPCR families is limited as they share little sequence similarity and 
contain different N-termini. Within GPCR families, for example the rhodopsin-like family (which 
contains approximately 700 members), there can be many subfamilies. The members of each 
subfamily share a higher degree of structural similarity than each large GPCR family. The differences 
between subfamilies, for example in the extracellular loop regions and side chains, confer the high 
diversity of ligand binding pockets and give rise to the vast number of physiological processes that 
GPCRs are involved in. Although many GPCRs are well characterised and their ligands are known, the 
ligands and function of a number of GPCRs are still unknown, and these are known as orphan 
receptors (Tang et al., 2012).   
Heterotrimeric G proteins 
 
G proteins (also known as guanine nucleotide-binding proteins) can bind guanosine triphosphate 
(GTP) and guanosine diphosphate (GDP), and act as molecular switches that regulate the ‘on’ and 
‘off’ state of particular proteins in a myriad of signalling pathways. They can exist in a monomeric 
form, called small GTPases, which are homologous to the α-subunit of heterotrimeric G proteins. 
Heterotrimeric G proteins are comprised of 3 parts: α, β and γ subunits (Gα, Gβ and Gγ, 
respectively). Gα and Gγ are tethered to the membrane by lipid anchors, and it is Gα that is 
responsible for binding GTP/GDP. 
When a GPCR is in the inactive state (i.e. in the absence of an activating ligand), Gα is bound to GDP, 
which allows Gα to also bind the β- and γ-subunits (in a dimer known as Gβγ) creating an inactive 
heterotrimeric complex. When the GPCR is in the active state (i.e. in a ligand-bound state) the 
dissociation of GDP from Gα is catalysed, allowing GTP to bind. A conformational change in the GPCR 
causes dissociation of Gα and Gβγ from the GPCR, and a conformational change in Gα after the 
exchange of GDP for GTP causes a decrease in affinity for Gβγ, leading to their dissociation (Lambert, 
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2008). The G protein subunits are still tethered to the membrane, but are no longer bound to the 
receptor. In this way, the subunits are able to move laterally in the membrane and interact with 
effector proteins in the signalling cascade, for example adenylyl cyclase (AC) or PLC (Purves et al., 
2001). Gα possesses intrinsic GTPase activity that converts GTP to GDP, but this process is relatively 
slow. GAPs are responsible for the rapid deactivation of Gα by binding to this subunit and 
accelerating the intrinsic GTP hydrolysis. GAPs that catalyse GTP hydrolysis of heterotrimeric G 
proteins include PLC-β1 (Berstein et al., 1992) and p115 RhoGTPase nucleotide exchange factors 
(RhoGEF) (Kozasa et al., 1998), which catalyse the hydrolysis of GTP on their respective upstream 
activators. Members of the regulators of G protein signalling (RGS) family are also GAPs. They 
increase the rate of Gα-bound GTP hydrolysis, effectively inhibiting Gα and Gβγ signalling pathways. 
When Gα is once again bound to GDP it reverts back to the inactive state, re-associates with Gβγ and 
binds to the inactive GPCR. 
G-protein subunits 
 
The signal that is relayed by the activity of G-protein subunits can be stimulatory or inhibitory, and 
GPCRs associate with specific types of G-protein subunits in order to transmit the correct signal. 
There are 16 mammalian genes encoding 23 α-subunits that belong to one of 4 subfamilies: Gαs, Gαi, 
Gαq/11 and Gα12/13. The βγ dimer is made from one of 5 Gβ-subunits and one of 12 Gγ-subunits 
(Hurowitz et al., 2000; Zhang et al., 2015). 
Gαs subunits, when in complex with GTP, are able to bind to all isoforms of AC (AC1–9). By binding to 
and activating AC, signalling through Gas increases the intracellular concentration of cyclic adenosine 
monophosphate (cAMP) as AC converts ATP to cAMP and pyrophosphate. Gi subunits, on the other 
hand, selectively inhibit AC1, AC5 and AC9 to reduce in intracellular concentration of cAMP (Godinho 
et al., 2015).  Gαq/11 subunits activate PLCβ, which hydrolyses PIP2 and releases IP3 and DAG into the 
cell (O’Connell et al., 2014). Gα12/13 involves the activation of RhoGEFs. RhoGEFs bind to and 
activate RhoA, which regulates downstream effectors including cytoskeletal proteins (Siehler, 2009).  
1.8.2 GPCRs in the heart 
 
To fulfil the body’s changing heart-rate requirements in the many different situations it encounters 
including periods of stress or exercise, the function of ion channels responsible for shaping the 
cardiac action potential can be regulated by GPCRs (among other mechanisms). Modulation of ion 
channel function in this way allows extracellular factors to influence heart rate. For example, the 
release of the catecholamines epinephrine and norepinephrine from the adrenal glands during 
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stress, physical activity and excitement results in increased heart rate and contractility. This occurs 
through the binding of these hormones to their receptors, which in turn transduce the signal into the 
cell, causing an alteration in ion channel function. These signals may also originate from the 
cardiovascular centre in the brain, which sends signals via the sympathetic and parasympathetic 
nervous systems to the heart, releasing norepinephrine and acetylcholine, respectively.  
Stimulatory effects on cardiac ion channel function 
 
Via sympathetic stimulation of the nerve fibres innervating the myocardium, norepinephrine is 
released onto the heart. Norepinephrine (along with epinephrine) is the chemical ligand for α- and β-
adrenergic receptors (ARs), but it is the β-ARs that are the predominant subtypes expressed in the 
heart, with the total β-AR population in the heart comprising approximately 80% β1-AR and 20% β2-
AR (Lohse et al., 2003; Xiao et al., 2006). When norepinephrine binds to the β1-AR the receptor 
becomes stabilised in the active conformation, allowing coupling to the G protein subunits. The Gαs 
subunit can then dissociate from GDP and bind GTP. The active Gαs subunit activates AC, which 
generates cAMP. Increased cAMP activates PKA by binding to its regulatory subunit and alleviating 
inhibition of the catalytic subunit, and this kinase phosphorylates a number of effector proteins 
including troponin I and phospholamban (Madamanchi, 2007; Wegener et al., 1989; Zhang et al., 
1995), leading to an increased rate of dissociation of Ca2+ from troponin C and an increased SR Ca2+ 
influx during diastole, respectively, together enabling more rapid muscle contraction and relaxation 
(Kang et al., 2007). 
In addition to these effectors that are involved in excitation-contraction coupling, PKA activation 
through β1-AR activation also leads to phosphorylation of a number of ion channels involved in 
shaping the cardiac action potential. The L-type Ca2+ current is a crucial component of the 
repolarisation phase of the cardiac action potential, and an increase in ICa,L is one of the major causes 
of an increase in inotropy. Phosphorylation of the L-type Ca2+ channel results in an increase in ICa,L 
due to an increase in channel open time and open probability, rather than an increase in single-
channel conductance (Van der Heyden et al., 2005).  
Despite β1-AR expression dominating in the heart, β2-AR activation has been shown to increase ICa,L. 
In contrast to β1-AR activation, however, this occurs without the accompanying modulation of 
troponin I and phospholamban (Xiao & Lakatta, 1993). This is suggested to occur through extremely 
localised elevation of cAMP levels, likely due to the fact that the β2-AR couples to Gαi as well as Gαs. 
In addition, the β2-AR has been shown to couple to the L-type Ca2+ channel in a signalling 
microdomain (Davare et al., 2001), together causing a rapid and spatially restricted signalling 
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pathway that is incapable of affecting regulatory proteins outside of its immediate vicinity. This 
observation is supported by studies in frog ventricular cells, where β2-AR expression predominates. 
Application of isoprenaline to cells had limited effect on L-type Ca2+ channels located at the opposite 
end of a cell. This effect was not reproduced with addition of forskolin (an AC activator), and was 
reduced when a phosphodiesterase inhibitor was added in combination with isoprenaline (Jurevicius 
& Fischmeister, 1996).  
An increase in ICa,L would lead to prolongation of the cardiac action potential if left unopposed. To 
shorten the APD, an enhancement of IKs also occurs as a result of β1-AR activation. The ability of β1-
AR activation to result in IKs augmentation is due to localisation of proteins involved in the signalling 
pathway to the channel complex, and this process is discussed in section 1.8.3. 
In addition to causing an increase in the IKs current, β1-AR activation has been shown to result in an 
increase in the IKr current. In canine ventricular myocytes, ISO, forskolin or intracellular application of 
cAMP analogues led to an increase in the IKr current by 30–50% (Harmati et al., 2011). Also, 
inhibition of PKA had no effect on the baseline IKr current.   
Inhibitory effects on cardiac ion channel function 
 
In contrast to the observations of Harmati and colleagues, other groups have found that the IKr 
channel is inhibited by PKA-dependent phosphorylation downstream of adrenergic stimulation.  
A study in guinea pig myocytes showed that application of the selective β1-AR agonist xamoterol 
caused inhibition of the IKr current in a concentration-dependent manner (Wang et al., 2014).  In 
addition to this, previous investigations found that the elevation in cAMP concentration resulting 
from β-AR activation not only leads to activation of PKA and hence phosphorylation of the hERG 
channel, but also regulation of the channel via direct binding to cyclic nucleotide binding sites on the 
channel itself (Cui et al., 2000). Again, the phosphorylation of the hERG channel through the 
mechanisms downstream of β-AR activation was found to cause a rapid inhibition of the hERG 
current.   
Similar to the IKs channel, PKA is thought to be localised to the hERG channel through binding to an 
AKAP protein. Li et al. (2008) reported that the PKA-RII-specific AKAP inhibitory peptide, AKAP-IS, 
reduces the PKA-dependent phosphorylation of the hERG channel, suggesting that PKA is localised to 
the channel by an AKAP. However, this group could not demonstrate an interaction between hERG 
and any cardiac-specific AKAPs in heterologous co-transfection experiments. 
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The inhibition of hERG by β1-AR activation could explain why the majority of cardiac events in 
individuals with KCNH2 mutations occur during episodes of emotional stress. However, the precise 
mechanism of regulation by PKA has not been elucidated. This is likely due to the differing origin of 
cell types used in the studies mentioned here.  
Chronic activation of cardiac GPCRs 
 
The above mentioned changes in ion channel function as a result of GPCR activation serve to provide 
a rapid and acute manipulation of cardiac contractility to ensure sufficient oxygenation of vascular 
tissue. In some circumstances, however, GPCR activation can give rise to more prolonged, chronic 
changes in the heart. This is known as ‘remodelling’, and may come in the form of an increase in cell 
size, organ size or chamber dimensions (Kang et al., 2007).  
Cardiac remodelling may occur through the activation of various different GPCRs, including 
catecholamines activating the α- and β-ARs, endothelin (ET)1 activating the endothelin ETA and ETB 
receptors or angiotensin (AT) II activating the ATI and ATII receptors.  
Activation of these GPCRs is usually intended to be a short-term event, such as in the fight-or-flight 
response in which β1-adrenergic stimulation occurs to increase contractility and heart rate. Chronic 
activation of such receptors can contribute to the onset and progression of heart failure. This is 
supported by the fact that β-AR antagonists are the standard therapy for individuals with heart 
failure (Bristow, 2000), and ATI antagonists and angiotensin-converting enzyme (ACE) inhibitors have 
been shown to reverse cardiac remodelling and slow the progression of heart failure (Cohn et al., 
2001; Lindholm et al., 2002; Pfeffer et al., 1992).   
1.8.3 Regulation of the IKs channel by GPCRs 
 
The increase in adrenergic drive that occurs during periods of increased sympathetic tone leads to 
enhancement of IKs activation. The β-AR-induced increase in the IKs current supresses the β-AR-
induced afterdepolarisations that may arise through the increased Ca2+ current (Burashnikov & 
Antzelevitch, 2000; Marban et al., 1986; Shimuzu et al., 1991). 
IKs regulation by β-adrenergic activation 
 
The exact mechanism by which β1-AR-dependent PKA activation results in enhanced IKs activity is still 
largely unknown. It is known, however, that the IKs signalling complex centres around AKAP9, or 
yotiao, which anchors PKA, phosphodiesterase (PDE) 4D3 (PDE4D3), AC9 and protein phosphatase 
81 
 
(PP) 1 in close proximity to the channel (Li et al., 2012; Marx et al., 2002; Terrenoire et al., 2009). The 
increase in cAMP concentration resulting from AC activation activates PKA, which phosphorylates the 
channel at Ser27 (Kurokawa et al., 2004) and Ser92 (Lopes et al., 2007). This is thought to cause a 
conformational change that leads to enhanced channel activation (figure 11). 
There have not yet been studies performed to investigate how the channel changes conformation 
following phosphorylation of the IKs channel, and how this causes activation. However, studies have 
suggested that PIP2 may be involved. In these experiments, the IKs channel was inhibited by 
activation of the α1-AR (a Gq-coupled GPCR), and this inhibition was reduced when 100 nM 
isoproterenol (a β1-AR agonist) was applied for 2 minutes (Lopes et al., 2007).  
 
 
Figure 11. Activation of the β1-AR leads to activation of the IKs channel. Activation of the β1-AR by the binding 
of agonists such as norepinephrine leads to the dissociation of Gα and Gβγ. Gα activates adenylate cyclase 
(AC), which catalyses the production of cAMP, resulting in an increase in the local concentration. Increased 
cAMP activates PKA, which phosphorylates the IKs channel on the KCNQ1 α-subunit at Ser27 and Ser92, leading 
to enhanced channel activation. Yotiao, also known as AKAP9, anchors the effector proteins in a 
macromolecular signalling complex, allowing rapid signal transduction downstream of β1-AR activation. 
 
IKs regulation by Gq-coupled GPCRs 
 
Cardiac Gq-coupled GPCRs include the ATI, ET1 and α1-AR. Activation of Gq-coupled GPCRs results in 
the depletion of PIP2 through activation of PLC. Several studies have shown that PIP2 depletion leads 
to inhibition of the IKs current (Kruse et al., 2012; Loussouarn et al., 2003; Matavel & Lopes, 2009) 
However, one of the second messengers produced from the hydrolysis of PIP2, DAG, subsequently 
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activates PKC, which has been shown to lead to activation of the IKs channel; Matavel & Lopes (2009) 
showed that the depletion of PIP2 and activation of PKC causes biphasic modulation of the IKs channel 
by Gq-coupled GPCRs (figure 12).  
 
 
Figure 12. Activation of Gq-coupled GPCRs leads to PIP2 hydrolysis. Activation of Gq-coupled GPCRs, such as 
the ATIR, results in dissociation of the Gα and Gβγ subunits. Gα activates PLC, which hydrolyses PIP2 in the PM 
to IP3 and DAG. DAG resides in the PM, whereas IP3 is released in the cytosol. PIP2 depletion arising from Gq-
coupled GPCR activation is thought to cause inhibition of the IKs channel. 
 
In their study, activation of the M1 receptor and the AT1 receptor by acetylcholine and angiotensin II, 
respectively, resulted in an inhibition phase followed by an activation phase. This group also 
activated the bradykinin (BK) 2 receptor using BK, but observed only inhibition of the IKs current, 
suggesting that an activation phase was not present or was concurrent with the inhibition phase and 
therefore masked. PIP2 hydrolysis was responsible for the IKs inhibition phase, whereas activation of 
PKC by DAG and the subsequent phosphorylation of the IKs channel were responsible for the 
activation phases observed.  
On the other hand, others have shown that PKC causes the downregulation of the IKs channel 
through phosphorylation of KCNE1 at Ser102. This occurs in human and rat, but not guinea pig as 
KCNE1 possesses an asparagine residue at this position in place of serine in this species (Varnum et 
al., 1993). The mechanism behind the downregulation of IKs by PKC-dependent phosphorylation of 
KCNE1 in humans is thought to be via an increase in channel internalisation (Kanda et al., 2011). This 
mechanism could be pathologically relevant, as α1-AR agonists (such as norepinephrine) activate PKC 
in cardiac myocytes. 
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In contrast to the results showing IKs inhibition resulting downstream of ATIR activation, are the 
findings that activation of the ATIR in guinea pig myocytes leads to activation of the IKs channel 
(Zankov et al., 2006; Zankov et al., 2009). These results may vary due to the different cell types used 
in the studies. These results do, however, support the presence of an activation phase in the 
experiments of Matavel & Lopes (2009). 
Activation of the ET1a receptor was found to cause inhibition of the IKs current in guinea pig 
ventricular myocytes (Washizuka et al., 1997). This is thought to be through a pertussis toxin-
sensitive mechanism and the resulting inhibition of AC, and it can result in a prolongation of the APD.  
Dual regulation by different GPCR families 
 
Dvir et al., (2014) investigated the molecular mechanism of a number of LQT-associated mutations in 
KCNQ1 and KCNE1 that are located in KCNQ1 helix C and the KCNE1 distal C terminus – two regions 
that are thought to interact. This group reported that the mutations in KCNQ1 helix C highlighted 
that this region is important for channel modulation by PIP2, and the KCNE1 distal C-terminus 
mutations suggested that this region is essential in IKs channel regulation by yotiao-mediated PKA 
phosphorylation.   
These experiments suggest that PIP2 could be involved in transforming the signal from IKs 
phosphorylation and conformational change of the channel into activation, but also that there could 
be crosstalk between the β1-AR and Gq-coupled GPCR regulation of the IKs channel in vivo.  
Matavel et al. (2010) found that as well as PKA, PKC also regulates the response of the IKs channel to 
PIP2-mediated inhibition. In this study, several LQT-associated mutations that affect the IKs-PIP2 
interaction (Arg174Cys, Arg243Cys, Arg366Gln and Arg555Cys) were shown to affect the PKA- and 
Gq-coupled GPCR-mediated regulation of the IKs channel, and the effects were diverse across the 
mutations studied. Matavel and colleagues proposed that the effects on channel regulation could be 
important in the risk stratification of LQT patients, and may also influence the treatment strategies 
employed. 
The mechanisms of IKs regulation by different cardiac GPCRs have not been fully elucidated, and the 
interplay between these remains an area of research that could help to understand mechanisms of 
arrhythmia generation in particular arrhythmias, such as LQTS. 
1.9 Conclusion and thesis content 
 
The IKs channel binds PIP2, and it has been show experimentally that this channel is inhibited by a loss 
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of PIP2 from the PM. It is also widely thought that the open conformation of this channel is stabilised 
by PIP2. Other KCNQ channels, namely the M channel, require PIP2 for opening, and physiologically 
this mechanism is used by the M1R to inhibit the M current. How PIP2 regulates the IKs channel and 
whether experimental data translates to physiological environments, however, is largely unknown.  
Physiologically, the IKs current contributes to phase-3 repolarisation during periods of increased 
sympathetic tone, but contributes little at resting heart rates. The mechanism behind this is via 
activation of the β1-AR, but how the activation of this receptor and the downstream activation of 
PKA transmits into enhanced IKs channel activation has not been investigated.  
When either of the IKs channel subunits, KCNQ1 or KCNE1, harbour mutation(s), the IKs current can 
become compromised and lead to LQTS types 1 and 5, respectively. The mechanisms underlying 
these mutations may be due to disrupted channel trafficking or function. In this laboratory, 
mutations in a PIP2 binding region in the proximal C-terminus of the IKs channel led to impaired 
channel trafficking.  
As well as studying how PIP2 regulates IKs channel function, and whether PIP2 is involved in the β1-
AR-induced enhancement of the IKs current, this thesis will detail experiments that determine 
whether PIP2 is involved in the anterograde trafficking of the IKs channel.  
In addition to investigating mechanisms of IKs channel regulation by PIP, this thesis will describe the 
compatibility of the rapamycin-inducible dimerisation system for studying the function of the IKs 





CHAPTER 2: Methodology 
2.1 Cell culture 
2.1.1 Passaging cells 
 
To provide a continuous supply of heterologous cells for use in the experiments within this project, 
cells were passaged approximately once per week. This practice discards the majority of cells during 
each passage and takes only a small portion, or subculture, to continue growing. This process may 
carry on with the same cells for a few months, before replacing them with new, earlier passage cells. 
Human embryonic kidney (HEK) 293 cell lines were grown in 75 cm2 (T75) cell culture flasks in 
minimum essential media (MEM [31095-029, Thermo Fisher Scientific] supplemented with 10% 
heat-inactivated foetal bovine serum (FBS) (10500-064, Life technologies)  and 100 units/ml penicillin 
and 100 µg/ml streptomycin (15140-122, Life technologies), described from here onwards as HEK293 
media. Chinese Hamster Ovary (CHO)-K1 cells were grown in 75 cm2 cell culture flasks in Ham-F12 
media (D8900, Sigma) supplemented with 10% FBS and 100 units/ml penicillin and 100 µg/ml 
streptomycin.  Cells were kept at 37°C and 5% CO2 in a humidified incubator.  
HEK293 and CHO-K1 cells were passaged when they reached approximately 80% density. Cells were 
first washed with 8 ml phosphate buffer saline (PBS [D8537, Sigma]) to remove any residual culturing 
media, then detached from the flask using 2 ml 0.25% trypsin (5 ml 2.5% trypsin [15090, Life 
technologies] in 45 ml PBS). Trypsin activity was terminated with the addition of 8 ml culture media. 
The required fraction of HEK293 or CHO-K1 cells was transferred to a new T75 flask containing 15 ml 
HEK293 or Ham-F12 media, respectively. Cells were commonly passaged using a 1:10 dilution: from 
10 ml of trypsinised cells, 1 ml was taken and transferred to the new flask. 
Cells were then incubated at 37°C and 5% CO2 for a minimum of 2 days before being passaged again. 
2.1.2 Seeding cells 
 
In order to use cells in experiments, a portion were taken from the main culture and adhered to a 
medium suitable for the desired experiment in a process known as ‘seeding’. Commonly, cells were 
seeded onto glass coverslips. Cells adhered onto glass coverslips were required for patch clamp and 
confocal microscopy experiments. Alternatively, cells were adhered to the bottom of a well in multi-
well plate. This was required for the in/on-cell western experiments.  
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To obtain the cells required, a portion were taken from the main culture after trypsinisation and 
added to wells in a multi-well plate. These wells either contained 4–5 x 10 mm coverslips (for patch 
clamp), 1 x 25 mm coverslip (for confocal microscopy) or were empty (for in/on-cell western assays). 
When untransfected cells were required on coverslips, they were seeded into wells containing 
coverslips 48 hours before use at a density of approximately 10%. The low density allowed space for 
cell division to occur so that on the day of experimentation the cells were at an appropriate density. 
When transfected cells were needed (i.e. for patch clamp experiments), they were seeded into wells 
without coverslips, 72 hours before use, at a density of approximately 50%. A higher density was 
used to allow cells to be effectively transfected before being passaged and re-seeded into new wells 
containing coverslips at a density of approximately 10%. 
When a monolayer of transfected cells was required for the experiment (i.e. in the in/on-cell western 
assay), cells were seeded at a density of 50%, 72 hours before transfection. After transfection, the 
cells were not passaged again and seeded into new wells, but left to divide in the original well to 
reach a high density. 
2.1.3 Transfection 
 
Transient transfection was routinely used throughout the project, and it allowed the transient 
expression of foreign cDNA in the heterologous cell lines used. Transient expression (in contrast to 
stable expression) occurs due to the lack of incorporation of cDNA into the cell’s own genome, 
meaning that the cDNA is lost when the cell divides (Kim & Eberwine, 2010). As the transfected 
cDNA can be changed from experiment to experiment, the transient transfection method provided a 
quick and flexible way to study the function of many different proteins in the same cell line. 
On the other hand, a stable transfection was occasionally performed, which involved the 
incorporation of cDNA into the cell’s own genome. This resulted in the expression of the transfected 
cDNA in the original cell, but also in new cells arising from cell division. A number of different cell 
lines were used throughout the project, each stably expressing one or more desired proteins. The 
production of stably expressing cell lines was performed in this project to prolong the expression of 
proteins that were to be constant through the experiments, allowing transient expression of other 
proteins in these cells. 
Viruses, calcium phosphate, cationic lipids and direct injection of cDNA are all valid methods of 
transfection, each with their own advantages and disadvantages (Kim & Eberwine, 2010). Cationic 
87 
 
lipids are most commonly used in the type of cells and the nature of experiments used throughout 
this project, and was the method chosen here.  
This method was effective at transfecting cDNA into the heterologous cell lines used, and the 
efficiency of transfection was routinely between 40–80%. The success of this method relies on the 
fact that the positively charged transfection lipids attract the negatively charged cDNA molecules, 
forming a complex that is endocytosed or phagocytosed by the cell and delivered to the nucleus.  
Fugene HD (E2311, Promega) and Lipofectamine 2000 (11668019, Thermo Fisher Scientific) were 
both used throughout the project. Depending on the experiment the cells were destined for, one 
transfection agent was favoured over the other; Fugene HD was used to transfect cells for 
electrophysiological experiments, while Lipofectamine 2000 was used to transfect cells for imaging 
experiments and in/on-cell western assays. 
Transfection of cells in a 6-well plate using FuGENE HD 
 The appropriate volume of cDNA and 200 µl Opti-MEM I (11058-021, Life 
technologies) were added to a 1.5 ml sterile microcentrifuge tube. The cDNA and Opti-
MEM I were mixed by vortexing. 5 µl FuGENE HD (E2311, Promega) was then added and 
the solution was mixed by gently tapping/flicking the tube. The cDNA/FuGENE HD/Opti-
MEM I solution was then left for complexes to form for 20 minutes at room temperature 
(RT).  
 The cells to be transfected were washed with 1 ml Opti-MEM I, and media was 
replaced with 2 ml antibiotic-free media. After 20 minutes, the total volume of 
cDNA/FuGENE HD/Opti-MEM I solution (200 µl) was taken and added to the cells. Cells 
were incubated with the cDNA/FuGENE HD complexes at 37°C and 5% CO2.  
 After 4 hours, media (containing complexes) was removed and cells were washed 
using 1 ml PBS. Cells were then incubated with 400 µl trypsin at RT for approximately 5 
minutes, and an appropriate volume of cell suspension was removed for seeding in a new 
well containing culture media and coverslips (e.g. 40 µl of cell suspension taken for 
seeding at 10% density). 
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Transfection of cells in a 6-well plate using Lipofectamine 2000 
 The appropriate volume of cDNA and 200 µl Opti-MEM I were added to a 1.5 ml 
sterile eppendorf tube. The cDNA and Opti-MEM I were mixed by vortexing. In a separate 
sterile eppendorf tube, 195 µl Optimem I and 5 µl Lipofectamine 2000 (Life technologies, 
11668-019) were added, mixed by gently pipetting and incubated at RT for 5 minutes.  
 The Opti-MEM I/Lipofectamine 2000 solution was added to the tube containing 
cDNA/Optimem I, and the solution was mixed by gently tapping/flicking the tube. The 
cDNA/Lipofectamine 2000/Opti-MEM I solution was incubated at RT for 15 minutes in 
order for cDNA-Lipofectamine 2000 complexes to form.  
 Cells to be transfected were washed as in the FuGENE HD protocol, and the 
remaining steps are the same, apart from the total volume of transfection mixture added 
to the cells was 400µl. Cells were left for 5 hours, after which, media was removed and 
cells were passaged and transferred to a new well, as in the FuGENE HD protocol.   
 
2.1.4 Generation of stably expressing cell lines 
 
A number of stably expressing HEK293 cell lines were made during this project. A stably expressing 
KCNH2 cell line and KCNJ2 cell line were made, and a stably expressing KCNQ1-GFP/KCNE1 cell line 
had been produced prior to the start of the project by Dr Stephen Harmer. 
In order to generate a stably expressing cell line, the cDNA used for transfection must contain an 
antibiotic-resistance gene. By incorporating antibiotic resistance into the cDNA plasmid, cells that 
successfully incorporate the plasmid into their genome are selected for by using antibiotic-containing 
culture media (known here as selection media). To ensure stably transfected cells had been selected 
for, untransfected cells were cultured in selection media in parallel, and the death rate of these two 
populations of cells was monitored. When the untransfected cells had died, the remaining cells in 
the transfected-cell population were assumed to have successfully incorporated the antibiotic-
resistance gene (and therefore also the gene of interest) into their genome. Individual colonies of 
cells were left to divide until their density reached approximately 60–80 % of a well in a 6-well plate.   
Commonly, the protein of interest is tethered to a fluorescent tag to enable visualisation of protein 
expression during experiments. This was exploited during the process of cell colony selection to 
ensure that cells that had survived contained the gene of interest in addition to the antibiotic-
resistance gene, but also to check that the colonies of cells were clonal (i.e. all cells originated from 
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the same cell, and hence expressed the fluorescently-tagged protein). Colonies that were not clonal 
were discarded.  
Unfortunately, the KCNH2 and KCNJ11 proteins were not fluorescently tagged, so to identify clonal 
colonies the electrophysiological properties of each respective colony were assessed using whole-cell 
patch clamp (WCPC). In order to do this, cells were seeded onto 10 mm coverslips, as detailed in 
section 2.1.2. The colony in which cells produced acceptable and reproducible current densities 
corresponding to the respective ion channel was kept, and inferior colonies were discarded.  
Production of a stably expressing cell line 
 Cells were first seeded into 1 well of a 6-well plate at a density of approximately 50%. The 
following day, cells were transfected using Lipofectamine 2000, as described in section 2.1.3.  
 After transfection, cells were passaged, similar to the method detailed in section 2.1.2. 
Here, however, cells were seeded into 100 mm cell culture dishes at various dilutions (1:20, 1:100, 
1:1000 and 1:10,000). A control plate of untransfected cells was seeded in parallel. Cells were 
incubated at 37°C and 5% CO2, in culture media containing the appropriate antibiotic (determined 
by the antibiotic-resistance gene contained within the plasmid).  
 Cells were left in all dishes to divide until 100% cell death occurred in the control plate. 
Then, antibiotic-selection media was removed from the transfected cells and replaced with PBS (10 
ml). PBS (100 µl) was drawn into a pipette tip whilst scraping an isolated colony, and this cell 
suspension was placed into a well in a 6-well plate containing antibiotic-free media (2 ml). 12–18 
colonies were picked, and each placed in a separate well. Antibiotic-free media was replaced with 
antibiotic-selection media after 24 hours. 
 Cells were left to divide until they reached a density of 60–80 %, then either passaged onto 
coverslips for electrophysiological investigation or viewed under a microscope to identify the most 
suitable clonal line for use in further experiments.  
 
2.2 Molecular Biology 
 
Molecular biology techniques were used throughout the project in order to isolate, amplify and 
manipulate DNA. 
Manipulation of the gene of interest, for example, through the introduction of mutations or 
restriction sites, was performed using the polymerase chain reaction (PCR). Bacterial amplification 
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was performed once a complete plasmid had been made, which allowed the production of a 
sufficient amount of plasmid for use in procedures such as transfection.  
A number of techniques were commonly used in sequence to produce the desired DNA plasmid 
constructs needed for progression of this project. These were the PCR, restriction digest, agarose gel 
electrophoresis, ligation and transformation, and a simplified cloning workflow is shown in figure 13. 
 
 
Figure 13. Molecular biology workflow. An overview of the step used to produce and amplify a DNA plasmid. 
DNA vectors and inserts can be produced using PCR or by restriction enzyme digestion. The resulting lengths of 
DNA (which are designed to have compatible ends) are ligated together, before being amplified using 
competent bacterial cells. To extract the DNA, the bacterial cells are lysed and the DNA plasmids are purified. 
The purified plasmid DNA can then be analysed to check the correct sequence has been produced. This is 
commonly done using a restriction digest or by Sanger sequencing.  
 
2.2.1 Polymerase Chain Reaction 
 
The polymerase chain reaction, or PCR, has long been used for the manipulation and amplification 
DNA fragments, and was invented by Mullis and his team in the 1980s (Saiki et al., 1985). In this 
project, PCR was used for molecular cloning and site-directed mutagenesis.  
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For the purpose of molecular cloning, regions of DNA from DNA plasmids or libraries (known as 
template DNA) were amplified using primers complementary to the 5’ and 3’ ends of the desired 
DNA sequence. The region between the forward and reverse primers is known as the target DNA, 
and is the region that was amplified.  
A thermally stable DNA polymerase was used to enable DNA denaturation at high temperatures 
before amplification, whilst keeping the DNA polymerase active throughout the heat cycle. Once 
amplified, the region of target DNA was purified and used in subsequent molecular cloning reactions. 
PCR DNA Polymerases 
 
The DNA polymerase from Thermus aquaticus (Taq) is commonly used in PCR reactions due to its 
thermostability (Saiki et al., 1988). The optimum temperature for Taq polymerase activity is 75°C, 
which enables high temperatures to be used during the PCR extension step of each cycle. High 
temperatures ensure that primers bind with a higher specificity, producing less unwanted 
amplification products as a result of non-specific binding (Lawyer et al., 1989).  
Throughout this project, however, Q5 high-fidelity DNA polymerase (M0491, New England Biolabs) 
was used due to its higher fidelity (>100 times higher than Taq polymerase) and low error rates. The 
Q5 high-fidelity DNA polymerase consists of a novel polymerase fused to the DNA binding domain of 
Sso7d, a chromatin protein from the hyperthermophillic archaebacterium Sulfolobus solfataricus (Su 
et al., 2000).   
Extraction of DNA from a completed PCR reaction 
 
Different methods exist to enable the extraction of DNA from a completed PCR reaction. Up to 10 µg 
of DNA can be purified quickly and efficiently using the QIAquick PCR purification kit (28104, 
Qiagen), which uses a silica gel that binds DNA in a high-salt buffer and allows elution of DNA in a 
low-salt buffer (or water). Once eluted, the DNA can be used immediately in downstream reactions.  
Alternatively, the completed PCR reaction can be loaded into an agarose gel, where DNA fragments 
are separated by size. The isolated PCR product can then be excised, but needs to be extracted from 





 Performing PCR using Q5 DNA polymerase 
The following were added to an RNase/DNase-free 0.2 ml microcentrifuge tube: 
DNA (50 ng) 
Forward primer (0.5 µl) 
Reverse primer (0.5 µl) 
5x Q5 reaction buffer (10 µl) 
10 mM deoxynucleotide triphosphates (dNTPs) (1 µl) 
Q5 DNA polymerase (1 µl) 
H2O (make up to 50 µl) 
 
Tubes were placed in a PCR machine, and the following protocol was started: 
1. Initialisation – Reaction was heated to 98°C for 2 minutes. 
2. Denaturation – Reaction was heated to 98°C for 30 seconds in order to denature the 
double-stranded DNA (dsDNA), yielding single-stranded DNA (ssDNA). 
3. Annealing – Reaction temperature was lowered to 60°C (variable, depending on 
experiment) for 30 seconds, allowing primer annealing to the template DNA. 
4. Extension – Reaction temperature was increased to 72°C for 1–5 minutes (variable, 
depending on experiment), to allow complementary dNTP addition to the DNA template via the 
action of Q5 DNA polymerase. 
5. Final extension – Reaction was held at 72°C for 5 minutes to ensure all extension was 
complete. 
6. Final hold – Immediately after completion, reactions were held for an indefinite amount of 
time at 4°C. 
 
 Steps 2–4 form 1 cycle. These steps were repeated for 35 cycles, between step 1 and 5 
 
 
2.2.2 Site-directed mutagenesis  
 
Site-directed mutagenesis (SDM) enables the introduction of specific alterations in a gene of interest 
using the PCR technique. Point mutations, replacement of amino acids and insertion or deletion of 
single amino acids can be performed using SDM. There are a number of different ways to introduce 




Early SDM techniques used two PCR reactions to create complementary DNA plasmids. The 
completed PCR reactions were combined to allow complementary DNA strands to anneal. The 
primers used in these reactions were complementary, and both contained the mutation to be 
introduced, but the positioning of the primer resulted in the ‘break point’ of the plasmid ending up 
in a different position. This resulted in a plasmid containing staggered single-stranded break points, 
which were subsequently repaired when expressed in a host cell (Jones et al., 1990).  
 
Current SDM methods use the same principles as the earlier method. However, the use of two PCR 
reactions is no longer required. Completely overlapping primers are now used within the same PCR 
reaction, each complementary to opposite DNA strands. After generation of each single-stranded 
circular plasmid, complementary strands anneal. In this project, the QuikChange II XL Site-Directed 
Mutagenesis kit (200521, Agilent Technologies) was used. 
 
The QuikChange II XL kit makes use of a genetically engineered version of Pfu DNA Polymerase, 
named PfuUltra high-fidelity DNA polymerase, which allows the highly precise replication of both 
plasmid strands as it exhibits an error rate many times lower than that of other commercially used 
polymerases (i.e. 18-fold lower than Taq polymerase). In addition to the high fidelity of this 
polymerase, it promotes the rapid extension and higher yield through the presence of the 
ArchaeMaxx polymerase-enhancing factor. This converts the inhibitory dUTP (generated from dCTP 
deamination) to harmless dUMP, improving PCR performance (Agilent Technologies Inc, 2015).  
 
The primers used in this method are synthetic, and bind to their complementary sequences on the 
DNA plasmid (at the site where the mutation is to be introduced). These primers are extended by 
PfuUltra high-fidelity DNA polymerase during the PCR temperature cycling stage, creating a circular 
plasmid with staggered nicks, which are repaired when expressed in a cell.  
 
Following the production of the mutated plasmids, the Dpn I endonuclease is added to the reaction 
mix. Dpn I (target sequence: 5´-Gm6ATC-3´) selectively digests the dam-methylated parental 





To perform SDM using QuikChange II XL Site-Directed Mutagenesis kit 
The following were added to an RNase/DNase-free 0.2 ml microcentrifuge tube: 
DNA (50 ng) 
Forward primer (0.5 µl) 
Reverse primer (0.5 µl) 
5x Q5 reaction buffer (10 µl) 
10 mM deoxynucleotide triphosphates (dNTPs) (1 µl) 
Q5 DNA polymerase (1 µl) 
H2O (make up to 50 µl)  
 
Reaction tubes were placed in a PCR machine and the following PCR cycle was commenced: 
1. 98°C for 2 minutes (initialisation) 
2. 98°C for 30 seconds (denaturation) 
3. 60 ± 5°C (variable, depending on experiment) for 30 seconds (annealing) 
4. 68°C for 2 minutes per kb of plasmid (extension)d 
5. 72°C for 5 minutes (final extension) 
6. 4°C (final hold) 
 
Steps 2–4 form 1 cycle. These steps were repeated for 18 cycles, in between step 1 and 5. 
 
Dpn I (1 µl) was then added to each reaction tube and incubated at 37°C for 1 hour.  10 µl of each 
reaction mixture was then used to transform XL10-Gold Ultra-competent cells. The transformation 
procedure is detailed in section 2.1.3. 
 
When the DNA plasmid containing the new mutation was amplified and purified, Sanger 





2.2.3 Restriction digest 
 
Restriction digests allow the production of DNA fragments that can be joined (ligated) together in 
further reactions to create a desired construct or sequence. Restriction enzymes, also called 
restriction endonucleases, were first used in 1971 to produce fragments of simian virus 40 DNA 
(Danna & Nathans, 1971). The use of restriction enzymes in molecular biology became routine as the 
number of known restriction enzymes increased, giving increased flexibility to DNA manipulations. 
Restriction enzymes recognise specific short stretches of DNA sequence and create double-stranded 
cuts in the DNA. These cuts produce either ‘sticky ends’ or ‘blunt ends’. When sticky ends are 
created, there is a 3’ or 5’ overhang of ssDNA (depending on the enzyme that was used). 
Naturally occurring restriction enzymes are classified into 4 groups (type I, II, III and IV). Type I 
restriction enzymes cut DNA sequences at random, at sites that are far from the recognition 
sequence. Type II restriction enzymes cut DNA at a specific point at, or close to, the recognition 
sequence (Pingoud & Jeltsch, 2001). The most common type II enzymes, known as orthodox type II 
restriction enzymes, assemble as a homodimer and recognise symmetric, or palindromic, sequences. 
In order to perform their function, these enzymes require the presence of Mg2+, which enables the 
cleavage of DNA at the specific sequence to give 5’-phosphate and 3’-OH ends. Other subtypes of 
the type II group of restriction enzymes include those that recognise asymmetric sequences (due to 
being formed from a heterodimer of subunits), those that interact with two copies of their 
recognition sequence, those that cleave DNA at both sides of the recognition sequence and those 
that recognise methylated DNA (Pingoud & Jeltsch, 2001). 
Artificial enzymes that recognise larger sequences of DNA can be created by fusing a DNA-binding 
domain to a nuclease domain. In this way, a restriction digest can be performed on any DNA 
sequence desired. Zinc-finger nucleases and transcription-activator-like effector nucleases are 
commonly used artificial enzymes, which are created by fusing the zinc-finger binding domain or the 
TAL effector binding domain to a nuclease domain (Townsend et al., 2009). 
For molecular cloning purposes, type II restriction enzymes are used due the predictable DNA 
binding and cleavage that they possess. Restriction enzymes that create sticky ends are more 
desirable than those that create blunt ends because of the relative ease of ligating two 
complementary sticky ends. Figure 14 depicts how a commonly used restriction enzyme, BglII, 
digests dsDNA. The enzyme recognises a specific sequence in the DNA (AGATCT), and cuts here to 
produce 5’ overhang sticky ends. 
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In single-digest reactions of circular plasmids, i.e. those that involve DNA digestion with only one 
restriction enzyme, complementary ends are produced that can easily re-ligate within the same 
reaction. In order to prevent this, the removal of the 5’ phosphate from each end can be performed 
with the addition of either calf-intestinal alkaline phosphatase (CIP) (M0290, New England Biolabs) 
or Antarctic phosphatase (AnP) (M0289, New England Biolabs) to the reaction.  
All restriction enzymes used in this project were purchased from New England Biolabs, and the 
reaction buffer (NEBuffer 1–4 [or 1.1–3.1 and Cutsmart]) in which the enzyme had the highest 
activity was used. 
Performing a restriction digest (20 µl reaction) 
The following were added to a sterile microcentrifuge tube: 
DNA (2–10 µg) 
10x NEBuffer (2 µl) 
Restriction enzyme(s) (1 µl each) 
CIP/AnP (if required, 1 µl) 
H2O (make up to 20 µl) 
 
 Reaction tubes were incubated at 37°C for 2–3 hours, after which the completed 
reactions were loaded into an agarose gel to enable purification of the digested DNA. 
 
 
2.2.4 Agarose gel electrophoresis and gel extraction 
 
The development of agarose gel electrophoresis revolutionised the separation of nucleic acid 
fragments, as previously separation could only approximate fragment size. Throughout this project, 
this technique was used for separation of DNA.  
Agarose is isolated from the seaweed Gelidium and Gracilaria, and once polymerised it forms a 
network of bundles containing pores that act like a DNA sieve. The extent to which DNA fragments 
move through the agarose gel is determined by their size, with smaller DNA fragments moving 
further through the agarose gel than larger DNA fragments. To induce the movement of DNA 
fragments (as this does not occur spontaneously) an electric field is applied across the agarose gel. 




To determine fragment size, a ‘DNA ladder’ is run in parallel, which contains DNA of a known size as 
a reference to which the sample DNA is compared. The distance over which a fragment of DNA 
travels is inversely proportional to the log of its molecular weight, as DNA has a uniform mass to 
charge ratio. The distance travelled by DNA fragments is also dependent on the agarose 
concentration of the gel, conformation of the DNA (i.e. linear or supercoiled), voltage applied to the 
gel and the type of electrophoresis buffer used (Lee et al., 2012).  
After completion of electrophoresis and sufficient separation of DNA fragments, extraction of DNA 
from the agarose gel was sometimes performed. This was required when DNA was to be used in 
further reactions, for example, ligation.  
The QIAquick gel extraction kit (28704, QIAGEN) enables the extraction of up to 10 µg of DNA from 
agarose gel by using a buffer to dissolve the agarose followed by the use of a silica gel to bind the 
DNA in a high-salt buffer. The DNA can then be eluted in a low-salt buffer (or water). These DNA 
extraction methods ensure the removal of primers, nucleotides, enzymes, mineral oil, salts, and 
agarose.   
 
To perform agarose gel electrophoresis 
 
The appropriate amount of agarose (1–2% w/v – depending on the size of DNA fragments) was 
added to 150 ml TAE buffer (40 mM Tris-acetate, 1 mM EDTA [disodium ethylenediaminetetraacetate 
in H20, pH 8.0 with NaOH]) and heated to solubilise the agarose. Once cooled but not set, Midori 
green DNA stain (7.5 µl; Nippon Genetics, MG04) was added and the gel solution was left to set in a 
prepared gel tray with gel comb(s) inserted. 
Gel loading dye (1:10; B7021S, New England Biolabs) was added to each restriction digest reaction. 
The set agarose gel was placed into a gel tank, and the reaction mixtures were added to individual 
wells of the gel along with 1 kb (N3232, New England Biolabs) and 100 bp (N3231, New England 
Biolabs) DNA ladders. 
A 90 mV potential difference was applied across the agarose gel and fragments were run for 
approximately 1 hour, until the bands were separated by an appropriate distance. Bands were then 
visualised using a UV AlphaImager system, and images were acquired using AlphaImager software on 
a PC. Fragments were cut out of the main agarose gel if required in downstream reactions, and 





Ligation reactions catalyse the formation of a phosphodiester bond between the 5’-phosphate and 
3’-hydroxyl ends of DNA (figure 14). The fragments of DNA with complementary sticky ends created 
in restriction digest reactions, described in section 2.2.3, are used here to assemble new DNA 
constructs. This technique uses naturally occurring enzymes that are usually involved in DNA repair. 
In this project, T4 DNA ligase (M0202, New England Biolabs), an ATP-dependent ligase, was used. As 
well as its use in joining sticky ends, T4 DNA ligase can also join blunt ends and repair single-stranded 
nicks in DNA and RNA (Rossi et al., 1997). 
For an efficient ligation it is recommended that a 3:1 ratio of insert to vector DNA is used, although 
this varies depending on the size of the fragments and the concentration of the DNA in the sample. 
After ligation, the new plasmid DNA can be inserted into bacterial cells for amplification. A control 
ligation reaction containing only vector DNA and DNA ligase should be performed in parallel to 
ensure the vector has cut properly and that the phosphatase (CIP/AnP) activity was successful (i.e. 
the digest was successful and the sticky ends created did not re-ligate with each other). There are 
commonly bacterial colonies that grow from transformation of this control ligation, but the number 





Performing DNA ligation with T4 DNA ligase (20 µl reaction) 
The following were added to a sterile microcentrifuge tube: 
Vector DNA (50 ng) 
Insert DNA (37.5 ng) 
T4 DNA Ligase buffer (2 µl) 
T4 DNA Ligase (1 µl) 
H20 (make up to 20 µl) 
 
 Reaction tubes were incubated at RT for 3 hours, and the reactions were gently mixed 
every hour. 




Figure 14. An example of restriction digests and the ligation of sticky ends. Restriction digest using BglII 
(AGATCT) of vector and insert DNA, forming sticky ends, and the subsequent ligation of complementary sticky 





Transformation occurs when a bacterial cell takes up foreign DNA, and this process is replicated here 
in order to yield a sufficient quantity of DNA for use in mammalian cell transfection. The bacterial 
transformation method exploits the rapid rate of bacterial growth, which allows amplification of DNA 
in a short time frame. Artificial induction of bacterial transformation requires the use of cells that 
have been made ‘competent’ (Griffiths et al., 2000). For DNA uptake to occur, a short ‘heat shock’ 
step is performed, which is thought to increase membrane fluidity and allow entry of DNA through 
membrane pores (Panja et al., 2008). 
The level of competency of bacterial cells differs between strains. Routine amplification of plasmids 
was performed using Top10 competent E. coli cells, but when smaller concentrations of plasmid (e.g. 
in ligation products) were used, XL10-Gold Ultra-competent cells were used because the proportion 
of total DNA successfully transformed is greater.  
Despite the fact that the DNA plasmids used in this project were destined for use in mammalian 
cells, they also contained a bacterial-resistance gene. For selection of bacterial colonies successfully 
transformed with the amplified plasmid, cells were incubated overnight on LB agar plates that 
contained the antibiotic corresponding to the antibiotic-resistance gene within the plasmid. Bacterial 
cells that were not successfully transformed do not survive the action of the antibiotic, and only 
plasmid-containing bacteria remain.  
A number of colonies are then picked and grown overnight at 37°C in either 5 or 50 ml LB media 




Performing a bacterial transformation using Top10 competent E. coli cells 
 Top10 competent E. coli (TT) cells were thawed on ice for 15 minutes. Plasmid DNA (1–5 
µl) was then added to TT cells (30–50 µl) in a sterile microcentrifuge tube, and the TT cell/DNA 
mix was incubated on ice for 30 minutes. 
 The TT cell/DNA mix was subject to heat shock by incubating at 42°C for 1 minute, and 
the mixture was immediately incubated on ice for 2 minutes. 
 LB media (800 µl) was added to each tube and incubated at 37°C for 45 minutes. The cell 
suspension was mixed by inverting the tube, and was performed every 15 minutes. 
 The cell suspension was centrifuged at 13,000 rpm for 1 minute. The supernatant was 
removed and the pellet was re-suspended in LB media (100 µl). The cell re-suspension (100 µl) 
was spread onto LB agar plates containing the appropriate antibiotic and incubated at 37°C for 16 
hours. 
 
2.2.7 DNA purification 
 
After amplification of DNA in bacterial cells, for example the TT or XL10-Gold Ultra-competent cells, 
the DNA requires extraction and purification before it can be used. For the purification of small 
volumes of DNA (i.e. yielded from amplification in bacterial cells that are then grown in 5 ml LB 
media overnight), the Plasmid Miniprep Kit (27405, Qiagen) was used, and for purification of larger 
volumes (i.e. when the same bacteria was grown in 50 ml overnight) the Qiagen Plasmid Purification 
Midiprep Kit (12145, Qiagen) was used. The Miniprep Kit allows isolation of up to 20 µg DNA, which 
is released from the bacterial cells after their lysis under alkaline conditions. The lysate produced is 
neutralised and adjusted to high-salt binding conditions. The DNA is then purified from the lysate by 
using a silica membrane, which binds the DNA in high-salt conditions, and DNA is subsequently 
eluted in low-salt conditions. The salt concentration of the buffer ensures that RNA, proteins and 




Purification of DNA using the Qiagen Plasmid Miniprep Kit  
 Bacterial cultures (1.5 ml) were transferred into a round-bottomed microcentrifuge tube 
and centrifuged at 13,000 rpm to pellet the bacterial cells. Supernatant was removed and this 
process was repeated. 
 The bacterial pellets were resuspended and the bacterial cells lysed by adding the 
appropriate buffers. The resulting reaction mixture was then added to a spin column containing 
the silica membrane, and tubes were centrifuged for 60 seconds at 13,000 rpm.  
 Supernatant was discarded and columns were washed twice with a high-salt buffer. DNA 
was then eluted into new microcentrifuge tube using 20 µl H2O.  
 
The Midiprep Kit uses similar alkaline conditions to the Miniprep Kit in order to perform bacterial cell 
lysis, after which the technique uses low-salt and low-pH conditions to bind DNA to QIAGEN resin. 
RNA, proteins, dyes and low-molecular-weight impurities do not bind to the resin and are hence 
removed. DNA can then be eluted in high-salt conditions, then concentrated and de-salted using 




Purification of DNA using the Qiagen Plasmid Purification Midiprep Kit 
  Bacterial cultures (50 ml) were transferred to a 50 ml falcon tube and centrifuged for 30 
minutes at 4000 rpm and 4°C to pellet the bacterial cells. The supernatant was then removed. 
 The bacterial pellets were resuspended and the bacterial cells lysed by adding the 
appropriate buffers. The lysate was then removed from the DNA-containing solution by gravity-
flow filtration.  
 The resulting solution was then added to gravity-flow Qiagen resin columns, and DNA 
was bound, washed and then eluted into 15 ml falcon tubes by sequentially adding the 
appropriate buffer.  
  Isopropanol (3.5 ml) was added to each tube and reaction tubes were centrifuged for 90 
minutes at 4000 rpm. Supernatant was removed and the DNA pellet was resuspended in 70% 
ethanol (1.5 ml), whilst transferring to a new microcentrifuge tube.  
 Reaction tubes were centrifuged for 10 minutes at 13,000 rpm to pellet the DNA, and this 
was repeated once more.  
 Supernatant was removed and the DNA pellet was left at RT for the remaining ethanol to 
evaporate. The DNA pellet was then resuspended and solubilised in 200 µl H2O.   
 
2.3 Confocal Microscopy 
 
Marvin Minsky developed the technique of confocal microscopy (CM) (Minsky, 1988) and 
contributed substantially to the advancement of biological imaging over the decades. Compared to 
conventional fluorescence microscopy using a digital camera, CM allows the acquisition of higher-
resolution images. However, the relative simplicity of optical microscopy still allows a high 
magnification of a sample, and is consequently the preferred method in some applications when in 
depth observations are not required. An additional factor taken into account when deciding the 
method of microscopy is cost; wide-field fluorescence microscopy is much cheaper than CM. 
On the other hand, when a higher degree of image resolution is required, CM may be used. The need 
for CM usually results from the expression of fluorescently tagged proteins or fluorescent organelle 
markers in cells. These fluorescent tags can be imaged using optical microscopy optimised for the 
use of fluorescence detection (i.e. using different filters for each fluorescent protein [FP]). However, 
the spatial resolution is poor in these conventional methods and their use is consequently limited to 
fluorescence detection rather than fluorescence localisation. The most common type of CM is laser 
scanning confocal microscopy (LSCM), which was used throughout this project. 
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2.3.1 Principles of confocal microscopy 
 
The way in which CM achieves high-resolution images is by means of point-by-point illumination and 
the elimination of out of focus emission light (Charman, 1998). In detail, light of the excitation 
wavelength travels through a pinhole before being focused on the specimen by the objective lens, 
allowing only a specific point in the specimen to be illuminated (the focal plane). Point-by-point 
illumination refers to the fact that each point in the focal plane is sequentially illuminated by a single 
beam of laser light. This excitation light is absorbed by the FPs in the focal plane, and light is emitted 
from them. The emission light is detected in the point-by-point order in which they were excited. 
In a perfect system, only the focal plane would be illuminated and only a single pinhole would be 
required. In reality, however, a small amount of light is absorbed by FPs that neighbour the focal 
plane, so a second pinhole is used. This pinhole is placed in a conjugate focal plane to the focal point 
of the objective lens. Light emitted from the specimen passes through this second pinhole before 
reaching the detector in order to eliminate out of focus light (i.e. light not originating from the focal 
plane). The detector used in CM is a photomultiplier tube. 
The aperture of the second pinhole can be altered to change the amount of light able to reach the 
detector. Decreasing the pinhole size allows more accurate detection of the light emitted from the 
focal plane, but this also limits the signal intensity. Accordingly, increasing the size of the pinhole 
yields stronger signal intensity, but has the risk of allowing light emitted from outside of the focal 
plane to be detected. 
In order for different light wavelengths to be passed through the same light path (i.e. excitation and 
emission wavelengths), a dichroic mirror is used. This mirror allows the excitation wavelength to be 
passed through to the cells whilst only letting the wavelength of the emission light back through to 
the detector. 
2.3.2 Considerations for image acquisition 
 
Using LSCM, image acquisition is performed by illuminating the specimen and collecting the emission 
light. In multicolour experiments, this first round of light detection is then followed by the 
illumination of the same focal plane using a different wavelength of light in order to excite a second 
FP within the specimen. The collection of emission light from this second FP then follows. Due to the 
sequential (rather than simultaneous) nature of point-by-point illumination and excitation of 
multiple FPs, the temporal resolution is LSCM is limited. 
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In order to ensure the detected signal is at a high enough level, the pinhole aperture needs to be of 
sufficient diameter. However, this can cause a reduction in resolution along the Z axis. Reducing the 
pinhole aperture produces images of higher constrast and better image quality, indicating that a 
compromise in pinhole aperture is required. In this project, the pinhole aperture was set to 1 Airy 
unit at all times. This describes the pinhole aperture that matches the diameter of the Airy disc, 
which is the circular diffraction pattern created by a light source passing through an aperture. 
If the signal intensity from a particular cell is weak, the gain of the photomultiplier tube can be 
increased, but this comes at the cost of also amplifying the signal of background noise. 
In addition to acquiring single images as described above, LSCM can be used for different multi-
image purposes. For example, time-series and Z-stacks can be created from multiple images taken of 
the same specimen. 
A time-series is constructed by acquiring subsequent images of the same focal place at 
predetermined, regular intervals. Post image-acquisition, these images can be compiled to reveal any 
changes in the localisation of fluorescently tagged proteins that occur over time. 
By acquiring multiple images along the Z-axis of a specimen, a Z-stack can be created. These 2-
dimensional images, only varying in depth along one axis, can be assembled to create one 3-
dimensional image. This can reveal relative spatial information about fluorescently tagged proteins 
within a cell. 
 
Acquiring an image using confocal microscopy 
 Cells (adhered to a coverslip) were placed on the microscope stage and the focus was 
altered to position the cells in an approximate focal plane. A more accurate focus of the desired 
focal plane was achieved using controls within the PC software (ZEN, ZEISS Microscopy).  
 Once the focal place was set, the excitation/emission protocol was started. The protocol 
sequentially excited the FPs and detected light emitted from them. Within multicolour 
experiments, the excitation and emission cycle was sequentially performed for each FP. 
 The image produced was subject to a number of offline corrections, including background 
filtering and contrast adjustment.  
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Fluorescent protein Excitation wavelength (nm) Emission wavelength (nm) 
Wild type GFP 396, 475 508 
eGFP 488 507 
eCFP 434 477 
eYFP 514 527 
mRFP1 584 607 
mCherry 587 610 
 
Table 4. The excitation and emission of commonly used fluorescent proteins. WT GFP was isolated from 
A. Victoria and has subsequently been enhanced to produced eGFP, eCFP and eYFP. mRFP1 and mCherry 






























Figure 15. Princples of confocal microscopy. Light from a laser passes through the illumination pinhole 
and is reflected onto the specimen to be imaged, where it is absorbed by molecules from the fluorescent 
protein tags. Light emitted from the focal point then passes through the confocal pinhole, in a conjugate 
focal plane to the point of illumination, and is detected. Light emitted from round the focal point will be 
out of focus when reaching the confocal pinhole, so will not reach and detector and is eliminated. 






2.4 Fluorescent dyes and proteins 
 
To illuminate regions of a cell for the purpose of identifying the location of proteins and cellular 
organelles, fluorescent dyes and proteins are used. Fluorescent molecules enable their visualisation 
by absorbing light of a certain wavelength and emitting light of a different wavelength. Synthetic 
fluorescent dyes, or fluorophores, were commonly used in the past for this, and are sometimes still 
used today. The most common of these are the xanthene derivatives, such as fluorescein and 
rhodamine. Even though the synthetic dyes were often successfully used, they still had many 
downfalls. For example, fluorescein has a high photobleaching rate and broad emission spectra, the 
latter of which limits its use in multi-colour experiments.  
Many features of fluorescent tags have to be considered when choosing the most suitable for use in 
microscopy experiments. Low cell toxicity is important as these fluorescent molecules are expressed 
in cells for a number of days before experiments are performed. Photostability also has to be 
considered; excessive photobleaching can occur from high-intensity excitation light during an 
experiment, and the reduced emission signal can cause artefacts to emerge in results. A third 
important factor is the Stoke’s shift: the difference between the optimal emission and excitation 
wavelength. A large Stoke’s shift is desirable as this prevents the crossover of emission and excitation 
wavelengths. During multicolour experiments, the Stoke’s shift of all fluorescent tags must be 
considered as the emission from one fluorescent molecule may excite another (Day & Davidson, 
2012), which is not usually the aim in standard confocal experiments.  
Today, FPS are more commonly used instead of synthetic fluorescent dyes as they possess more 
desirable characteristics. In the 1960s, Osamu Shimomura isolated the chemiluminescent protein, 
aequorin, from the green-glowing jellyfish, Aequorea Victoria (A. Victoria). Aequorin, however, emits 
blue light. Along with his colleagues, Shimomura identified that A. Victoria also contains a green 
fluorescent protein (GFP), and the energy in the form of the blue light from aequorin was absorbed 
by GFP and emitted at a different wavelength, resulting in the visible green luminescence of A. 
Victoria (Morise et al., 1974).  
Furthering this discovery, it was found that GFP consists of a single peptide chain over 200 amino 
acids in length, 3 of which (Ser-Tyr-Gly) form the chromophore (Cody et al., 1993). This, along with 
the fact that GFP can be excited in the absence of A. Victoria-specific proteins, means that GFP can 
be cloned and expressed in other systems. This meant that by simply linking GFP to a protein of 
interest, protein localisation can be visualised in a myriad of cells types. Within this project, a 




WT GFP has been modified to produce an enhanced version, named eGFP, via the addition of a point 
mutation (Ser65Thr). eGFP possesses increased emission light intensity and increased photostability 
compared to WT GFP, and also has only one excitation maxima. eGFP was used as a template to 
produce an array of different coloured FPs. Table 4 includes some of these (cyan fluorescent protein 
[eCFP] and yellow fluorescent protein [eYFP]) along with other FPs used in this project. The 
monomeric red fluorescent protein (mRFP1) was created through the optimisation of DsRed, a red 
fluorescent protein (RFP) isolated from the coral Discosoma Striata (D. Striata), which naturally forms 
a tetramer (Campbell et al, 2002). Another monomeric red fluorescent protein from D. Striata used 
in this project is named mCherry.  
Many of the protein constructs used in this project contain FPs. When investigating the trafficking of 
Kv7.1 using imaging techniques these FPs are indispensable, as without them the visualisation of 
construct localisation would not be possible. Illumination of different cellular organelles and the PM 
also plays an important role in microscopy experiments, as this gives reference to the localisation of 
the construct/protein of interest. 
Although the attachment of a FP to the Kv7.1 protein is required in imaging experiments, this 
fluorescent tagging also proves helpful in electrophysiological experiments, where identification of 
cells expressing the protein of interest is required.  
2.5 Electrophysiology 
 
Electrophysiological approaches are used to measure the transmembrane potential and the electrical 
changes that occur as a result of an applied stimulus. Changes in Vm can occur from externally 
applied electrical stimuli, direct pharmacological activation/inhibition of ion channels or indirect 
activation/inhibition of ion channels, e.g. via GPCR activation. The ability to measure the changes in 
Vm, and therefore ion flow across the membrane, allows the function of PM ion channels to be 
investigated. 
Some of the early iterations of electrophysiological recordings were performed by Hodgkin and 
Huxley in the 1940s and early 1950s. The pair first inserted a fine capillary electrode into a squid 
giant axon to record the potential difference across the nerve membrane. This revealed an action 
potential characterised by a large depolarising overshoot beyond 0 mV followed by a small 
hyperpolarisation beyond the baseline potential (Hodgkin & Huxley, 1939). Following this, Hodgkin 
and Huxley introduced the concept of voltage-clamp, where the membrane is maintained at a 
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constant potential, allowing the current flowing across the squid axonal membrane to be recorded. 
With the help of Katz, the voltage sensitivity and kinetics of the ion channels within the membrane 
were also investigated (Hodgkin et al., 1952). This collection of work provided the crucial first 
understandings of nerve excitability and the action potential. 
Since then, the principles of this method have been adapted and developed, and now the function of 
endogenous channels in native cells can be investigated as well as the function of transiently 
expressed channels in heterologous cell lines. In addition to this, the development of different 
electrophysiological methods has enabled the measurement of single-channel activity or 
macroscopic whole-cell currents. 
2.5.1 Patch clamp 
 
The patch clamp technique was developed by Neher and Sakmann, who published this method in 
1976. This new technique was first used to record the single-channel currents from nicotinic 
acetylcholine receptors in denervated frog muscle fibres (Neher & Sakmann, 1976). This method was 
more sensitive than previously used electrophysiological methods and enabled a high enough 
resolution of currents for single channel fluctuations to be detected.  
In the most commonly used patch-clamp configuration, the voltage-clamp principle is employed to 
enable the membrane potential to be held constant. In a physiological environment, the 
depolarisation in a cell’s membrane potential as a result of ion flux may lead to the activation of Kv 
channels and the consequent return of the membrane potential to Rm. This is not the case in patch 
clamp – the membrane potential is ‘clamped’ to prevent its alteration by ion channel activity. In this 
way, the ionic current that passes through the membrane via any active ion channels can be 
measured. An alternative configuration is occasionally used, known as current-clamp, which allows 
the change in membrane potential to be recorded when the cell is subject to fixed amplitudes of 
current. Throughout this project, the voltage-clamp method of patch clamp was used, and the term 
‘patch clamp’ will be used from here on synonymously with the term ‘voltage clamp’. 
2.5.2 Patch clamp equipment 
 
Microscope: 
An inverted light microscope is required in the patch clamp setup for visualisation of the cell and 
pipette. Without this, the fine control and manipulation of the pipette onto the cell to form a seal 
would not be possible. Microscopes for patch-clamp use are engineered to reduce the vibration 




A micromanipulator allows movement of the patch pipette in 3 axes, usually with the option of a 
coarse (fast) and fine (slow) control. The fine control is used to carefully guide the pipette onto the 
cell membrane. Once a seal is formed, the pipette must stay in place and not drift, to ensure a GΩ 
seal can be maintained throughout the experiment. 
Pipettes: 
Pipettes for patch-clamp come in various different sizes and glass types. Commonly used for 
electrophysiological experiments are borosilicate glass pipettes, due to their desirable properties: 
low softening temperature, high electrical resistivity and chemical resistance. Pipettes commonly 
contain a filament running the length of the inside to aid pipette filling. Pipettes come in either thin- 
or thick-walled varieties, the thick-walled being ideal for single-channel experiments because the 
noise and pipette capacitance are low. Thin-walled pipettes are ideal for WCPC experiments, 
however, as they provide a lower access resistance (Rycroft et al., 2006). 
The glass for patch-clamp pipettes is pulled to yield two similar pipettes. This can be performed in 
manual vertical pullers, or newer, automated horizontal pullers. The pipettes are pulled in 2 stages: 
the first determines the taper of the pipette tip, and the second determines the final diameter of the 
pipette tip. 
Once pulled, the pipettes can be fire-polished. This makes the tip smoother, and higher-resistance 
seals can usually be achieved by fire-polishing. 
Silver-chloride electrode: 
In order for electric current to be converted to ionic current, and vice versa, a silver-chloride (Ag-Cl) 
electrode is used. A silver electrode is coated with Ag-Cl either by dipping it in bleach containing 
hypochlorite or through electrophoresis in a chloride solution (Zhao et al., 2008). This electrode is 
wired to the amplifier, and is present in the glass pipette in contact with the high KCl-containing 
intracellular solution during recordings. Ag-Cl electrodes are widely used due to the reversible 
reaction responsible for current transduction: when electrons pass down the electrode, Cl- 
dissociates from the Ag-Cl electrode into the intracellular KCl solution, hence converting electrical 
current to an ionic one. As this reaction is reversible, chloride ions in the intracellular solution can 
reform the Ag-Cl coating, providing a free electron that converts the ionic current to the electrical 




𝐴𝑔𝐶𝑙 + 𝑒− = 𝐴𝑔 + 𝐶𝑙−      Equation 2.1 
 
Amplifier: 
The amplifier allows the manipulation of the membrane potential or current. A representative 
voltage-clamp protocol is shown in figure 17. The Axopatch 200B (Axon), used in this project, 
provides low-noise patch-clamp recordings, and can actively cool the amplifier headstage for low 
thermal noise. The amplifier in a patch-clamp setup allows pipette and membrane capacitance 
cancellation, and series resistance compensation and prediction to be performed.   
Digitiser: 
A digitiser converts one or more channels of analog signal into a series of digital values, which is does 
using an A/D converter. For example, when recording the current through one or a number of ion 
channels, a digitiser may calculate the output of the patch clamp amplifier at regular time intervals 
and provide the digital value to the computer.  
Storage and analysis equipment: 
To record and store the data from patch-clamp experiments, PC software is used. The pClamp 
software (Axon) is used in this project, and includes Clampex 10 for data acquisition and Clampfit 10 
for offline analysis. 
Solutions: 
Depending on the patch-clamp configuration and the ion channels being investigated, the 
extracellular and intracellular (pipette) solutions differ in composition. Standard extracellular 
solutions contain a low K+, high Na+ concentration, while the intracellular solution contains a high K+ 
and low Na+ concentration. Solutions also contain a Ca2+ chelator, for example, EGTA, to buffer the 
intracellular free Ca2+ levels to a minimum. ATP is also commonly added to intracellular solutions in 
WCPC experiments to maintain ATP-dependent processes.     
2.5.3 Patch clamp principles 
Patch clamp electronics: 
The way in which a patch-clamp amplifier clamps the Vm at a particular voltage is via a feedback 
system (figure 16). To clamp the membrane potential, current flows from the amplifier’s output if the 
two inputs are not equal. The two amplifier inputs are the command potential (Vcmd) (positive input) 
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and the pipette potential (Vp) (negative input).  If the membrane potential (or Vp, as it is the tip of 
the pipette that is clamped) is the same as Vcmd, there will be no current flow. When membrane 
current flows, Vp will change and move away from Vcmd. To restore Vp to Vcmd, current of an equal 
amount, but opposite sign, will be applied through the output via a feedback resistor (Rf). 
According to Ohm’s law, the voltage drop (Vout – Vp) that occurs across the resistor determines the 
current that flows though the pipette (Ip). As Vp is clamped at Vcmd, the amplifier continuously 
measures the difference between Vout and Vcmd, and adjusts Ip accordingly to clamp the membrane 
potential at the desired voltage (Rycroft et al., 2006). 
 
𝐼𝑝 =  
(𝑉𝑜𝑢𝑡 − 𝑉𝑐𝑚𝑑)
𝑅𝑓
    Equation 2.2 
 
For large macroscopic recordings, low resistance feedback resistors are used. Larger resistance values 
give higher sensitivity to recordings and ensure that Vp comes closer to Vcmd. However, the resistance 
of Rf is limited when recording larger currents due to the power supply of the amplifier. Typically, 
with a 12 V amplifier and 500 MΩ Rf, the amplifier will saturate at an Ip value of 24 nA. 
Cellular electrical characteristics: 
The electrical workings of the patch-clamp technique can be demonstrated using simple equivalent 
circuits, where Vm is the membrane potential, Cm is the membrane capacitance and Rm is the 
membrane resistance. A capacitor is defined as an insulator that separates two areas of conducting 
regions (e.g. the PM lipid bilayer, which separates two high conducting regions, the intracellular and 
extracellular solutions). 
In a cell, the membrane potential creates a driving force for ion movement across the PM. Ohm’s law 
(V = IR, that can be rearranged to I = V/R) denotes that that at a particular voltage (V), the current (I) 
is proportional to the resistance (R) across the membrane. In a physiological setting, the membrane 
potential is not fixed. As the membrane resistance changes (with the opening and closing of ion 
channels in the PM) and the current flow through the capacitance is charged and discharged, the 






While the PM capacitance is charging during a patch-clamp experiment, the current recorded is not 
the total current, but the current passing through the capacitor. This also occurs when the capacitor 
discharges. These capacitive currents can be seen in WCPC experiments after breaking into the cell 
whilst subjecting the cell to a test pulse. 
The glass walls of the pipette also act as a capacitor, between the intracellular and extracellular 
solutions (Ogden & Stanfield, 1994). This capacitance can be reduced by coating the pipette with 
SigmaCote, a silicone coating that thickens the pipette wall. To further reduce pipette capacitance, 
the depth of solution in the bath can be lowered so only the very tip of the pipette remains in the 
solution. 
The electrode resistance (Re) also introduces unwanted error to recordings. As the voltage is clamped 
to the end of the electrode, and not the PM, a voltage drop across Re will cause the voltage reaching 
the PM to differ. 
The Re can interact with the capacitance properties of the PM and cause problems when performing 
patch-clamp recordings. As the capacitor needs to be charged and discharged it slows any change in 
membrane voltage, and therefore slows the effect of membrane potential change on current 
characteristics. This time course (T) of voltage change follows an exponential relationship, and is the 
combination of the electrode resistance and membrane capacitance (equation 2.3). 
 
𝑇 =  𝑅𝑒𝐶𝑚     Equation 2.3 
 
Similarly, any current that flows across the membrane will be subject to the same time course error, 
meaning any fast current signals will be filtered by Cm and Re. 
 
Capacitance cancellation: 
Cancellation of the pipette and cell capacitance is important for a number of reasons. Firstly, it 
prevents saturation of the amplifier at large voltage steps (Ogden & Stanfield, 1994). When the 
power supply of the amplifier is exceeded, the correct current is not driven round the circuit, and the 
current or voltage cannot be clamped correctly. Secondly, cancellation allows the capacitance to be 
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charged by an extra ‘capacity current’ that bypasses the recording amplifier (and therefore does not 
alter the cell response). The pipette capacitance is cancelled upon sealing to the PM, and the cell 
capacitance is cancelled when sufficient access to the cell is gained (i.e. in WCPC, when the patch is 
ruptured). 
Series resistance compensation: 
Series resistance (Rseries) is the term given to the summed resistances of the pipette and cell, which 
cause unwanted filtering effects and voltage errors in the recording circuit, causing Vm to differ 
significantly from the Vcmd. Any current injected into the cell from the amplifier will be subject to a 
voltage drop across electrode resistance, and Ohm’s law (V=IR) denotes that an increase in either 
current or resistance increases the voltage drop (Barbour, 2014).  It is important to account for this 
during set-up and recordings. Resistance can be lowered to an extent by choosing low-resistance 
pipettes. This can be achieved by widening the pipette tip, but widening the tip too far can cause 
problems in producing high-resistance seals with the PM.  
The effects of Rseries can be predicted (i.e. the voltage error that will result), and because of this, a 
current can be injected to compensate for these effects. Driving extra current through the electrode 
mimics the situation that would occur by having a lower-resistance pipette, and the PM is therefore 
clamped at a voltage closer to Vcmd (Barbour, 2011). In theory, Rseries can be compensated for by 
around 90%, but in practice Rseries is compensated for by approximately 70%. 
For effective Rseries compensation it is required that pipette and cell capacitance cancellation be 
performed. Any current transients arising from charging the capacitance can interfere with the 
current recorded, and therefore the extra current injected for Rseries compensation. 
Transient prediction: 
By performing cell capacitance cancellation prior to Rseries compensation, the voltage drop caused by 
charging the membrane capacitance is not estimated as accurately as possible, and the 
compensation that is applied may not be sufficient. By measuring the cancellation current used to 
cancel the cell capacitive currents, an extra correction can be made to the current injected through 
the electrode. This effectively ‘overshoots’ the pipette potential at the beginning of a command, and 
as a result, the cell’s capacitance is charged more quickly than if the cancelled capacitance current 



















Figure 16. The patch-clamp feedback system equivalent circuit. The amplifier output is determined by the 
difference between the positive (Vcmd) and negative (Vp) inputs. Deviation of Vp from Vcmd causes current to be 
driven across the feedback resistor (Rf), and a current (Ip) is supplied to bring Vp back to Vcmd. Adapted from 









Figure 17. Patch-clamp I-V voltage protocol. Representative voltage protocol used in patch clamp experiments to 
record the relationship between current and voltage (when recording the IKs current) Voltage is held at -80 mV for 
1 second before a depolarising step for 6 seconds between -80mV and +80mV, which then steps to -20 mV for 2 












Figure 18. Configurations of the patch clamp technique. From cell-attached, inside-out can be achieved by 
pulling the pipette away from the cell. By stretching the membrane slowly from the whole-cell configuration 
until it breaks, outside-out can be performed. Perforated patch is achieved by forming small pores in the 
membrane with, for example, amphotericin B. The whole-cell and perforated patch configurations measure the 
total ionic current in the cell, whereas cell-attached, inside-out and outside-out record the ionic current 




2.5.4 Patch-clamp configurations 
 
A standard patch-clamp procedure involves forming a high-resistance giga-ohm (GΩ) seal (>1 GΩ) 
between a glass pipette and the PM of a cell. The patch of membrane in the tip of the pipette is then 
ruptured, pulled away from the cell, left intact or perforated, depending on the patch clamp 
configuration (figure 18). The different patch-clamp configurations are briefly described below: 
Cell-attached:  
This configuration of the patch-clamp technique is arguably the simplest, as it requires only a tight 
seal between the patch pipette and cell membrane. It is commonly used for investigation of single-
channel activity and recordings of spontaneous action potential firing (Perkins, 2006). This 
configuration is also the most physiological, because none of the intracellular environment is 
disrupted by dialysis with the pipette solution. 
Inside-out: 
After forming a GΩ seal, pulling the membrane patch away from the cell will result in a small area of 
membrane in the tip of the pipette for recording, with the intracellular side of the cell exposed to the 
bath solution. In this method, all cytoplasmic constituents are lost, therefore providing a method for 
investigating the influence of exogenously applied intracellular constituents on the membrane 
(Rycroft et al., 2006). 
Whole-cell: 
In the whole-cell configuration, the patch of membrane in the tip of the pipette is ruptured by 
applying gentle suction. While running a test pulse protocol, it is clear when access to the cell is 
gained due to the sharp cell capacitance spikes that appear, indicating that electrical access to the 
whole cell has been successfully obtained. Because the membrane patch is ruptured there is a 
continuous environment between the pipette and cell intracellular solutions, meaning the cell’s 
cytoplasmic constituents will become diluted over time. 
Outside-out: 
After rupturing the membrane patch, i.e. going to whole-cell configuration, the pipette can be slowly 
withdrawn from the cell until the membrane stretches and breaks. The broken edges of membrane 
should seal with each other, resulting in the extracellular membrane being in contact with the bath 
solution, and the intracellular membrane being in contact with the pipette solution. Similar to the 
cell-attached configuration, this allows investigation of single-channel activity, but using outside-out 
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patch-clamp means the effect of extracellular agents on the single channels can also be studied 
(Rycroft et al, 2006).    
Perforated patch: 
A slight variation of the WCPC, perforated patch does not rupture the whole patch inside the pipette, 
but instead perforates it using pore-forming substances in the pipette solution. Nystatin and 
amphotericin B are two antibiotics that are used for membrane perforation. Perforating the PM in 
the tip of the pipette rather than rupturing it, gives limited access to the cell. However, K+, Na+ and 
Cl- ions are permeable, giving electrical access. Ca2+ cannot cross the membrane through the pores 
that are made, along with higher molecular weight cellular constituents such as ATP (Lippiat, 2008). 
Perforated patch, therefore, maintains an intracellular environment that is physiological while 
recording.   
2.6 Methods of phosphoinositide manipulation 
 
The role of PIP2 and other PIs in the regulation of ion channels can be assessed by mutation of the 
proposed PIP2-binding regions within these proteins, but is also commonly investigated by altering 
the levels of membrane PIs themselves. The benefit of this latter method is that the channel in 
question remains in its WT state, containing no mutations that may or may not interfere with 
properties other than PI binding.  
2.6.1 Non-specific methods of altering phosphoinositide concentration 
 
Activation of Gq-coupled GPCRs is a common method used to induce PLC activation and the resulting 
reduction of PIP2 at the PM by hydrolysis (Lee & Rhee, 1995). This method was used by Daleau & 
Turgeon (1994), who observed that angiotensin II reduced the IKs current in guinea pig ventricular 
myocytes, and Matavel & Lopes (2009) in their study into the effects AT1, M1 and BK2 receptor 
activation on IKs channel function, who found that activation of Gq-coupled receptors regulates IKs 
channels in a biphasic manner.  
In these kinds of experiments PIP2 depletion occurs, but a multitude of other cellular signalling 
pathways are also set in motion upon GPCR stimulation. Solely from the hydrolysis of PIP2 to form IP3 
and DAG, there are many downstream effects: IP3 binds to the Ins3PR, resulting in Ca
2+ release from 
the SR (Lee et al., 2003), and DAG activates PKC (Tewson et al., 2012) (figure 19).  Using receptor 
activation in an attempt to determine the precise role of PIP2 in a physiological process greatly 






Figure 19. Signalling downstream of Gq-coupled GPCR activation. (1) Activation of a Gq-coupled GPCR, for 
example the ATIR by angiotensin II, causes activation of PLC. (2) PLC hydrolyses PIP2 to DAG and IP3. IP3 is 
released into the cytoplasm while DAG remains anchored in the PM. (3) IP3 binds to the inositol-3-phosphate 
receptor (Ins3PR) in the ER membrane, which when activated releases Ca
2+
 from the ER (or SR) into the 
cytoplasm, and DAG activates PKC.  
 
Other methods that can be used, but are unfortunately also non-specific, include the inhibition of PI-
kinase activity by wortmannin, the steroid metabolite of the fungi Penicillium funiculosum. This 
technique is widely used to study the effects of PIP2 depletion, because at micromolar 
concentrations wortmannin inhibits PI4K activity leading to loss of PI4P, the precursor PI to PIP2 
(Nakanishi et al., 1995; Meyers & Cantley, 1997). This method does not take into account effects on 
PI4P or the fact that at lower (nanomolar) concentrations, wortmannin inhibits PI3K activity. PI3K 
inhibition will halt the synthesis of PIP3, a PI shown to bind to KCNQ1 along with many other anionic 
phospholipids (Thomas et al, 2011). Nonetheless, wortmannin has been used by various groups in 
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studies investigating the effects of PIP2 depletion on Kv channels (Brown et al, 2007; Suh & Hille, 
2002; Rodriguez-Menchaca et al, 2012). 
Despite the use of wortmannin providing a means for PIP2 depletion, that lack of its specificity for 
one PIK means it can only provide crude answers regarding the effects of PIP2 depletion. 
Distinguishing between the effects of PIP2 and PIP3 depletion on the channel in this situation is not 
possible. However, using wortmannin as a quick tool to uncover any striking effects of PIP2 depletion 
can be beneficial and precede more specific studies, and Matavel & Lopes (2009) reported that 100 
nM WTM treatment (a concentration that completely inhibits PI3K activity) caused no inhibition of IKs 
current in their studies.  
2.6.2 Phosphoinositide phosphatases 
 
PI phosphatases dephosphorylate a certain PI to another PI without releasing second messengers 
into the cell, and provide an answer to the problem of non-specific PI-depletion methods. For 
example, PI 4-phosphatases and PI 5-phosphatases are able to dephosphorylate PIP2 on the 4 and 5 
positions, respectively. This results in a decrease of the PIP2 concentration without activation of 
downstream pathways.  
Voltage-sensitive phosphatases 
 
In the recent past it was recognised that the voltage-sensor domains contained within some ion 
channels, such as Kv channels, are not unique in their ability to convert the input of a change in 
membrane potential to an output of an alteration in protein function (Hossain et al., 2008; Murate et 
al., 2005; Sasaki et al., 2006).   
Voltage-sensitive phosphatases (VSPs) act in a similar way to ion channels, in the respect that a VSP 
can convert a change in membrane potential into alteration in protein function – in VSPs this is the 
activation of a phosphatase domain.  VSPs are endogenously expressed in some organisms, but can 
be expressed in experimental systems to enable manipulation of PIP2 levels in the PM. Like voltage-
gated ion channels, these phosphatases contain an integral membrane VSD, but instead of a PD the 
VSP contains a cytoplasmic phosphatase domain. VSPs from ascidian, Ciona intestinalis, (Ci-VSP) and 
zebrafish, Danio rerio, (Dr-VSP) both contain a VSD that is homologous to S1–4 (i.e. the VSD) of Kv 
channels, and a phosphatase domain similar to that of PTEN (Hossain et al., 2008). 
When the membrane potential changes these VSPs exhibit a gating charge, which suggests a 
conformational change in the VSD in response to the change in membrane voltage. This 
conformational change in the VSD is translated into activation of the phosphatase domain, leading to 
122 
 
depletion of surrounding lipid molecules (Murata et al., 2005). Murata & Okamura (2007) found that 
VSPs are activated in response to depolarisation of the membrane, and unlike PTEN, whose substrate 
is PIP3, these VSPs dephosphorylate PIP2.  
The activation of Dr-VSP and Ci-VSP occurs at physiologically relevant membrane potentials, i.e. 
those that are experienced by myocytes during the cardiac action potential (figure 20). Because of 
this, these VSPs are useful in deciphering how cellular processes respond to PIP2 depletion. In this 
project, both Ci-VSP and Dr-VSP were used to deplete PIP2 at the PM whilst recording the response 
of the IKs current.  
 
Figure 20. Structure and activation of voltage-sensitive phosphatases. A – Schematic representation of 
voltage-sensitive phosphatases. The transmembrane S1–S4 domains are linked to an intracellular phosphatase 
domain. Depolarisation of the PM activates the voltage-sensitive phosphatase, causing a conformational 
change in the phosphatase domain to enable dephosphorylation of PIP2 to PI4P. B – ‘Gating’ or sensing 
currents evoked at 160 mV under whole-cell patch clamp from tsA201 cells transfected with Ci-VSP (blue) and 
Dr-VSP (red). C – charge–voltage (Q–V) relations of Ci-VSP (blue) and Dr-VSP (red). Normalised values of Off-
charges are shown as mean and standard deviations, collected from 6 and 5 cells for Ci-VSP and Dr-VSP, 
respectively. Maximum Off-charges were 2.89 ± 0.3 pC pF
−1
 and 0.11 ± 0.1 pC pF
−1
 for Ci-VSP and Dr-VSP, 




2.6.3 Chemically induced dimerisation systems 
 
The chemically induced dimerisation (CID) systems that have been developed also make use of PI 
phosphatase activity, but induce lipid depletion in a different way. These systems also avoid the 
problems faced by other non-specific methods by being selective for particular PI species and 
preventing the release of second messengers into the cell. CID systems exploit the ability of certain 
chemicals to bind two different proteins simultaneously, which results in the dimerisation of the two 
proteins. One such chemical, rapamycin, is an immunosuppressant drug that is used in cancer 
treatment as it possesses anti-tumour and immunosuppressant properties (Law, 2005).  
Rapamycin binds to FK506 binding protein (FKBP) 12, a member of the immunophillin family. This 
structurally diverse group of proteins possess peptidylprolyl cis-trans isomerase activity (Ballou & Lin, 
2008), which is inhibited upon binding of the drug. Tacrolimus (FK506) also binds to FKBP and, like 
the structurally unrelated cyclophillins, displays immunosuppressant activity when in the protein-
drug complex by docking with the protein phosphatase 2B (PP2B) and inhibiting its phosphatase 
activity. This leads to the phosphorylation of PP2B substrates, including nuclear factor of activated T 
cells, and as a result of this, a number of genes important in the T cell immune response are not 
expressed and the immune response is supressed (Barik et al., 2006).  
The FKBP-rapamycin complex exerts its function in a different way – by binding to the mammalian 
target of rapamycin (mTOR). mTOR is a serine/threonine kinase that is part of the PI3K-related kinase  
family, as its catalytic site closely resembles that of PI3K. mTOR has many functions physiologically, 
including promoting cell growth, proliferation and survival. The binding of mTOR to the FKBP-
rapamycin complex via one of its catalytic pockets, known as the FKBP-rapamycin binding (FRB) 
domain (figure 21), results in the inhibition of some of its functions. As mTOR is upregulated in many 
cancers, inhibition of mTOR activity can be useful in cancer therapy (Porta et al., 2014). 
Given that rapamycin binds to both FRB and FKBP, and that these protein domains can be linked to a 
variety of effector proteins, this system can be used for a wide variety of PI manipulations within a 
cell. Throughout this project, various constructs containing the FRB and FKBP domains were used. 
These constructs were either tethered to the location of phosphoinositide (i.e. the PM or Golgi) or 
contained phosphatase domains (to dephosphorylate PIs).  
2.6.4 Lipid-depleting constructs used in CID 
 
Constructs that were tethered to cell membranes containing the PIs of interest were linked to the 
FRB domain. Untagged LYN11-FRB (LYN11-targeted-FRB) (20147, Addgene; deposited by Tobias 
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Meyer), LYN11-FRB-CFP (38003, Addgene) and LYN11-FRB-mCherry (38004, Addgene; both 
deposited by Robin Irvine), and Tgn38-FRB from Tamas Balla were used in this project. Only the 
fragment of mTOR that binds the FKBP-rapamycin complex was contained in the FRB-containing 
constructs. LYN11-FRB constructs are tethered to the PM by a LYN11 sequence (GCIKSKGKDSA) 
(Inoue, 2005) which is then attached to the FRB domain, and Tgn38-FRB is tethered to the TGN by 
using the integral TGN membrane protein, Tgn38, in which a Tyr motif in the cytoplasmic domain is 
responsible for its localisation (Bos et al., 1993). A fluorescent tag was also attached to a number of 
these constructs to allow their visualisation, and was attached to the C-terminal end of the 
constructs used here. The names and characteristics of these constructs are shown in table 5.  
FKBP-containing constructs were ones that included phosphatase domains or kinase domains: PJ 
(37999), PJ-SAC (38000), PJ-INPP5E (38001) and PJ-DEAD (38002) (all from Addgene; all deposited by 
Robin Irvine). All these constructs contain an RFP tag at the N-terminal end. Each of these constructs 
consists of an RFP domain, SAC1 domain, INPP5E domain and an FKBP domain. The SAC1 domain of 
these constructs codes for the SAC1 PI-phosphatase, which dephosphorylates PIs on the 4-position. 
However, interestingly this phosphatase has no activity against PIP2. The INPP5E domain codes for an 
IP3 5-phosphatase, which dephosphorylates PIP2 on the 5 position.  
In PJ, named so because of its similarity to synaptojanin, both phosphatase domains are active. PJ-
SAC contains an inactivating mutation (Asp1263Ala) in the INPP5E domain, and PJ-INPP5E contains 
an inactivating mutation (Cys779Ser) in the SAC1 domain. Therefore, PJ-SAC dephosphorylates only 
PI4P at the 4-position, and PJ-INPP5E dephosphorylates only PIP2 at the 5-position. PJ-DEAD contains 
both inactivating mutations (Asp1263Ala and Cys779Ser). Hence, PJ-DEAD is a control construct 
(figure 22).  
Due to the membrane-tethered nature of FRB-containing constructs, rapamycin addition causes the 
translocation of the FKBP-containing constructs to that same membrane. Figure 23 uses PJ and 
LYN11-FRB as an example, showing that after rapamycin is applied to the cells containing these 
constructs and the consequent dimerisation has occurred, the FKBP-containing construct can exert 




















Figure 21. FRB-Rapamycin-FKBP binding. The chemical tructure of rapamycin showing the FKBP and FRB 
binding domains (Edwards et al, 2007). FRB and FKBP bind to separate sites on the rapamycin molecule, and as 














Figure 22. Lipid-depleting construct plasmid map and mutation location. Top: plasmid map of the Pseudojanin 
construct, and bottom: each of the lipid-depleting constructs showing the location of the inactivating mutation 





Figure 23. Rapamycin-induced recruitment of lipid-depleting constructs to the plasma membrane.  
Pseudojanin (PJ), a fusion of RFP, SAC1 phosphatase, INPP5E phosphatase and an FKBP domain, and its 
rapamycin-induced recruitment to the plasma membrane-bound LYN11-FRB-CFP through the simultaneous 
binding of the FKBP and FRB domains to the rapamycin molecule. The SAC1 phosphatase converts PI4P to PI, 
and the INPP5E phosphatase converts PI(4,5)P2 (PIP2) to PI4P.    
CID construct Function  
Pseudojanin PIP2 and PI4P depletion 
PJ-INPP5E PIP2 depletion 
PJ-SAC PI4P depletion 
PJ-DEAD No PI depletion (Control) 
CF-PIPKi PIP2 synthesis 
LYN11-FRB-CFP PM-tethered FRB, tagged with CFP 
LYN11-FRB-mCherry PM-tethered FRB, tagged with mCherry 
LYN11-targeted-FRB PM-tethered FRB (untagged) 
Tgn38-FRB TGN-tethered FRB, tagged with YFP 
 
Table 5. CID constructs and their functions. Each construct used in the rapamycin-induced dimerisation and a 
summary of its function. PJ, PJ-SAC, PJ-INPP5E, PJ-DEAD and CF-PIPKi are FKBP-containing constructs, and the 




All statistical tests were performed in Graphpad Prism. Paired and unpaired Student’s T tests and 
one-way analysis of variance (AVONA) with Dunnett’s or Bonferroni’s post hoc test were performed 
127 
 
in this project. A Boltzmann function was applied to steady state of activation graphs to fit a 
sigmoidal curve to the data. These will all be described below.   
Student’s t-test 
 
A Student’s t-test is used to determine if the mean of two samples from a normally distributed small 
population with assumed equal variance are significantly different from one another, taking into 
account the variability of the data. A t-test calculates the difference between group means divided 
by the variability within each group (standard error of the difference). To calculate the standard error 
of the difference, the variance for each group is divided by the number of samples in each respective 
group, and these two values are then added and the square root of these taken. The formula for a t-
test is shown in equation 2.4 








     Equation 2.4 
The t value is then looked up in a table of significance to determine whether the t value is large 
enough to say that the difference is not likely to have occurred by chance. The confidence level is 
commonly set at 95%, which means that 5% of the time statistical significance would be found 
between the two small groups of samples even if there was none. To determine statistical 
significance using the table of significance, the degrees of freedom must also be known. This is 
calculated as the sum of the number of samples in both groups minus 2. The p value that is produced 
must be <0.05 (using a 95% confidence level) to reject the null hypothesis. 
A paired t-test is performed when the two sample groups are linked, for example through a ‘before 
and after’ observation or when two treatments are applied to the same subject. In this project a 
paired t-test was used to determine statistical significance before and after drug application. An 




A one-way ANOVA is used to determine statistical significance between the means of 2 or more 
independent (unrelated) groups in which the samples are normally distributed and have assumed 
equal variance (although in this project this test was used only when 3 or more groups were 
compared).  
The sum of squares (SS) values for between-group SS (SSA) and within-group SS (SSs/A) need to be 
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calculated to perform a one-way ANOVA. SSA represents the variation due to treatment, and SSs/A 
represents variation due to individual differences in the score. SSA examines the difference between 
the group means by calculating the variance of each mean around the grand mean, and SSs/A 
examines error variation around each group mean. The df is calculated for each SS value as shown in 
equations 2.5 and 2.6, where a is the number of groups, n is the number of samples within each 
group and N is the total number of samples across all groups. 
𝑑𝑓𝐴 = 𝑎 − 1     equation 2.5 
 
𝑑𝑓𝑠/𝐴 = 𝑎(𝑛 − 1) = 𝑁 − 𝑎    equation 2.6 
The mean sum of squares (MS) is then calculated for both between- and within-group SS by diving by 




      equation 2.7 
If the estimates of the variance between groups is almost the same (i.e. the null hypothesis is true), 
then the F ratio will be close to 1. Using an F table, the p value can be estimated using the F ratio and 
df values.  
On its own, a one-way ANOVA determines significance between any groups compared, but does not 
specify between which groups this is. To do this, a post hoc test is performed. 
The Dunnett’s multiple comparison test calculates significance between the mean of one group and 
the means of every other group, and this test determines the confidence levels for each individual 
comparison. Using this test, each group can be compared to a single control group. The Bonferroni 
test can be used to compare all pairings of groups to specifically determine statistical significance 
between groups. This test suggests that the p value should be equal to the alpha value divided by the 
number of groups, which increases the confidence level. This is introduced because the Bonferroni 
test takes into account familywise error, which represents the probability that any one of a set of 
comparisons is a Type I error (due to chance). The more tests that are performed means that the 
likelihood that significance is proven due to chance increases. To keep the pairwise alpha value at 
0.05, the Bonferroni test recalculates the familywise alpha value. For this reason, however, this test 
can lack power and can lead to a non-significant p value even when a one-way ANOVA has proven 





The Boltzmann function is a form of nonlinear regression analysis that allows a nonlinear curve to be 
fit to the data to describe it in the form of y=f(x), where y is the dependent variable that is measured 
in the experiment and x is the independent variable and its value on the x axis is fixed. f is the 
function used to describe the relationship between y and x. The Boltzmann equation is shown in 













CHAPTER 3: Characterisation of the rapamycin-induced dimerisation system for 




Among the many mechanisms that regulate the function of the IKs channel, including β-subunit 
association (Barhanin et al., 1996; Sanguinetti et al., 1996; Tinel et al., 2000) and β-adrenergic 
signalling through PKA (Walsh & Kass, 1988), is the interaction between the channel and PIP2. This 
minor PM PI and major signalling molecule is thought to regulate the IKs channel by binding near the 
VSD-PD interface, where it stabilises the open conformation of the channel (Loussouarn et al., 2003; 
Zaydmann et al., 2013). Physiologically, Gq/11-coupled receptor activation leads to PIP2 depletion 
through activation of PLC (Lee & Rhee, 1995; Rhee & Choi, 1992). The hydrolysis of PIP2 by PLC 
results in the production of DAG and IP3. It is now known that the loss of PIP2 from the PM in this 
signalling event is the cause of reduced IKs current in experimental systems, and that the presence of 
PIP2 is required for IKs function (Matavel & Lopes, 2009). The experiments leading to these 
conclusions included excised-patch recordings, where it was observed that upon excision of the 
membrane patch the IKs current would run down. Additionally, subsequent addition of PIP2 to the 
exposed patch could restore the IKs current (Loussouarn et al., 2003). 
Several groups have been involved in locating the region of the KCNQ1 subunit where PIP2 binds or 
interacts, and a number of regions have been identified. Park and colleagues mutated residues 
thought to be involved in PIP2 binding and found that IKs channels containing the KCNQ1 mutations 
Arg243His, Arg539Trp or Arg555Cys had a reduced affinity for a soluble analogue of PIP2. The mutant 
channels had a reduced current density, which could be counteracted by direct application of PIP2 to 
the intracellular side of the PM in excised patches (Park et al., 2005).   
Previous work in this laboratory (Thomas et al., 2011) identified a PIP2 binding region in the proximal 
C-terminus of the KCNQ1 subunit. Additionally, in unpublished work it was found that mutations in 
this PIP2 binding region resulted in an increased level of channel retention in the ER. The ER-
retention was observed using confocal microscopy, where co-localisation of the GFP-tagged KCNQ1 
subunit with DsRed2-ER, a fluorescent ER-marker, was used as a surrogate marker for retention of 
the channel in the ER. I have subsequently repeated these experiments and found a similar trend 
(figure 24). The mechanisms that lead to increased ER-retention of the channel are unknown, but 
could be due to a role that PIP2-binding plays in anterograde trafficking of the channel from the ER 
through the secretory pathway to the PM. Alternatively, the introduced mutation(s) could cause 
protein misfolding and consequently reduce the ability of the channel to exit the ER. 
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The study of PIP2-binding-region mutations in KCNQ1 has shed some light on how the IKs channel is 
regulated by PIP2. However, studies that manipulate PIP2 levels whilst recording the effect on the WT 
channel are mostly limited to those using non-selective PIP2-depletion mechanisms that may also 
result in complex downstream effects. Examples include the activation of Gq/11-coupled receptors, 
which leads to PIP2 depletion via PLC activation and the release of the second messengers DAG and 
IP3 into the cell, or addition of wortmannin, which inhibits PI4K activity (and hence the production of 
PI4P, the precursor to PIP2) at higher concentrations than those that cause PI3K inhibition (Matavel & 
Lopes, 2009), meaning that effects of both PI3K and PI4K inhibition will be observed. Other 
limitations of previous studies aiming to investigate the effect of PIP2 manipulation on channel 
function include the use of the inside-out configuration of patch clamp (Li et al., 2005). In the inside-
out – or excised-patch – method, the glass micropipette is pulled away from the cell membrane after 
the formation of a giga-seal, revealing the intracellular side of the PM. This method leads to the 
gradual loss of PIP2 from the PM and concomitant rundown of the IKs current (Loussouarn et al., 
2003). This method is employed as it creates the lower baseline reading of IKs current density to 
which the current density after PIP2 addition can be compared, but all other intracellular contents 
are lost with unknown consequences. Another drawback of this method is that the use of soluble 
PIP2 analogues is non-physiological (Park et al., 2005), and a channel’s interaction and reaction with 
different isoforms of membrane phospholipids may be far more diverse than we imagine. The 
rapamycin-induced dimerisation system provides an answer to these pitfalls of previously used 
methods, in that it does not require the use of non-physiological methods of recording (i.e. WCPC 
and P-WCPC can be used), neither does it result in the release of second messengers (as in the case 
of GPCR activation).  
The rapamycin-induced dimerisation system has been used quite extensively to investigate the effect 
of manipulating local pools of PIs. For example, Fili and colleagues recruited myotubularin, a PI 3-
phosphate, to Rab5-positive endosomes to elucidate whether targeted depletion of PI3P led to 
disruption of normal endocytic trafficking through these endosomes (Fili et al., 2006), and Dickson 
and colleagues depleted PI4P at the PM, Golgi or both to determine the location of PIP2 precursor 
pools of PI4P, using the PIP2-sensitive KCNQ2/3 current as an indicator of PIP2 depletion (Dickson et 
al., 2014). This system has also been used to selectively deplete PIP2 at the PM to determine the role 
of PIP2 in transient receptor potential (TRP)M8 channel activity, and transferrin and epidermal 
growth factor receptor internalisation (Varnai et al., 2006). Others have also used this system to 
investigate how manipulation of PIP2 at the PM affects a range of different ion channels (Kruse et al., 
2012; Lukacs et al., 2007; Suh & Hille, 2006)  
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Despite its extensive and varied use in PI manipulation over the past decade, the rapamycin-induced 
dimerisation system has not been used solely for the purpose of investigating the role of PIP2 in the 
regulation of trafficking and function of the IKs channel.  As a consequence, a number of experiments 
were initially performed to characterise whether this dimerisation system can be used to model the 
effect of PIP2 depletion on the IKs channel.  
This chapter describes the characterisation of this system, which involves direct dephosphorylation 
of PI4P and/or PIP2 at the PM (Suh & Hille, 2006; Varnai et al., 2006). Rapamycin is used as a 
dimerising agent, which is added to cells expressing two constructs that bind to distinct sites on the 
rapamycin molecule. When rapamycin is added to the cells, a construct containing PI-phosphatase 
domains is recruited to a PM-anchored construct. The dimerisation of the two constructs brings the 
phosphatase domains into close proximity to the PM, where PIP2 and PI4P may reside. By 
dephosphorylating instead of hydrolysing PIP2 during intact cellular recordings, this system avoids 
the problems associated with other PI manipulation systems.  
Aims: To characterise and establish the effectiveness of the rapamycin-inducible dimerisation system 







Figure 24. The effect of introducing mutations into a PIP2-binding region in the C-terminus of KCNQ1 on the 
localisation of the KCNQ1 subunit in CHO-K1 cells. A – The localisation of WT and mutant KCNQ1-GFP in CHO-
K1 cells. The left column shows the GFP-tagged KCNQ1 subunit, the middle column shows DsRed-ER, an ER 
marker, and the right column shows the merged images. The top row shows the localisation of the WT KCNQ1-
GFP with KCNE1, while all rows below show the localisation of the mutant KCNQ1 subunits investigated (all 
n=25, except KCNQ1(R360A-GFP), where n=24). B – A bar graph showing the proportion of ER colocalisation of 








The following plasmids were obtained from Addgene and were deposited there by the Irvine 
laboratory, with exception of LYN11-targeted-FRB, which was deposited by the Tobias Meyer 
laboratory.  
PJ (#37999), PJ-SAC (#38000), PJ-INPP5E (#38001) and PJ-DEAD (#38002) consist of the same 
domains. PJ-SAC contains the Asp1263Ala mutation to inactivate the INPP5E domain, and PJ-INPP5E 
contains the Cys779Ser mutation to inactivate the SAC1 domain. PJ-DEAD contains the inactivated 
version of both enzymes. These four constructs are contained within the pmRFP-C1 mammalian 
expression vector (figure 22). For full cloning details please refer to Hammond et al. (2012).  
LYN11-FRB-CFP (#38003) and LYN11-targeted-FRB (#20147) contain both the PM-targeted LYN11 
sequence and the FRB domain, while LYN11-FRB-CFP also contains a C-terminal CFP domain. LYN11-
targeted-FRB is contained in the pC4-RHE mammalian expression vector, and LYN11-FRB-CFP is 
contained in the pmCherry-N1 mammalian expression vector. Both of these PM-targeted FRB-
containing constructs were used interchangeably throughout the project, and the term LYN11-FRB 
will be used in their place.  
3.2.2 Electrophysiology 
 
Currents were recorded from a KCNQ1-eGFP/KCNE1 stably expressing HEK293 cell line (referred to as 
HEK-IKs cells from here onwards) either untransfected or transiently transfected. Untransfected HEK-
IKs cells were used 48–72 hours after seeding, and transfected HEK-IKs cells were used 48–72 hours 
after transfection. For lipid-depleting experiments, 500 ng PJ, PJ-SAC, PJ-INPP5E or PJ-DEAD were 
transfected with 500 ng of LYN11-FRB. Additionally, where stated, 100 ng empty eYFP-C1 vector was 
transfected for identification of successfully transfected cells by epifluorescence. All transfections 
were performed using FuGENE HD as described in section 2.1.3. 
WCPC was used to record the IKs current in HEK-IKs cells, and IK1 or IKr currents from HEK-IK1 and HEK-
IKr cells, respectively. WCPC experiments were carried out at room temperature using an Axopatch 
200B amplifier (Axon Instruments) and transfected cells were identified using epifluorescence. 
Extracellular bath solution for all experiments with HEK-IKs and HEK-IK1 cells contained (mM) 150 
NaCl, 5 KCl, 10 HEPES, 2 MgCl2 and 1 CaCl2 (pH 7.4 with NaOH). Extracellular bath solution for all 
experiments with HEK-IKr cells contained (mM) 150 NaCl, 4 KCl, 10 HEPES, 1 MgCl2, 1.8 CaCl2 and 5 
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glucose (pH 7.4 with NaOH). In all experiments, Rseries was compensated for by 70% using the 
amplifier circuitry. 
The intracellular pipette solution contained (mM) 150 KCl, 10 HEPES, 5 EGTA, 2 MgCl2, 1 CaCl2 and 5 
(Na)2ATP (pH 7.2 with KOH). Pipette resistance, when pipettes were filled with intracellular solution, 
was 2–3 MΩ. Pipette tips were coated with SigmaCote (SL2, Sigma) after being filled with 
intracellular solution, to reduce pipette capacitance. After seal formation and successful membrane-
patch rupture, cells were left to dialyse for 2 minutes before recording. I-V protocols were recorded 
by holding the cells at -80mV before a 6-second activation pulse, from -80 mV to +50 mV or +80 mV, 
in 10 mV increments. After the 6-second pulse, a 2-second repolarising step to -20 mV was used to 
record tail currents, before stepping back to -80 mV. 
In experiments involving the perfusion of rapamycin (sc-3504, Santa Cruz) over the cells, extracellular 
solution containing rapamycin (5 μM) was perfused for 2 minutes, and perfusion was then returned 
to rapamycin-free extracellular solution. 
Inclusion criteria for recordings to be analysed included: a leak current of less than 10% macroscopic 
current amplitude, maximum current amplitude of 19 nA and maximum Rs of 10 MΩ. Data from all 
experiments was analysed using Clampfit (Molecular Devices, CA, U.S.A) and GraphPad Prism (San 
Diego, CA, U.S.A). Current density (CD) was calculated by normalising the peak current value at the 
end of each activating pulse to the cell capacitance (nA/pF). Peak tail current density (PTCD) was 
calculated by normalising the peak tail current value at the start of the repolarising pulse to cell 
capacitance (pA/pF). Steady state activation (SSA) curves allow the voltage at which half-maximal 
activation occurs (V0.5) to be calculated.  These were constructed by plotting normalised PTCD 
density values (y/ymax) against membrane potential (Vm). Curves were fitted and V0.5 values were 
determined using a Boltzmann function. 
3.2.3 Statistical analysis 
 
Data are expressed as mean ± SE, and Boltzmann functions were generated using GraphPad Prism. A 
Student T Test was used to determine statistical significance for single comparisons (p <0.05), and a 
one-way ANOVA (p <0.05) was used to determine significance when multiple groups were compared. 
For one-way ANOVA analyses, a Bonferroni’s multiple comparison test was used to compare each 
pair of conditions. Where possible, an asterisk (*) was added to graphs to indicate that the 
comparison to control reached statistical significance.  
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3.2.4 Confocal microscopy 
 
Live cells were imaged using a Zeiss LSM510 (Mark 4) (Carl Zeiss, Oberkochen, Germany) confocal 
microscope and a Plan-Apochromat 63x oil lens objective. CFP and YFP were excited with a multiline 
argon laser (CFP: wavelength 458 nm; YFP: wavelength 488 nm) and RFP was excited using a 
helium/neon laser (wavelength 543 nm). When imaging CFP, a 465-510 bandpass (BP) filter was 
used, and when imaging GFP a 505–530 BP filter was used, which prevented bleedthrough of the 
GFP fluorescence into the spectrum of the RFP signal. YFP was also imaged using the 505–530 BP 
filter to avoid overlap between the YFP and RFP spectra. Images were taken at 1024 x 1024 frame 
size, a bit depth of 16bit, and a pinhole aperture of 1 Airy unit.. The two FPs expressed  were excited 
sequentially to prevent crosstalk. Post image acquisition, images were median-filtered, converted to 




3.3.1 Cellular localisation of lipid-depleting constructs, and their rapamycin-induced dimerisation 
 
Before using the lipid-depleting constructs for patch clamp experiments, their cellular localisation 
and ability to translocate after the addition of rapamycin was determined using confocal microscopy. 
When lipid-depleting constructs were transiently expressed in HEK293 cells they showed a 
cytoplasmic and nuclear localisation, which was observed using confocal microscopy. In the same 
cells, the LYN11-FRB-containing constructs were localised to the PM (figure 25A). 
To assess the effectiveness of rapamycin at inducing the dimerisation of the FRB- and FKBP-
containing constructs, rapamycin (5μM) was added to cells so the movement of the constructs could 
be visualised. When rapamycin was added to cells expressing PJ and LYN11-FRB, PJ visibly 
translocated to the PM in approximately 30 seconds (figure 26). Quantification of PJ and LYN11-FRB 
signal intensity confirm that PJ moved from the cytoplasm to the PM on addition of rapamycin 
(figure 26B), and this is supported by the observation that the RFP signal intensity in the cytoplasm 
reduced by approximately  60% and 70% after 1 and 2 minutes of rapamycin (5 µM) perfusion, 
respectively (figure 26C). 
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3.3.2 Effect of transiently expressing lipid-depleting constructs in HEK-IKs and CHO-K1 cells on the 
IKs current 
 
After the cellular localisation of the constructs and ability to induce translocation of PJ to the PM 
upon the addition of rapamycin was confirmed, these constructs were transiently expressed in HEK-
IKs cells, and the IKs current was recorded using WCPC (figure 26). The enzymatically dead mutant of 
the lipid-depleting constructs, PJ-DEAD, was expressed with LYN11-FRB in these cells to ensure no 
change in the IKs current occurred that could not be attributed to the phosphatase domains. 
Expression of PJ-DEAD and LYN11-FRB had no effect on the IKs current density or peak tail current 
density (figure 26B). 
Next, PJ-SAC, PJ-INPP5E or PJ were transiently expressed with LYN11-FRB in HEK- IKs cells, and the IKs 
current was recorded in each condition. Expression of PJ-SAC with LYN11-FRB had no effect on the IKs 
current density or peak tail current density (p=NS), while expression of PJ-INPP5E with LYN11-FRB 
resulted in a reduction of the IKs current density and peak tail current density by approximately 50% 
(p<0.005 across all voltages analysed for both CD and PTCD). The current in the presence of PJ-
INPP5E and LYN11-FRB was also significantly reduced compared to PJ-DEAD and LYN11-FRB (p<0.001 
across all voltages analysed for both CD and PTCD). Expression of PJ with LYN11-FRB in HEK-IKs cells 
caused a complete loss of the IKs current (p<0.001 across all voltages analysed for CD and PTCD when 
compared to control or PJ-DEAD). It was therefore not possible to normalise tail current values for 
currents recorded when the cells were expressing PJ and LYN11-FRB, and the voltage-dependence of 
activation curve could not be plotted. Analysis of the voltage-dependence of activation during 
expression of PJ-DEAD, PJ-SAC or PJ-INPP5E with LYN11-FRB showed there was an effect on the V0.5 
values (figure 26C), which was significant (p<0.05) between control and PJ-DEAD and PJ-INPP5E, 
respectively. There was also a significant difference (p<0.05) between the V0.5 values for PJ-SAC and 
PJ-INPP5E.  
Due to the complete loss of IKs current that was observed in the HEK-IKs cells when expressing PJ with 
LYN11-FRB, a similar experiment was performed in CHO-K1 cells to rule out cell-type-specific effects. 
The IKs channel subunits, KCNQ1 and KCNE1, were expressed in CHO-K1 cells with LYN11-FRB and PJ-
DEAD, and the resulting current was recorded in WCPC. While expressing PJ-DEAD, an IKs-like current 
was recorded. However, the expression of PJ in place of PJ-DEAD caused almost a complete loss of 
the current (figure 30) as previously seen in HEK-IKs cells, which was significant (p<0.0001) across all 
voltages analysed for both CD and PTCD.  
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3.3.3 The effect of rapamycin-induced recruitment of lipid-depleting constructs on the cellular 
localisation of Tubby in HEK293 cells 
 
To determine if the loss of IKs current observed in both HEK-IKs cells and CHO-K1 cells transiently 
expressing the IKs channel subunits was due to loss of PIP2, Tubby-YFP was used as an indicator of 
PIP2 depletion. Tubby-YFP binds to PIP2 through its PIP2-binding domain, and upon depletion of PIP2, 
Tubby-YFP will move from the PM (Quinn et al., 2008).  
PJ-DEAD or PJ were transiently expressed with LYN11-FRB and Tubby-YFP in HEK293 cells, and a time 
series experiment was performed using confocal microscopy. When rapamycin (5 μM) was added to 
cells expressing PJ-DEAD or PJ with LYN11-FRB and Tubby-YFP, both PJ-DEAD and PJ translocated from 
the cytosol/nucleus to the PM in 30–45 seconds (figures 28A & 29A). In cells expressing PJ-DEAD, 
there was no movement of Tubby-YFP after translocation of PJ-DEAD to the PM (figure 28). However, 
in cells expressing PJ, Tubby-YFP underwent a rapid redistribution after the translocation of PJ to the 
PM. At 45 seconds after rapamycin addition, Tubby-YFP had partially moved from the PM to the 
cytosol, and at 60 seconds had showed a complete redistribution (figure 29). Quantification of PJ/PJ-
DEAD and Tubby-YFP signal intensity before and after rapamycin (5 µM) addition confirms that as PJ-
DEAD moved from the cytoplasm to the PM on addition of rapamycin (figure 28B), the fluorescence 
intensity did not alter for Tubby-YFP; however, when PJ translocated from the cytoplasm to the PM, 
Tubby-YFP moved from the PM to the cytoplasm. These observations are supported by the analysis 
of fluorescence signal intensity in a region of cytoplasm, which showed the decrease in RFP signal 
intensity from both PJ and PJ-DEAD after rapamycin (5µM) addition, and the concomitant increase in 
Tubby-YFP in cells expressing PJ, but not in those expressing PJ-DEAD (figure 28C & 29C).   
3.3.4 Effect of transiently expressing PJ in the absence of LYN11-FRB in HEK-IKs cells 
 
Due to the inhibition of the IKs current that occurred when PJ or PJ-INPP5E were transiently expressed 
with the PM-located LYN11-FRB in both HEK-IKs and CHO-K1 cells, PJ was expressed in HEK-IKs cells 
without its dimerisation partner, LYN11-FRB. 
Expression of PJ alone in HEK-IKs cells did not cause complete inhibition of the IKs current, as 
previously seen when PJ was expressed with LYN11-FRB. Instead, only a partial reduction 
(approximately 50%) of the IKs current and tail current densities was observed, but this was also a 
significant reduction compared to control cells (current density: 30 mV & 40 mV = p<0.05; 50 mV = 
p<0.01; peak tail current density: 30 mV = p<0.05; 40 mV & 50 mV = p<0.01) (figure 31).    
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3.3.5 Effect of incubating HEK-IKs cells in OptiMEM I whilst transiently expressing lipid-depleting 
constructs 
 
In all previous experiments, HEK293 cells and cell lines were incubated in MEM media (detailed in 
section 2.1.1). This media is supplemented with FBS and antibiotics to support the growth of the 
cultured cells. Whilst this does not commonly interfere with experiments, FBS does contain many 
non-defined growth-promoting and survival-enhancing factors, which could potentially interfere with 
the dimerisation system components. To ensure that contents of the culture media were not 
interfering with the dimerisation system and causing the IKs inhibition observed, OptiMEM I was used 
in place of MEM media to culture the cells in the 24 hours prior to patch clamp experiments. 
Incubation of HEK-IKs cells expressing PJ and LYN11-FRB in OptiMEM I for 24 hours prior to WCPC 
recording still resulted in complete inhibition of the IKs current, showing no difference between the 
incubation of cells in OptiMEM I and the normal culture media. There remained a significant 













Figure 25. The localisation of lipid-depleting constructs in HEK293 cells. Cellular localisation of lipid-depleting 
constructs and LYN11-FRB-CFP construct. LYN11-FRB-CFP has a plasma membrane localisation, and the lipid-
depleting constructs are expressed throughout the cytoplasm and nucleus. Pseudojanin and LYN11-FRB-CFP 
show the same expression pattern when expressed together. Images were taken using confocal microscopy. 




Figure 26. The localisation of pseudojanin (PJ) in HEK293 cells before and after the rapamycin-induced 
recruitment of PJ to the PM in HEK293 cells.  A – Rapamycin(Rap)-induced dimerisation of PJ and LYN11-FRB-
CFP. Pseudojanin contains the FKBP domain, which translocates to the PM, the location of LYN11-FRB, upon 
addition of Rap. Top panel: Before rapamycin addition. Lower panels: Increasing time after addition of 
rapamycin showing the increased PM signal of the PJ construct. Images taken using confocal microscopy. B – 
Normalised (y/ymax) intensity of fluorescence of CFP and RFP along the red line illustrated in the top right-hand 
image (before Rap) and bottom right-hand image (+ Rap 60 secs) in A. Green represents LYN11-FRB-CFP and 
red represents PJ in both B and C. C – Change in fluorescence intensity over time measured from region of 
interest shown by red box in top right-hand image in A (relative to value from image 1 of time series). 










































































































































































































































































































































































































































































































































































































Figure 28. The localisation of Tubby-YFP in HEK293 cells before and after the rapamycin-induced recruitment 
of PJ-DEAD to the PM in HEK293 cells. A – Rapamycin (Rap)-induced dimerisation of PJ-DEAD and LYN11-
targeted-FRB (the untagged version of LYN11-FRB) and the localisation of Tubby-YFP. Pseudojanin contains the 
FKBP domain, which translocates to the PM, the location of LYN11-targeted-FRB, upon addition of rapamycin 
(Rap). Tubby localises to the PM in the presence of a sufficient concentration of PIP2. Top panel: Before 
rapamycin addition. Lower panels: Increasing time after addition of rapamycin showing the increased PM 
signal of PJ-DEAD, whilst Tubby-YFP remains at the PM. Images taken using confocal microscopy. B – 
Normalised (y/ymax) intensity of fluorescence of YFP and RFP along the red line illustrated in the top right-hand 
image (before Rap) and bottom right-hand image (+ Rap 60 secs) in A. Green represents Tubby-YFP and red 
represents PJ-DEAD in both B and C. C – Change in fluorescence intensity over time measured from region of 
interest shown by red box in top right-hand image in A (relative to value from image 1 of time series). 




Figure 29. The localisation of Tubby-YFP in HEK293 cells before and after the rapamycin-induced recruitment 
of PJ to the PM in HEK293 cells. A – Rapamycin (Rap)-induced dimerisation of Pseudojanin (PJ) and LYN11-
targeted-FRB (the untagged version of LYN11-FRB) and the localisation of Tubby-YFP. Pseudojanin contains the 
FKBP domain, which translocates to the PM, the location of LYN11-targeted-FRB, upon addition of rapamycin 
(Rap). Tubby localises to the PM in the presence of a sufficient concentration of PIP2. Top panel: Before 
rapamycin addition. Lower panels: Increasing time after addition of rapamycin showing the increased PM 
signal of PJ and the redistribution of Tubby-YFP from the PM to the cytosol. Images taken using confocal 
microscopy. B – Normalised (y/ymax) intensity of fluorescence of YFP and RFP along the red line illustrated in 
the top right-hand image (before Rap) and bottom right-hand image (+ Rap 60 secs) in A. Green represents 
Tubby-YFP and red represents PJ in both B and C. C – Change in fluorescence intensity over time measured 
from region of interest shown by red box in top right-hand image in A (relative to value from image 1 of time 




Figure 30. The effect of expressing CID constructs in CHO-K1 cells expressing the IKs channel. A – 
Representative traces of currents recorded in WCPC from CHO-K1 cells transiently expressing the KCNQ1 and 
KCNE1 subunits with LYN11-FRB and either PJ-DEAD or PJ. B – Voltage protocol used to elicit current recorded. 
C – Mean current density (top) and peak tail current density (bottom) of currents recorded in WCPC from CHO-
K1 cells transiently expressing the KCNQ1 and KCNE1 subunits with LYN11-FRB and either PJ-DEAD (n=12) or 
Pseudojanin (PJ) (n=11). Data are presented as mean ± SE. An unpaired t-test was performed to determine 







Figure 31. The effect of expressing pseudojanin alone on the IKs current in HEK-IKs cells. A – Representative 
traces of currents recorded in WCPC from untransfected HEK-IKs cells (control), and HEK-IKs cells transiently 
expressing PJ. B – Voltage protocol used to elicit current recorded. C – Mean current density (top) and peak tail 
current density (bottom) of currents recorded in WCPC from untransfected HEK-IKs cells (control; n=12) and 
HEK-IKs cells transiently expressing PJ (n=12). Data are presented as mean ± SE. An unpaired t-test was 





Figure 32. The effect of expressing lipid-depleting constructs on the IKs current in HEK-IKs cells incubated in 
Opti-MEM I. A – Representative traces of currents recorded in WCPC from untransfected HEK-IKs cells (control; 
n=9), and HEK-IKs cells transiently expressing PJ and LYN11-FRB that were incubated in Opti-MEM I for 24 hours 
prior to recording (n=10). B – Voltage protocol used to elicit current recorded. C – Mean current density (left) 
and peak tail current density (right) of currents recorded in WCPC from untransfected HEK-IKs cells (control) and 
HEK-IKs cells transiently expressing PJ and LYN11-FRB that were incubated in Opti-MEM I for 24 hours prior to 
recording. Data are presented as mean ± SE. An unpaired t-test was performed to determine statistical 




3.3.6 Effect of transiently overexpressing lipid-depleting constructs in CHO-K1 cells transiently 
expressing KCNQ1 without KCNE1 
 
To investigate whether the KCNE1 subunit plays a role in the IKs inhibition that occurred in HEK-IKs 
cells and CHO-K1 cells expressing the IKs channel subunits, the KCNQ1 subunit was transiently 
expressed in CHO-K1 cells with LYN11-FRB and either PJ or PJ-DEAD. CHO-K1 cells were used here 
instead of HEK-IKs cells because the outward steady state current from the homomeric KCNQ1 
channel is not large enough to be effectively distinguished from the macroscopic endogenous 
outward HEK293-cell current. 
Expression of KCNQ1 with PJ-DEAD and LYN11-FRB in CHO-K1 cells elicited a current resembling that 
of the homomeric KCNQ1 channel in WCPC. However, when PJ and LYN11-FRB were expressed 
together, there was a drastic and significant loss of the KCNQ1 steady state (p<0.0001 across all 
voltages analysed) and tail currents (p<0.0005 across all voltages analysed) (figure 33). As there was 
virtually no resulting tail current when expressing PJ with LYN11-FRB, the voltage-dependence of 
activation curve could not be plotted. 
3.3.7 Effect of transiently overexpressing lipid-depleting constructs in HEK-IK1 cells, and the effect 
of recruiting the lipid-depleting constructs to the plasma membrane using rapamycin 
 
As other K+ currents contribute to phase-3 repolarisation, the sensitivity of these to expression of the 
lipid-depleting constructs was investigated. For comparison with the IKs channel expressed in the 
HEK-IKs cell line, the IK1 (Kir2.1) channel was stably expressed in HEK293 cells, and the resulting cell 
line named HEK-IK1. The use of this cell line enabled further investigation into whether the effect of 
lipid-depleting construct expression is specific to KCNQ1-containing channels.   
LYN11-FRB and either PJ-DEAD, PJ-INPP5E or PJ were transiently expressed in HEK-IK1 cells, and 
inward currents were recorded in WCPC using the voltage protocol shown in figure 34B.  
Transient expression of PJ-DEAD, PJ-INPP5E or PJ with LYN11-FRB in HEK-IK1 cells caused no change to 
the IK1 current when compared to untransfected HEK-IK1 cells (p=NS) (figure 34A & C). As the IK1 
current was not affected by expression of the lipid-depleting constructs with LYN11-FRB, it was 
possible to record the effect of FRB-FKBP dimerisation by perfusing rapamycin over the cells. 
First, untransfected HEK-IK1 cells were subjected to repeated I-V protocols every 1 minute to record 
the stability of the IK1 current over a prolonged period of time. When repeated I-V relationships were 
recorded in untransfected HEK-IK1 cells, there was no change in peak inward current density (p=NS) 
and no change in the I-V relationship over time (figure 35A, E & F). 
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Once it had been established that the IK1 current remained stable over a prolonged recording period 
in WCPC, the rapamycin-induced dimerisation experiments were performed. Rapamycin (5µM) was 
perfused over HEK-IK1 cells expressing PJ-DEAD and LYN11-FRB for 2 minutes after the completion of 
the first I-V recording. The IK1 current was recorded every minute for 8 minutes. Over a period of 8 
minutes, there was no change in peak inward current density (p=NS) or I-V relationship over time 
(figure 35B & G). The same experiment was repeated in HEK-IK1 cells expressing PJ-INPP5E and 
LYN11-FRB, and after 8 minutes there was no change in the peak inward current density (p=NS). 
Finally, rapamycin was added to cells expressing PJ and LYN11-FRB. After rapamycin (5 μM) perfusion 
for 2 minutes there was a gradual but complete inhibition of the peak inward IK1 current density over 
approximately 6 minutes (p<0.05 at +1 min rap, and p<0.005 at +2 minutes rap onwards), with only 
endogenous HEK293 current remaining from 6 minutes (figure 35C & G). This current at all time 
points after the addition of rapamycin was significantly reduced compared to control (p<0.001 across 
all time points analysed) and PJ-DEAD (p<0.001 across all time points analysed).  
3.3.8 Effect of transiently overexpressing lipid-depleting constructs in HEK-IKr cells, and the effect 
of recruiting the lipid-depleting constructs to the plasma membrane using rapamycin 
 
In addition to the IKs and IK1 currents, the IKr current plays a major role in phase-3 repolarisation, and 
is a major component of the repolarisation reserve. In light of the different response to lipid-
depleting construct expression of the IKs and IK1 currents, the effect of this expression on the IKr 
current was also investigated. Similar to the HEK-IKs and HEK-IK1 cell lines, a HEK-IKr cell line was made 
(HEK293 cells stably expressing the IKr [hERG] channel) to allow effective comparison between the 
different channels. 
PJ or PJ-DEAD were expressed with LYN11-FRB in HEK-IKr cells, and the resulting current was recorded 
using WCPC using the voltage protocol shown in figure 36B. 
Transient expression of LYN11-FRB with either PJ-DEAD or PJ in HEK-IKr cells had no effect on the IKr 
current when compared to the current elicited from untransfected HEK-IKr cells (figure 36A & C). As 
the IKr current was not affected by co-expression of PJ or PJ-DEAD with LYN11-FRB, it was possible to 
record the effect of FRB-FKBP dimerisation by perfusing rapamycin over the cells. 
First, untransfected HEK-IKr cells were subjected to repeated I-V protocols every 2 minutes to record 
the IKr current and its stability over 10 minutes. When repeated I-V relationships were recorded in 
untransfected HEK-IKr cells there was only a minor reduction in the peak tail current density (p=NS) 




Once the relative stability of the IKr current in untransfected HEK-IKr cells was established, rapamycin 
(5 µM) was perfused onto HEK-IKr cells expressing PJ-DEAD and LYN11-FRB for 2 minutes after 
completion of the first I-V recording. Over a period of 10 minutes, there was a small reduction in 
peak tail current density, which was not significant (p=NS) and was similar to untransfected cells, and 
there was no change in the I-V relationship over time (figure 37B & F). When rapamycin was 
perfused over HEK-IKr cells expressing PJ and LYN11-FRB for 2 minutes, there was a small inhibition of 
the peak tail current (figure 37B & F) beyond that seen in untransfected HEK-IKr cells and cells 
expressing PJ-DEAD and LYN11-FRB, but this was not significant (p=NS). At t=0 mins, there was no 
significant difference between PJ or PJ-DEAD compared to control, and PJ compared to PJ-DEAD 
(assessed using a one-way ANOVA with Bonferroni’s multiple comparison test). From t=2 mins 
onwards there remained no significant difference between PJ and control, whilst there was a 






Figure 33. The effect of expressing lipid-depleting constructs in CHO-K1 cells expressing the homomeric 
KCNQ1 channel. A – Representative traces of currents recorded in WCPC from CHO-K1 cells transiently 
expressing the KCNQ1 subunit with LYN11-FRB and either PJ-DEAD or PJ. B – Voltage protocol used to elicit 
current recorded.  C – Mean current density (left) and peak tail current density (right) of currents recorded in 
WCPC from CHO-K1 cells transiently expressing the KCNQ1 subunit with LYN11-FRB and either PJ-DEAD (n=11) 
or Pseudojanin (n=10). Data are presented as mean ± SE. An unpaired t-test was performed to determine 













































































































































































































































































































































Figure 35.  Stability of the IK1 current and the effect of rapamycin-induced recruitment of lipid-depleting 
constructs on the IK1 current in HEK-IK1 cells in whole-cell patch clamp. A – Representative current traces from 
HEK-IK1 cells recorded at t = 0 and 6 minutes in WCPC. B – Representative current traces recorded in WCPC 
from HEK-IK1 cells expressing PJ-DEAD or PJ-INPP5E with LYN11-FRB, before and 6 minutes after the start of 
rapamycin (5μM) addition. C – Representative current traces recorded in WCPC of HEK-IK1 cells expressing PJ 
with LYN11-FRB, before and 2, 4 and 6 minutes after the start of rapamycin (5μM) addition. D – Voltage 
protocol used to elicit the currents recorded in WCPC. E – Mean current density from untransfected HEK-IK1 
cells recorded at t = 0 and t = 10 minutes in WCPC. F – Current density at -150 mV over approximately 8 
minutes, relative to that at t = 0, from untransfected HEK-IK1 cells recorded in WCPC. G – Current density at -
150 mV recorded in WCPC over a period of 8 minutes after the start of rapamycin (5μM) addition (orange bar), 
relative to the value before rapamycin addition, in HEK-IK1 cells (control; n=11) or HEK-IKs cells expressing PJ-
















































































































































































































































































































Figure 37. Stability of the IKr current and the effect of rapamycin-induced recruitment of lipid-depleting 
constructs on the IKr current in HEK-IKr cells in whole-cell patch clamp. A – Representative current traces from 
HEK-IKr cells (control) recorded at t = 0 and 10 minutes in WCPC. B – Representative current traces recorded in 
WCPC from HEK-IKr cells expressing PJ-DEAD or PJ with LYN11-FRB, before and 10 minutes after the start of 
rapamycin (5μM) addition. C – Voltage protocol used to elicit the currents recorded in WCPC. D – Mean current 
density recorded in WCPC from untransfected HEK-IKr cells (control; n=9) recorded at t = 0 and t = 10 minutes. E 
– Current density at 0 mV over approximately 10 minutes, relative to that at t = 0, from untransfected HEK-IKr 
cells (control; n=9). F – Current density recorded in WCPC at 0 mV over a period of 10 minutes after the start of 
rapamycin (5μM) addition (orange bar), relative to the value before rapamycin addition, in HEK-IKr cells 
expressing PJ-DEAD (n=10) or PJ (n=10) with LYN11-FRB. Relative current density from untransfected HEK-IKr 
cells (n=9) included for comparison. Data are presented as mean ± SEM. 
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3.3.9 Effect of titrating active lipid-depleting construct expression with pcDNA3.1 or PJ-DEAD on 
the IKs current 
 
To try to reduce the inhibition that occurs when expressing PJ or PJ-INPP5E with LYN11-FRB in cells 
expressing the IKs current, a titration of the lipid-depleting constructs was attempted. There was 
hope that a reduction in the amount of lipid-depleting construct expressed in the cell would lead to a 
concomitant reduction of the inhibition caused by expression of said construct. Previously, 
expression of PJ-INPP5E or PJ with LYN11-FRB caused partial and total loss of the IKs current, 
respectively. This occurred when using 500 ng of each plasmid DNA for transfection. Titration of PJ 
using the pcDNA3.1 empty vector as a transfection bulking agent (to total 500 ng) was attempted to 
try to recover the IKs current. Using 200 ng PJ per transfection enabled partial recovery of the IKs 
current, and titration of PJ to 50 ng per transfection led to a further recovery of the IKs current. Full 
recovery of the IKs current was deemed to be when the current density reached a similar level to that 
recorded when PJ-DEAD and LYN11-FRB were expressed together in HEK-IKs cells (figure 38 A & C) 
The lipid-depleting constructs contain a fluorescent tag (RFP), and due to this, successfully 
transfected cells can be identified by exciting the fluorescent protein and detecting the emitted 
fluorescence by eye. As the amount of PJ was titrated to just 50 ng per transfection, however, there 
were difficulties in visualising transfected cells. To overcome this, YFP can be co-transfected with 
LYN11-FRB, PJ (50 ng) and pcDNA3.1 (450 ng), but the IKs current density recorded in the presence of 
these constructs varied to such an extent that there became uncertainty regarding the actual level of 
PJ in each cell. 
To solve this problem, PJ-INPP5E was titrated, but this time PJ-DEAD was used in place of pcDNA3.1 
The use of PJ-INPP5E allows a larger ratio of PJ-INPP5E to PJ-DEAD, because PJ-INPP5E expression 
previously caused a less severe reduction in IKs current density. The use of PJ-DEAD not only allows 
titration of PJ-INPP5E plasmid uptake during transfection, but also titration of the expression of PJ-
INPP5E in the cell (which pcDNA3.1 cannot provide).  
Titration of PJ-INPP5E from 500 ng per transfection to 200 ng per transfection, using PJ-DEAD to total 
500 ng, resulted in recovery of the IKs current to a comparable level compared to control cells (figure 
39 A & C). Despite not being able to successfully recover the IKs current using PJ using feasible means, 
PJ-INPP5E can still be used to investigate the role of PIP2 in the regulation of the IKs channel. Due to 
the fact that that all 4 lipid-depleting constructs contain RFP tags, however, means that using PJ-
DEAD to titrate PJ-INPP5E expression introduced uncertainty regarding the ratio of PJ-INPP5E to PJ-
DEAD in each cell (i.e. two cells of equal RFP intensity may contain vastly different amounts of PJ-




Figure 38. The effect of titrating PJ with pcDNA3.1 on IKs current inhibition in HEK-IKs cells. A - Representative 
traces of currents recorded in WCPC from HEK-IKs cells transiently expressing PJ-DEAD (500 ng) with LYN11-FRB) 
(n=16), and HEK-IKs cells transiently expressing PJ at 500 (n=11), 200 (n=23) or 50 ng (n=33), which were also 
transfected with 0, 300 and 450 ng pcDNA3.1, respectively. B – Voltage protocol used to elicit current recorded. 
C – Mean current density (top) and peak tail current density (bottom) of currents recorded in WCPC from HEK-
IKs cells expressing PJ-DEAD with LYN11-FRB or PJ at 500, 200 or 50 ng with LYN11-FRB. D – Steady state of 
activation curves, constructed by plotting normalised peak tail current densities (y/ymax) against test potential 
with a Boltzmann function (solid lines). Data are presented as mean ± SE. A one-way ANOVA with Dunnett’s 
post hoc test was used to determine statistical significance between PJ-DEAD and other groups in B, between 
+30 mV and +50 mV, and between V0.5 values obtained from C. A Boltzmann function was applied to data in C 






Figure 39. The effect of titrating PJ-INPP5E with PJ-DEAD on IKs current inhibition in HEK-IKs cells. A – 
Representative traces of currents recorded in WCPC from HEK-IKs cells transiently expressing PJ-DEAD (500 ng) 
with LYN11-FRB) (n=16), and HEK-IKs cells transiently expressing PJ-INPP5E at 500 (n=24), 200 (n=18) or 50 ng 
(n=18), which also expressed 0, 300 and 450 ng PJ-DEAD, respectively. B – Voltage protocol used to elicit 
current recorded. C – Mean current density (top) and peak tail current density (bottom) of currents recorded in 
WCPC from HEK-IKs cells expressing PJ-DEAD with LYN11-FRB or PJ-INPP5E at 500, 200 or 50 ng with LYN11-FRB 
and 0, 300 and 450 ng PJ-DEAD, respectively. D – Steady state of activation curves, constructed by plotting 
normalised peak tail current densities (y/ymax) against test potential with a Boltzmann function (solid lines). 
Data are presented as mean ± SE. A one-way ANOVA with Dunnett’s post hoc test was used to determine 
statistical significance between PJ-DEAD and other groups in B, between +30 mV and +50 mV, and between V0.5 





Manipulation of cellular PIP2 levels using methods such as excised-patch recordings (Loussouarn et 
al., 2003), Gq/11-coupled receptor activation (Matavel & Lopes, 2009) and exogenous application of 
PIP2 analogues (Park et al., 2005) gave insights into the dependence of the IKs channel on PIP2 for 
function. However, what these experimental methods did not allow was a combination of direct and 
physiological manipulation of PIP2 levels within the cell.  
The rapamycin-induced dimerisation system allows the selective and inducible depletion of 
endogenous PIP2 and/or PI4P, the effect of which can be observed in real-time. The rapamycin-
induced dimerisation system has been previously used to investigate the depletion of many different 
ion channels, including the IKs channel and other members of the KCNQ family. 
In this chapter, I have shown that whilst the lipid-depleting constructs are expressed and recruit in 
the same way as previously shown (Hammond et al., 2012), expression of these constructs in HEK-IKs 
cells alters the function of the IKs channel in WCPC, hindering the investigation into the role of PIP2 in 
regulation of the IKs current in this project.   
 
Lipid-depleting constructs cause inhibition of the IKs current in heterologous cells 
 
Using confocal microscopy, the cellular localisation of each lipid-depleting construct and LYN11-FRB 
were found to be consistent with the localisation of the same constructs used by Hammond et al. 
(2012), and the recruitment of these constructs using rapamycin behaved in the same way as similar 
constructs (containing the same rapamycin-binding domains) used by Suh et al. (2006). The time-
course of recruitment of these constructs also paralleled that seen by Suh et al. (2006). These 
observations suggest that when expressed in cells for patch-clamp experiments, the lipid-depleting 
constructs possess the correct localisation and recruitment properties.  
To confirm that as a result of lipid-depleting construct recruitment, lipid depletion occurs at the PM, 
the Tubby-YFP construct was co-transfected with PJ/PJ-DEAD and LYN11-FRB. Tubby is a transcription 
factor that localises to the PM due to the presence of a PI-binding domain that selectively binds PIP2. 
By recruiting PJ-DEAD to LYN11-FRB at the PM with rapamycin (5 µM) and observing the localisation 
of Tubby-YFP over time, it was clear that PIP2 levels at the PM were not affected as Tubby-YFP 
remained localised at the PM. This is in contrast to the rapid redistribution of Tubby-YFP from the PM 
to the cytosol after recruitment of PJ to the PM, showing that PIP2 depletion occurs after rapamycin-
induced recruitment of PJ.  
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Kruse et al. (2012) used the rapamycin-induced dimerisation system to investigate the effect of direct 
PIP2 depletion on a number of Kv channels, as this had only previously been performed with the 
KCNQ2/3 channel. Interestingly, this group used PJ to deplete PIP2 and PI4P with all channels apart 
from the IKs channel, where they used Inp54p in place of PJ. Inp54p is similar to PJ-INPP5E, in that it 
only depletes PIP2.  
In my experiments, when PJ or PJ-INPP5E (which deplete PIP2 and PI4P, or only PIP2, respectively) 
were expressed with LYN11-FRB in HEK-IKs cells, inhibition of the IKs current occurred. In the case of 
PJ, a complete loss of the IKs current was observed. This effect could only be due to the active 
phosphatase domains that dephosphorylate PIP2 and PI4P, because when PJ-SAC (which depletes 
solely PI4P) or the inactive construct, PJ-DEAD, were expressed with LYN11-FRB there was no change 
in the IKs current characteristics. I would argue that in the experiments of Kruse et al. (2012) they 
experienced the same or similar difficulties as I did with PJ and LYN11-FRB, and used Inp54P in the 
place of PJ to enable a greater IKs current density to be recorded. In the same study, the current 
density in the presence of PJ-DEAD and LYN11-FRB (or even IKs in the absence of any construct) was 
not shown, and so any inhibition caused by the expression of Inp54p with LYN11-FRB could not be 
assessed.   
Kruse et al. (2012) performed their studies in tsA-201 cells, which could cause some difference in 
results as HEK293 cells were used here. To rule out cell-type-specific effects, LYN11-FRB and either PJ 
or PJ-DEAD were expressed in CHO-K1 cells that were also transiently expressing the IKs channel 
subunits, KCNQ1 and KCNE1. Confirming that this observation was not cell-type-specific, the same 
loss of current was noted upon expression of LYN11-FRB with PJ, but not PJ-DEAD. 
Could a low level of lipid depletion occur by expressing active lipid-depleting constructs, even in the 
absence of rapamycin? 
 
The phosphatase domains of the lipid-depleting constructs are constitutively active (with the 
exception of those in PJ-DEAD and the mutated domains in PJ-SAC and PJ-INPP5E), which could, in 
theory, confer a lower steady-state baseline level of cellular PIP2 (and/or PI4P in the case of PJ and PJ-
SAC, respectively). Using confocal imaging it is clear that the lipid-depleting constructs are expressed 
throughout the cell. Whilst rapamycin-induced dimerisation concentrates the lipid-depleting 
constructs at the PM, the constitutive phosphatase activity combined with the cytosolic expression 
of the constructs could allow a low level of lipid depletion by constructs that are coincidentally close 
to the PM in the absence of rapamycin, as suggested by DeRose et al. (2013). 
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Even without LYN11-FRB, expression of PJ in HEK-IKs cells caused a 50% reduction in IKs current 
density, supporting the notion that expression of the phosphatase-containing constructs may lead to 
lipid depletion due to constitutive activity of these domains. In addition to this, the fact that LYN11-
FRB expression confers increased inhibition of the IKs current indicates that there may be a low level 
interaction between these two constructs, possibly between the FRB and FKBP domains in the 
absence of rapamycin. 
Could there be an interaction between the FRB and FKBP domains? 
 
Based on the studies that were performed in different cell types and with different incubation media, 
it appears that no exogenous component was responsible for the IKs   inhibition caused, which led to 
the conclusion that there could be an interaction between the lipid-depleting constructs. An 
interaction between the two constructs could concentrate the phosphatase-containing construct at 
the PM.  
Choi et al. (1996) reported protein domains involved in an FKBP–FRB interaction in the absence of 
rapamycin.  These were Tyr2105 (in the 40s loop) of FRB with the oxygen atom of Lys47 (in the α4 
domain) of FKBP, and Arg2042 (in the 80s loop) of FRB with Thr85 and Gly86 (in the α1 and α2 
domains respectively) of FKBP. In 1999, a 2.2 Angstrom resolution structure of the FRB-rapamycin-
FKBP complex was solved, which showed many more residues involved in the protein-protein 
interaction between FRB and FKBP (Liang et al., 1999).  
Despite a conflicting report that these two domains do not interact (Banaszynski et al., 2005), the 
previous structural studies do provide an explanation as to why LYN11-FRB may confer an increased 
inhibitory effect of PJ on the IKs current. Rapamycin strengthens the dimerisation of FRB and FKBP, 
but even a transient and weak interaction could provide a slight concentration of the lipid-depleting 
construct at the PM, resulting in the incompatibility of this CID system with investigation of the IKs 
channel.  
Can titration of the lipid-depleting constructs recover the IKs current sufficiently? 
 
Whether there is an interaction between the FRB and FKBP domains or not, reducing the 
concentration of lipid-depleting constructs in the cell should lead to a reduction in lipid depletion 
and a consequent recovery of the IKs current (in the case of PJ-INPP5E and PJ). First, a proportion of PJ 
plasmid DNA was replaced by pcDNA3.1 plasmid DNA during transfection to reduce the uptake of PJ 
DNA into the cells. By using 200 ng PJ a partial recovery occurred, and a larger recovery occurred by 
using 50 ng PJ (bulked to 500 ng using pcDNA3.1). However, it was obvious that the expression of PJ 
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varied in the cells that were co-transfected with YFP, and the detection by eye (epifluorescence) of 
such a low level of RFP-tagged construct was difficult and subjective. 
The use of PJ-INPP5E instead of PJ would not completely hamper the investigation into the role of 
PIP2 in IKs regulation. Even though it has been shown that PI4P and PIP2 can both activate the TRPV1 
channel (Hammond et al., 2012) because the channel has a broad polyanionic lipid requirement, 
PI4P is mainly thought to reside in the PM as a precursor for PIP2 synthesis. However, Thomas et al., 
(2011) showed that the KCNQ1 C-terminus could bind a range of PIs, including PIP2 and PI4P, but the 
functional role of this binding has not been investigated.  
The increased IKs inhibition that PJ causes over PJ-INPP5E may be due to the removal of the PIP2 
precursor pool, or it may be that PI4P can maintain a level of IKs function in the absence of PIP2, but 
this is also being removed. PJ-INPP5E and PJ-SAC still allow the role of these lipids to be investigated 
individually.  
Because of the reduced level of IKs inhibition caused by PJ-INPP5E expression compared to PJ 
expression, PJ-INPP5E was titrated in HEK-IKs cells. Instead of using pcDNA3.1 as a transfection 
bulking agent, PJ-DEAD was co-transfected to provide a means of titrating the cellular expression of 
PJ-INPP5E. The presence of the inactive construct with PJ-INPP5E would reduce the number PJ-
INPP5E constructs able to interact with FRB through their FKBP domain, but this solution does not 
address the inherent problem with using the rapamycin-inducible dimerisation system to investigate 
the IKs channel – specifically the low level of PIP2 depletion that appears to be causing inhibition of 
the IKs current. Nonetheless, titration of PJ-INPP5E with PJ-DEAD could enable investigation into how 
PIP2 depletion affects the IKs channel.  
Other cardiac K+ channels show varying sensitivities to PIP2 and/or PI4P depletion 
 
In my experiments, the IKs channel was highly sensitive to changes in PIP2 levels in WCPC. It is 
thought that the IKs channel β-subunit, KCNE1, confers an increased channel sensitivity to PIP2 (Li et 
al., 2011), effectively causing amplification of the current. In order to investigate how the homomeric 
KCNQ1 channel (i.e. without KCNE1) was affected by co-expression of PJ and LYN11-FRB, the KCNQ1 
subunit was transiently transfected into CHO-K1 cells with LYN11-FRB and either PJ or PJ-DEAD. CHO-
K1 cells were used in place of HEK293 cells because of the presence of negligible endogenous 
outward currents, allowing accurate recording of the relatively small current elicited by homomeric 
KCNQ1 channels. As expected, PJ-DEAD and LYN11-FRB expression resulted in a current resembling 
that of the homomeric KCNQ1 channel (Kv7.1). The loss of this current when expressing PJ and 
LYN11-FRB suggests that the Kv7.1 channel is sensitive to PM PIP2 levels, even in the absence of 
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KCNE1, and the low level of lipid depletion that may occur with expression of these constructs is 
sufficient to affect Kv7.1 function. As the sensitivity to PIP2 levels is lower in KCNQ1 channels 
compared to the IKs channel, this would suggest that the level to which PIP2 is reduced by expression 
of PJ and LYN11-FRB (in addition to the effect of intracellular solution dialysis in WCPC) is far below 
the minimum level required for IKs function. 
Surprisingly, no one has attempted to overcome these problems despite a number of publications 
highlighting the inherent drawbacks of this CID system (Cabantous, et al., 2013; DeRose et al., 2013; 
Phua et al., 2012; Varnai et al., 2006). Many others have, however, successfully used the rapamycin-
inducible dimerisation system to probe how these phospholipids affect different ion channels. Of the 
other ion channels investigated, the Kir2.1 and Kv11.1 channels are also present in ventricular 
myocytes and are both involved in ventricular repolarisation. These channels have been reported to 
show differing PIP2 binding affinities and as a result, differing sensitivities to PIP2 depletion (Kruse et 
al., 2012). 
To investigate if the expression of the lipid-depleting constructs with LYN11-FRB affected the IK1 and 
IKr currents in a similar fashion to the IKs current, a HEK-IK1 and HEK-IKr cell lines that stably express the 
Kir2.1 and Kv11.1 channels, respectively, were used. Expression of PJ or PJ-DEAD with LYN11-FRB in 
either of these cell lines had no effect on the IK1 or IKr currents. When rapamycin was added to these 
cells, recruitment of PJ to the PM in HEK-IK1 cells caused a gradual and complete depletion of the IK1 
current, and in HEK-IKr cells caused a 25% reduction in the IKr current over the course of the 
experiment. These results indicate that the rapamycin-induced dimerisation system can be an 
effective tool to investigate how direct PIP2 depletion affects the function of an ion channel. 
Ironically, due to the constitutive phosphatase activity, possible interaction with LYN11-FRB and 
concomitant depletion of PIP2 and/or PI4P, there may be difficulties in using the system to investigate 
the role of PIP2 in the regulation of channels highly sensitive to PIP2 depletion. As previously 
mentioned Kruse et al. (2012) did not use PJ in their studies and instead used Inp54p. One can 
speculate that this choice was made due to the difficulties in using PJ to investigate the role of PIP2 in 
the regulation of IKs function.  
 
3.5 Conclusions and future directions 
 
Through characterisation of the rapamycin-inducible dimerisation system, it is clear that in its 
current state it is not optimal for use in the investigation of highly PIP2-sensitive channels. 
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The KCNQ family of ion channels is known to be PIP2 sensitive, and work on the KCNQ2/3 current has 
shown a role for PIP2 in the regulation of this channel (Hernandez et al., 2009; Liu et al., 2008; Suh et 
al., 2006). By comparing the effect of expressing the lipid-depleting constructs on the IKs channel to 
the IK1, IKr and Kv7.1 channels, each thought to have different PIP2 sensitivities, it became apparent 
that the rapamycin-inducible dimerisation system can only be used effectively with channels that are 
not overly sensitive to PIP2 depletion. For this reason, the investigation of the IKs channel was 
hampered. 
Unfortunately, other methods of PIP2 depletion are either indirect or result in downstream effects 
that have unknown or complex consequences, including the release of second messengers by Gq/11-
coupled GPCR activation and inhibition of multiple kinases by wortmannin. Due to this, it is 
important to directly dephosphorylate PIP2 using a system such as rapamycin-inducible dimerisation, 
so the effects can be directly attributed to the loss of PIP2 from the PM.  
Of greatest importance in these kinds of studies are the channels with the highest PIP2 sensitivity, 
because these channels could be regulated physiologically by manipulation of endogenous PIP2 
levels. Based on my findings, the rapamycin-inducible dimerisation system is not suitable for use with 
channels with the highest PIP2 sensitivity in the most widely-used patch clamp configuration, WCPC, 
and researchers wishing to investigate such channels in this way would have to optimise this system 
or find alternative methods of selective and direct PIP2 depletion. The rapamycin-induced 
dimerisation system will be used in Chapter 5 to investigate the role of PIP2 in the regulation of IKs 
function in P-WCPC, which is widely accepted to be the most physiological of all patch clamp 
configurations.  
In the experiments described in this chapter, PJ-DEAD is the control construct, and is composed of 
the same domains as the active constructs, the only difference being the Asp1263Ala and Cys779Ser 
mutations in SAC1 and INPP5E, respectively. This provides the best negative control possible, as any 
effect of PJ (or the other active constructs) can only be attributed to the enzyme activity. It is for this 
reason that the IKs inhibition that occurred when PJ/PJ-INPP5E and LYN11-FRB were expressed 
together was attributed to constitutive lipid depletion. In order to strengthen this reasoning, 
measurements of PIP2 and PI4P concentration could be performed in the absence and presence of 




CHAPTER 4: Optimisation of rapamycin-induced phosphoinositide depletion system 
4.1 Introduction 
 
The rapamycin-induced dimerisation system has previously been used to investigate the role of PIP2 
in KCNQ function (Suh et al., 2006), clathrin-coated pit formation (Zoncu et al., 2006) and receptor-
mediated endocytosis (Abe et al., 2008); small GTPases in neutrophil migration (Inoue & Meyer, 
2008); and Akt kinase in apoptosis (Li et al., 2002). Despite this method appearing to be a promising 
tool to investigate the role of PIP2 in the regulation of IKs channels, in practice there were significant 
set-backs, described in Chapter 3. In my experience with the rapamycin-inducible dimerisation 
system, the expression of PJ with LYN11-FRB in HEK-IKs cells acted to inhibit the IKs current before the 
addition of rapamycin, suggesting that lipid depletion occurs upon over-expression of these 
constructs. 
The work in Chapter 3 highlights that the lipid-depleting constructs are not suitable in their current 
form to investigate the effect of PIP2 depletion (with or without simultaneous PI4P depletion) on the 
IKs channel. Based on the actions on the IKs current, it appears that the phosphatase domains 
contained in the constructs are able to come into contact with their substrates at the PM prior to 
rapamycin-induced recruitment.  
To overcome this, a number of different methods were attempted, which will be described below: 
Altering the rapamycin-induced dimerisation system 
 
DeRose et al. (2013) suggest that by tethering the effector protein (i.e. PJ) away from the PM, the 
constitutive phosphatase activity can be restricted away from the phospholipid substrates in the PM 
until rapamycin addition. This method was employed in the manipulation of small GTPases, where 
the FKBP-GTPase construct was tethered to the PI4P-binding FAPP1 domain. This domain binds to 
PI4P, enriched at the trans-Golgi network, through its PH domain (Phua et al., 2012).  
Part of this chapter describes how the lipid-depleting constructs were altered in a way to restrict 
them away from the PM and, in an alternative attempt, LYN11-FRB mutants were made in order to 
disrupt the potential interaction between the FRB and FKBP domains. PJ and PJ-INPP5E were 
targeted to three different locations within the cell, and the extent to which this helped recover the 
IKs current was measured. PJ was first targeted to the early endosomes using two N-terminal FYVE 
domains from the early endosomal antigen 1 (EEA1) protein (Gillooly et al., 2000). PJ was also 
targeted to the nucleus using either an N-terminal monopartite or bipartite nuclear localisation 
signal (NLS). Both of these NLS’s utilise the classical nuclear import pathway, which involves the 
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active transport of NLS-containing proteins from the cytoplasm to the nucleus through nucleoporins, 
facilitated by the action of specialised carrier proteins called importins (Lange et al., 2007).  Finally, 
PJ-INPP5E was targeted to the Golgi by inserting an N-terminal FAPP1 domain. 
With exception of the nuclear-targeted constructs, this construct optimisation exploits the organelle-
specific nature of many PI species. In order to perform specific signalling functions by targeting 
effector proteins to subcellular membrane compartments, PIs such as PI3P and PI4P concentrate in 
the early endosomes and Golgi, respectively. Many proteins contain PI-binding domains, the most 
well characterised being the PH domain. The FYVE zinc finger domains used here bind to PI3P, which 
is highly concentrated within the cell at the early endosomes. The FAPP1 PI-binding domain localises 
to the Golgi through a phenomenon known as coincidence detection; the FAPP1 domains requires 
the binding of both PI4P and ARF1 for membrane targeting, and as these are found together at the 
TGN, the FAPP1 domain localises here (He et al., 2011). 
Producing an alternative chemically induced dimerisation system 
 
Miyamoto et al. (2012) developed a CID system using components of the gibberellin signalling 
system as a way of creating an orthogonal CID system to the rapamycin-induced dimerisation system 
that also works on a timescale of seconds.   
Gibberellins are a group of plant hormones that regulate growth and influence various 
developmental processes, including stem elongation, germination, dormancy and flowering. All 
identified gibberellins are diterpenoid acids, containing either 19 or 20 carbons – the former group 
also comprising a 5-member lactone ring. In general, the 19-carbon gibberellins are the more 
biologically active, and are hydroxylated on carbons 3 and 13.  
One such giberrellin, known as gibberellic acid or gibberellin A3 (GA3), was the first to be structurally 
characterised. It is a pentacyclic diterpene acid, and promotes cellular growth and elongation. GA3 is 
sometimes used in the agricultural industry to exploit its growth-promoting properties. 
Gibberellic acids bind to the gibberellic acid (GA) receptor, which is a soluble receptor named GA 
insensitive dwarf 1 (GID1). The GA-GID1 complex then binds to DELLA proteins, which belong to the 
GRAS family of plant-specific nuclear proteins. DELLA proteins inhibit GA-promoted processes, and 
binding of GA-GID1 to DELLA leads to their degradation via the ubiquitin-proteasome pathway 
(Eckardt, 2007). However, DELLA proteins also induce expression of upstream GA biosynthetic and 
GA receptor genes, implicating a role of DELLA proteins in GA homeostasis via a feedback mechanism 
(Sun, 2010).   
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The way in which GAs bind to GID1 and DELLA proteins is similar to the way that rapamycin binds to 
FKBP proteins and the FRB domain of mTOR, making this plant hormone of particular interest to 
those using CID systems. The rapamycin-induced dimerisation system utilises the fact that both FRB 
and FKBP bind to separate epitopes of the rapamycin molecule to induce dimerisation of these two 
protein domains. These two binding events are independent of each other, and there is no control 
over the order in which rapamycin binds to either of the domains. On the other hand, GAs cannot 
bind to both GID1 and a DELLA protein in any order: GAs must first bind to GID1 and undergo a 
conformational change that enables binding of the DELLA protein, and hence the formation of the 
DELLA-GA-GID1 complex.  
In this CID system, GA3 was modified to increase its cell permeability by adding an acetoxymethyl 
(AM) group, which masks the negative charge of GA3 until endogenous esterases cleave the AM 
group and release the active GA3 molecule within the cell. Miyamoto and colleagues used the DELLA 
protein known as gibberellin-insensitive (GAI), and determined that the minimal domain required for 
dimerisation is residues 1–92, which incorporates the DELLA domain and a TVHYNP motif (Miyamoto 
et al., 2012).  
This group showed that the rapamycin- and gibberellin-induced dimerisation systems are completely 
orthogonal by inducing, in the same cell, the translocation of CFP-FKBP and YFP-GID1 to LYN11-FRB-
mCherry and mCherry-GAI(1-92), respectively. By creating a system that does not originate from 
mammalian systems, any interactions between cellular components and the exogenously-expressed 
proteins should be reduced to a minimum.  
Abolishing the FKBP-FRB interaction in the rapamycin-induced dimerisation system 
 
In an attempt to reduce or abolish FKBP-FRB interactions that occur in the absence of rapamycin, 
identified by Choi et al. (1996), residues involved in this interaction in the FRB domain (as discussed 
in chapter 3) were mutated. The mutation of these residues may lead to a reduction in the affinity of 
the FRB and FKBP domains for each other, and I hypothesise that this will reduce the inhibition of the 
IKs current that occurs when the lipid-depleting constructs and LYN11-FRB are expressed together. To 
test this hypothesis, site-directed mutagenesis will be used to mutate residues in FRB that are 
involved in the FRB-FKBP interaction to alanine. The mutant LYN11-FRB constructs will be expressed 
with PJ in HEK-IKs cells, and the resulting IKs current will be recorded to determine whether the 
mutation was successful.    




2) To assess whether the mutation of interacting residues in the FRB domain will reduce the 
potential interaction in the absence of rapamycin.  
3) To incorporate the lipid-depleting constructs into an alternative CID system 
The overall aim of this chapter is to generate a CID system that is compatible with studying the IKs 
current. 
4.2 Methods 
4.2.1 Design of constructs 
 




Mono-NLS-PJ was made by incorporating the monopartite NLS (mono-NLS) sequence into the PCR 
primers (shown below), using the PJ plasmid as the template DNA. Specifically, the mono-NLS 
forward primer (FPr) contained an NheI restriction site (GTAAGC), a Kozak sequence, the mono-NLS 
sequence and the first 12 residues of mRFP in the 5’ to 3’ direction.  The mono-NLS sequence was 
taken from Kalderon et al. (1984), and is the SV40 Large T Antigen (TAg)-based sequence, 
126PKKKRKV132. 
Bi-NLS-PJ was made using the same method as mono-NLS-PJ, but the bipartite NLS (bi-NLS) sequence 
replaced the mono-NLS sequence in the FPr. The bi-NLS sequence was taken from Robbins et al. 
(1991) and is the Nucleoplasmin NLS-based sequence, 153AVKRPAATKKAGQAKKKKLD172. Primers used 
to create bi-NLS-PJ are shown below.  
Reverse primers (RPr) for both Mono-NLS-PJ and Bi-NLS-PJ contained the last 8 residues of mRFP and 
the BspEI restriction site (TCCGGA) in the 3’ to 5’ direction. 
By incorporating NheI and BspEI restriction sites at the 5’ and 3’ ends, respectively, the mono/bi-NLS-
mRFP PCR products were easily inserted into a PJ vector (with mRFP removed using NheI and BspEI) 





















Figure 40. DNA sequence for NLS-containing modified lipid-depleting constructs. Both mono- and bi-NLS-
containing constructs start with an NheI restriction site (orange), followed by a kozak sequence (black) and 
start codon (ATG; purple). The mono- or bi-NLS sequence then follows, which is immediately followed by mRFP 
(start of mRFP sequence shown in red). Both sequences run from 5’ to 3’ (left to right).  
 
  
Mono-NLS Forward Primer:  
5’-AGAAGAGCTAGCCGCCACCATGCCAAAAAAGAAGAGAAAGGTAGCAGCCTCCTCCGAGGA 
CGTCATCAAGGAGTTCATGCGC-3’  
NLS Reverse Primer:  
5’-TCTGAGTCCGGAGGCGCCGGTGGAGTGGCGGCCCTCG-3’ 
 
Bi-NLS Forward Primer: 
5’-AGAAGAGCTAGCCGCCACCATGGCTGTAAAGAGGCCTGCGGCTACCAAAAAAGCAGGCCA 
GGCAAAGAAGAAGAAACTTGACGCAGCCTCCTCCGAGGACGTCATCAAGGAGTTCATGCGC-3’ 






2xFYVE-PJ was made using PCR, with double-stranded cDNA from mouse liver (a gift from Dr Claudio 
Mauro, WHRI, QMUL) as the template DNA. Two Hrs (FYVE) domains, separated by a flexible linker, 
were amplified and fused to the N-terminus of the PJ construct, separated by a second flexible linker. 
The Fpr for amplification of FYVE domain 1, FYVE(D1), incorporated an NheI restriction site 
(GTAAGC), a Kozak sequence and the first 10 residues of the FYVE sequence. The Rpr for FYVE(D1) 
contained a BamHI restriction site (GGATCC), the flexible linker (amino acid sequence: QGQGS) and 
the final 9 residues of the FYVE sequence.   
For amplification of the second FYVE domain, FYVE(D2), the Fpr incorporated a BamHI restriction site 
(GGATCC) and the first 10 residues of the FYVE sequence. The Rpr for FYVE(D2) contained an NheI 
restriction site (GCTAGC) and the final 9 residues of the FYVE sequence. 
To insert a flexible linker region between FYVE(D2) and the start of the PJ construct (mRFP), an mRFP 
domain preceded by the flexible linker (FL-mRFP) was created using PCR. The Fpr contained an NheI 
restriction site (GCTAGC) followed by the 19 residues required for the linker. This was followed by the 
first 13 residues of mRFP, removing the start codon, ATG, and inserting GCA (Ala). The Rpr used was 
the same as for mono-NLS-PJ and bi-NLS-PJ, and contained the last 8 residues of mRFP and the BspEI 
restriction site (TCCGGA). 
In a single ligation reaction, FYVE(D1) (NheI, BamHI), FYVE(D2) (BamHI, NheI) and FL-mRFP (NheI, 
BspEI) were inserted into the PJ vector with RFP removed (NheI, BspEI), to create the 2xFYVE-PJ 





FYVE Hrs (D1) Forward Primer:  
5’-CCTCTAGCTAGCCGCCACCATGGAAAGTGATGCCATGTTCGCTGCTGAAAGAG-3’ 
FYVE Hrs (D1) Reverse Primer:  
5’-GGAGATGGATCCCTGGCCCTGTGCCTTCTTGTTCAGCTGCTCATAGCAG-3’ 
FYVE Hrs (D2) Forward Primer:  
5’-CCTCTAGGATCCGAAAGTGATGCCATGTTCGCTGCTGAAAGAG-3’ 






FAPP1-PJ-INPP5E was made by PCR, using YFP-FAPP1-PH (from Dr Maria Deak, University of Dundee) 
as the template DNA, incorporating an NheI restriction site (GCTAGC) and the first 10 residues of the 
FAPP1 sequence in the FPr, and an AgeI restriction site (ACCGGT) 3’ of the final 12 residues of the 
FAPP1 sequence in the RPr.   
As the AgeI restriction site in PJ-INPP5E is not unique, PJ-INPP5E was digested using NheI and BglII, 
and then the resulting insert fragment (mRFP) was digested with AgeI. The digested mRFP insert 
(AgeI, BglII) and FAPP1 insert (NheI, AgeI) were inserted into the PJ-INPP5E vector (NheI, BglII) using 
a ligation reaction, resulting in the FAPP1-PJ-INPP5E construct shown in figure 41.  
  
FAPP1 Forward Primer:  
5’-CCAAAAGCTAGCACCATGGAGGGGGTGTTGTACAAGTGGACCAAC-3’ 






























Figure 41. Modified lipid-depleting construct plasmid maps. Plasmid maps and representative construct 





The YFP-GID1 (#37305) and LYN-CFP-GAI(1–92) (#37311) were purchased from Addgene (deposited 
by Takanari Inoue). To incorporate the phosphatase domains required to achieve lipid depletion 
upon dimerisation of GID1 and GAI, the YFP-GID1 construct was altered using molecular cloning 
techniques as follows: 
The GID1 domain was amplified from YFP-GID1 by PCR, using customised primers (shown below) to 
incorporate an NheI restriction site followed by a flexible linker region, 3’ of the start of the GID1 
sequence, and a stop codon followed by a BamHI restriction site, 5’ of the GID1 sequence. The 
phosphatase enzymes, INPP5E and SAC1, were amplified from PJ as one fragment, incorporating the 
NotI and NheI restriction sites 3’ and 5’ of the amplified region, respectively. These two amplified 
regions (GID1 and phosphatase domains) were added into a ligation reaction with a vector backbone 
containing RFP, created by digesting the PJ plasmid with NotI and BamHI. The resulting plasmid can 














GID1 Reverse Primer:  
5’-CGTGGGATCCTTAACATTCCGCGTTTACAAACGCCGAAAT-3’ 
Enzymes Forward Primer:  
5’-GCACGCGGCCGCGAGTGCTGGTGGTAGTGCTGGTGGTAGTGCT-3’ 






Figure 42. GID1-containing lipid-depleting construct plasmid map. Plasmid map and representative construct 
image for PJ-GID1, the lipid-depleting construct in the gibberellin-induced dimerisation system. 
4.2.2 Confocal microscopy 
 
Live cells were imaged using a Zeiss LSM510 (Mark 4) (Carl Zeiss, Oberkochen, Germany) confocal 




Currents were recorded from HEK-IKs cells either untransfected or transiently transfected. 
Untransfected HEK-IKs cells were used 48–72 hours after seeding, and transfected HEK-IKs cells were 
used 48–72 hours after transfection. For lipid-depleting experiments, 500 ng of modified lipid-
depleting construct was transfected with 500 ng of LYN11-FRB. All transfections were performed 
using FuGENE HD as described in section 2.1.3. 
WCPC or P-WCPC (where stated) were used to record the IKs current in HEK-IKs cells.  Both P-WCPC 
and WCPC experiments were carried out at room temperature using an Axopatch 200B amplifier 
(Axon Instruments) and transfected cells were identified using epifluorescence. Extracellular bath 
solution for all experiments contained (mM) 150 NaCl, 5 KCl, 10 HEPES, 2 MgCl2 and 1 CaCl2 (pH 7.4 
with NaOH). In all experiments, Rseries was compensated for by 70% using the amplifier circuitry. 
In WCPC, the solutions and recording procedures are as described in chapter 3. In P-WCPC, the 
intracellular pipette solution contained (mM) 70 K2SO4, 10 NaCl, 10 HEPES, 2 MgCl2 and 1 CaCl2 (pH 
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7.2 with KOH). The P-WCPC pipette solution was supplemented with 0.24 mg/ml amphotericin B to 
permeabilise the cell membrane. A stock (60 mg/ml) of amphotericin B was made, and a fresh 
dilution to 0.24 mg/ml was made every 1–2 hours. Before filling pipettes with amphotericin B, 
pipette tips were dipped into amphotericin-B-free intracellular solution, to prevent permeabilisation 
of the cell membrane before GΩ seal formation. Pipette resistance, after being filled with 
intracellular solution, was 1–2 MΩ. After seal formation, cells were left until Raccess was stable and 
below 20 MΩ (although most recordings achieved 15 MΩ or below), before recording. I-V protocols 
were recorded by holding the cells at -80 mV before a 6-second activation pulse, from -80 mV to +80 
mV, in 10 mV increments. After the 6-second pulse, a 2-second repolarising step to -20 mV was used 
to record tail currents, before stepping back to -80 mV. 
In P-WCPC experiments involving the perfusion of rapamycin over the cells, extracellular solution 
containing rapamycin (5 μM) was perfused for 2 minutes, and perfusion was then returned to 
rapamycin-free extracellular solution. 
Data from all experiments was analysed as described in chapter 3.  
4.2.3 Statistical analysis 
 
Data are expressed as mean ± SE, and Boltzmann functions were generated using GraphPad Prism. A 
one-way ANOVA (p<0.05) was used to determine significance when multiple groups were compared, 









4.3.1 Using two FYVE domains to target PJ to early endosomes, and the ability to induce 
translocation of this construct to the plasma membrane with rapamycin 
 
A first attempt at restricting PJ away from the PM led to the insertion of the 2xFYVE domain at the N-
terminal end of the PJ construct, which was named 2xFYVE-PJ. Before using any of the altered 
constructs in patch-clamp experiments, their cellular localisation was assessed using confocal 
microscopy to ensure the desired localisation was achieved and, if so, whether rapamycin could 
induce dimerisation of these with the PM-anchored LYN11-FRB. 
When the 2xFYVE-PJ construct was expressed in HEK293 cells, it was immediately apparent that the 
construct did not solely localise to early endosomes. The cellular localisation appeared to include 
early endosomes, but there was a large amount of signal also localised to the Golgi (figure 43). 
Despite the unsuccessful localisation of the 2xFYVE-PJ construct to the early endosomes, this 
construct was primarily restricted away from the PM, and only a very low level of unrestricted 
construct was detected in the cytosol. 
As the aim was to restrict the phosphatase domains away from the PM, and this had been achieved, 
rapamycin was added to HEK293 cells expressing 2xFYVE-PJ and LYN11-FRB. To determine the ability 
of rapamycin to induce translocation of this modified lipid-depleting construct to the PM from the 
early endosomes/Golgi compartments, rapamycin was added and the translocation of the construct 
monitored. Unfortunately, addition of rapamycin (5µM) to HEK293 cells expressing 2xFYVE-PJ and 
LYN11-FRB did not result in translocation of the 2xFYVE-PJ construct from either the Golgi or early 
endosomes to the PM. The 2xFYVE-PJ construct remained localised to the early endosomes/Golgi 
throughout the time course of the experiment (figure 43). 
4.3.2 Using a nuclear localisation signal to target PJ to the nucleus, and the ability to induce 
translocation of this construct to the plasma membrane with rapamycin 
 
As a second attempt at restricting PJ away from the PM, the PJ construct was altered to include an 
NLS. Two different types of NLS were used (monopartite and bipartite), both at the N-terminal end of 
PJ, creating two different PJ-NLS constructs: mono-NLS-PJ and bi-NLS-PJ.  
Again, to determine the localisation of these constructs, confocal microscopy was used. From this it 
was evident that both the mono-NLS-PJ and bi-NLS-PJ constructs successfully localise to the nucleus 
when transiently expressed with LYN11-FRB in HEK293 cells (figures 44 & 45). In the case of mono-
NLS-PJ, there was also a small amount of unrestricted construct detected in the cytosol.  
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As both of these NLS-containing constructs had successfully been restricted (or mostly restricted, in 
the case of mono-NLS-PJ) away from the PM (and to the desired location), the ability of rapamycin to 
induce translocation of each construct to the PM could be tested.  
Upon addition of rapamycin (5µM) to HEK293 cells expressing mono-NLS-PJ and LYN11-FRB, there 
was a rapid recruitment of the cytosolic (i.e. unrestricted) portion of mono-NLS-PJ to the PM (figure 
44), and a ring of mono-NLS-PJ at the PM could be seen approximately 30 seconds after the addition 
of rapamycin. However, no detectable translocation of the nuclear-restricted mono-NLS-PJ occurred 
in the timeframe of the experiment. Quantification of mono-NLS-PJ and LYN11-FRB signal intensity 
(figure 44B) showed that mono-NLS-PJ moved from the cytoplasm to the PM on addition of 
rapamycin, but it was unclear upon analysing the signal intensity at a region of the PM whether the 
fluorescence signal intensity of mono-NLS-PJ increased over time (figure 44C). In HEK293 cells 
expressing bi-NLS-PJ and LYN11-FRB, there was no translocation of the nuclear-restricted construct 
to the PM after rapamycin (5 µM) addition over the course of the experiment.  
4.3.3 The effect of transiently expressing mono-NLS-PJ in HEK-IKs cells on the IKs current, and the 
effect of rapamycin addition 
 
Even though rapamycin was unable to induce translocation of the nuclear-restricted mono-NLS-PJ 
construct, there may have been a translocation of the unrestricted construct to the PM. Because the 
majority of the mono-NLS-PJ construct was restricted away from the PM and the cytoplasmic mono-
NLS-PJ may  translocate to the PM upon rapamycin addition, the effect of mono-NLS-PJ expression in 
HEK-IKs cells was assessed in WCPC. 
Mono-NLS-PJ and LYN11-FRB were expressed in HEK-IKs cells to find out if the extent of nuclear-
targeting was sufficient to recover the IKs current (i.e. by preventing lipid depletion at the PM). In 
WCPC, there was no significant change (p=NS) in the IKs current density or peak tail current density, 
and a small change in the steady state of activation compared to untransfected HEK-IKs cells, which 
was significant at +10 mV (p<0.05) (figure 47A, B, & D).  The V0.5 changed from 9.4 mV ± 0.53 mV to 
25.5 mV ± 1.6 mV, which was assessed using a Boltzmann function, but this was not significant 
(p=NS) (figure 47C).  
As the IKs current could be recorded and was at a comparable level to control in the presence of 
mono-NLS-PJ and LYN11-FRB, P-WCPC was used to find out whether the rapamycin-induced 
recruitment of cytoplasmic mono-NLS-PJ to the PM, which was visualised using confocal microscopy, 
had any effect on the IKs current. The stability of the IKs current over time in P-WCPC is shown in 
figure 61 in chapter 5.  
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First, an I-V was recorded, which was followed by perfusion of rapamycin (5 µM) for 2 minutes during 
a second I-V protocol. I-V relationships were recorded every 3 minutes after the start of rapamycin 
perfusion for a total of 12 minutes. There was no change in the steady state current density or peak 
tail current density of the IKs current and no change in the steady state of activation 11 minutes after 
rapamycin exposure (p=NS) (figure 47F & G). 
4.3.4 Using the FAPP1 domain to target PJ-INPP5E to the Golgi apparatus, and the ability to induce 
translocation to the plasma membrane with rapamycin 
 
In a final attempt at optimising the CID system by restricting the lipid-depleting constructs away from 
the PM, the FAPP1 domain was inserted into the N-terminal end of PJ-INPP5E. The FAPP1 domain 
was used to target this construct to the Golgi. The FAPP1-PJ-INPP5E construct successfully localised 
to the Golgi when expressed in HEK293 cells with LYN11-FRB (figure 46). There was also a low level 
of expression detectable in the cytoplasm of most cells, but to a lesser extent than the mono-NLS-PJ 
or 2xFYVE-PJ constructs.   
Due to the success at restricting this construct away from the PM, the ability of rapamycin to induce 
translocation of FAPP1-PJ-INPP5E to the PM was assessed. Addition of rapamycin (5µM) to HEK293 
cells expressing FAPP1-PJ-INPP5E and LYN11-FRB caused the Golgi-localised signal to translocate in 
part to the PM. The movement of FAPP1-PJ-INPP5E to the PM occurred on a timescale of minutes; at 
2 mins post rapamycin addition there was an accumulation of FAPP1-PJ-INPP5E at the PM, which was 
further increased and accompanied by a more noticeable movement of the construct from the Golgi 
by the 4 minute time point (figure 46). These observations are supported by quantification of the 
FAPP1-PJ-INPP5E and LYN11-FRB signal intensity (figure 46B), which showed that FAPP1-PJ-INPP5E 
increased at the PM after addition of rapamycin (5 µM). This was further supported by analysis of 
FAPP1-PJ-INPP5E signal intensity over time at a region of the PM, which showed that the 
fluorescence signal intensity of FAPP1-PJ-INPP5E increased at the PM by approximately 60% after 
addition of rapamycin (figure 46C).   
4.3.5 The effect of transiently expressing FAPP1-PJ-INPP5E in HEK-IKs cells on the IKs current, and 
the effect of rapamycin addition 
 
Because the FAPP1-PJ-INPP5E construct was successfully localised to the Golgi and there appeared to 
be translocation of the construct from this location to the PM after rapamycin addition, FAPP1-PJ-
INPP5E and LYN11-FRB were expressed in HEK-IKs cells to find out if the extent of Golgi-localisation 
was sufficient to recover the IKs current. In WCPC, no significant change in the IKs current density or 
peak tail current density was observed (figure 48A, B & D), and there was only a small change in the 
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steady state of activation compared to untransfected HEK-IKs cells, which was significant at +10 mV 
(p<0.05) (figure 48C).  The V0.5 changed from 9.4 mV ±0.53 mV to 24.1 mV ±1.1 mV, but this 
difference did not reach statistical significance (p=NS) 
As the IKs current could be recorded, and was a comparable level to control in the presence of FAPP1-
PJ-INPP5E and LYN11-FRB, P-WCPC was used to assess whether the rapamycin-induced recruitment 
of FAPP1-PJ-INPP5E to the PM that was visualised using confocal microscopy had any effect on the IKs 
current.  
In HEK-IKs cells expressing FAPP1-PJ-INPP5E and LYN1-FRB an I-V was recorded, which was followed 
by perfusion of rapamycin (5 µM) for 2 minutes during a second I-V protocol. I-V relationships were 
recorded every 3 minutes after the start of rapamycin perfusion, for a total of 12 minutes. There was 
no change in the steady state current density or peak tail current density of the IKs current and no 






























Figure 43. The localisation of 2xFYVE-PJ in HEK293 cells before and after rapamycin addition.  The top row 
shows HEK293 cells transiently expressing 2xFYVE-PJ and LYN11-FRB-CFP. The 5 centre and bottom rows show 
the localisation of these constructs in the same cell at different time points after the addition of rapamycin (5 





Figure 44. The localisation of mono-NLS-PJ in HEK293 cells before and after rapamycin addition.  A – The top 
row shows HEK293 cells transiently expressing mono-NLS-PJ and LYN11-FRB-CFP. The 5 centre and bottom rows 
show the localisation of these constructs in the same cell at different time points after the addition of 
rapamycin (5 µM) to the cell. Images were obtained using confocal microscopy. B – Normalised (y/ymax) 
intensity of fluorescence of CFP and RFP along the red line illustrated in the top right-hand image (before Rap) 
and bottom right-hand image (+ Rap 180 secs) in A. Green represents LYN11-FRB-CFP and red represents 
mono-NLS-PJ in both B and C. C – Change in fluorescence intensity over time measured from region of interest 
shown by red box in top right-hand image in A (relative to value from image 1 of time series). Representative 











Figure 45. The localisation of bi-NLS-PJ in HEK293 cells. HEK293 cells transiently expressing Bi-NLS-PJ and 
LYN11-FRB-CFP. LYN11-FRB-CFP is localised at the PM, while bi-NLS-PJ is localised to the nucleus. Images were 
obtained using confocal microscopy. 
      





Figure 46. The localisation of FAPP1-PJ-INPP5E in HEK293 cells, before and after rapamycin addition. A – The 
top row shows HEK293 cells transiently expressing FAPP1-PJ-INPP5E and LYN11-FRB-CFP. The 5 centre and 
bottom rows show the localisation of these constructs in the same cell at different time points after the 
addition of rapamycin (5 µM). Images were obtained using confocal microscopy. Arrows highlight areas of 
FAPP1-PJ-INPP5E membrane localisation.  B – Normalised (y/ymax) intensity of fluorescence of CFP and RFP 
along the red line illustrated in the top right-hand image (before Rap) and bottom right-hand image (+ Rap 240 
secs) in A. Green represents LYN11-FRB-CFP and red represents FAPP1-PJ-INPP5E in both B and C. C – Change in 
fluorescence intensity over time measured from region of interest shown by red box in top right-hand image in 






Figure 47. The effect of recruiting a nuclear-targeted PJ construct to the plasma membrane using rapamycin, 
on the IKs current in HEK-IKs cells.  A – Mean current density and B – peak tail current density recorded in 
WCPC from untransfected HEK-IKs cells (control; n=12) or HEK-IKs cells transiently expressing mono-NLS-PJ with 
LYN11-FRB (n=9). C – Steady state of activation curve, constructed by plotting normalised peak tail current 
densities (y/ymax) against test potential (WCPC). D – Representative current traces recorded in P-WCPC from 
untransfected HEK-IKs cells (control) at t = 0 mins and t = 8 mins, and HEK-IKs cells expressing mono-NLS-PJ with 
LYN11-FRB, before and 8 mins after the start of rapamycin (5μM) perfusion. E – Voltage protocol used to elicit 
the currents recorded in P-WCPC.  F – Relative current over time from untransfected HEK-IKs cells (control; n=9), 
and HEK-IKs cells transiently expressing LYN11-FRB and mono-NLS-PJ (n=10), measured at +30mV, recorded in P-
WCPC. Rapamycin (5μM) was perfused over HEK-IKs cells expressing mono-NLS-PJ with LYN11-FRB for 2 minutes 
after the 1
st
 I-V recording (orange bar). G – Steady state of activation curve, constructed by plotting normalised 
peak tail current densities (y/ymax) against test potential for HEK-IKs cells transiently expressing mono-NLS-PJ 
with LYN11-FRB before and after 11 mins of rapamycin addition (P-WCPC). Data are presented as mean ± SE. A 
one-way ANOVA with Dunnett’s post hoc test was used to determine significance between the current at t=0 
(baseline) and all other time points in F, unpaired t-tests were used to compare untransfected vs construct-
expressing cells at each time point in F, the Boltzmann equation was applied to data in C and G to fit sigmoidal 





Figure 48. The effect of recruiting a Golgi-targeted PJ-INPP5E construct to the plasma membrane using 
rapamycin, on the IKs current in HEK-IKs cells. A – Mean current density and B – peak tail current density 
recorded in WCPC, from untransfected HEK-IKs cells (control; n=12) or HEK-IKs cells transiently expressing LYN11-
FRB and FAPP1-PJ-INPP5E (n=9). C – Steady state of activation curve, constructed by plotting normalised peak 
tail current densities (y/ymax) against test potential (WCPC). D – Representative current traces recorded in P-
WCPC from untransfected HEK-IKs cells (control) at t = 0 mins and t = 8 mins, and HEK-IKs cells expressing FAPP1-
PJ-INPP5E with LYN11-FRB, before and 8 mins after the start of rapamycin (5μM) perfusion. E – Voltage 
protocol used to elicit the currents recorded in P-WCPC. F – Relative current over time from untransfected HEK-
IKs cells (control; n=9) and HEK-IKs cells transiently expressing FAPP1-PJ-INPP5E with LYN11-FRB (n=9) measured 
at +30mV, recorded in P-WCPC. Rapamycin (5μM) was perfused over HEK-IKs cells expressing mono-NLS-PJ and 
LYN11-FRB for 2 minutes (orange bar) after the 1
st
 I-V recording (orange bar) in P-WCPC G – Steady state of 
activation curve, constructed by plotting normalised peak tail current densities (y/ymax) against test potential, 
for HEK-IKs cells transiently expressing FAPP1-PJ-INPP5E with LYN11-FRB before and after 11 mins of rapamycin 
addition (P-WCPC). Data are presented as mean ± SE. A one-way ANOVA with Dunnett’s post hoc test was used 
to determine significance between the current at t=0 (baseline) and all other time points in F, unpaired t-tests 
were used to compare untransfected vs construct-expressing cells at each time point in F, and the Boltzmann 
equation was applied to data in C and G to fit sigmoidal curves. Paired and paired t-tests were used to compare 
V0.5 values obtained from Boltzmann functions in C and G, respectively.  
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4.3.6 The effect of mutating residues involved in the FRB-FKBP interaction on the IKs current in 
HEK-IKs cells 
 
Despite confocal imaging showing that the FAPP1-PJ-INPP5E construct was effectively restricted from 
the PM, and WCPC recordings confirming that the inhibition seen with un-restricted PJ-INPP5E had 
been abrogated, the recruitment of this construct in P-WCPC did not affect the IKs current. Whether 
this was due to insufficient recruitment of FAPP1-PJ-INPP5E to the PM or another mechanism is 
unknown, but results in chapter 5 would suggest that PJ may not be able to reduce the PIP2 
concentration to below the threshold require for IKs activation in P-WCPC. 
To try to reduce the IKs inhibition in the presence of PJ or PJ-INPP5E with LYN11-FRB, the interaction 
between the FRB and FKBP domains that was postulated in chapter 3 was targeted. In order to 
abolish the interaction between the FRB and FKBP domains, mutations were introduced to the FRB 
domain by site-directed mutagenesis. Four LYN11-FRB mutants were made: Phe2039Ala (F2039A), 
Arg2042Ala (R2042A), Val2094Ala (V2094A) and Tyr2105Ala (Y2105A) (amino acid number refers to 
the original location in the full length mTOR protein). When the LYN11-FRB(R2042A), LYN11-
FRB(V2094A) or LYN11-FRB(Y2105A) mutants were expressed with PJ in HEK-IKs cells, a complete loss 
of the IKs current was observed, and when the LYN11-FRB(F2039A) mutant was expressed with PJ in 
HEK-IKs cells a small current remained, but was significantly different from control cells (CD and PTCD: 
p<0.005 across all voltages analysed) (figure 49). 
A double mutant, LYN11-FRB(R2042A/Y2105A), and two triple mutants, LYN11-
FRB(F2039A/V2094A/Y2105A) and LYN11-FRB(F2042A/V2094A/Y2105A) were also made, to try to 
further decrease any interaction between the two domains. The mutants LYN11-
FRB(R2042A/Y2105A) and LYN11-FRB(R2042A/V2094A/Y2105A) caused a complete loss of the IKs 
current in HEK-IKs cells when expressed with PJ (CD and PTCD: p<0.005 across all voltages analysed), 
whereas LYN11-FRB(F2039A/V2094A/Y2105A) only resulted in a partial loss of the IKs current, but 
this was still significant (CD: p<0.05 across all voltages analysed, except 70 mV, where p=NS; PTCD: 
p<0.05 across all voltages analysed) (figure 49). 
As the LYN11-FRB(F2039A/V2094A/Y2105A) mutant did not cause a complete loss of IKs current 
when expressed with PJ, the ability of rapamycin to recruit one of the lipid-depleting constructs to 
the mutant LYN11-FRB construct was assessed using confocal microscopy. Time series imaging 
showed that addition of rapamycin (5 µM) to HEK293 cells expressing PJ-DEAD and LYN11-
FRB(F2039A/V2094A/Y2105A) did not result in translocation of PJ-DEAD to the PM (figure 50). 
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4.3.7 Incorporating the lipid-depleting constructs into the gibberellin-induced dimerisation system 
 
The newly created ‘PJ-GID1’ construct was Sanger sequenced to confirm the correct sequence had 
been achieved and each PCR fragment had been inserted into the vector correctly. PJ-GID1 (500 ng) 
was then expressed in HEK293 cells and visualised using fluorescence microscopy to confirm that the 
construct could be expressed in the heterologous cell system that would be used for future 
experiments. Using confocal microscopy, the correct localisation of PJ-GID1 and LYN-CFP-GAI(1–92) 
was observed (figure 52).  
In order to confirm that the construction of PJ-GID1 was successful, the ability to induce 
translocation to LYN-GAI in the PM had to be proven. First, the ability of GA3-AM to induce 
dimerisation of YFP-GID1 and LYN-CFP-GAI(1–92) was investigated by acquiring images in a time 
series using confocal microscopy.  
Figure 51 shows that YFP-GID1 translocated to the PM in under 30 seconds after the addition of 
GA3-AM to HEK293 cells expressing YFP-GID1 and LYN-GAI(1–92). Quantification of YFP-GID1 and 
LYN-CFP-GAI(1–92) signal intensity (figure 51B) showed that YFP-GID1 moved from the cytoplasm to 
the PM on addition of GA3-AM. This is supported by analysis of the signal intensity of YFP-GID1 at a 
region of the PM, which showed that after addition of GA3-AM, YFP-GID1 signal intensity increased 
here over time (figure 51C). These findings confirm that the esterases required to cleave the AM 
group from GA3-AM (producing the active GA3) are present in HEK293 cells.  
Next, the ability of GA3-AM to induce translocation of PJ-GID1 to the PM was tested. Figure 52 shows 
that after addition of GA3-AM to HEK293 cells expressing PJ-GID1 and LYN-GAI(1-92), there was no 
translocation of PJ-GID1, which remained homogenously localised throughout the cytosol and 
nucleus. These observations were confirmed by performing quantification of the PJ-GID1 and LYN-
CFP-GAI(1–92) signal intensity (figure 52B), which showed that PJ-GID1 did not translocate from the 
cytoplasm to the PM on addition of GA3-AM (figure 52C), and this was supported by analysis of the 
signal intensity of PJ-GID1 at a region of the PM, which showed that there was no change in the PJ-






Figure 49. The effect of expressing PJ with mutant LYN11-FRB constructs on the IKs current in HEK-IKs cells.  A 
– Representative traces recorded in WCPC of currents from untransfected HEK-IKs cells (control), and HEK-IKs 
cells transiently expressing PJ with LYN11-FRB mutants. B – Voltage protocol used in WCPC to elicit the currents 
recorded. C – Mean current density and D – peak tail current density of currents recorded in WCPC from 
untransfected HEK-IKs cells (control; n=9) or HEK-IKs cells transiently expressing LYN11-FRB containing the 
mutation(s) F2039A (n=4) R2042A (n=5), V2094A (n=5), Y2105A (n=5), R2042A/Y2105A (n=5), 
R2042A/V2094A/Y2105A (n=5) or F2039A/V2094A/Y2105A (n=6). Data are presented as mean ± SE. A one-way 
ANOVA with Dunnett’s post hoc test was used to determine significance between the current from control cells 




























Figure 50. The localisation of PJ-DEAD and LYN11-FRB(F2039A/V2094A/Y2105A) in HEK293 cells before and 
after rapamycin addition. The top row shows HEK293 cells transiently expressing PJ-DEAD and LYN11-
FRB(F2039A/V2094A/Y2105A). The 5 centre and bottom rows show the localisation of these constructs in the 
same cell at different time points after the addition of rapamycin (5 µM). Images were obtained using confocal 




Figure 51. The localisation of YFP-GID1 and LYN-CFP-GAI(1–92) in HEK293 cells, and the GA3-AM-induced 
recruitment of YFP-GID1 to LYN-CFP-GAI(1–92).  A – The top row shows HEK293 cells transiently expressing 
YFP-GID1 and LYN-CFP-GAI(1–92) before the addition of GA3-AM (100 µM). The two centre and bottom rows 
are of the same cell at different time points after the addition of GA3-AM (100 µM). Images were obtained 
using confocal microscopy. B – Normalised (y/ymax) intensity of fluorescence of CFP and YFP along the red line 
illustrated in the top right-hand image (before GA3-AM) and bottom right-hand image (+ GA3-AM 120 secs) in 
A. Blue represents LYN-CFP-GAI(1–92) and yellow represents YFP-GID1 in both B and C. C – Change in 
fluorescence intensity over time measured from region of interest shown by red box in top right-hand image in 




Figure 52. The localisation of PJ-GID1 and LYN-CFP-GAI(1–92) in HEK293 cells, and the GA3-AM-induced 
recruitment of PJ-GID1 to LYN-CFP-GAI(1–92). A – The top row shows HEK293 cells transiently expressing PJ-
GID1 and LYN-CFP-GAI(1–92) before the addition of GA3-AM. The two centre and bottom rows are of the same 
cell at different time points after the addition of GA3-AM (100 µM). Images were obtained using confocal 
microscopy. B – Normalised (y/ymax) intensity of fluorescence of CFP and RFP along the red line illustrated in 
the top right-hand image (before Rap) and bottom right-hand image (+ Rap 120 secs) in A. Green represents 
LYN-CFP-GAI(1–92) and red represents PJ-GID1 in both B and C. C – Change in fluorescence intensity over time 
measured from region of interest shown by red box in top right-hand image in A (relative to value from image 1 





In Chapter 3, I found that the rapamycin-induced dimerisation system was not optimal for 
investigating how PIP2 depletion affects the IKs channel. In contrast to other groups’ work with this 
system investigating the function of other ion channels (Hammond et al., 2012; Kruse et al., 2012; 
Suh et al., 2006), and my own experiments with the Kir2.1 and hERG channels (chapter 3), I found 
that expression of the active lipid-depleting constructs with the PM-anchored LYN11-FRB construct 
led to inhibition of the IKs current. The constitutive activity of the lipid-depleting constructs coupled 
with their ubiquitous cellular-expression led to the conclusion that the constructs were in contact 
with, and consequently causing dephosphorylation of, the PI substrates in the PM. There also 
appeared to be an interaction between the lipid-depleting constructs and LYN11-FRB, which acted to 
increase the effect of lipid-depletion on the IKs channel, even in the absence of rapamycin. 
In an ideal world, an inactive construct would exist that could be switched to the active conformation 
when bound to rapamycin, but the creation of such a construct is unfortunately very complex and 
beyond the scope of my project. An alternative approach to limit the exposure of the phospholipid 
substrates to the active enzyme domains of the lipid-depleting constructs (in the absence of 
rapamycin) is to alter the localisation of the constructs within the cell. Originally expressed almost 
ubiquitously throughout the cell, the lipid-depleting constructs were modified in a way to restrict 
their expression to the Golgi, nucleus or early endosomes.    
The subcellular targeting of lipid-depleting constructs affected their ability to undergo rapamycin-
induced translocation the PM 
 
The modified lipid-depleting constructs (mono-NLS-PJ, bi-NLS-PJ, 2xFYVE-PJ and FAPP1-PJ-INPP5E) 
varied in success regarding their localisation to the destination subcellular organelles. 
Bi-NLS-PJ was the only construct to be entirely targeted to the desired intracellular location. 
Ironically, the bipartite NLS used to localise the construct to the nucleus was so successful that this 
construct could not translocate out of the nucleus to the PM in the presence of rapamycin in a 
suitable timeframe. This is not to say, however, that the bi-NLS-PJ construct would not translocate 
from the nucleus to the PM over a period of hours. Unfortunately, this timescale is not compatible 
with the patch clamp experiments required to assess the effects of construct recruitment on IKs 
channel function.  
The mono-NLS-PJ construct displayed less complete targeting to the nucleus. Again, however, the 
translocation of the nuclear-localised construct was unsuccessful on the timescale required, and only 
the low level of cytoplasmic mono-NLS-PJ could be recruited to the PM. 
193 
 
The importin-α receptor contains a number of different binding regions for NLS motifs, which bind 
monopartite and bipartite sequences in different ways. The monopartite NLS is known to interact 
with a few of these binding regions, whereas the bipartite NLS interacts with many more (Conti & 
Kuriyan, 2000). This could explain why the bi-NLS-PJ construct showed a higher extent of nuclear 
localisation compared to the mono-NLS-PJ construct.  
The least successful modified construct was 2xFYVE-PJ, which failed to localise solely to the early 
endosomes as intended. A double FYVE domain (2xFYVE) was used here because the single domain 
has been shown to exhibit a low affinity for PI3P, whereas the inclusion of a second FYVE sequence 
was found to increase the affinity for PI3P (Gilooly et al., 2000). Instead of being localised to the 
early endosomes, the 2xFYVE-PJ construct was seen at the early endosomes and Golgi.  This could be 
due to the fact that the early endosomes can shuttle cargo back to the Golgi (Grant & Donaldson, 
2009), which could transfer the construct between the two compartments and lead to an 
accumulation of this construct at the Golgi. Nevertheless, this construct was restricted from the PM, 
but rapamycin addition could not induce the translocation of this construct from either location to 
the PM. This could be due to an extremely high affinity of 2xFYVE for PI3P, or the unexpected 
localisation observed may indicate logistical problems regarding movement of the construct within 
the cell. 
The most promising of the modified constructs was FAPP1-PJ-INPP5E, which successfully localised to 
the Golgi and, unlike the other three modified constructs, also appeared to translocate to the PM 
after addition of rapamycin. The FAPP1 domain was used by Phua et al. (2012) to target small 
GTPases to the Golgi, and in line with my results, this group found that the FAPP1-conatining 
construct translocated to the PM after rapamycin addition. Phua et al. (2012) also discuss that FAPP1 
binds to PI4P with a dissociation constant (Kd) of 230 nM, and state that the Kd of FKBP for rapamycin 
is 0.2 nM and the Kd of FRB for rapamycin is 12 nM (Banaszynski et al., 2005), meaning that the 
FKBP- FAPP1-containing GTPase construct used in their study would likely remain at the PM after 
rapamycin addition, once dissociated from the Golgi. This means that FAPP1-PJ-INPP5E (which 
contains both the FAPP1 and FKBP domains) would also dissociate from the Golgi and freely diffuse 
through the cytosol, where rapamycin could then concentrate it at the PM.  
PJ-INPP5E was used in the place of PJ as the template for the FAPP1-modified construct here due to 
the presence of the active SAC1 domain in PJ, which dephosphorylates PI4P. This may have presented 
problems with targeting because the FAPP1 domain achieves its Golgi localisation by binding to ARF1 
and PI4P in the TGN. The targeting of a PI4P-depleting construct using a PI4P-binding domain did not 
appear to be the most sensible option! 
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Phua and colleagues (2012) decided not to use a nuclear-targeted construct in their studies as they 
deemed the onset of dimerisation too slow due to the added step of nuclear export. However, the 
mono-NLS-PJ construct was selected here (because of the recruitment of cytoplasmic construct to 
the PM) for investigation into the effect of PIP2 depletion on the IKs current, in addition to FAPP1-PJ-
INPP5E. These constructs were expressed in HEK-IKs cells with LYN11-FRB and the effect was 
compared to untransfected HEK-IKs cells. 
WCPC experiments showed that there was no inhibition of the IKs current when expressing either 
mono-NLS-PJ or FAPP1-PJ-INPP5E with LYN11-FRB. When rapamycin was added to the cells to induce 
dimerisation of these constructs with LYN11-FRB in P-WCPC, no change in the IKs current was 
observed. This could indicate that the depletion of PIP2 and/or PI4P had no effect on the IKs current, 
or that the recruitment of the lipid-depleting constructs was unsuccessful. However, a more 
plausible explanation (which is also discussed in chapter 5) is that re-synthesis of PIP2 is made 
possible in P-WCPC, and this prevents the depletion of PIP2 by PJ or PJ-INPP5E (and hence the mono-
NLS-PJ and FAPP1-PJ-INPP5E constructs). 
Mutating FKBP-interacting residues in FRB could not overcome IKs inhibition when expressed with PJ 
 
Fortunately, the LYN11-FRB construct gave another route to try to optimise the rapamycin-inducible 
dimerisation system. In chapter 3, I suggested that there could be an interaction between the FRB 
domain of LYN11-FRB and the FKBP domain of the lipid-depleting constructs in the absence of 
rapamycin. This theory was based on the observed increase in IKs inhibition when both LYN11-FRB 
and PJ were expressed in HEK-IKs cells compared to the expression of PJ alone, and the protein-
protein interaction sites identified by structural analysis of the FRB-rapamycin-FKBP complex (Liang 
et al., 1999). 
There are 21 interactions between 6 residues in the FRB domain and 8 residues in the FKBP domain, 
of which 3 FRB residues are also involved in the binding of rapamycin (Liang et al., 1999). The FRB 
residues involved in the protein-protein interaction with FKBP are Phe2039, Arg2042, Val2094, 
Thr2098, Tyr2105 and Arg2109; the residues that contribute to rapamycin binding are Phe2039, 
Arg2042 and Tyr2105. Mutation of Phe2039, Arg2042, Val2094 and Tyr2105 to Ala altered 5, 7, 5 and 
2 interactions, respectively, and the double (R2042A/Y2105A) and triple (F2039A/V2094A/Y2105A 
and R2042A/V2094A/Y2105A) mutants altered 9, 12 and 14 interactions, respectively. Despite 
altering (and possibly abolishing) up to two thirds of the interaction sites between FRB and FKBP, 
there was still a complete loss of the IKs current when expressing the LYN11-FRB mutants with PJ, 
with the exception of the triple mutant LYN11-FRB(F2039A/V2094A/Y2105A). It was later discovered 
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that this mutant was unable to bind rapamycin (evidenced by the lack of visible PJ-DEAD 
translocation after rapamycin addition). 
Incorporating the lipid-depleting constructs into the gibberellin-induced dimerisation system was not 
successful 
 
The inability to recruit PJ-GID1 to the PM could be due to the arrangement of domains within the 
construct. I also attempted to create 2 other GID1-containing PJ constructs, but was unable to 
successfully clone the required domains into the vector in the other conformations.  
With more time, perhaps other PJ-GID1 constructs could be created that would enable the successful 
investigation of the effect of PIP2 depletion on the IKs current.  
4.4 Conclusions and Future Directions 
 
The inherent problems with the rapamycin-inducible dimerisation system constructs are 1) that the 
lipid-depleting constructs are constitutively expressed without restriction from the PM, and 2) that 
the lipid-depleting constructs and LYN11-FRB appear to interact with each other even before the 
initiation of dimerisation. 
It appears that the subcellular-organelle targeting that remedied these drawbacks could not itself be 
overcome by rapamycin in the case of the NLS-containing and 2xFYVE-containing constructs. The 
FAPP1-PJ-INPP5E construct could be recruited to the PM from the Golgi, but it had no effect on the 
IKs current. This could be due to, for example, a higher affinity of FAPP1 for PI4P and ARF1 than of 
FKBP for rapamycin, which would favour the binding of FAPP1-PJ-INPP5E to the Golgi and impede the 
ability to recruit the construct to the PM. However, translocation of FAPP1-PJ-INPP5E was seen using 
confocal microscopy, so it is more likely that the level of PIP2 depletion achieved was not sufficient to 
alter IKs channel function.   
Regarding the LYN11-FRB mutants that were made, it is clear that not all combinations were 
explored, and with more time others could have been made. However, reviewing the combinations 
already attempted, it seems unlikely that others would abolish the FRB-FKBP interaction and recover 
the IKs current whilst preserving the rapamycin-binding ability of the FRB domain.   
Obviously an avenue not explored was the alteration of protein structure to inactivate the enzyme 
domains prior to rapamycin-binding. This would negate the need to abolish the FRB-FKBP 
interaction, because the proximity of the enzymes to the PM would not be a problem if they were 
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inactive. Whether this method is possible remains to be explored, and was regrettably beyond the 
scope of this project. 
Instead of pursuing different ways to improve the rapamycin-inducible dimerisation system, it could 
seem sensible to accept that this system is not optimal for use with particularly PIP2-sensitive ion 
channels, as demonstrated by the results I have presented from my work on the IKs channel so far. 
Instead, efforts could be focused on finding another method to allow the direct and physiological 
manipulation of PIP2 and/or PI4P, or exploiting an alternative CID method such as the gibberellin-
induced dimerisation system. I attempted to incorporate the lipid-depleting phosphatase domains 
from the rapamycin system into the gibberellin-induced dimerisation system, but the construct 
produced was not able to be recruited to the PM after addition of GA3-AM. In a personal 
communication with Takanari Inoue, I was told that recruitment of Inp45p-YFP-GID1 (which depletes 
PIP2) to the PM was not very efficient and did not show a strong decrease in PIP2. In addition to this, 
the expression of the GID1- and GAI-containing constructs appears to be compromised due to a 
competition for transcription and translation. The Inoue laboratory concluded that the gibberellin-
based dimerisation system is not as robust as the rapamycin-based dimerisation system. In light of 
this communication and my own experiences, it may be in the best interest of other researchers to 









Substantial effort has been made to establish the specific mechanisms by which different KCNQ1 
mutations compromise the IKs current. It was previously believed that this only occurred through the 
assembly of dysfunctional channels that could not function correctly at the PM (Bianchi et al., 2000). 
Since these findings, however, it has been shown that a large number of mutations in the KCNQ1 
subunit cause defective anterograde trafficking of the channel to the PM (table 6).  
Experimentally, many mutant channels show increased colocalisation (compared to WT channel) 
with a fluorescent ER marker, indicating retention in the ER. A number of KCNQ1 mutations can also 
cause a DN reduction of the amount of WT channel that reaches the PM (Aizawa et al., 2004; Li et 
al., 2009; Thomas et al., 2005), where the mutant subunit acts antagonistically on the WT subunit. 
Channel trafficking and disease 
 
Dysfunctional membrane trafficking of cellular proteins is associated with a plethora of diseases. A 
well-known example is cystic fibrosis (CF), where approximately 70% of people with CF harbour a 
homozygous deletion of phenylalanine at position 508 of the cystic fibrosis transmembrane 
conductance regulator (CFTR) gene (ΔF508-CFTR). The ΔF508-CFTR mutation causes protein 
misfolding that impairs the trafficking of the CFTR channel (Cheng et al., 1990), leading to defective 
electrolyte transport and viscous secretions in the airway epithelia and other organ systems (Cutting, 
2015).  
Regarding cardiac disease, defective ion channel trafficking has been found to be responsible for a 
number of cardiac arrhythmias. For example, mutations in the IKr channel (hERG) can cause LQT2, 
and most of the mutations identified in this channel cause a reduction of its expression at the PM 
(Anderson et al., 2006; Anderson et al., 2014). This is due to the production of poorly folded 
channels that cannot be successfully trafficked to the PM, and so are subsequently degraded in the 
ER or proteasome (Zhou et al., 1998). Baroudi and colleagues reported that a double mutation 
(Arg1232Trp/Thr1620Met) in the cardiac Na+ channel, Nav1.5, caused a reduced expression of this 
channel at the PM. This mutation is found in a number of people with Brugada syndrome, a 
ventricular arrhythmia characterised by ST-segment elevation that can lead to sudden cardiac death 
(Baroudi et al., 2002). 
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Mutations in the IKs channel α-subunit that cause channel trafficking defects can result in different 
severities of LQTS. When one KCNQ1 allele is mutated causing loss of protein production or 
degradation of the protein, the remaining single copy may not be able to produce normal levels of 
KCNQ1 protein, which results in haploinsufficiency. This may not lead to severe symptoms if the level 
of channel production is sufficient. This can also result from the ER-retention of mutant channels 
whilst WT channels are successfully trafficked to the PM (Sato et al., 2009; Wilson et al., 2005). Other 
mutations may cause channels to be retained in the ER, for example, but exert a dominant negative 
effect over the WT channel subunit, causing a greater reduction of KCNQ1 channels able to reach the 
PM. DN trafficking mutations that are homozygously inherited commonly cause JLNS, because the 
number of functional channels that reach the PM is not sufficient to sustain the K+ conductance 
required in the inner ear ad heart. 
Phosphoinositides and membrane trafficking 
 
When proteins undergo trafficking through the cell to reach their final destination, they pass 
through, or are embedded in the membranes of, many different cellular organelles (figure 53). These 
organelles have distinct membrane identities in order to recruit organelle-specific effector proteins 
that are required for the successful trafficking of cargo proteins. One way in which these organelles 
selectively recruit their required effector proteins is through PI binding. 
In this chapter, specific PIs will be depleted from the Golgi and the PM, and the effect of this on IKs 
trafficking and function will be investigated. At the PM, PIP2 and PI4P are the dominant 
phosphorylated PI species. PI4P is thought to be present for the production of PIP2 (Dickson et al., 
2014), whilst PIP2 is involved in a myriad of cellular processes (Czech, 2000; Remedios & Nosworthy, 
2008; Suh & Hille, 2008). One role of PIP2 is in the regulation and stabilisation of CCPs, which form 
CCVs that recycle membrane proteins from the PM back into the cell. It was found that selective 
depletion of PIP2 caused the loss of endocytic CCPs, confirming that this lipid is essential for their 





Mutation Location Clinical 
manifestation 




Gly58Asp C-terminus (A 
domain, helix C) 
RWS 
 
Homotetrameric Gly289Asp channels 
show prominent trafficking defect, 
but measurable currents when co-
assembled with WT KCNQ1 
Aromolaran 
et al., 2014 
Arg555His C-terminus (A 
domain, helix D) 
RWS 
 
Homotetrameric Arg555His channels 
show significant trafficking defect 
that is completely rescued by WT 
KCNQ1 
Aromolaran 
et al., 2014 
ΔSer276 S5 TMD RWS 
(asymptomatic) 
ΔSer276 retained in ER whilst WT 
KCNQ1 localised to PM – results in 
haploinsufficiency 
Gouas et al., 
2004 
Glu261Asp S4-S5 linker JLNS 
 
At 1:1 ratio, Glu261Asp caused DN 
retention of WT KCNQ1 in ER and 
reduction in current density 
Wilson et 
al., 2005 
1008delCys S6 TMD JLNS 
 
Retained in the ER and led to 




Arg518X C-terminus  
(helix B) 
JLNS Retained in ER and unable to interact 







Retained in ER as homotetrameric 








Retained in ER as homotetrameric 




ΔVal595 C-terminus (A 




Trafficking defect and little current 
due to impaired subunit binding, but 
no DN effect over WT KCNQ1 
Sato et al., 
2009 
Pro631fs/19 Distal C-terminus RWS (compound 
heterozygote with 
ΔV595) 
Retained in the ER due to a newly-
generated retention signal, but no DN 
effect over WT KCNQ1 
Sato et al., 
2009 
Ala590Thr C-terminus (A 
domain, helix D) 
RWS Reduced current and cell-surface 




Arg190Gln Cytoplasmic loop 
between S2 and S3 




Table 6. KCNQ1 mutations that cause IKs channel trafficking defects.  A non-exhaustive list of mutations in 
the KCNQ1 α-subunit of the IKs channel, identified in RWS or JLNS patients, that have been found to cause 






Figure 53. Anterograde trafficking of ion channels. After translation, ion channels are transported from the ER 
to the PM embedded in the membrane of organelles and vesicles. An ion channel is trafficked from the ER 
through the ERGIC (endoplasmic reticulum-Golgi intermediate compartment) and to the Golgi. From there it is 
transported to the PM in secretory vesicles that fuse with the PM.  
Although the main pool of cellular PIP2 is at the PM (which may contribute to the regulation of 
function and trafficking of the IKs channel), there are also detectable levels of PIP2 in the Golgi (Watt 
et al., 2002). The presence of PIP2 in the Golgi is supported by the finding that PI4P 5-kinases that 
phosphorylate PI4P to PIP2 are recruited and activated by ARF1 at the Golgi (Godi et al., 1999; Jones 
et al., 2000). In addition, a PIP2-binding domain was found in the Golgi-localised scaffold protein 
spectrin (Martin, 2001).   
PI4P is the PI usually associated with the Golgi as it is highly concentrated here (Godi et al., 1999; Roy 
& Levine, 2004). PI4P aids in recruiting proteins such as FAPP1 and FAPP2. These proteins localise to 
the TGN via coincidence detection of PI4P and ARF1, and are involved in the budding and fission of 
protein-carrying vesicles destined for the PM (Godi et al., 2004). 
KCNQ1 trafficking 
 
The interactions that the KCNQ1 channel is involved in as it passes through the secretory pathway 
are largely unknown, but the channel is known to bind a wide variety of PIs (Thomas et al., 2011). K+ 
channels, including the KCNQ1 channel, contain regions responsible for ER retention and export (Ma 
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et al., 2001; Stockklausner et al., 2001). This in part regulates and allows the timely export of the 
channel from the ER, which is required to control the renewed supply of channels as old ones are 
recycled from the PM. 
Although mutations introducing ER retention motifs can result in impaired channel trafficking (Sato 
et al., 2009), mutations that cause channel trafficking defects do not necessarily have to be located 
in the regions responsible for ER exit or retention; mutations that cause aberrant channel trafficking 
have been identified throughout the length of the channel sequence, including those in the C-
terminal calmodulin-binding region (Schmitt et al., 2007), the N-terminal domain (Dahimene et al., 
2006) and the TM domains (Eldstrom et al., 2010).   
Such mutations also include those investigated in this laboratory (Thomas et al., 2011), which are 
located in a PIP2 binding region of the KCNQ1 subunit. In unpublished work, these mutations caused 
increased colocalisation with a fluorescent ER-marker compared to the WT channel. I have repeated 
this work to confirm the ER-retention observed for these channel mutants (figure 24). These 
mutations (Lys354Ala, Lys358Ala, Arg360Ala and Lys362Ala) were introduced into the KCNQ1 subunit 
singly and in combination with each other to create single, double, triple and quadruple PIP2-
binding-region mutants. In addition to showing that mutations in this region caused increased ER-
retention, Thomas and colleagues (2011) found that mutation or charge neutralisation in this region 
caused a reduction of PIP2 binding. 
It is possible that the ER-retention observed when mutating the PIP2 binding region could be a result 
of protein misfolding. Alternatively, it could be linked to the reduction in PIP2 binding. It was also 
observed that the KCNQ1 subunit displays a broad binding affinity for other PI species (Thomas et al., 
2011). Different PIs are involved in different stages of the secretory pathway, and whether these PIs 
are involved in the successful forward trafficking of the IKs channel has not been investigated. 
This chapter describes the use of on-cell and in-cell western assays for quantitative analysis of the 
cell-surface expression and total cellular expression of the VSV-KCNE1-KCNQ1 construct. This assay 
was developed by others in this laboratory, and is based upon previously published methods 
(Dahimène et al., 2006; Delisle et al., 2009). The manipulation of PI levels at the PM and Golgi was 
achieved using the rapamycin-induced dimerisation system, described independently in 2006 by two 
groups (Varnai et al, 2006; Suh et al., 2006), using either the PM-anchored LYN11-FRB or the TGN-
targeted Tgn38-FRB for recruitment of the phosphatase-containing constructs to the PM and Golgi, 
respectively. The use of this assay made it possible to investigate the effect of direct PIP2 and PI4P 
depletion at the PM, and PI4P depletion at the TGN, on the trafficking of the IKs channel in 
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heterologous cells. In addition to this, patch-clamp will be used to investigate the role of PIP2 in the 
regulation of IKs function, as previously described in chapters 3 and 4.  
Aims: To investigate the role of PIP2 and PI4P in the regulation of IKs channel function by depleting 
PIP2 and/or PI4P at the PM, and IKs channel trafficking to the PM by selectively depleting PIP2 and/or 
PI4P in distinct cellular membranes, both using the rapamycin-induced dimerisation system. 
 
5.2 Methods 
5.2.1 Constructs and chemicals 
  
The VSV-E1-Q1 construct consists of the VSV epitope (11 amino acid sequence from the vesicular 
stomatitis virus G protein (YTDIEMNRLGK) (Maout et al., 1997) fused to the extracellular side of 
KCNE1. The C-terminal end of KCNE1 is then fused to the N-terminal end of KCNQ1 as described in 
Wang et al. (1998). The VSV epitope is used for detecting the cell-surface expression of the KCNQ1-
KCNE1 channel complex (Dahimene et al., 2006). 
SAR1 (secretion-associated RAS-related protein 1) is a small GTPase that is involved in ER to Golgi 
trafficking by regulating the coat assembly and fission of new COPII vesicles at the ER (Kuge et al., 
1994; Long et al., 2010). The SAR1 His79Gly mutant (SAR1-H79G; a gift from Philip Wedegaertner, 
Thomas Jefferson University, Philidelphia, USA), is a constitutively active SAR1 that cannot hydrolyse 
GTP and consequently prevents COPII vesicle trafficking between the ER and Golgi. The KCNQ1 
Glu261Asp mutant, (KCNQ1-E261D), was created in our laboratory by Dr Andrew Wilson (Wilson et 
al., 2005). The KCNQ1-E261D subunit causes DN retention of WT KCNQ1 in the ER. The constitutively 
active ARF1 Gln71Leu mutant (pARF1-Q71L) was purchased from Addgene (#11385). This mutant 
lacks the ability to hydrolyse GTP and as a result, prevents the formation and release of COPI vesicles 
from the Golgi (Dascher & Balch, 1996). 
PJ, PJ-SAC, PJ-DEAD, LYN11-FRB and Tgn38-FRB were used in the rapamycin-induced dimerisation 
system to enable depletion of phosphoinositides from the PM and Golgi. PJ-FAPP1 was made by 
inserting the FAPP1 domain into the N-terminal region of the PJ construct, as described in Chapter 4, 
and is a Golgi-localised version of PJ. 
Wortmannin (#1232, Tocris Bioscience) is a steroid fungal metabolite that is used experimentally to 
inhibit PI 3-kinase activity at nanomolar concentrations and PI 4-kinase activity at micromolar 
concentrations (Hansen et al., 1995; Wyman et al., 1996). Brefeldin A (B7651, Sigma Aldrich) is a 
lactone antibiotic produced by fungal organisms, which inhibits anterograde protein transport from 
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the ER (Sciaky et al., 1997). Rapamycin (sc-3504, Santa Cruz) is a chemical product of an Easter Island 
bacterium that possesses antifungal properties (Bastidas et al., 2012), and is used as an anti-cancer 
drug (Law et al., 2005) and the dimerising agent for FRB- and FKBP-containing constructs in a 
research setting.  
5.2.2 Electrophysiology 
 
HEK-IKs cells for WCPC and P-WCPC were incubated as described in section 3.2.2. WCPC and P-WCPC 
solutions and recordings were as described in section 3.2.2 and 4.2.3, respectively.   
In P-WCPC experiments investigating the effect of wortmannin on the IKs current, extracellular 
solution containing wortmannin (10 µM) was perfused after the first I-V protocol until the end of the 
final I-V protocol. 
In experiments involving the perfusion of rapamycin over the cells, extracellular solution containing 
rapamycin (5 μM) was perfused for 2 minutes, and perfusion was then returned to rapamycin-free 
extracellular solution. 
Data were analysed as described in section 3.2.2.  
5.2.3 In/on-cell western assay 
 
Sterile CELLSTAR 24-well plates (Greiner Bio-One Ltd., Stonehouse, UK) were coated with poly-L-
lysine (P4707, Sigma Aldrich) before HEK293 cells were seeded at 30% confluence in 1 ml media. 
After 2 days incubation at 37°C and 5% CO2, cells were transfected using Lipofectamine 2000, 
following the protocol in section 2.1.3. Cells were then left for 48 hours before performing the assay. 
How this assay is used to detect the cell-surface and total channel expression of the VSV-E1-Q1 
construct can be seen in figure 54. 
Cells were transfected with a total of 2 µg cDNA per well. In each well, 1 µg VSV-E1-Q1 cDNA was 
used, and the remaining 1 µg used was either SAR1-H79G, KCNQ1-E261D, ARF1-Q71L or a 
combination of 500 ng PJ/PJ-SAC/PJ-DEAD and 500 ng LYN11-FRB/Tgn38-FRB. For control wells, and 
those destined for the addition of wortmannin or brefeldin A, 1 µg pcDNA3.1 was transfected with 
VSV-E1-Q1. 
For the in-cell western assay, cells were washed with PBS+ (PBS supplemented with 1 mM MgCl2 & 
0.1 mM CaCl2) then fixed with a 3.7% formaldehyde solution (PBS
+ + formaldehyde) for 20 minutes. 
After fixing, cells were washed with PBS+, and then permeabilised with 0.1% triton-X100 solution 
(PBS+ + triton-X100). Cells were washed with PBS+ and incubated in HEK293 media for 30 minutes. 
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Primary antibody (Ab) was added (α-KCNQ1 [SC-20816, Santa Cruz]) in 500 µl HEK293 media at 
1:1000 dilution, and cells were incubated on a rocking platform at room temperature for 1 hour. Cells 
were washed with PBS+ before adding secondary Ab (α-Rabbit Dylight 800 [5151S, New England 
Biolabs]) in 500 µl HEK293 media at 1:1000 dilution. During secondary Ab incubation, cells were 
protected from light and incubated on a rocking platform at room temperature for 1 hour. Cells were 
then washed 3 times with PBS+, and 500 µl PBS+ was added to each well for visualisation. The plate 
was visualised using the LI-COR Odyssey Plate Reader system. 
For the on-cell western assay, one of two protocols was used (noted in figure legends with either 
[37°C live on-cell assay] or [4°C fixed on-cell assay], respectively). The 4°C fixed on-cell assay was 
used when cellular processes needed to be halted at an exact timepoint. 
37°C live on-cell assay: Cells were incubated at 37°C throughout. To start, primary Ab (α-VSV [V5507, 
Sigma]) was added in 200 µl HEK293 media at 1:500 dilution for 1 hour. Cells were then washed 
three times for 10 mins in HEK293 media. Secondary Ab was then added (α-mouse DyLight800 
[5257S, New England Biolabs]) in 500 µl HEK293 media at 1:1000 dilution for 1 hour. Cells were 
washed twice with PBS+, and 500 µl PBS+ was added to each well for visualisation. The plate was 
visualised using the LI-COR Odyssey Plate Reader system.  
4°C fixed on-cell assay: Primary Ab (α-VSV) was added in 200 µl ice-cold HEK293 media at 1:500 
dilution for 1 hour at 4°C. Cells were then washed once in ice-cold HEK293 media and twice in ice-
cold PBS+. Cells were then fixed using 3.7% formaldehyde for 20 minutes. After fixing, cells were 
washed with PBS+, then secondary Ab was added (α-mouse DyLight800) in 500 µl HEK293 media at 
1:1000 dilution for 1 hour at RT. Cells were washed twice with PBS+, and 500 µl PBS+ was added to 
each well for visualisation. The plate was visualised using the LI-COR Odyssey Plate Reader system.  
Rapamycin (5 µM) was added to relevant wells in 1 ml HEK293 media, either 1 hour or 24 hours 
before the start of the assay. Wortmannin (10 µM) was added in 1 ml HEK293 media 1 hour prior to 

















Figure 54. Principles of the on- and in-cell western assays. In the on-cell western assay, the VSV epitope of the 
VSV-E1-Q1 channel is detected by the α-VSV primary Ab. In the in-cell western assay the cells are 
permeabilised, and an α-KCNQ1 Ab is used to detect an epitope in the C-terminus of the KCNQ1 subunit. A 
secondary Ab linked to a fluorescent dye is used to detect the primary Ab in both assays to enable visualisation 




Imaging setup, acquisition and analysis of the in/on-cell western assay 
To ensure the signal detected in the in/on-cell western assays was reproducible across plates, the cell 
density was calculated for each plate and the same cell density was used throughout. The timing of 
transfection was also considered due to the cell loss that can occur at low cell densities.  
In each plate replicate, non-transfected cells were included as a control to ensure no differences 
were seen in background levels of fluorescence between plates.  
Image acquisition was performed using the following settings: 
Channel: 800 nm 
Plate: Microplate 2 (setting for a 24-well plate) 
Focus offset: 3 mm 
Scan Quality: Medium (169 m resolution) 
An initial scan was performed for each plate at a scanning intensity of 5, after which a decision was 
made whether to rescan at a higher or lower intensity depending on the strength of the signal.  
To normalise the results from different experiments relative intensity was calculated by first 
normalising each triplicate well against the average. The background intensity value (untransfected 
control) was then subtracted. All data was then normalised to averaged and background subtracted 
values for the control wells (VSV-E1-Q1 + pcDNA3.1). This approach has previously been used in our 
laboratory and is as described by (Aziz et al., 2012). 
5.2.4 Statistical analysis 
 
Data are expressed as mean ± SE, and Boltzmann functions were generated using GraphPad Prism. 
Each condition in the in/on-cell western assays was performed in triplicate within each plate, and 
each plate was repeated 3 times. A Student’s T Test was used to determine statistical significance for 
single comparisons (p <0.05), and a one-way ANOVA (p<0.05) was used to determine significance 
when multiple groups were compared. For one-way ANOVA analyses, a Bonferroni or Dunnett’s 






5.3.1 Development of in/on-cell western assay: Effect of SAR1-H79G and KCNQ1-E261D on VSV-
KCNE1-KCNQ1 cell surface and total cellular expression 
 
Before the effect of PIP2 depletion using the rapamycin-inducible dimerisation system on VSV-E1-Q1 
trafficking was investigated, the response to different cellular manipulations was studied to confirm 
that changes in VSV-E1-Q1 intracellular and/or PM expression could be detected.  
To ensure that the level of VSV-E1-Q1 construct at the PM could be altered by manipulating proteins 
involved in KCNQ1 trafficking, the SAR1-H79G mutant or the KCNQ1-E261D mutant were expressed 
with the VSV-E1-Q1 construct for 48 hours. 
Expression of SAR1-H79G significantly reduced the surface expression of VSV-E1-Q1 (p<0.001), whilst 
having no effect on the total level of VSV-E1-Q1 expression (p=NS). The expression of the KCNQ1-
E261D mutant subunit caused a significant reduction in cell-surface expression of VSV-E1-Q1 
(p<0.005) that was similarly not accompanied by an alteration in the total cellular expression of VSV-
E1-Q1 (p=NS) (figure 55). 
5.3.2 Development of in/on-cell western assay: Effect of wortmannin and brefeldin A on VSV-
KCNE1-KCNQ1 cell surface and total cellular expression 
 
Pharmacological manipulation of VSV-E1-Q1 expression was also performed to enable inhibition of 
certain cellular processes. When HEK293 cells transiently expressing VSV-E1-Q1 were incubated for 1 
hour with wortmannin (10 µM), which inhibits both PI3K and PI4K activity at the concentration used 
(Hansen et al., 1995; Nakanishi et al., 1995; Wymann et al., 1996; Yano et al., 1993), there was no 
change in the total VSV-E1-Q1 channel expression. Wortmannin incubation did, however, cause a 
significant reduction in cell-surface expression of the VSV-E1-Q1 construct (p< 0.01) (figure 55). 
Incubation of VSV-E1-Q1-expressing HEK293 cells with brefeldin A (5 µM) for 24 hours resulted in a 
small amount of cell death. The total cellular expression of VSV-E1-Q1 was significantly reduced 
(p<0.001) after 24 hours brefeldin A incubation, but it is unclear whether this was solely due to the 
loss of total cell number or whether there was an actual reduction in VSV-E1-Q1 protein expression. 
Brefeldin A incubation also significantly reduced the cell-surface expression of the VSV-E1-Q1 




5.3.3 Effect of PIP2 and PI4P depletion at the plasma membrane on VSV-KCNE1-KCNQ1 cell-surface 
and total cellular expression 
 
To investigate whether transient expression of the lipid-depleting constructs affected VSV-E1-Q1 
trafficking, VSV-E1-Q1 was expressed with LYN11-FRB and either PJ or PJ-DEAD. Expression of PJ-
DEAD and LYN11-FRB for 48 hours did not result in changes in the cell-surface or total cellular 
expression of VSV-E1-Q1 when compared to the VSV-E1-Q1 control (VSV-E1-Q1 + pcDNA3.1). 
Similarly, expression of PJ and LYN11-FRB had no effect on either the total or cell-surface expression 
of the VSV-E1-Q1 construct (figure 56). 
After it was established that the expression of the lipid-depleting constructs did not affect VSV-E1-Q1 
trafficking, the effect of acute and prolonged PIP2 and PI4P depletion was investigated. To induce 
recruitment of PJ/PJ-DEAD to the PM, cells were incubated with rapamycin (5µM) for 1 or 24 hours. 
Incubation of HEK293 cells transiently expressing VSV-E1-Q1, PJ-DEAD and LYN11-FRB with 
rapamycin for 1 hour prior to the start of the assay had no effect on either the total or cell-surface 
expression of VSV-E1-Q1. Incubation of HEK293 cells expressing VSV-E1-Q1, PJ and LYN11-FRB with 
rapamycin for 1 hour also had no effect on the cell-surface or total expression of the VSV-E1-Q1 
construct (figure 56) (p=NS). In addition, rapamycin (5 µM) incubation for 24 hours in HEK293 cells 
expressing VSV-E1-Q1 with PJ/PJ-DEAD and LYN11-FRB had no effect on the VSV-E1-Q1 total or cell-




Figure 55. Manipulating the cell-surface and total expression level of VSV-KCNE1-KCNQ1. A and B show 
representative assay plates from the on- and in-cell western assay, enabling quantification of the cell surface 
and total cellular expression respectively. The VSV-E1-Q1 construct was co-expressed with either pcDNA3.1, 
SAR1-H79G or KCNQ1-E261D. Cells expressing VSV-E1-Q1 with pcDNA3.1 were incubated with either 10 µM 
wortmannin (WTM) for 1 hour or 5 µM brefeldin A (Brf A) for 24 hours.  Each condition was performed in 
triplicate within each plate, and a total of 3 independent experiments were performed. Mean data from three 
independent experiments represented in A and B are shown in C and D respectively. Data represented as mean 





Figure 56. Depletion of PIP2 at the PM does not affect the cell-surface or total expression level of VSV-KCNE1-
KCNQ1. A and B show representative assay plates from the on- and in-cell western assay, enabling 
quantification of the cell surface and total cellular expression respectively. The VSV-E1-Q1 construct was co-
expressed with pcDNA3.1, or with LYN11-FRB and Pseudojanin (PJ) or PJ-DEAD.  Cells expressing LYN11-FRB 
with either PJ or PJ-DEAD were incubated in the absence of 5 µM rapamycin (Rap), or in the presence of Rap 
for 1 hour or 24 hours. Each condition was performed in triplicate within each plate, and a total of 3 
independent experiments were performed. Mean data from three independent experiments represented in A 




5.3.4 Effect of PJ-FAPP1, ARF1-Q71L and brefeldin A on VSV-KCNE1-KCNQ1 cell surface and total 
expression levels 
 
As the Golgi is involved in anterograde trafficking and is home to a large portion of cellular PI4P, and 
the KCNQ1 channel binds PI4P, the effect of depleting PI4P at the TGN was studied. First, however, 
alternative methods of altering cellular PI4P were attempted before using the rapamycin-induced 
dimerisation system to deplete solely PI4P at the Golgi.  
Similar to the expression of SAR1-H79G and KCNQ1-E261D being used to alter the trafficking of the 
VSV-E1-Q1 construct from the ER, different ways to alter the Golgi-mediated trafficking of the VSV-
E1-Q1 construct were attempted. 
PJ-DEAD-FAPP1 localises to the TGN through the binding of its FAPP1 domain to ARF1 and PI4P. This 
could sequester PI4P, causing a reduced pool of PI4P able to interact with effector proteins and cargo 
at the Golgi, so the effect of this construct was investigated. Expression of VSV-E1-Q1 and PJ-DEAD-
FAPP1 in HEK293 cells had no effect on the total expression of the VSV-E1-Q1 construct (p=NS) and 
no effect on the cell-surface expression (p=NS).  
Accordingly, expression of VSV-E1-Q1 with PJ-FAPP1 in HEK293 cells had no effect on the total 
cellular expression of the VSV-E1-Q1 construct, but there was a small reduction (p=NS) in the cell-
surface expression (figure 58). 
The ARF1 mutant, ARF1-Q71L, was also used to alter Golgi function. ARF1-Q71L disrupts traffic to the 
Golgi and between Golgi compartments. Expression of ARF1-Q71L with VSV-E1-Q1 in HEK293 cells 
led to a significant reduction in cell-surface expression (p<0.001), but there was not an 
accompanying change in the total cellular expression of the construct (p=NS). 
Brefeldin A was previously used as a positive control for the disruption of VSV-E1-Q1 trafficking in 
section 5.3.2, but the concentration and incubation time (which were based on published work) had 
a severe effect on cell survival. Here, HEK293 cells expressing VSV-E1-Q1 were incubated with 
brefeldin A (0.5 µM) for 24 hours prior to the start of the assay. In this instance, brefeldin A 
incubation caused a small, but significant (p<0.001) reduction in total VSV-E1-Q1 expression, but 
reduced the cell-surface expression of VSV-E1-Q1 to approximately 20% of the VSV-E1-Q1 control 
value (figure 58) (p<0.05). With this concentration of brefeldin A there did not appear to be a 
reduction in cell number, but the cells adhered to the bottom of the well became smaller and more 
circular, which affected the coverage of the wells. 
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5.3.5 Effect of PIP2 and/or PI4P depletion at the Golgi on VSV-KCNE1-KCNQ1 cell surface and total 
level of expression 
 
Before studying how depletion of PIP2 and/or PI4P may affect trafficking of the VSV-E1-Q1 construct, 
the ability to recruit the lipid-depleting constructs to Tgn38-FRB was assessed using confocal 
microscopy (figure 57).  After rapamycin (5 µM) was added to HEK293 cells expressing PJ and Tgn38-
FRB, colocalisation between PJ and Tgn38-FRB occurred after 15–30 seconds.  
After the ability to induce translocation of PJ to Tgn38-FRB was confirmed, the effect of this 
recruitment on the trafficking of VSV-E1-Q1 was studied. To investigate whether expression of the 
lipid-depleting constructs affected VSV-E1-Q1 trafficking in the presence of the Golgi-located Tgn38-
FRB, VSV-E1-Q1 was expressed in HEK293 cells with Tgn38-FRB and either PJ, PJ-SAC or PJ-DEAD.  
Expression of PJ-DEAD and Tgn38-FRB for 48 hours did not cause a change in the cell-surface or total 
cellular expression of VSV-E1-Q1 expression when compared to the VSV-E1-Q1 control (VSV-E1-Q1 + 
pcDNA3.1). Similarly, expression of PJ-SAC and Tgn38-FRB had no effect on either the total or cell-
surface expression of the VSV-E1-Q1 construct (figure 59). Expression of PJ with Tgn38-FRB did, 
however, result in a small reduction of the cell-surface expression, reducing the level to 
approximately 75% of the control level of expression (p<0.05) (figure 58). 
To recruit the lipid-depleting constructs to the Golgi and study whether PIP2 and/or PI4P depletion 
here resulted in any change (or further change, in the case of PJ in VSV-E1-Q1 trafficking), HEK293 
cells expressing VSV-E1-Q1, Tgn38-FRB and either PJ-DEAD, PJ-SAC or PJ were incubated with 
rapamycin (5 µM) for 1 or 24 hours.  
Incubation of cells expressing PJ-DEAD and Tgn38-FRB with rapamycin for 1 hour prior to the start of 
the assay had no effect on either the total or cell-surface expression of VSV-E1-Q1 (p=NS), and 1 
hour incubation of cells expressing PJ-SAC and Tgn38-FRB with rapamycin also had no effect on the 
cell-surface or total expression of the VSV-E1-Q1 construct (figure 59) (p=NS).  
Incubating cells expressing Tgn38-FRB and either PJ-DEAD, PJ-SAC or PJ with rapamycin for 24 hours 
had no significant effect on the VSV-E1-Q1 total or cell-surface expression in any of the conditions 




Figure 57. The rapamycin-induced recruitment of PJ to Tgn38-FRB at the Golgi. The localisation of PJ and 
Tgn38-FRB in HEK293 cells, and the rapamycin-induced recruitment of PJ to Tgn38-FRB. The top row shows 
HEK293 cells transiently expressing PJ and Tgn38-FRB. The 5 centre and bottom rows show the same cell at 
different time points after the addition of rapamycin (5 µM) to the cell. Images were obtained using confocal 




Figure 58. Manipulating the cell-surface and total expression levels of VSV-KCNE1-KCNQ1 by depleting Golgi 
PIP2/PI4P. A and B show representative assay plates from the on- and in-cell western assay, enabling 
quantification of the cell surface and total cellular expression respectively. The VSV-E1-Q1 construct was co-
expressed with either pcDNA3.1, PJ + Tgn38-FRB, PJ-FAPP1, PJ-DEAD-FAPP1 or pARF1-Q71L. Cells expressing 
VSV-E1-Q1 with pcDNA3.1 were incubated with 0.5 µM brefeldin A (Brf A) for 24 hours.  Each condition was 
performed in triplicate within each plate, and a total of 3 independent experiments were performed. Mean 
data from three independent experiments represented in A and B are shown in C and D respectively. Data 





Figure 59. Depletion of PI4P at the Golgi does not affect the cell-surface or total expression level of VSV 
KCNE1-KCNQ1. A and B show representative assay plates from the on- and in-cell western assay, enabling 
quantification of the cell surface and total cellular expression respectively. The VSV-E1-Q1 construct was co-
expressed with pcDNA3.1, or with Tgn38-FRB and PJ-SAC) or PJ-DEAD.  Cells expressing Tgn38-FRB with either 
PJ or PJ-DEAD were incubated in the absence of 5 µM rapamycin (Rap), or in the presence of Rap for 1 hour or 
24 hours. Each condition was performed in triplicate within each plate, and a total of 3 independent 
experiments were performed. Mean data from three independent experiments represented in A and B are 




5.3.6 Problems with IKs current stability in the whole-cell patch clamp configuration 
 
Anterograde trafficking of the IKs current does not appear to be regulated by PIP2, but the regulation 
of channel function is still possible. In chapter 3, I successfully recovered the IKs current using a 40:60 
ratio of PJ-INPP5E to PJ-DEAD, which may allow characterisation of the effect of PIP2 depletion on IKs 
function by recruiting the lipid-depleting constructs to the PM. 
First, HEK293 cells expressing the IKs channel subunits, KCNQ1 and KCNE1, with PJ-DEAD and LYN11-
FRB were subject to repeated I-V protocols in order to assess the stability of the IKs current in WCPC. 
Rapamycin (5μM) was perfused over the cells for 2 minutes after completion of the first I-V 
recording, after which a second I-V protocol was run. Cells expressing PJ-DEAD were first used (as a 
control) to establish the stability of the IKs current under the experimental conditions and time-
course that would be used for other lipid-depleting constructs. 
As can be seen in figure 60, the current density and peak tail current density recorded from the 
second I-V protocol were significantly reduced compared to those recorded from the first I-V 
protocol (CD: p<0.01; PTCD: <0.01). Over a period of 5 minutes (3 minutes for the I-V protocol and 2 
minutes for rapamycin perfusion) there was a 36% reduction in CD and a 44% reduction in PTCD. This 
effect could not be attributed to activity of the phosphatase domains in the lipid-depleting construct 
because PJ-DEAD was used. Due to the extensive channel rundown observed it was not possible to 
test the effects of the recruitment of the active PJ constructs in WCPC. 
5.3.7 IKs current stability and the effect of wortmannin in the perforated patch configuration 
 
Based on the previous findings and those of others (Yang et al., 2009) it is clear that the IKs current is 
susceptible to rundown in WCPC. In order to test whether the preservation of the intracellular 
environment would prevent channel rundown, the stability of the IKs current was assessed using the 
perforated-patch configuration of WCPC. 
To test the stability of the IKs current in P-WCPC, I-V protocols were repeated every 4 minutes, where 
t=0 denotes sweep 12 of the first I-V (during sweep 12, the PM is clamped at +30 mV before 
dropping to -20 mV to elicit the tail current, and is where each value of relative CD and relative PTCD 
is taken from in each I-V recording). 
Figure 61A, C, D & E show that after 16 minutes, the CD and PTCD remain similar to the values 
recorded in the first I-V. The V0.5 values, calculated using a Boltzmann function on normalised PTCD 
densities, did not change between the first I-V (38.0 ± 1.84 mV) and the  
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I-V protocols run at + 4, 8, 12 or 16 minutes (31.9 ± 1.41 mV, 34.58 ± 1.15 mV, 39.5 ± 1.49 mV and 
36.7 ± 1.23 mV respectively) (figure 61F). 
Before investigating the effect of recruiting the lipid-depleting constructs to the PM with rapamycin, 
an alternative, previously published method of PIP2 and PI4P depletion was attempted as a positive 
control. WTM, an inhibitor of PI 4-K activity when used at micromolar concentrations, was 
continuously perfused over untransfected HEK-IKs cells after completion of the first I-V protocol, and 
I-V protocols were repeated for a period of 15 minutes. 
Perfusion of WTM (10 µM) over untransfected HEK-IKs cells caused a reduction in IKs CD and PTCD 
(figure 61 A, C, D & E). In detail, 2 minutes of WTM perfusion caused a noticeable reduction in the IKs 
current, and 50% of the current was inhibited after approximately 8 minutes. The voltage-
dependence of activation did not significantly change throughout the addition of WTM (figure 61F). 
Comparison of the V0.5 values of normalised tail currents before (44.8 mV ± 1.42) and at + 2, 6 and 10 
minutes of WTM addition (37.3 mV ± 1.62, 40.8 mV ± 1.6 and 45.2 mV ± 2.6, respectively) shows 
only a slight variation between these (which was significant at + 2 mins, p<0.05), but no change 
between the values before WTM addition and after 10 minutes of WTM (10 μM) addition. Analysis 
of the voltage-dependence of activation at 16 minutes of WTM addition was not possible in some 
cells because the tail current density was reduced to such an extent that it could not be accurately 
measured. 
5.3.8 Effect of recruiting lipid-depleting constructs to the PM on the IKs current in HEK-IKs cells 
 
Now that a stable system to record IKs currents had been established, rundown of the IKs current 
would not interfere with the interpretation of any results from patch-clamp experiments spanning >1 
I-V recording. P-WCPC was used from here onwards when investigating the effects of lipid depletion 
on the IKs current. 
First, however, the effect of expressing the PJ constructs on the IKs current in P-WCPC was assessed. 
When expressing any of the lipid-depleting constructs with LYN11-FRB in HEK-IKs cells, there was no 
significant difference in the CD or PTCD when compared to control at any of the voltages analysed 
(p=NS) (figure 62A, B & C), which was assessed using a one-way ANOVA with Bonferroni’s post hoc 
test. There was also no difference between the CD or PTCD of PJ-DEAD and any of the active lipid-
depleting constructs (p=NS). There appeared to be little change in the V0.5 value between control and 
PJ-DEAD, PJ-SAC, PJ-INPP5E and PJ (37.98 ±1.84, 45.69 ±1.08, 41.65 ±1.35, 47.46 ±1.53 and 44.93 
±1.23, respectively), but a one-way ANOVA with Bonferroni’s post hoc test showed that there was a 
significant difference between control and PJ-DEAD (p<0.05), PJ-INPP5E (p<0.005) and PJ (p<0.05). 
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There was not, however, a significant different between the V0.5 values from PJ-DEAD and any other 
construct (figure 62D).  
As it was evident that expression of the active lipid-depleting constructs had little effect on the IKs 
current when recorded in P-WCPC, the effect of recruiting the constructs to the PM using rapamycin 
was investigated.  
First, PJ-DEAD and LYN11-FRB were expressed in HEK-IKs cells, and after a first I-V protocol, a second 
was run immediately whilst rapamycin (5 μM) was perfused over the cells for 2 minutes. I-V 
protocols were repeatedly recorded until the IKs current had been recorded at +2, 5, 8 and 11 
minutes rapamycin addition.  T=0 denotes sweep 12 of the first I-V (during sweep 12, the PM is 
clamped at +30 mV before dropping to -20 mV to elicit the tail current, and is where each value of 
relative current density and relative peak tail current density is taken from in each I-V recording). At 
t=11 minutes, the IKs CD and PTCD were not significantly different from the current measured at t=0, 
before rapamycin perfusion (p=NS) (figure 62F & G). 
After it was established that both perfusion of rapamycin and recruitment of PJ-DEAD to the PM did 
not affect the IKs current, the active lipid-depleting constructs were expressed in turn (in the place of 
PJ-DEAD) in HEK-IKs cells. The same protocol was followed for recording the IKs current in P-WCPC, 
with 2 minutes of rapamycin (5 μM) perfusion commencing after completion of the first I-V 
recording. 
The recruitment of either PJ-SAC, PJ-INPP5E or PJ to the PM with rapamycin did not act to alter IKs CD 
or PTCD over the period of the experiment (figure 62F & G) (p=NS), and there was also no difference 
between values at each time point for control compared to each lipid-depleting construct, or 
between PJ-DEAD and the active lipid-depleting constructs (p=NS), assessed using a one-way ANOVA 





Figure 60. Stability of the IKs current in HEK-IKs cells in the whole-cell patch clamp configuration. A – 
Representative current traces recorded in WCPC from HEK-IKs cells before and after 2 minutes rapamycin (Rap) 
(5µM) perfusion. B – Voltage protocol used to elicit currents recorded in WCPC.  
C – Mean current density (left) and peak tail current density (right) recorded in WCPC from HEK-IKs cells 
transiently expressing PJ-DEAD and LYN11-FRB (n=7) before and after approximately 5 minutes from the start 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































A number of LQT1-associated mutations have been characterised in heterologous cell systems and 
found to be defectively trafficked to the PM (table 6). The identification of a PIP2-binding region in 
the KCNQ1 subunit and the observation that mutations within this domain caused retention of the 
channel in the ER, led to the hypothesis that PIP2 binding to the channel could be required for its 
anterograde trafficking (figure 24).  
The discovery in chapter 3 and in this chapter that the rapamycin-inducible dimerisation system was 
not optimal for investigation of IKs function does not preclude using it to study the role of PIP2 in IKs 
trafficking. PJ-DEAD and LYN11-FRB/Tgn38-FRB expression provide the optimal negative control, and 
PJ-DEAD with LYN11-FRB have already been shown to have no effect on the IKs current in WCPC 
experiments (because the construct contains inactive enzyme domains; chapter 3).  
Overcoming IKs rundown using the perforated whole-cell patch clamp configuration 
 
First, the stability of the IKs channel was assessed, and I observed that the IKs current was subject to 
rundown in the WCPC configuration. This occurred when expressing PJ-DEAD in HEK-IKs cells, and so 
the loss of IKs current density over the 5-minute recording period cannot be attributed to 
phosphatase activity and lipid depletion. Current rundown is known to occur with channels that are 
particularly sensitive to changes in intracellular signalling molecules, which are lost in WCPC as the 
pipette solution dialyses the intracellular solution (Dufy et al., 1986; Hattori et al., 2003; Loussouarn 
et al., 2003). 
To overcome the rundown that occurred in WCPC, the P-WCPC was used. Amphotericin B, an 
antifungal drug, was included in the pipette solution to form ion-permeable pores in the PM. These 
pores prevent large signalling molecules from being lost over time, which occurs by dilution of the 
intracellular milieu with the pipette solution in the whole-cell configuration. In P-WCPC, the IKs 
current was stable over a period of 15 minutes, enabling the effect of rapamycin perfusion and the 
consequent recruitment of lipid-depleting construct to the PM to be investigated. First, however, an 
agent known to cause the gradual loss of PIP2 from the cell was used to provide a positive control in 
P-WCPC. Wortmannin, a steroid metabolite of the fungi Penicillium funiculosum, inhibits PI4K activity 
at micromolar concentrations (Matavel & Lopes, 2009), and when continuously perfused over HEK-IKs 
cells there was a gradual reduction of the IKs current density with no change in the voltage-
dependence of activation. This suggests that the reduction of PIP2, caused by removal of its 
precursor, PI4P, does inhibit the IKs current. 
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When recruiting the lipid-depleting constructs to the PM using rapamycin, there was no change in 
the current density over the course of 11 minutes after rapamycin addition for any of the constructs. 
This appears to be in contrast to the observed effect that each construct has when currents were 
recorded in WCPC, and, most surprisingly, there was a drastic decrease in the inhibition caused by 
expression of PJ or PJ-INPP5E with LYN11-FRB (without rapamycin).   
A possible explanation for this is that the level of PIP2 in the PM before membrane rupture in WCPC 
is sufficient to allow activation of the IKs channel, but the turnover of PIP2 in the PM is so rapid that 
the PIP2 level dips below that required by the channel for activation before the start of a WCPC 
recording. In P-WCPC the intracellular environment is maintained, retaining the energy requirements 
of PIP2 synthesis within the cell. This could explain why HEK-IKs cells expressing PJ or PJ-INPP5E and 
LYN11-FRB elicit a smaller current in WCPC than the respective currents in P-WCPC. When the lipid-
depleting constructs were recruited to the PM in P-WCPC there was no change in the IKs current, 
suggesting that the IKs channel is regulated differently in P-WCPC than in WCPC. The confocal 
experiments using Tubby-YFP as a marker for PIP2 depletion show that even in intact cells, PIP2 levels 
are reduced by recruiting PJ to the PM (which means that re-synthesis and maintenance of PIP2 
levels during PJ recruitment are not responsible for the lack of response observed in P-WCPC when PJ 
was recruited to the PM with rapamycin).  
In P-WCPC, the IKs channel may be regulated differently than in WCPC, but in addition, PIP2 may be 
regulated differently, which may have a knock on effect on channel regulation. PIP2 is synthesised in 
a number of locations within the cell – including membranes of the trafficking organelles, which are 
known to easily transfer membrane constituents between one another – and the cell may be able to 
redirect PIP2 produced at these locations to the PM. On the other hand, the activity of the kinases 
that are involved in PIP2 production at the PM may be regulated differently in the different patch 
clamp configurations.  
Despite there being no change in the IKs current after recruitment of the lipid-depleting constructs to 
the PM and consequent PIP2 depletion, addition of WTM did result in a large inhibition of the IKs 
current. Even though WTM is not specific in its inhibition of PI4Ks, it does suggest that if PIP2 
depletion occurs to a certain extent, the IKs current is inhibited, meaning that the IKs current may bind 
PIP2 tightly and hence show a low sensitivity to PIP2 depletion when in physiological conditions (i.e. 
P-WCPC). This could be due to the presence of KCNE1, which increases the channel’s sensitivity to 
PIP2 (Li et al., 2011).  
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Any of the mechanisms discussed above could negate the effect of PIP2 depletion resulting from 
rapamycin-induced recruitment of PJ or PJ-INPP5E, explaining not only the P-WCPC results in this 
chapter, but the lack of effect on trafficking that will be discussed below. 
Establishing the in/on-cell western assay as a tool to investigate the role of PIP2 in IKs channel 
trafficking  
 
To calibrate the in- and on-cell western assays so that the effect of PIP2 and/or PI4P depletion on IKs 
channel trafficking could be investigated, a number of positive control experiments were performed. 
These were known to affect broad trafficking pathways or specifically KCNQ1 surface expression. The 
expression of the SAR1 mutant, SAR1-H79G, and the KCNQ1 DN mutant, KCNQ1-E2691D, both 
caused a reduction in the cell-surface expression of the VSV-E1-Q1 construct whilst preserving the 
total amount of channel expression in the cell. SAR1 is a small GTPase that is involved in ER to Golgi 
trafficking by regulating the coat assembly and fission of new ER vesicles (Kuge et al., 1994; Long et 
al., 2010). The SAR1 mutant, SAR1-H79G, is a non-hydrolysable version of SAR1 that remains in the 
GTP-bound state rendering it constitutively active. This mutant has a DN effect over WT SAR1 and 
prevents vesicle trafficking between the ER and Golgi (Takida & Wedegaertner, 2004), explaining the 
reduction of VSV-E1-Q1 cell-surface expression. 
The function of another crucial component of protein trafficking, ARF1, was compromised by 
expression of the constitutively active mutant, ARF1-Q71L. This mutant remains restricted in its GTP-
bound form, which causes an accumulation of cargo in pre-Golgi intermediates and prevents 
transport through Golgi compartments (Dascher & Balch, 1994). Again, disruption of VSV-E1-Q1 
trafficking after production in the ER explains the reduction in cell-surface expression whilst there 
was no change in total channel expression. 
The KCNQ1-E261D mutant has a DN effect over the WT channel (Huang et al., 2001; Wilson et al., 
2005). The reduction in VSV-E1-Q1 cell-surface expression recorded here when KCNQ1-E261D was 
co-expressed complements results published by Wilson and colleagues (2005), who observed with 
confocal microscopy that in both CHO-K1 cells and a murine myoblast cell line that KCNQ1-E261D 
increased the colocalisation of WT KCNQ1 with DsRed-ER (a fluorescent ER marker), indicating ER-
retention of the WT subunit.  
In addition to these cellular manipulations brought about by expressing mutant proteins, 1-hour 
incubation with WTM reduced the cell-surface expression of VSV-E1-Q1 without altering the total 
channel expression. These three methods of disrupting channel trafficking interfered at stages after 
the production of the channel protein in the ER, so it is unsurprising that the total channel 
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expression was unchanged. However, the effect of WTM on VSV-E1-Q1 cell-surface expression 
cannot be directly attributed to the inhibition of PI4K (and the resulting reduction of PIP2) because 
WTM is non-selective in its action on PI4K. At both high and low concentrations, WTM is a potent 
inhibitor of PI3K (Wymann et al., 1996). Depending on the class of PI3K, these enzymes 
phosphorylate either PI or PIP2 to form PI3P and PI-3,4,5-P3 (PIP3), respectively. PI3P is found in the 
endocytic pathway, highly concentrated on early endosomes, and is therefore involved in the 
recycling of membrane proteins. Disruption of the cellular PI3P levels may therefore lead to altered 
trafficking of the channel.  
Supporting this are results from preliminary data obtained from an in-/on-cell western assay in which 
VSV-E1-Q1-expressing HEK293 cells were exposed to wortmannin for 7.5 and 15 minutes (figure 63). 
The purpose of this experiment was to investigate the mechanism behind the reduction in IKs current 
when IKs-expressing cells are exposed to WTM, i.e. can the reduction in current observed over a 
period of 15 minutes be explained by a reduction in cell-surface expression? 
Despite only performing 1 repeat of this assay, previous results show this assay to be robust and the 
results highly reproducible.  
From the in-/on-cell western assay performed here it is clear that there was no change in VSV-E1-Q1 
expression over the range of time points evaluated. These time points run parallel to the recordings 
in P-WCPC, where a 50% reduction in IKs current density was observed after 8 minutes. This suggests 
that short-term WTM exposure, and the inhibition of PI4K that is assumed to lead to IKs inhibition, 
inhibits the IKs current through a purely functional mechanism (i.e. channel closure) rather than a 
reduction in cell-surface expression.  
Kjeken et al. (2015) found that WTM treatment of rat liver endothelial cells led to the release of EEA1 
from early endosomes and disrupted transport between early endosomes and lysosomes. It was also 
observed by another laboratory that treatment of CHO-K1 cells expressing the transferrin receptor 
with WTM led to a 60% increase in receptor internalisation and a 35% decrease in recycling rate due 
to inhibition of PI 3-kinase activity (Martys et al., 1996). These studies, together with the preliminary 
data that I obtained, suggest that the reduction of VSV-E1-Q1 surface expression after the longer 
exposure to WTM may be due to inhibition of PI3K activity and not inhibition of PI4K activity.  
In contrast to the methods that caused altered cell-surface expression with no accompanying change 
in total channel expression, incubation of the cells with brefeldin A (5 µM) for 24 hours caused 
complete loss of the cell-surface channel expression and a severe reduction of total channel 
expression. Even using a lower concentration of brefeldin A (0.5 µM) led to a small reduction in total 
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channel expression, and a large reduction of VSV-E1-Q1 cell-surface expression. This is likely due to 
the fact that brefeldin A prevents COPI-mediated transport from the Golgi to the ER, and previous 
reports have found that this results in retrograde transport of Golgi lipids and proteins to the ER, 
which leads to degradation of the Golgi (Sciaky et al., 1997). This process can lead to ER stress and 
apoptosis – evidenced here by the reduced cell number, which was even apparent by visual 
inspection using a bright-field microscope. The reduced signal in the in-cell assay could therefore 
partly be due to the reduction in cell number. Cells were originally incubated with 5 µM brefeldin A 
because this concentration had previously been used to incubate cells for 24 hours in the study of 
KCNQ1-KCNE1 assembly, with no cell death being reported (Vanoye et al., 2010). When this 
concentration was reduced to 0.5 µM, however, there was no visible reduction in cell number, but a 
change in cell morphology and a reduction in the total expression of VSV-E1-Q1 did occur.  
The cellular manipulations that were used to disrupt KCNQ1 trafficking (whether directly or 
indirectly) showed that the in/on-cell western assays can be used to report changes in VSV-E1-Q1 





Figure 63. Short-term inhibition of PI4K using wortmannin does not affect the cell-surface or total expression 
level of VSV-KCNE1-KCNQ1. A and B show representative assay plates from the on- and in-cell western assay, 
enabling quantification of the cell surface and total cellular expression, respectively. The VSV-E1-Q1 construct 
was co-expressed with pcDNA3.1, and cells were incubated in the absence of 10 µM wortmannin (WTM), or in 
the presence of WTM for 7.5 or 15 mins. Each condition was performed in triplicate within each plate. Mean 
data from one experiment represented in A and B are shown in C and D respectively. Data represented as 




Depletion of PIP2 and PI4P from the PM and PI4P from the Golgi did not affect VSV-E1-Q1 trafficking 
 
To find out if depletion of PIP2 at the PM affected trafficking of the VSV-E1-Q1 construct, VSV-E1-Q1 
was expressed with either pcDNA3.1, or PJ-DEAD/PJ and LYN11-FRB. Cells expressing the lipid-
depleting constructs were incubated without rapamycin or with rapamycin for 1 hour or 24 hours, to 
assess the acute and long-term effects of PIP2 depletion at the PM on trafficking. None of these 
conditions resulted in any changes in the expression of the VSV-E1-Q1 construct, suggesting that the 
reduction of PIP2 does not affect the anterograde trafficking and expression of the VSV-E1-Q1 
construct, neither does it alter the rate of internalisation of the VSV-E1-Q1 construct. 
Thomas and colleagues (2011) found that the cluster of basic residues in the proximal C-terminal of 
KCNQ1 bound not only to PIP2, but to a range of other PI species. Could the mutations in this binding 
region have caused increased ER-retention due to the reduction in binding of a different PI? As PI4P 
is present at the Golgi at higher concentrations than in the rest of the cell, and is suggested to be 
involved in the forward trafficking of proteins destined for the cell surface, I selectively depleted PI4P 
and/or PIP2 at the Golgi. 
To provide positive controls for the depletion of PIs at the Golgi, a number of Golgi-targeted 
constructs were used. PJ-FAPP1, which is targeted to the Golgi and depletes PI4P and PIP2, and the 
PJ-DEAD-FAPP1 control construct were used. It was expected that PJ-FAPP1 would cause a reduction 
of PI4P and PIP2 at the Golgi, but the extent to which this would occur was unknown. Compared to 
PJ-DEAD-FAPP1, PJ-FAPP1 caused a slight reduction in cell-surface expression of the VSV-E1-Q1 
construct.  
The way in which these enzyme domains would act at the Golgi was unknown because they were 
targeted using the PI4P-binding domain, FAPP1 (for localisation of FAPP1-containing constructs, see 
figure 46 in chapter 4). The presence of the FAPP1 domain may have a ‘protective’ effect over PI4P, 
lowering the pool of PI4P available for dephosphorylation and hence maintaining PI4P levels. 
Alternatively, these two constructs may sequester PI4P with binding of the FAPP1 domain, effectively 
causing PI4P depletion. The observations that PJ-FAPP1 resulted in a slight reduction in VSV-E1-Q1 
cell-surface expression compared to PJ-DEAD-FAPP1 (p=NS) and that PJ-DEAD-FAPP1 did not 
significantly alter VSV-E1-Q1 expression compared to control, suggest that these constructs do not 
sequester PI4P, and PI4P is available to the enzyme domains for dephosphorylation (although the 
size of the available pool of PI4P remains unknown). 
In order to specifically deplete PI4P and/or PIP2 at the Golgi to decipher the individual role of PI4P in 
KCNQ1 trafficking, PJ or PJ-SAC were expressed with Tgn38-FRB. Dickson et al. (2013) showed that 
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recruitment of PJ-SAC to the Golgi using Tgn38-FRB caused the depletion of PI4P using tandem PH 
domains of oxysterol-binding protein homolog 2 (PHOSH2×2) as a reporter of PI4P. PHOSH2x2 moved from 
the TGN to the cytoplasm upon recruitment of PJ-SAC to the TGN, indicating that the level of PI4P 
here had reduced. Szentpetery et al. (2014) also recruited PJ-SAC to the Tgn38-FRB at the Golgi using 
rapamycin to investigate the relevance of PI4P in vesicular trafficking from the Golgi, and reported 
that depletion of PI4P using this method caused a rapid decline in the trafficking of VSVg from the 
Golgi to the PM. In contrast to this, I found that there was no change in VSV-E1-Q1 cell-surface 
expression when PJ-SAC was recruited to the Golgi with either 1 or 24 hours rapamycin incubation. 
The disparity between the results obtained here and by Szentpetery and colleagues regarding the 
effect of Golgi PI4P depletion may be due to the different proteins being investigated, different cell 
type used (HEK293 vs COS-7 cells) and the different methods of quantification (i.e. in- and on-cell 
western assay used here compared to confocal microscopy where a change in fluorescence intensity 
of VSVg at the Golgi was measured). 
There was a small but significant reduction in the cell-surface expression of VSV-E1-Q1 when PJ was 
expressed in the cells with Tgn38-FRB (without rapamycin), but not when the cells were incubated in 
rapamycin for 24 hours.  
Of course, there are limitations to this technique that may hinder the detection of subtle changes to 
VSV-E1-Q1 expression, or parameters that are not optimal for the detection of these changes. An 
example this may be that after 48 hours of VSV-E1-Q1 expression the PM becomes saturated with 
the VSV-E1-Q1 construct and small changes may be difficult to detect. In addition, high expression 
levels may mask the effect that PIP2 or PI4P depletion would produce at physiological IKs expression 
levels.  
 
5.5 Conclusion and Future Directions 
 
Using the rapamycin-induced dimerisation system to deplete PIP2 and/or PI4P at the PM and Golgi, I 
was able to investigate whether these phospholipids played a role in regulating the function and 
anterograde trafficking of the IKs channel. It emerged that depletion of these lipids did not affect the 
function of the IKs channel when tested in physiological conditions (i.e. in P-WCPC), nor did it affect 
the total cellular expression in any instance, and the cell-surface expression of the channel was only 
reduced (by approximately 25%) when PJ was expressed with Tgn38-FRB.  
Although it appears from these results that PIP2 is not involved in the regulation of IKs function or 
trafficking, this may not be the case; it has been suggested that the relatively low levels of PIP2 in the 
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secretory pathway is important in silencing the channel whilst it is in transit (Hilgemann et al., 2001). 
If this mechanism of silencing is not in place, opening of the IKs channel (or any other ion channel for 
that matter) could cause stress to the intracellular environment. The silencing that the channel 
experiences whilst in transit to the PM is re-established when the channel is recycled back from the 
PM.  
To further the study into KCNQ1 trafficking, other methods can be used in the future. Even though 
the rapamycin-inducible dimerisation system is specific for particular PI species, the methods of 
targeting the constructs to particular cellular compartments can interfere with results or confuse the 
interpretation of these. For example, when expressing FAPP1-containing constructs, which localise to 
the TGN through binding to ARF1 and PI4P, PI4P levels may be altered in an unknown way. Even 
though it appears there was no change in VSV-E1-Q1 expression when PJ-DEAD-FAPP1 was expressed 
in the cells, the actual effect on PI4P levels cannot be explored by this assay.  
In chapter 3, expression of PJ with LYN11-FRB resulted in a loss of IKs function, even in the absence of 
rapamycin. However, the P-WCPC experiments in this chapter led me to hypothesise that the 
channel may be regulated differently in a more physiological environment, but the cell could also 
upregulate certain PI-production pathways to counteract any lipid depletion that may occur by action 
of the lipid-depleting constructs. In the in/on-cell western assays, the cells remain intact (i.e. the 
intracellular environment is not tampered with and remains in a physiological state, similar to cells in 
P-WCPC experiments). The P-WCPC recordings in this chapter would suggest that even upon 
recruitment of PJ to the PM with rapamycin, there is a regulation of the IKs channel that maintains 
channel activity even in the face of PIP2 depletion. The experiments using Tubby-YFP as a marker of 
PIP2 depletion indicate that PIP2 levels do decrease at the PM. However, this does not mean that 
trafficking pathways show the same sensitivity, and the chronic effect of rapamycin exposure to 
trafficking pathways cannot be predicted from such short-term recordings.  
One way to overcome this uncertainty would be to knockdown the expression of a phosphatase 
involved in the production of PI4P or PIP2 and record the effect on cell-surface expression of the VSV-
E1-Q1 construct.  
As previously mentioned, a possible limitation of the in-/on-cell assay is the overexpression of the 
VSV-E1-Q1 channel. This may prevent either the increase of VSV-E1-Q1 at the PM (i.e. the PM is 
saturated) or the sensitivity of the technique is not high enough to detect the % increase in PM 
expression. To remedy this, the amount of VSV-E1-Q1 construct used in transfections could be 
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optimised to enable a high enough level of expression for robust detection, but a low enough level to 
allow increases in expression to be detected.  
One surprising observation of these experiments is that the depletion of PIP2 and its precursor, PI4P, 
at the PM (by recruiting PJ to LYN11-FRB with rapamycin) did not change cell-surface expression 
levels. As PIP2 is involved in CCV formation it would be expected that a reduction or depletion of PIP2 
would affect this process. PIP2 in the PM is required for CCV formation, but subsequent depletion of 
PIP2 needs to occur for CCV budding to complete the process of membrane internalisation. Even 
though depletion is required for the final stages of endocytosis, chronic depletion of PIP2 may not 
allow initial CCV formation, inhibiting the whole internalisation process. If the rate of recycling of 
VSV-E1-Q1 was reduced by the loss of PIP2 at the PM, an increase in VSV-E1-Q1 expression at the PM 
could be expected.  
To investigate whether depletion of PIP2 and/or PI4P at the PM reduces the rate of channel 
endocytosis, an assay quantifying the level of channel internalisation could be performed, and this 









In previous chapters, I found that the IKs current was inhibited by PIP2 depletion under certain 
experimental conditions. The IKs inhibition that I observed in WCPC after PIP2 depletion resulting 
from rapamycin-induced dimerisation supports work previously published by Kruse et al. (2012), 
who used a PI5K to selectively deplete PIP2. This group used PJ to deplete PIP2 (and PI4P) when 
investigating other channels, but when investigating the effect of PIP2 depletion on the IKs current it 
appears that PJ was not suitable (but this was not stated in the published results). Others have also 
investigated how the IKs channel responds to PIP2 depletion, including Matavel & Lopes (2009), who 
induced PIP2 depletion with Gq-coupled GPCR activation, and Loussouarn et al. (2003), who used the 
gradual rundown of PIP2 after patch excision in electrophysiological experiments. 
In contrast, the P-WCPC experiments performed in Chapter 5 using the rapamycin-induced 
dimerisation system to cause PIP2 and/or PI4P depletion indicated that when the intracellular 
environment is maintained, PIP2 depletion may not affect the IKs channel to the extent previously 
suggested.  
It seems reasonable to suggest, however, that the IKs channel might still be regulated physiologically 
by changes in PIP2 levels, as this channel contains a PIP2 binding region in the proximal C-terminus 
(Thomas et al., 2011), the movement of the VSD in the KCNQ1 subunit is coupled to pore opening by 
PIP2 (Zaydman et al., 2013) and this channel does appear to be more sensitive to changes in PIP2 
concentration than other cardiac ion channels (Kruse et al., 2012). 
β1-adrenergic signalling and the IKs channel 
 
During the ventricular action potential, the IKs current does not contribute greatly to repolarisation. 
However, in a setting of increased adrenergic drive, various studies have shown that the IKs current 
increases in amplitude (Kurokawa, et al., 2002; Matavel, et al., 2010; Moline et al., 2014; Volders et 
al., 2003) and can hence supply the increased repolarising current needed to counteract the 
increased inward L-type Ca2+ current. This notion is supported by the fact that β-blockers, which 
prevent signalling through the β-AR, reduce the occurrence of potentially fatal cardiac arrhythmias 
that can occur during increased adrenergic signalling in patients with KCNQ1 or KCNE1 mutations 
(LQT1 and LQT5, respectively) (Moss et al., 2000).  
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Physiologically, the IKs channel associates with AKAP 9, also known as yotiao, which localises proteins 
involved in the β1-adrenergic response to the IKs channel (Li et al., 2012; Marx et al., 2002; Terrenoire 
et al., 2009). The β1-AR primarily binds to the stimulatory Gα subunit, Gs, and when this receptor is 
activated by catecholamines such as epinephrine and norepinephrine, Gα dissociates from Gβγ and 
activates AC9. This in turn increases the local concentration of cAMP, leading to activation of PKA. 
AC9 and PKA are both brought into close proximity to the IKs channel by yotiao.  PKA then 
phosphorylates the IKs channel at Ser27 (Kurokawa et al., 2004) and possibly Ser92 (Lopes et al., 
2007), which results in conformational changes in the channel that lead to enhanced activation.  
Interaction between PIP2 and β1-AR-dependent mechanisms of IKs regulation 
 
The way the IKs channel is modulated by PIP2 and β1-AR activation is not completely understood, but 
what is even more complex is whether an interaction is present between these two regulatory 
mechanisms or whether they overlap. In the IKs channel complex, the KCNE1 subunit influences 
channel opening in response to membrane depolarisation, but this subunit also sits in a prime 
position to impact the regulation of the IKs channel by PIP2, and increases the sensitivity of the IKs 
channel to PIP2 by 100 times compared to the Kv7.1 channel (KCNQ1 alone) (Li et al., 2011). 
Furthermore, when the Pro127Thr mutation was introduced to the KCNE1 C-terminus, the yotiao-
dependent cAMP-mediated upregulation of the IKs current was supressed due to a reduced 
phosphorylation of the KCNQ1 subunit at Ser27 (Dvir et al, 2014). Evidently, these two regulatory 
processes converge at a structural point in the IKs channel complex, and could consequently be 
influenced by one another. 
The exact mechanism that converts phosphorylation of the KCNQ1 subunit into enhancement of the 
IKs current is not known, but considering that PIP2 lies at the interface between the VSD and PD 
(Zaydman et al., 2013), an interaction between the PIP2- and β1-AR-dependent regulation of the IKs 
channel could be possible. This could be exhibited in a number of ways, including a change in PIP2 
levels altering the effect of β1-AR activation or β1-AR signalling acting through PIP2 to bring about 
upregulation of the IKs current.  
It is now widely thought that the IKs channel is dependent on PIP2 for channel opening as this PI 
stabilises the open state of the channel (Loussouarn et al., 2003), and studies have shown that the IKs 
channel can be activated by exogenous PIP2 application (Zaydman & Cui, 2014). This is supported by 
my work presented in chapters 3 and 5.  
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Liou et al. (1999) show that the activation of PKA upregulates the activity of the ROMK1 channel by 
enhancing the strength of PIP2–channel interaction. Whether this is the case for the IKs channel will 
be investigated in this chapter.   
Hypothesis: That PIP2 plays a role in β1-mediated augmentation of the IKs current. 




6.2.1 Constructs and chemicals 
 
The VSP from Ciona intestinalis, Ci-VSP, and the VSP from Danio rerio, Dr-VSP, were a gift from 
Professor Yasushi Okamura (Osaka University, Japan). Both Ci-VSP and Dr-VSP convert PIP2 to PI4P 
through dephosphorylation. The Ci-VSP and Dr-VSP inserts are contained within the pIRES2-EGFP 
vector. This vector contains GFP after an IRES element, and the two inserts (Dr-VSP and GFP) are 
therefore expressed in cells in approximately a 1:1 ratio, enabling identification of cells expressing 
comparable levels of the VSP.  
Isoproterenol (ISO), an agonist of the β1-AR, was used to augment the IKs current. In all experiments, 
100 nM ISO was used. HEK293 cells endogenously express the β1-AR, so exogenous expression of 
this receptor was not required.  
The CF-PIPK construct was obtained from Tobias Meyer (Stanford University, U.S.A; Suh et al., 2006). 
CF-PIPK is PI4P kinase and contains the FKBP domain. As such, this construct can be used in the 
rapamycin-inducible dimerisation system along with LYN11-FRB. Using CF-PIPK to selectively 
phosphorylate PI4P to PIP2 will enable the response of the IKs current to an increase in only PIP2 
levels to be recorded. 
6.2.2 Electrophysiology  
 
WCPC or P-WCPC (where stated) were used to record the IKs current in HEK-IKs cells. HEK-IKs cells for 
WCPC and P-WCPC were incubated as described in section 3.2.2. WCPC and P-WCPC solutions and 
recordings were as described in section 3.2.2 and 4.2.3, respectively.   
In WCPC, I-V protocols were recorded by holding the Vm at -80mV before a 2 or 6 second activation 
step (depending on the experiment), from -80 mV to +80 mV (or +120 mV in experiments with Ci-
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VSP or Dr-VSP) in 10 mV increments. After the 2 second activation step, a 2 second repolarising step 
to -20 mV was used to record tail currents, before stepping back to -80 mV. 
To assess the ISO-induced change in IKs at a higher temporal resolution than repeated I-V protocols 
can offer, a sweep protocol was used. Within one sweep, the Vm was held at -80 mV before a 6-
second activation step to +30 mV. After this activation step, the Vm was stepped to -20 mV to elicit a 
tail current, and then the Vm returned to the holding potential of -80 mV. This one sweep was 
repeated every 10 seconds, and the current was recorded at the same time point in each to enable 
the change in current characteristics over time to be visualised.   
Data were analysed as described in section 3.2.2.  
6.2.3 Statistical analysis 
 
Data are expressed as mean ± SE, and Boltzmann functions were generated using GraphPad Prism. A 
Student’s T Test was used to determine statistical significance for single comparisons (p<0.05), and a 
one-way ANOVA with Bonferroni’s multiple comparison test (p<0.05) or Dunnett’s test (p<0.05) were 
used to determine significance when multiple groups were compared. 
 
6.3 Results 
6.3.1 The effect of isoproterenol on the IKs current in HEK-IKs cells 
 
To enable the comparison of the IKs current in the presence and absence of ISO, HEK-IKs cells were 
pre-incubated with ISO before recording.   
Before performing experiments where cells were pre-incubated with ISO, ISO (100 nM) was perfused 
whilst HEK-IKs cells were recorded in P-WCPC. This was done to determine the amount of time it 
would take for any effect on the IKs current to plateau. For these recordings, a voltage protocol 
consisting of 1 sweep was used (figure 64), which was repeated every 10 seconds. This allowed the 
IKs current to be recorded over time at the same voltage.  
First, HEK-IKs cells were recorded in P-WCPC in the absence of ISO until a stable baseline was 
reached. ISO (100 nM) was then perfused onto the cells and the +30 mV sweep protocol was 
continued until the IKs current response plateaued. Figure 64 shows a representative current trace 
and time course data for the same cell, where perfusion of ISO (100 nM) led to an increase in CD and 
PTCD of approximately 100% over a period of around 8 minutes. Based on this data, cells in the 
following experiments (utilising I-V protocols in WCPC to record the IKs current in the presence of 
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ISO) were subject to ISO (100 nM) perfusion for 10 minutes before the commencement of the WCPC 
recordings.   
When HEK-IKs cells were pre-incubated with ISO (100 nM) for 10 mins, the IKs CD increased compared 
to HEK-IKs cells in the absence of ISO, between Vm values of 0 mV to +70 mV. At 0 mV, the IKs current 
was 2.87 times greater, at 30 mV, 1.19 times greater and at 50 mV, 1.47 times greater than the 
current at the same respective Vm in HEK-IKs cells. When the Vm reached +80 mV, however, the 
current density values were not significantly different. The PTCD showed a similar trend to the values 
of CD between HEK-IKs cells in the presence or absence of ISO (100 nM). The steady state of 
activation for HEK-IKs cells pre-incubated in ISO (100 nM) was shifted to more hyperpolarised 
potentials compared to that for untreated HEK-IKs cells, and the value of V0.5 was significantly 
different, changing from 31.94  ± 0.54 mV to 11.48 ± 0.29 mV (p<0.005).   
The activation kinetics of the IKs current when recorded in HEK-IKs cells pre-incubated with ISO (100 
nM) for 10 mins were significantly quicker between +20 mV and +80 mV compared to untreated 
HEK-IKs cells (p<0.01). Also, the deactivation time constant (measured after a test pulse to +40 mV) 
significantly reduced (figure 65E and F).  
 
6.3.2 The effect of increasing cellular PIP2 levels on the IKs current in HEK-IKs cells  
 
To increase the PIP2 concentration within the intact cell during patch-clamp experiments, a construct 
named CF-PIPK was expressed in cells along with LYN11-FRB. CF-PIPK is similar to the PJ-related 
constructs used in previous chapters, but contains a PI5K domain in place of the PI phosphatase 
domains. This construct can also be used in the rapamycin-induced dimerisation system, so can be 
recruited to the PM upon addition of rapamycin to cells expressing these two constructs.  
To enable the direct comparison of the effects of ISO and the increase in PIP2 concentration on the IKs 
current, CF-PIPK and LYN11-FRB were expressed in HEK-IKs cells. Overexpression of the lipid-depleting 
constructs (i.e. PJ and PJ-related constructs) with LYN11-FRB in HEK-IKs cells (chapter 3) led to 
inhibition of the IKs current without recruitment of the lipid-depleting constructs to the PM with 
rapamycin, when investigated using WCPC. Due to this observation, it was expected that CF-PIPK 
would act in a similar fashion, but instead of causing lipid depletion (and hence current inhibition) 
this construct would lead to an increase in PIP2 at the PM even in the absence of rapamycin. 
CF-PIPK and LYN11-FRB were expressed in HEK-IKs cells and the IKs current was recorded in WCPC 
using the voltage protocol shown in figure 65.  
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Transient expression of CF-PIPK with LYN11-FRB in HEK-IKs cells caused an increase in the IKs current 
at all membrane potentials above those where activation of the IKs channel occurs compared to 
untransfected HEK-IKs cells, which was significant across all voltages analysed (p<0.01). In addition, 
the PTCD increased approximately 2-fold across membrane potentials between 0 mV and 50 mV, and 
was significantly increased across all voltages analysed (p<0.05). The steady state of activation was 
left-shifted compared to untransfected HEK-IKs cells, and the V0.5 was significantly different, changing 
from 31.94 ± 0.54 mV to 15.27 ± 0.50 mV (p<0.005) (figure 65).   
The activation of the IKs current when CF-PIPK and LYN11-FRB were expressed in HEK-IKs cells was 
significantly quicker between +20 mV and +70 mV compared to HEK-IKs cells (p<0.05), and the 
deactivation was significantly slowed (measured after a test pulse to +40 mV) (p<0.01) (figure 65E 
and F).  
Even though CF-PIPK was not recruited to the PM with rapamycin, this PI4P 5-K appeared to increase 
the PIP2 concentration, causing the changes in IKs current observed here. Without recruitment of CF-






Figure 64. The time course of the effect of isoproterenol on the IKs current. A – Representative current trace 
recorded in P-WCPC from HEK-IKs cells perfused with ISO (100 nM) after a stable baseline current had been 
reached, showing a sweep before ISO addition and when the IKs current plateaued after approximately 8 
minutes of ISO perfusion. B – Voltage protocol used to elicit the currents recorded in P-WCPC. C – Current 
density (left) and peak tail current density (right) recorded in P-WCPC from an untransfected HEK-IKs cell 




Figure 65. The effect of increased PIP2 or β1-adrenergic receptor enhancement on the IKs current in HEK-IKs 
cells. A – Representative traces of currents recorded in WCPC from untransfected HEK-IKs cells (control), HEK-IKs 
transiently expressing CF-PIPK with LYN11-FRB or untransfected HEK-IKs cells pre-incubated for 10 mins with 
ISO (100 nM). B – Voltage protocol used to elicit currents recorded in WCPC. C – Mean current density (top) 
and peak tail current density (bottom) of currents recorded in WCPC from untransfected HEK-IKs cells (control), 
HEK-IKs cells  expressing CF-PIPK with LYN11-FRB (n=15) and untransfected cells pre-incubated with ISO (100 
nM) (n=14). D – Steady state of activation, constructed by plotting normalised peak tail current densities 
(y/ymax) against test potential. E – Activation kinetics and F – Deactivation time constance (measured following 
a test pulse to +40 mV) of IKs currents from untransfected HEK-IKs cells (control), HEK-IKs cells expressing CF-PIPK 
with LYN11-FRB and HEK-IKs cells pre-incubated with ISO (100 nM). Data are presented as mean ± SE. A one-
way ANOVA with Dunnett’s post hoc test was used to determine statistical significance between control and all 
other groups in C and F, between +30 mV and +80 mV, in E across all voltages, and between V0.5 values 
obtained from D. A Boltzmann function was applied to data in D to fit a sigmoidal curve. 
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6.3.3 The effect of voltage-sensitive phosphatase activation on the IKs current in HEK-IKs cells  
 
To investigate how PIP2 concentration affects the response of the IKs channel to β1-AR activation 
(using ISO), a VSP was used to progressively deplete PIP2 with increasing depolarisation of the PM. 
This strategy was chosen because it has previously been used by others to ‘titrate’ the levels of PIP2 
in the PM whilst recording channel function (Falkenburger et al., 2010; Rjasanow et al., 2015). 
Furthermore, the VSPs dephosphorylate PIP2 and not PI4P, and the VSPs exist in an inactive state 
until activated by increasing voltage. This provides a selective, inducible and reversible method of 
titrating PIP2 on a timescale of seconds. Before performing this, however, the VSP that is most 
suitable to use with the IKs current was determined.  
Dr-VSP and Ci-VSP both activate in response to membrane depolarisation, and 50% Dr-VSP activation 
occurs at approximately +100 mV (Okamura et al., 2009). Each VSP was transiently expressed in HEK-
IKs cells and the IKs current was recorded using the voltage protocol shown in figure 66.  
When Ci-VSP was expressed in HEK-IKs cells, there was an inhibition of the IKs current compared to 
untransfected HEK-IKs cells, and it appeared that even at the lower membrane potentials, PIP2 
became depleted to an extent that severely impacted the IKs current (figure 66). Because of the 
drastic inhibition caused by Ci-VSP, only n=3 were recorded, therefore only representative traces are 
shown in figure 66.   
In contrast, when Dr-VSP was expressed in HEK-IKs cells, the lower membrane potentials that activate 
the IKs channel (approximately >0 mV) did give rise to sizable IKs current, but this was still reduced 
(p<0.05) compared to untransfected HEK-IKs cells (figure 66).  
It appears that Ci-VSP activates across a very similar voltage range to the IKs channel, and so Dr-VSP 
should be used with the IKs channel to allow recording of IKs current before PIP2 depletion from VSP 
activation. The effects seen with these two VSPs clearly reinforces that the IKs channel is dependent 
on PIP2 for its function. The effect of ISO perfusion or CF-PIPK expression on the IKs current was 
investigated in the setting of PIP2 depletion by Dr-VSP activation from here onwards. 
6.3.4 The effect of PI4P 5-K expression on the IKs current in HEK-IKs cells that also express a voltage-
sensitive phosphatase 
 
After establishing that Dr-VSP was optimal for use with the IKs channel, manipulations to regulatory 
mechanisms of the IKs channel could then be performed and the effect of gradual PIP2 depletion by 
VSP activation could be observed.  
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CF-PIPK, LYN11-FRB and Dr-VSP were transiently expressed in HEK-IKs cells and the IKs current was 
recorded using the voltage protocol shown in figure 67B.  
When compared to HEK-IKs cells only expressing Dr-VSP, the IKs CD and PTCD recorded in HEK-IKs cells 
expressing CF-PIPK, LYN11-FRB and Dr-VSP significantly increased across all IKs channel-activating 
membrane potentials (p<0.05). This can be explained by the fact that CF-PIPK may show a basal level 
of activity and Dr-VSP may act to sequester PIP2 prior to activation, but that the increased 
production of PIP2 by overexpression of CF-PIPK can override the effective PIP2 depletion brought 
about by Dr-VSP activation.  
Figure 67 shows the normalised PTCD values, and curves were fitted using a Boltzmann function. V0.5 
values were analysed with a one-way ANOVA with Bonferroni’s post hoc test, which showed that 
there was a significant difference between the values for CF-PIPK (2.41 ± 0.67 mV) and Dr-VSP (7.71 
± 0.67 mV; p<0.001), and between CF-PIPK and control (6.95 ± 1.05 mV; p<0.01). Comparing relative 
CD and PTCD showed that Dr-VSP expression with CF-PIPK and LYN11-FRB was significantly different 
to Dr-VSP cells (p<0.05), but not significantly different from control cells across all voltages compared 
(p=NS).  
6.3.5 The interaction between PKA- and PIP2-dependent mechanisms of IKs regulation  
 
In a similar fashion to the experiments looking into the effect of PI4P 5-K activity on the IKs current 
whilst activating Dr-VSP, the effect of ISO was also investigated so the two could be compared. This 
comparison allowed investigation into whether PIP2 is involved in the β1-AR-activation-induced 
increase in the IKs current.  
As before, ISO (100 nM) was perfused over cells for 10 mins prior to WCPC recordings, but this time 
the HEK-IKS cells transiently expressed Dr-VSP. IKs currents were recorded in HEK-IKs cells using the 
voltage protocol shown in figure 67B.  
After 10 mins of ISO (100 nM) perfusion in HEK-IKs cells expressing Dr-VSP, the IKs current was 
significantly increased compared to HEK-IKs cells expressing Dr-VSP in the absence of ISO across all 
voltages analysed (p<0.5). The IKs CD and PTCD were very similar to those elicited when CF-PIPK and 
LYN11-FRB were expressed with Dr-VSP in HEK-IKs cells, and to control cells. The pre-incubation with 
ISO appeared to reverse the effect of PIP2 depletion resulting from Dr-VSP activation, up to 80 mV. 
The V0.5 value, however, changed significantly between control cells and those expressing Dr-VSP also 
pre-incubated with ISO (6.95 ± 1.05 mV vs. 0.00 ± 0.71 mV; p<0.0001) (figure 67D). When the 
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membrane potential reached +80 mV, the CD values diverged and began to increase when compared 
to cells expressing CF-PIPK, but this trend did not reach significance (p=NS) (figure 67C).   
Figure 67 also shows the normalised PTCD values of IKs cells expressing Dr-VSP that were pre-
incubated for 10 mins with ISO (100 nM), and curves were fit using a Boltzmann function. V0.5 values 
were analysed with a one-way ANOVA with Bonferroni’s post hoc test, which showed that there was 
no significant difference between the values for control (4.72 ± 0.81 mV), Dr-VSP (3.92 ± 3.2 mV; 
p=NS) or Dr-VSP also incubated with ISO (100 nM) for 10 mins (-4.20 ± 1.76 mV; p=NS). Comparing 
relative CD and PTCD values showed that Dr-VSP expression with 10 mins ISO (100 nM) pre-
incubation was significantly different to control cells (p<0.05) (figure 68). In addition, the relative CD 
was significantly different from that of HEK-IKs cells expressing Dr-VSP from 70 mV–90 mV (p<0.05), 
and the relative PTCD was significantly different from that of HEK-IKs cells from 80 mV–110 mV 
(p<0.05). The relative CD and PTCD values were significantly different between HEK-IKs cells 
expressing Dr-VSP with CF-PIPK and LYN11-FRB and HEK-IKs cells expressing Dr-VSP pre-incubated 
with ISO (100 nM) for 10 mins from 90 mV–120 mV (p<0.05).   
6.3.6 The effect of isoproterenol on the IKs current in HEK-IKs cells that also express PJ 
 
As pre-incubation with ISO (100 nM) was able to overcome Dr-VSP-induced PIP2 depletion, the ability 
to overcome PIP2 depletion caused by PJ expression was studied.  
As performed for previous pre-incubation experiments, ISO (100 nM) was perfused over cells for 10 
mins prior to WCPC recordings, but this time the HEK-IKs cells transiently expressed PJ and LYN11-
FRB. IKs currents were recorded in HEK-IKs cells using the voltage protocol shown in figure 69.   
Figure 69 shows currents recorded from HEK-IKs cells, HEK-IKs cells pre-incubated with ISO and HEK-IKs 
cells expressing PJ with LYN11-FRB, previously shown in this chapter and chapter 3. When cells 
expressing PJ with LYN11-FRB were pre-incubated with ISO (100 nM) for 10 mins prior to recording, 
there was a recovery of the IKs current when compared to the current recorded from cells expressing 
PJ and LYN11-FRB without ISO pre-incubation. This recovery was significant between +30 mV and +50 
mV (p<0.05). This current, however, was reduced compared to control cells at the more positive 
voltages used, but this was not a significant difference when comparing CD (p=NS) and PTCD values 
(p=NS) between +30 mV and +50 mV.  
V0.5 values were determined by fitting a Boltzmann function to the normalised PTCD, which showed 
that compared to control (9.33 ± 0.53 mV), pre-incubation of cells expressing PJ and LYN11-FRB with 
ISO (100 nM) caused a hyperpolarising shift (2.23 ± 0.46 mV), which was significant (p<0.001). The 
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shift in V0.5 was not to the extent of untransfected cells pre-incubated with ISO (-11.55 ± 0.99 mV), 
and there was a significant difference between this and cells pre-incubated with ISO also expressing 




Figure 66. Comparison of the effect of different voltage-sensitive phosphatases on the IKs current in HEK-IKs 
cells. A – Representative current traces recorded in WCPC from untransfected HEK-IKs cells (control) and HEK-IKs 
cells expressing Dr-VSP or Ci-VSP. B – Voltage protocol used to elicit the currents recorded in WCPC. Mean data 




Figure 67. The effect of gradual PIP2 depletion using a voltage-sensitive phosphatase in the setting of 
increased PIP2 or β1-adrenergic receptor activation on the IKs current in HEK-IKs cells. A – Representative 
traces of currents recorded in WCPC from HEK-IKs cells (control) and HEK-IKs cells expressing Dr-VSP, Dr-VSP with 
CF-PIPK and LYN11-FRB or Dr-VSP whilst being pre-incubated for 10 mins with ISO (100 nM). B – Voltage 
protocol used to elicit currents recorded in WCPC. C – Mean current density (top) and peak tail current density 
(bottom) of currents recorded in WCPC from HEK-IKs cells (control) and HEK-IKs expressing Dr-VSP (n=12), Dr-
VSP with CF-PIPK and LYN11-FRB (n=16) or Dr-VSP whilst being pre-incubated for 10 mins with ISO (100 nM) 
(n=14). D – Steady state of activation curves, constructed by plotting normalised peak tail current densities 
(y/ymax) against test potential. Data are presented as mean ± SE. A one-way ANOVA with Bonferroni’s post hoc 
test was used to determine statistical significance across all groups in C, between +30 mV and +120 mV (+80 
mV in the case of control cells), and between V0.5 values obtained from D. A Boltzmann function was applied to 





Figure 68. Comparison of the relative effects of gradual PIP2 depletion using a voltage-sensitive phosphatase 
in the setting of increased PIP2 or β1-adrenergic receptor activation on the IKs current in HEK-IKs cells. A – 
Normalised current recorded in WCPC from untransfected HEK-IKs cells (control) (n=9), HEK-IKs cells transiently 
expressing Dr-VSP (n=12), Dr-VSP with CF-PIPK and LYN11-FRB (n=16) or Dr-VSP whilst being pre-incubated for 
10 mins with ISO (100 nM) (n=14). Peak tail current density was normalised to the maximum and minimum 
mean peak tail current density values. B – Relative current density (left) and relative peak tail current density 
(right) of currents recorded in WCPC, constructed by plotting y/ymax against test potential. Data are presented 
as mean ± SE. A Boltzmann function was applied to data in A to fit sigmoidal curves. A one-way ANOVA with 
Bonferroni’s post hoc test was used to determine statistical significance between V0.5 values from A, and all 




Figure 69. Effect of β1-adrenergic receptor activation on the IKs inhibition caused by expression of lipid-
depleting constructs in HEK-IKs cells. A – Representative traces of currents recorded in WCPC from 
untransfected HEK-IKs cell (control), HEK-IKs cells expressing PJ, untransfected HEK-IKs cells pre-incubated for 10 
mins with ISO (100 nM) and HEK-IKs cells expressing PJ also pre-incubated with ISO (100 nM) for 10 mins. B – 
Voltage protocol used to elicit currents recorded in WCPC. C – Mean current density (top) and peak tail current 
density (bottom) of currents from HEK-IKs cell (n=12), HEK-IKs cells expressing PJ with LYN11-FRB (n=11), 
untransfected HEK-IKs cells pre-incubated for 10 mins with ISO (100 nM) (n=7) and HEK-IKs cells expressing PJ 
with LYN11-FRB also pre-incubated with ISO (100 nM) for 10 mins (n=14). D – Steady state of activation curves, 
constructed by plotting normalised peak tail current densities (y/ymax) against test potential. Data are 
presented as mean ± SE. A one-way ANOVA with Dunnett’s post hoc test was used to determine statistical 
significance between control and all other groups in C, between +30 mV and +50 mV, and between V0.5 values 






PIP2 lies in an optimal position within the IKs channel complex to be involved in different regulatory 
processes, including the effect that KCNE1 has on the homomeric KCNQ1 channel (Li et al., 2011). 
Due to the sensitivity of the IKs channel to PIP2 depletion that others have previously found (Kruse et 
al., 2012; Loussouarn et al., 2003; Matavel & Lopes, 2009), it is thought that this channel might be 
regulated physiologically by depletion of PIP2 from the PM (addressed in chapter 3 and 5).  
PIP2 is known to stabilise the open state of the IKs channel (Loussouarn et al., 2003), and Zaydman et 
al. (2013) suggested that PIP2 couples voltage-sensor movement to pore opening. Supporting these 
findings, the experiments I performed in chapter 3 suggest that PIP2 is critical for IKs channel function.   
One aspect of the IKs channel’s regulation that has not been studied extensively is how 
phosphorylation of the KCNQ1 subunit at Ser27 and Ser92 by PKA, downstream of β1-AR activation, 
leads to enhancement of the IKs current. An increase in the macroscopic current could suggest that 
the channel remains in the open state for a longer period of time, indicating that PIP2 may be 
involved. Drawing on evidence from others regarding the role of PIP2 in coupling voltage-sensor 
movement to pore opening (Zaydman et al., 2013), I hypothesised that PIP2 is involved in the 
enhancement of the IKs current resulting from PKA-dependent phosphorylation.  
Increasing PIP2 at the PM enhances the IKs current 
 
To decipher whether a change in PIP2 alone is responsible for this augmentation in IKs current, the 
PI4P 5-K, CF-PIPK, was used to increase the PIP2 concentration within the cell. Despite not recruiting 
PJ to LYN11-FRB at the PM with rapamycin, experiments with the lipid-depleting constructs in 
chapter 3 revealed that the enzyme activity of the lipid-depleting constructs could bring about 
changes in PIP2 concentration that were sufficient to completely abolish IKs function. As such, CF-PIPK 
was initially overexpressed with LYN11-FRB to assess whether the IKs current was affected prior to 
rapamycin addition. Indeed, the IKs current was significantly increased compared to untransfected 
HEK-IKs cells, reflecting the increase in PIP2 caused by overexpression of the CF-PIPK construct. Others 
have reported that overexpression of a PIP 5-K increased the PIP2 concentration in rat atrial 
myocytes (Bender et al., 2002) or sympathetic neurons (Winks et al., 2005). 
In addition to establishing that CF-PIPK can increase PIP2 in the PM, and that this can be detected as 
an increase in the IKs current, this experiment revealed that the IKs channel does not reside in a PIP2-
saturated state (at least in the HEK293 stably-expressing cell line used here), as increased PIP2 
concentrations led to changes in the channel’s biophysics. This strengthens the possibility that β1-AR 
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activation could lead to a change in how PIP2 influences the function of the IKs channel, as there 
exists scope for channel augmentation to occur.   
Activating the β1-adrenergic receptor enhances the IKs current 
 
The effect of β1-AR activation on the IKs current resulting from pre-incubating HEK-IKs cells with ISO 
(100 nM) is different in some ways to the effect of overexpressing CF-PIPK in these cells. Up to a 
voltage of approximately +30 mV, the IKs current behaves in a similar manner, but after this the 
responses diverge; pre-incubation with ISO (100 nM) does not result in a significant change in IKs CD 
at voltages ≥50 mV when compared to control cells.  
This data is largely in accordance with previously published studies, which have shown an increase in 
IKs CD in the presence of ISO, and a hyperpolarising shift in the voltage-dependence of activation 
(Imredy et al., 2008; Severi et al., 2009). This group did observe a larger increase in IKs current 
compared to the results I obtained, but this may be due to the difference in cell types studied (a 
HEK293 cell line compared to guinea-pig ventricular myocytes).   
ISO pre-incubation increased activation kinetics of the IKs channel, resulting in larger currents at more 
negative membrane potentials, but also decreased the time taken for deactivation. This is in contrast 
to the effect that CF-PIPK had, which was to speed up activation whilst increasing the time taken for 
deactivation. β1-AR activation in the heart acts to increase the force of contraction, but also to 
increase heart rate. The increase in both activation and deactivation kinetics observed here when 
pre-incubating HEK-IKs cells with ISO fits with the need for an increase in repolarising current paired 
with the capacity for rapid reactivation.  
The fact that the effect on IKs channel deactivation differs between these two conditions suggests 
that in addition to the possibility that PIP2 may be involved in transmitting β1-AR activation to the IKs 
channel, other cellular processes are likely to be involved in the overall process, in particular 
deactivation of the channel.  
Voltage-sensitive phosphatase activation and the IKs current 
 
As another means of deciphering how PIP2 is involved in regulating the function of the IKs channel, 
VSPs were expressed in HEK-IKs cells. Unfortunately, the expression of both Ci-VSP and Dr-VSP 
decreased the IKs current prior to when activation of the respective VSP is thought to occur, which is 
detailed in Okamura et al. (2009) and here in Chapter 2. The extent to which the IKs current was 




The reason behind why the IKs current is inhibited by overexpression of the VSPs (even before 
activation) could lie in the VSPs’ mechanism of PIP2 dephosphorylation. The VSPs may exist in a PIP2-
bound state at membrane potentials negative to those that activate the VSP, which could sequester 
PIP2 and consequently reduce the available pool. Alternatively, there may be activation of these VSPs 
at more hyperpolarised potentials than previously reported. Falkenburger and colleagues (2010) 
suggested that the number of VSP molecules in the PM may far surpass the number of PIP2 
molecules, effectively causing rapid PIP2 ‘depletion’ by binding PIP2 before a full cycle of enzymatic 
activity.   
Rescue of PIP2-depletion-induced IKs inhibition with β1-AR activation   
 
To further probe whether the increase in IKs current resulting from β1-AR activation involves PIP2, the 
response of the IKs current to CF-PIPK expression and ISO pre-incubation was assessed in the 
presence of PIP2 depletion via Dr-VSP activation. Expression of CF-PIPK with LYN11-FRB (and hence 
an increase in the PM PIP2 concentration) was able to overcome the PIP2 loss brought about by 
activation of Dr-VSP. 
If the PKA-dependent increase in IKs requires the presence of PIP2 in the PM, then perhaps activation 
of β1-AR with ISO would lead to minimal enhancement of the IKs current when PIP2 is depleted from 
the PM using Dr-VSP. On the other hand, if PKA phosphorylation of the IKs channel leads to an 
increase in PIP2 sensitivity or PIP2 concentration, then the IKs current density may increase compared 
to when expressing Dr-VSP alone. Indeed, the IKs current density did increase in the setting of PIP2 
depletion. This could suggest that PKA-dependent increases in the IKs current act through PIP2. 
However, combined with the previous results showing differing effects on activation and 
deactivation kinetics, it is probable that PIP2 is one of a number of signalling molecules involved in 
how the current is augmented.  
If PKA-mediated phosphorylation of the channel enhanced the sensitivity or strength of interaction 
with PIP2, then a depolarising shift in the inhibition caused by activation of Dr-VSP should be 
observed. From figure 67 it is evident that this did not change, and V0.5 values were not significantly 
different (p=NS). This is in contrast to Rjasanow et al. (2015), who showed that KCNQ2/3 mutants 
that reduce PIP2 binding alter the voltage at which Ci-VSP reduces the current (i.e. they shift the 
voltage at which inhibition occurs to more hyperpolarised potentials). Following the logic that a 
weaker channel-PIP2 interaction had this effect, an increase in the channel-PIP2 interaction would 
cause inhibition at membrane potentials that cause a greater PIP2 depletion by the activation of Dr-
VSP. On the other hand, signalling through the β1-AR may reduce the IKs channel’s need for PIP2 to 
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function, and this would be expected to have the same effect on the Dr-VSP-induced inhibition 
described above.  
Although the voltage at which the initial plateau or maximum current before inhibition (depending 
on the condition) was reached did not change, the effect on the current after that point was 
different between groups. Dr-VSP and Dr-VSP with CF-PIPK and LYN11-FRB caused an inhibition of 
the current after ~40 mV, although the current began to increase after 90 mV when CF-PIPK and 
LYN11-FRB were co-expressed. However, when cells were pre-incubated with ISO (100 nM) for 10 
mins the current was not inhibited, but actually increased. The same effect was not seen for PTCD, 
where there was inhibition across all groups compared to control, but to a lesser extent when cells 
were pre-incubated with ISO (100 nM) for 10 mins. This effect could imply that physiologically, Gq-
coupled GPCR activation is not effective at regulating the IKs current through PIP2 depletion during 
β1-AR signalling due to the channel requiring less PIP2 in the PM to function. This, however, was not 
investigated during this project, but these results imply that β1-AR can largely override PIP2-
dependent regulation.  
The mechanism behind how PKA-dependent phosphorylation of the channel leads to IKs channel 
augmentation is still unknown. Liou and colleagues investigated whether PKA activates the ROMK1 
channel through manipulation of PIP2, and concluded that PKA does so by enhancing the channel’s 
interaction with PIP2 (Liou et al., 1999). Considering the results obtained in this chapter that are 
discussed above, it seems unlikely that PIP2 is the only signalling molecule involved in the PKA-
dependent augmentation of the IKs current. However, activation of the β1-AR did manage to partially 
overcome IKs inhibition caused by PIP2 depletion arising from PJ expression, arguing that the 
relationship between the IKs channel and PIP2 is altered during this signalling event, suggesting that 
the IKs channel could be regulated in a similar way to the ROMK1 channel.  
The experiments I conducted in this chapter were different to those of Liou and colleagues – I 
performed PIP2 depletion by dephosphorylation (Dr-VSP activation and PJ expression), and recorded 
the effect of β1-AR activation on the inhibition of the IKs current caused by these PIP2 depletion 
methods, which uses channel function as a surrogate marker for the interaction of the channel with 
PIP2. On the other hand, Liou et al. (1999) directly studied phosphorylation of the IKs channel and 
PIP2 affinity of the channel using biochemical methods.  
Given that β1-AR activation with ISO provided the channel with a means to overcome Dr-VSP-
activation-induced inhibition, the ability of ISO pre-incubation to overcome PJ-induced inhibition was 
investigated. Despite ISO pre-incubation being unable to rescue the IKs current to the level of control 
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cells, it did significantly hyperpolarise the V0.5 value compared to control. This provides further 
evidence to suggest that β1-AR activation and the following PKA-dependent phosphorylation of the 
IKs channel do not solely transduce the signal via manipulation of PIP2.  
Interestingly, β1-AR activation was able to partially recover the IKs inhibition caused by 
overexpression of PJ with LYN11-FRB. This could suggest that PIP2 is directly involved with IKs 
enhancement here. However, it is important to note that when pre-incubating PJ-expressing cells 
with ISO (100 nM) the 2 minutes of intracellular dialysis that are routinely performed in WCPC 
experiments before recording were omitted. This reduced level of dialysis may have led to a higher 
initial CD. Therefore, in the future this experiment should be repeated to incorporate the 2 minutes 
of dialysis before recording so that a direct comparison can be made.  
 
6.5 Conclusions and future directions 
 
By manipulating the levels of PIP2 in the PM using VSPs, the mechanism of IKs enhancement upon β1-
AR activation was investigated.  
The IKs channel is known to require PIP2 for function (Loussouarn et al, 2003), and I have presented 
results in this chapter that show that an increase in the PIP2 level in the PM (brought about by 
overexpression of a PIP 5-K in this instance) enhances the amplitude of the IKs current whilst shifting 
the voltage-dependence of activation to more hyperpolarised potentials. Work by others has shown 
that activation of the β1-AR causes enhancement of the IKs current (Kurokawa, et al., 2002; Matavel, 
et al., 2010; Moline et al., 2014; Volders et al., 2003), and I demonstrated here that this 
enhancement is accompanied by a hyperpolarising shift in the voltage dependence of activation.  
By comparing the effects of the PIP 5-K with the effects of β1-AR activation on the IKs current, and by 
looking at how the current responded when PIP2 was depleted by Dr-VSP activation, I concluded that 
the PKA-dependent alterations in the IKs current do not solely act through a mechanism involving 
PIP2. I have not obtained enough evidence to completely accept or reject the hypothesis that PIP2 
plays a role in the β1-mediated augmentation of the IKs current, and have not elucidated the 
mechanism underlying augmentation of the IKs current downstream of β1-AR activation. To elucidate 
whether any changes to the channel occur independent of PKA-dependent phosphorylation, PKA 
inhibitors could also be used. 
To further investigate the roles of PIP2 and β1-AR in the regulation of the IKs channel, experiments 
mimicking those used in Liou et al (1999) could be performed, and experiments that follow β1-AR 
255 
 
activation with Gq-GPCR activation would provide valuable insights into the physiological reasons 





CHAPTER 7: Discussion, conclusions and future directions 
7.1 Discussion 
 
The IKs current constitutes part of the repolarisation reserve in the human myocardium, and whilst it 
does not play a major role at resting heart rates, this current becomes a crucial component of 
repolarisation in the setting of increased sympathetic tone and high heart rates (Jost et al., 2005; 
Silva & Rudy, 2005). The formation of the IKs current requires the presence of the KCNE1 β-subunit 
(Barhanin et al., 1996; Sanguinetti et al., 1996), but also the minor membrane PI, PIP2 (Loussouarn et 
al., 2003; Zaydman et al., 2013). Several studies helped to reach the conclusion that the IKs channel 
requires PIP2 for its function, and PIP2 is believed to stabilise the open conformation of the channel. 
PIP2 binding regions have been identified in different areas of the channel, but it has been asserted 
that PIP2 interacts with the channel in a prime position to influence how KCNE1 affects the IKs channel 
and how the channel converts voltage sensor movement to pore opening (Li et al., 2011; Zaydman et 
al., 2013). 
Mutations in the KCNQ1 or KCNE1 subunits can lead to LQTS (Dvir et al, 2014; Kapplinger et al., 
2009), and different mechanisms – including trafficking and functional defects (Aizawa et al., 2004; 
Bianchi et al., 2000) – have been shown to be responsible for the decrease in IKs current available 
during cardiac repolarisation. Previously in this laboratory, mutations within a PI binding region in 
the proximal C-terminus of KCNQ1 led to retention of the channel in the ER (unpublished data, 
Thomas et al., 2011).  
This project aimed to investigate how PIP2 is involved in the regulation of function and trafficking of 
the IKs channel, in order to better understand the possible mechanisms underlying the generation of 
LQTS caused by mutations in KCNQ1. A summary of this project can be seen in figure 70, while the 
major findings of this project are summarised and discussed below. 
Sensitivity of the IKs current to PIP2 depletion 
 
Using the rapamycin-inducible dimerisation system to deplete PIP2 from the PM in HEK-IKs cells, it 
was immediately apparent that the IKs channel requires PIP2 for channel opening, as when PIP2 was 
selectively depleted from the PM the IKs current was inhibited. This supports the notion that PIP2 
stabilises the open state of the IKs channel. In addition, I found that this channel is more sensitive to 
PIP2 depletion than the hERG and Kir2.1 channels, both also present in the heart and involved in 
cardiac repolarisation. This supports data from Kruse et al. (2012), who used the rapamycin-inducible 
dimerisation system to investigate the PIP2 sensitivity of a number of ion channels. 
257 
 
However, by comparing the effect of lipid-depleting construct expression on the IKs current elicited in 
both WCPC and P-WCPC, it was clear that the cellular environment during patch-clamp recordings 
affected the amplitude of the IKs current when the lipid-depleting constructs were expressed: WCPC 
recording of HEK-IKs cells expressing PJ with LYN11-FRB led to a complete loss of IKs current, whereas 
P-WCPC recording of HEK-IKs cells expressing PJ with LYN11-FRB caused no change in the IKs current 
when compared to control. The maintenance of the IKs current in P-WCPC suggests that in a 
physiological environment, i.e. in the cardiac myocyte, the IKs current may not be as sensitive to PIP2 
depletion as some in vitro studies may suggest (i.e. those performed in WCPC). 
Given these results that were obtained in P-WCPC, the configuration of patch clamp that mimics a 
physiological environment closer than any other, it is of great interest now to decipher just how PIP2 
regulates the channel physiologically. In order to further investigate the physiological regulation of 
the IKs channel by PIP2 depletion, studies involving the activation of cardiac Gq-coupled GPCRs should 
be performed. The IKs current in these studies should be recorded in P-WCPC to ensure the cell 
retains many of the intracellular cofactors required by the cell to undergo normal PIP2 turnover, as 
the IKs channel runs down with the gradual loss of PIP2 from the PM (Matavel & Lopes, 2009). 
 
The effect of PIP2 and/or PI4P depletion on IKs channel trafficking 
 
I found that PIP2 is not involved in IKs channel anterograde trafficking to the PM, despite PIP2 binding 
region mutations causing retention of the channel in the ER. This was demonstrated by using the 
rapamycin-induced dimerisation system in HEK cells expressing the VSV-E1-Q1 construct and 


































































































































































This suggests that the PIP2 binding-region mutations that were introduced into the proximal C 
terminus by Thomas and colleagues (2011; unpublished data), which I have since repeated, did not 
cause ER-retention of the channel through a reduced capacity to bind PIP2. Rather, disrupted 
anterograde trafficking was more likely caused by KCNQ1 protein misfolding independent of effects 
on PIP2 binding.  
Thomas et al. (2011) found that the region that binds PIP2 also binds a number of other PIs. It is 
possible that PIP2 is required for activation of the channel, and other PIs are involved in regulating IKs 
channel trafficking.  
Using the rapamycin-inducible dimerisation system  
 
Throughout this project, the rapamycin-inducible dimerisation system was used with the knowledge 
that it was not optimal for investigating the IKs channel. However, it did selectively deplete PI4P 
and/or PIP2. Even though in chapter 4 I tried to optimise the system by targeting the lipid-depleting 
constructs to intracellular organelles and mutating residues in the FRB domain to attempt to reduce 
potential FRB-FKBP interactions, I was not able to produce an improved system that would enable 
the lipid-depleting constructs to be expressed in cells also expressing the IKs channel without 
affecting the functional properties of the IKs channel.  
Another inducible dimerisation system was developed by Miyamoto and colleagues (2012), using the 
plant hormone gibberellin to dimerise two proteins (which can be engineered to be tethered to 
phosphatase domains as in the FRB- and FKBP-containing constructs used throughout the project). In 
chapter 4 I tried to customise the components of the gibberellin-induced dimerisation system to 
incorporate the phosphatase domains used in the rapamycin-induced dimerisation system. 
Unfortunately, the cloned construct, PJ-GID1, did not recruit to the PM upon exposure of the cells to 
the dimerising agent, GA3-AM.  
For further investigation into the role of PIP2 in the regulation of the IKs channel careful consideration 
should be given when using these dimerisation systems, as depletion of PIP2 may occur and affect 
the channel’s function before dimerisation of the recruitable domains during baseline recordings.  
The effect of β1-AR activation on the IKs current 
 
Recent research has reported that the effects of PIP2 and β1-AR-dependent augmentation of the IKs 
channel to converge (Dvir et al., 2014), and PKA-dependent phosphorylation of the ROMK1 channel 
has been shown to act through PIP2 (Liou et al., 1999). However, evidence that this occurs with the IKs 
channel has not yet been provided, nor has a mechanism been proposed. By activating the β1-AR 
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whilst manipulating the levels of PIP2 in the PM, I began to probe how PIP2 may or may not be 
involved in the adrenergic regulation of the IKs channel. I could not provide definitive evidence to 
conclude that PIP2 is or is not involved. However, the results presented in chapter 6 do provide 
preliminary data suggesting that PIP2 may be involved, but the β1-AR-induced augmentation of the 
IKs current does not solely rely on PIP2 to convey this signal to the channel.  
In addition to this, it appears that under adrenergic stimulation the IKs channel may be less sensitive 
to PIP2 depletion, which could provide evidence to suggest the β1-AR and Gq-coupled GPCR 
pathways of IKs regulation interact. The overriding of PIP2 regulation by β1-AR signalling may occur 
due to the channel’s sensitivity to phosphorylation, which may be conserved in the P-WCPC 
configuration.  In a state of increased adrenergic drive, which requires increased repolarisation 
reserve to counteract the increase in Ca2+ current through the L-type Ca2+ channel and contribute to 
the increased force of contraction, the IKs current may become less sensitive to PIP2 depletion (and 
hence closure) to increase the proportion of channels available for activation.  
7.2 Conclusions 
 
In conclusion, the results presented in the previous chapters confirm that PIP2 in the PM is crucial for 
IKs channel opening. PIP2 is not, however, required for IKs anterograde channel trafficking, but these 
experiments do not rule out a role for many other PIs in the regulation of this process. Regarding the 
physiological role of β1-AR-induced augmentation of the IKs channel, my results suggest that PIP2 
could be in part involved in this process, but also that the channel may become less sensitive to PIP2 
depletion when under sympathetic stimulation, increasing the availability of the IKs channel during 
periods which require a larger repolarisation current.  
7.3 Future directions 
7.3.1 Future direction of chapter 4 
 
An assay to investigate the role of PIP2 in internalisation of the IKs channel 
 
In chapter 4, I found that depleting PIP2 and PI4P from the PM did not change the total or cell-
surface expression of the VSV-E1-Q1 construct, which was investigated using the in- and on-cell 
western assays, respectively. The way this assay was performed, however, did not enable the 




Mechanisms of endocytosis 
 
CME is one process by which ion channels can be internalised for recycling or degradation. The 
clathrin lattice that forms on the intracellular side of the PM recruits a number of clathrin-associated 
proteins, which promote membrane curvature and vesicle formation. One of these recruited 
proteins is the adaptor protein 2 (AP-2), which is crucial in the formation of CCVs. There is evidence 
to suggest that PIP2 is crucial for recruitment of the AP-2 complex (Gaidarov & Keen, 1999). Further 
supporting this, the inositol 5-phosphatase synaptojanin, whose substrates are PIP2 and PIP3, was 
discovered due to its role in synaptic vesicle endocytosis (Cremona et al., 1999).  
A number of TM proteins have been found to be internalised by CME, including RTKs (Goh & Sorkin, 
2013) and Kir3.x channels (Nagi et al., 2015). Others, including the TGF-β type 1 receptor (Zhao et al., 
2012), are internalised via a caveolin-dependent mechanism, and O’Kelly (2015) found that the two-
pore domain K+ channels can be internalised via clathrin-dependent or clathrin-independent 
mechanisms depending on the external cue. In addition, there are little-studied mechanisms of 
endocytosis, such as the clathrin- and calveolin-independent pathway utilised by the interleukin-2 
receptor (Basquin et al., 2015). 
 Assay design 
 
In order to enable quantification of the rate of internalisation, a similar assay to that used in chapter 
4 would be used. In this internalisation assay, cells expressing VSV-E1-Q1 with lipid-depleting 
constructs and LYN11-FRB would be incubated with primary Ab (α-VSV) at 4°C for 1 hour, and then 
incubated at 37°C for either 2, 5, 10, 20 or 30 minutes. For each time point, all experimental 
conditions would be performed in 2 plates: one for the in-cell western and one for the on-cell 
western. After incubation at 37°C, the cells would be washed and the secondary Ab would be added, 
then the assay would proceed as described in chapter 4. By assessing the VSV-E1-Q1 expression at a 
number of time points, internalisation of the labelled VSV-E1-Q1 can be followed. 
If VSV-E1-Q1 is internalised via CME, I predict that internalisation would occur in control and PJ-
DEAD-expressing cells, but not in cells where PIP2 and PI4P depletion occurred. If this process is not 
CME-dependent, however, I would not expect the rate of internalisation to differ between control 




7.3.2 Future direction of chapter 6 
 
Using Gq-coupled GPCR activation to investigate the physiological role of PIP2 depletion in regulation 
of the IKs channel 
 
In this project I have used the rapamycin-induced dimerisation system to induce PIP2 and/or PI4P 
depletion upon addition of rapamycin, used VSPs to deplete PIP2 through activation of the 
phosphatase domain, and applied WTM to cells to deplete PIP2 via inhibition of PI4K activity. Whilst 
these methods are helpful in pushing PIP2 depletion as far as possible and investigating the role of 
PIP2 in IKs regulation without other interfering cellular processes (with the exception of WTM 
exposure), these systems are not physiological. 
To complement the experiments performed with these non-physiological methods, I would express 
different Gq-coupled GPCRs in HEK-IKs cells and activate the receptors by applying their respective 
agonists. Experiments would be performed in P-WCPC to enable recording of the IKs current over 
multiple subsequent IV protocols without risk of current run down, so that observation of the effect 
of receptor activation would be possible.  
PLC is activated upon activation of Gq-coupled GPCRs, which causes hydrolysis of PIP2 at the PM, 
resulting in its depletion and the concomitant production of IP3 and DAG. This release of second 
messengers was purposefully avoided in the rapamycin-induced depletion system and when using 
VSPs because the effect of solely depleting PIP2 was under question. Taking into consideration the 
results obtained in chapter 5, where the use of P-WCPC prevented the inhibition of IKs current that 
was previously seen in WCPC when expressing the same lipid-depleting constructs, the physiological 
environment evidently plays a huge role in the in vitro response of the IKs channel. Maintaining a 
cellular environment that is as close to physiological as possible will greatly benefit the 
understanding of how PIP2 regulates the IKs channel. 
The Gq-GPCRs that would be used in these experiments are the AT1, ET1 and α1-AR, as these are 
present in cardiac myocytes and can therefore provide valuable information on how the IKs channel is 
regulated in the heart. This work could be extended to investigate how LQTS-associated mutations 
affect the channel’s response to β1-AR and Gq-coupled GPCR activation, separately and together (as 
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